<SEC-DOCUMENT>0001264931-20-000139.txt : 20200714
<SEC-HEADER>0001264931-20-000139.hdr.sgml : 20200714
<ACCEPTANCE-DATETIME>20200714170725
ACCESSION NUMBER:		0001264931-20-000139
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20200714
DATE AS OF CHANGE:		20200714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jupiter Wellness, Inc.
		CENTRAL INDEX KEY:			0001760903
		STANDARD INDUSTRIAL CLASSIFICATION:	PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
		IRS NUMBER:				832455880
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-239229
		FILM NUMBER:		201027652

	BUSINESS ADDRESS:	
		STREET 1:		725 N. HWY A1A
		STREET 2:		SUITE C-106
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33458
		BUSINESS PHONE:		561-325-0482

	MAIL ADDRESS:	
		STREET 1:		725 N. HWY A1A
		STREET 2:		SUITE C-106
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33458

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CBD Brands, Inc.
		DATE OF NAME CHANGE:	20181206
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>cdbs1a1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>AS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION ON JULY 14, 2020&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"> <B>Registration
No. 333-239229</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 4.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Amendment No. 1 to&nbsp;</B> </P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jupiter Wellness, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt">2844</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt">83-2455880</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other Jurisdiction of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Incorporation or Organization)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Primary Standard Industrial</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Classification Code Number)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>725 N. Hwy A1A, Suite C-106</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jupiter, FL 33477</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tel: (561) 244-7100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Brian S. John</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jupiter Wellness, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>725 N. Hwy A1A, Suite C-106</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jupiter, FL 33477</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tel: (561) 244-7100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>With copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; text-align: center"><B>Gregory Sichenzia, Esq.</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>Christopher
                                         J. Bellini</B></P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Arthur S. Marcus, Esq.</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Cozen O&rsquo;Connor P.C.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jacob
                                   Tabman, Esq.</B></P>


</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>33 South 6<SUP>th
                                   </SUP>Street, Suite 3800</B></P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Sichenzia Ross Ference
                                   LLP</B></P>


</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Minneapolis, MN 55402</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>1185 Avenue of the Americas, 37 FL</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Telephone: (612)
                                   260-9029</B></P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New
                                   York, NY 10036</B></P>



</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Telephone: (212) 930-9700</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Facsimile: (212) 930-9725</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Approximate date of commencement of proposed
sale to the public:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As soon as practicable after the effective
date of this registration statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box. [X]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. [&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. [&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. [&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by a check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%"><FONT STYLE="font-size: 10pt">Large Accelerated Filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Accelerated Filer [&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Non-Accelerated Filer [X] </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Smaller Reporting Company [X]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging Growth Company [X]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided to Section 7(a)(2)(B) [&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price(1)(2)</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of<BR>
    Registration Fee </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 59%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units (3) </FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,625,000</FONT></TD>
    <TD STYLE="width: 4%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
    </FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock, par value $0.001
    per share, included in the Units </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants included in the Units (6) </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock underlying the warrants
    included in the Units </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">8,500,000</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to be issued to the Underwriters
    </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock underlying warrants
    to be issued to the Underwriters </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">787,500</P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8) </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total </FONT> </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> 17,912,500 </P></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT> </TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> 2,325.04 </P></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
    </FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose of calculating the registration
    fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416 under the Securities Act, the shares
    being registered hereunder shall be deemed to cover additional securities to be offered to prevent dilution and thus includes
    such indeterminate number of shares of common stock as may be issuable with respect to the shares being registered hereunder
    as a result of stock splits, stock dividends or other similar transactions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD STYLE="text-align: justify">Each Unit consists of one share of common stock and one warrant, each whole warrant exercisable
    for one share of common stock.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 150,000 shares of common stock and/or Warrants to
    purchase up to 150,000 additional shares of common stock (equal to 15% of the number of shares of common stock and Warrants
    underlying the Units sold in the offering) that the underwriters have a 45-day option to purchase to cover over-allotments,
    if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(5)</TD>
    <TD STYLE="text-align: justify">Included in the price of the Units. No separate registration fee required pursuant to Rule
    457(g) under the Securities Act of 1933, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(6)</TD>
    <TD STYLE="text-align: justify">The Warrants are exercisable at a price per common share of $8.50.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(7)</TD>
    <TD STYLE="text-align: justify">No fee pursuant to Rule 457(g) under the Securities Act of 1933, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have agreed to issue to the Representative, upon closing
    of this offering, warrants exercisable for a period of five years commencing on the effective date of this registration statement,
    which period shall not extend further than five years from such effective date, representing 7% of the aggregate number of
    shares of common stock included in the Units issued in this offering, exclusive of the shares of common stock to cover the
    over-allotment. The warrants are exercisable at a price per share equal to 150% of the public offering price of the Units
    offered hereunder. Resales of shares of common stock issuable upon exercise of the Underwriters&rsquo; warrant are being similarly
    registered on a delayed or continuous basis. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> (9) </TD>
    <TD STYLE="text-align: justify"> Previously paid. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THE REGISTRANT HEREBY AMENDS THIS REGISTRATION
STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT
WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT
TO SAID SECTION 8(a), MAY DETERMINE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red">The information in this prospectus
is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to
buy these securities in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%"> <FONT STYLE="font-size: 10pt; color: red"><B>PRELIMINARY PROSPECTUS</B></FONT> </TD>
    <TD STYLE="width: 30%; text-align: center"> <FONT STYLE="font-size: 10pt; color: red"><B>SUBJECT TO COMPLETION</B></FONT> </TD>
    <TD STYLE="width: 33%; text-align: right"> <FONT STYLE="font-size: 10pt; color: red"><B>DATED JULY 14, 2020</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1,000,000 Units, Each Consisting of One Share of Common Stock
and a Warrant to Purchase One Share of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="image_005.gif" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0"><B>JUPITER WELLNESS, INC.</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 37%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">We are offering 1,000,000 units (each,
a &ldquo;Unit&rdquo;), each Unit consisting of one share of common stock, par value $0.001 per share, and one warrant (each a
&ldquo;Warrant&rdquo;), in a firm commitment initial public offering at an assumed price of US$7.50 per Unit. Each Warrant is
immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of US$8.50 and will
expire five (5) years from the date of issuance. The shares of common stock and Warrants may be transferred separately immediately
upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">&nbsp;We intend to apply to list our shares of common stock and Warrants
for trading on the Nasdaq Capital Market, subject to official notice of issuance, under the symbols &ldquo;JUPW&rdquo; and &ldquo;JUPWW&rdquo;.
Completion of this offering is contingent on the approval of our listing application for trading on the Nasdaq Market.</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">We are an emerging growth company
under the Jumpstart our Business Startups Act of 2012, or JOBS Act, and, as such, may elect to comply with certain reduced public
company reporting requirements for future filings. Investing in our securities involves a high degree of risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in our securities is highly
speculative and involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 8 of this prospectus for a discussion
of information that should be considered in connection with an investment in our securities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of
this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total </B></FONT><B><FONT STYLE="font-size: 12.5pt"><SUP>(2)(3)</SUP></FONT></B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%"><FONT STYLE="font-size: 10pt">Public offering price<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 15%">7.50</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 15%">7,500,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions</FONT><FONT STYLE="font-size: 12.5pt"><SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">.60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Proceeds to Jupiter Wellness, Inc. (before expenses)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">6.90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right">6,900,000</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The public offering price and underwriting discount and commissions
    in respect of each Unit correspond to the public offering price per share of common stock of $7.49 and the public offering
    price per accompanying warrant of $0.01.</FONT></TD>
    <TD STYLE="width: 10px">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include a non-accountable expense allowance equal
    to 1.5% of the public offering price payable to WestPark Capital, Inc. (the &ldquo;Underwriter&rdquo;), the representative of
    the underwriters. See &ldquo;Underwriting&rdquo; for a description of compensation payable to the underwriters.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD STYLE="text-align: justify">Assumes no exercise of the over-allotment option to purchase shares and/or Warrants which
    we have granted to the underwriters as described below.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD STYLE="text-align: justify">Assumes no exercise of the Warrants included in the Units.</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">We have granted the
underwriters a 45-day option to purchase up to 150,000 shares of common stock and/or Warrants to purchase up to 150,000 additional
shares of common stock (equal to 15% of the number of shares of common stock and Warrants underlying the Units sold in the offering)
from us in any combination thereof at the public offering price per share of common stock and per Warrant, respectively, less
the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">The underwriters expect
to deliver the securities to purchasers in the offering on or about &nbsp;June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font: 16pt Times New Roman, Times, Serif"><B>WestPark
    Capital, Inc.</B></FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="text-align: center; font: 14pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><B>KINGSWOOD CAPITAL MARKETS</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;&nbsp; Division of Benchmark Investments, Inc.</P>

<P STYLE="margin: 0">&nbsp;</P>
</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center; width: 100%">&nbsp;<IMG SRC="image_001.gif" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="toc"></A>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#ProspectusSummary"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 48px; text-align: center">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#TheOffering"><FONT STYLE="font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">5</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#SummarySelectedFinancialAndOtherData"><FONT STYLE="font-size: 10pt">SUMMARY SELECTED FINANCIAL AND OTHER DATA</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">6</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#RiskFactors"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">9</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#CautionaryNote"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#UseOfProceeds"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DividendPolicy"><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#Capitalization">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#Dilution">DILUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">24</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#DescriptionOfCapitalStock"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">25</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DescriptionOfSecuritiesWeAreOffering">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">28</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#MDA">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">30</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DescriptionOfBusiness"><FONT STYLE="font-size: 10pt">DESCRIPTION OF BUSINESS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">41</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#Management">MANAGEMENT</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">47</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#ExecutiveCompensation"><FONT STYLE="font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">51</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#CertainRelationships"><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">52</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#SecurityOwnershipOfCertainBeneficialOwnersAndManagmentAndRelatedStockholderMatters">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">52</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#SharesEligibleForFutureResale"><FONT STYLE="font-size: 10pt">SHARES ELIGIBLE FOR FUTURE SALE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">53</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#MaterialUSFederalIncomeTaxConsiderations">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#Underwriting">UNDERWRITING</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">56</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#DeterminationOfOfferingPrice">DETERMINATION OF OFFERING PRICE</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">58</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#InterestOfNamedExpertsAndCounsel"><FONT STYLE="font-size: 10pt">INTERESTS OF NAMED EXPERTS AND COUNSEL</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">59</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#Experts">EXPERTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">59</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#LegalMatters"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">59</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#WhereYouCanFIndAdditionalInformation"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">59</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#IndexToFinancialStatements"><FONT STYLE="font-size: 10pt">INDEX TO FINANCIAL STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should rely only
on the information contained in this prospectus or contained in any free writing prospectus we may authorize to be delivered or
made available to you. Neither we nor any of the underwriters have authorized anyone to provide any information or make any representations
other than those contained in this prospectus or in any free writing prospectus. We take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers
to buy, the Units only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is
accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the Units.
Our business, financial condition, results of operations, and prospects may have changed since such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 1.5in; float: left; white-space:nowrap">Through and including</FONT> , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the
25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to deliver a prospectus
when acting as an underwriter and with respect to an unsold allotment or subscription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For
investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering
or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the
United States. You are required to inform yourselves about, and to observe any restrictions relating to, this offering and the
distribution of this prospectus outside of the United States. See &ldquo;Underwriting&rdquo; on page 44.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">i</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STATEMENT REGARDING INDUSTRY AND MARKET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any market or industry
data contained in this prospectus is based on a variety of sources, including internal data and estimates, independent industry
publications, government publications, reports by market research firms or other published independent sources. Industry publications
and other published sources generally state that the information contained therein has been obtained from third-party sources believed
to be reliable. Our internal data and estimates are based upon information obtained from trade and business organizations and other
contacts in the markets in which we operate and our management&rsquo;s understanding of industry conditions, and such information
has not been verified by any independent sources. Accordingly, investors should not place undue reliance on such data and information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TRADEMARKS AND TRADE NAMES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We own or have rights to
various trademarks, service marks and trade names that we use in connection with the operation of our business. This prospectus
may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners.
Our use or display of third parties&rsquo; trademarks, service marks, trade names or products in this prospectus is not intended
to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service
marks and trade names referred to in this prospectus may appear without the <FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT>,
TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights or the right of the applicable licensor to these trademarks, service marks and trade names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ii</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="ProspectusSummary"></A>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>This summary
highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. You should read this entire prospectus carefully, especially the &ldquo;Risk Factors&rdquo;
section of this prospectus and our financial statements and the related notes appearing at the end of this prospectus, before
making an investment decision. Except as otherwise indicated, references to &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;,
and the &ldquo;Company&rdquo; refer to Jupiter Wellness, Inc. and its wholly-owned subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jupiter Wellness, Inc.
(&ldquo;Company,&rdquo; &ldquo;Jupiter Wellness&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo;) was originally
incorporated in the State of Delaware on October 24, 2018. Our principal business address is 725 N. Hwy A1A, Suite C-106, Jupiter,
FL 33477.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently authorized
to issue a total of 100,000,000 shares of common stock with a par value of $0.001 and 100,000 shares of Preferred Stock with a
par value of $0.001. As of March 31, 2020, we had 6,893,000 shares of common stock and no shares of Preferred Stock outstanding.
In addition, there are outstanding warrants to purchase 1,158,000 shares of common stock at $0.50 per share which expire on November
1, 2020 and 224,660 Director options to purchase 224,660 shares of
common stock of which 75,000 have an exercise price of $3.00 and 149,660 have an exercise price of $0.25. The options expire between
March 2024 and April 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Below is a summary of the
business activities that we carry out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Business Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a cutting-edge wellness hemp-derived cannabidiol, or CBD,
consumer product development company. We are in the early stage of manufacturing, distributing, and marketing a diverse line of
consumer products infused with CBD. We have a proprietary, trademarked line of products: CaniSun, CaniSkin and CaniDermRX. Under
the CaniSun brand, we are marketing three proprietary CBD-infused sun care lotion formulas containing various sun protection factors,
or SPFs. Under the CaniDermRX brand, we are exploring a formulation of CBD with over-the-counter, or OTC, consumer products that
have potentially therapeutic and medical applications. Specifically, we are exploring the use of such topical solutions for the
treatment of eczema, dermatitis, and actinic keratosis, a non-prescription lotion/lip balm for the treatment of symptoms of cold
sores, and a prescription product for the treatment of burns. The CaniDermRX topical solution for the treatment of eczema dermatitis
is the lead product candidate and will be initially tested in humans as an investigational cosmetic ingredient followed by clinical
trials subject to the regulations of the United States Food and Drug Administration (&ldquo;FDA&rdquo;) under an investigational
new drug, or IND, application. In parallel, we plan to initiate the development of other products. We originally anticipated developmental
studies to be completed in the first quarter of 2020, however, these studies were delayed due to COVID-19. We are also actively
seeking to acquire or license products in the OTC skin care market that can be infused with CBD and marketed under our CaniSkin
and CaniDermRX brand names. There can be no assurances that we will acquire or enter into such partnership or licensing agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The endocannabinoid system, which is a body system affected by CBD, plays a pivotal role
in maintaining a healthy skin through modulating pain sensation, cell proliferation and inflammation. Our strategy for treatment
of skin indications is, therefore, to focus on the use of CBD containing topical formulations and to explore potential combinations
of CBD and other agents that may augment and act synergistically with CBD. We will explore this strategy by conducting controlled
clinical trials to try to ultimately gain FDA approval for specific indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>CaniSun Brand</U></I></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under our CaniSun Brand,
we developed a CBD-infused sunscreen with broad-spectrum SPF protection. We have completed lab testing for CBD solubility&ndash;infusing
clear, colorless, odorless, and 99.5% pure CBD isolate with three different sun care active ingredients, homosalate, octisalate
and octocrylene, which have already been approved by the FDA. The CBD-infused sun care market is fairly nascent in the United
States; we believe that there are currently no major competitors in the category. We see an opportunity to become the leading
manufacturer of CBD-infused sun care products, marketing the CaniSun brand through an extensive digital and social media awareness
campaign. We announced the launch of our CaniSun sun care line of SPF 30, SPF 50 and SPF 55 face lotion on June 6, 2019. We also
sell our CBD-infused lip balm and CBD-infused SPF 30 sunscreen spray on our website Canisun.com.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently have additional
CaniSun products in various stages of development as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 30 Lip Balm; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 15 sunscreen lotion; and</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Mineral-based
                                         sunscreen lotions (SPF 30 and 50); </FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the products listed
above are in the developmental stage, whereby we are finalizing the formula to be used in each product, respectively. For CBD-infused
product candidates in development, such as our CBD-infused SPF 30 Lip Balm and CBD-infused SPF 15 sunscreen lotion, we have already
identified the sun care active ingredient formula (which has already been FDA approved) to be infused with CBD. Once the respective
formulas for each of our product candidates are created, the product candidates will undergo three months of stability testing.
Provided that the product candidates pass the stability testing, we intend to sell the products on our CaniSun website. The formula
for our mineral-based sunscreen lotion (SPF 30 and 50) (product iii) above) includes certain minerals instead of chemicals typically
used in sunscreen lotions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Overall, we believe
that our currently offered sunscreen products comply with the FDA Final Rule for sunscreen products under 21 CFR 352 Sunscreen
products for Over-the-Counter Human Use. Therefore, we believe that our sunscreen products fall within the FDA monograph and that
FDA premarket approval and testing is not required. Our products have been tested for SPF Evaluation (SPF rating), Critical Wave
Length (Broad Spectrum claim) and Water Resistance, each of which is defined within the monograph and labeled accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the testing
on these products is standard testing for suncare products. Such testing protocols are not intended to test for any effects of
adding CBD. In addition to these tests that were conducted to support the claims on the package, each batch is also tested for
appearance, color, odor, pH, viscosity, specific gravity, analytical for the sunscreen active ingredients, and microbial content
testing.</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products
are tested each time they are manufactured. DCR Labs manufactures our products and has represented to us that it is compliant
with the FDA&rsquo;s Current Good Manufacturing Practice, or CGMP, regulations in accordance with 21 CFR 210/211 required for
Over-the-Counter drug products. DCR Labs has self-imposed health and safety standards to ensure compliance with the
FDA&rsquo;s CGMPs.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to continually
update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis. JupiterWellnessinc.com
is our primary corporate website, which will serve as the primary source of information about us for investors and contain press
releases, clinical trial pipeline, lab reports, blog posts, and additional information about each of our brands. We anticipate
that each brand will have its own front-facing website dedicated to retail sales and brand specific information. For example,
our line of sun care products, CaniSun, has its own website at CaniSun.com and allows for online retail purchase of the entire
product line. As we expand our brands (CaniSkin and CaniDermRX), we anticipate utilizing the same strategy and dedicating a new
e-commerce website to each brand moving forward. We are also building a website dedicated to servicing our wholesale and larger
distributor clients. This website will have more information about each product and provide a central location for larger retailers
to find more in-depth information about all of our brands in one place.</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We plan to leverage
our websites with a social media presence across multiple platforms designed to utilize product reviews to increase brand loyalty,
brand recognition and sales. The references to our website in this prospectus are inactive textual references only. The information
on our website is neither incorporated by reference into this prospectus nor intended to be used in connection with this offering.
We also see growth potential in developing retail locations. We intend to utilize cross-promotion marketing campaigns with our
products and product category expansion that leverages our existing distribution channels. We have built an e-commerce platform
designed to connect us directly to consumers. We use the platform to sell products, educate customers and build brand loyalty.</P>




<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>CaniSkin
Brand and CaniDermRX Brand</U></I></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently developing
other products such as CBD-infused skin care lotion under the CaniSkin brand. Specifically, a CBD-infused moisturizing face serum
is under development. We must first finalize the formula to be used in the face serum, and, once approved, the product candidate
will undergo stability testing. We intend to sell the product, provided it first passes stability testing, on our website for
CaniSkin products. Additionally, we are developing innovative dermatological treatments under the CaniDermRX brand that are specialized
to treat atopic dermatitis and other dermatological conditions such as burns, skin cancer and herpes cold sores, respectively.
Subject to obtaining FDA approval, we intend for our experimental-stage product for the treatment of atopic dermatitis to compete
with Dupixent, an FDA-approved product for treating atopic dermatitis, and for our experimental-stage product for the treatment
of herpes cold sores to compete with Silvadene and Abreva, FDA-approved products for treating herpes cold sores. These products
require more extensive testing to show both safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we plan
to seek acquisition opportunities in the branded consumer products space, including but not limited to other OTC therapeutic brands
and skin care brands that can be developed, manufactured, marketed and distributed under our CaniSkin and CaniDermRX brand names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
filed a provisional patent number 62/884,955 on 08/09/2019 on an Aspartame/CBD combination and intend to develop
products containing a combination of CBD and Aspartame under the CaniDermRX name for the treatment of pain and inflammation.
We believe that our CaniDermRX product candidates have the potential to treat many skin indications such as atopic
dermatitis, pruritis-itch, non-atopic dermatitis/eczema, psoriasis, dermatomyositis, scleroderma, seborrheic dermatitis,
actinic keratosis, epidermolysis bullosa and cutaneous neoplasias. Aspartame is a rigorously tested food ingredient. Reviews
by major governmental regulatory bodies have previously found the ingredient safe for consumption at higher levels than we
contemplate using in our CaniDermRX product candidates. </FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">We
believe that our formulations that include Aspartame, such as topical cr&egrave;me, lip balm, powder and dog treats,
are well-tolerated by, and safe for, users.&nbsp;We believe that infusing CBD in our products may help alleviate irritation
that may be caused by applying sun care products and may lead to reduced inflammation.&nbsp;In human skin, receptors of
the endocannabinoid system are found in differentiated keratinocytes, hair follicle cells, sebaceous glands, immune cells,
and sensory neurons. Activation of cannabinoid receptor type 2, or CB2, for which CBD is a ligand receptor in these cells
has been shown to reduce pain and itch sensation, regulate keratinocyte differentiation and proliferation, decrease hair
follicle growth, and modulate the release of damage-induced keratins and inflammatory mediators to control the homeostasis of
the skin environment.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>




</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<DIV STYLE="border: Black 1pt solid; padding: 5px">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is estimated by
BDS Analytics and Arcview Market Research that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024
and that there will be a compound annual growth rate of 49 percent by 2024 across all distribution channels. While sun care products
and other skin care products may represent a lesser portion of such market, we see great potential to grow and generate
revenues as the overall CBD market achieves market acceptance and increased spending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to Grand
View Research, the U.S. sun care market size was estimated at US $1.95 billion in 2016. The growing consumer awareness regarding
the ill-effects of over exposure to ultraviolet, or UV, rays on the undefended skin is expected to propel growth. The sun care
market is a highly competitive market and product differentiation in the sun care market is generally low. Given the relatively
low amount of product differentiation, we see an opportunity to carve out a unique market share with our CBD-infused sun care
products. We cannot make any claims as to such benefits prior to performing certain testing. We see an opportunity, although there
can be no assurance that we will be successful, to become a leading manufacturer of CBD-infused sun care products, marketing the
CaniSun brand through an extensive digital and social media awareness campaign. We announced the launch of our CaniSun sun care
line of SPF 30, SPF 50 and SPF 55 face lotion on June 6, 2019. We also sell our CBD-infused lip balm and CBD-infused SPF 30 sunscreen
spray on our website Canisun.com. We currently have additional CaniSun products in various stages of development as follows:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 30 Lip Balm; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 15 sunscreen lotion; and</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Mineral-based
                                         sunscreen lotions (SPF 30 and 50); </FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the
products listed above are in the developmental stage, whereby we are finalizing the formula to be used in each product,
respectively. For CBD-infused product candidates in development, such as our CBD-infused SPF 30 Lip Balm and CBD-infused SPF
15 sunscreen lotion, we have already identified the sun care active ingredient formula (which has already been FDA approved)
to be infused with CBD. Once the respective formulas for each of our product candidate are created, the product candidates
will undergo three months of stability testing. Provided that the product candidates pass the stability testing, we intend to
sell the products on our CaniSun website. The formula for our mineral-based sunscreen lotion (SPF 30 and 50) (product iii)
above) includes certain minerals instead of chemicals typically used in sunscreen lotions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Growth Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We plan to seek acquisition opportunities in the branded consumer products space, including but not limited to other
non-CBD OTC therapeutic brands and skin care brands that can be manufactured, marketed and distributed under our CaniSkin and CaniDermRX
brand names. We may market such products as they are currently comprised or may seek to add CBD to such products. In the event
we decide to add CBD to such products, we intend to first conduct FDA regulated clinical trials for safety and efficacy testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective February
21, 2020, Jupiter Wellness Inc. (&ldquo;Jupiter Sub&rdquo;), our wholly-owned subsidiary, entered into a membership interest
purchase agreement with Magical Beasts LLC (&ldquo;Magical Beasts&rdquo;), a Nevada limited liability corporation, and Krista
Whitley, its sole interest holder, pursuant to which Jupiter Sub acquired all of the membership interests in Magical Beasts
(the &ldquo;Magical Beasts Acquisition&rdquo;).&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
the Magical Beasts Acquisition, on February 21, 2020, Jupiter Sub and Magical Beasts entered into a sales agency agreement
(the &ldquo;Sales Agency Agreement&rdquo;), pursuant to which Magical Beasts and Ms. Whitley will act as a sales agent for
Jupiter Sub&rsquo;s products. The Sales Agency Agreement shall terminate on December 31, 2020. The Magical Beasts&rsquo;
Acquisition and the Sales Agency Agreement significantly expand our sales and marketing capabilities. It has also
significantly improved our web capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 21, 2020, Jupiter Sub entered into a sales distributor agreement (the
&ldquo;Distribution Agreement&rdquo;) with Ayako Holdings, Inc. (&ldquo;Ayako&rdquo;), a Nevada corporation, pursuant to which
Ayako retained Jupiter Sub as its exclusive sales and distribution agent for certain of its products. The Distribution Agreement,
as extended, shall terminate on December 31, 2022. The Distribution Agreement includes an intellectual property licensing agreement
(the &ldquo;Licensing Agreement&rdquo;) with Ayako, Magical Beasts and Happy Rat Licensing, LLC, a Nevada limited liability company,
(collectively, the &ldquo;Licensor&rdquo;), dated February 18, 2020, pursuant to which the Licensor assigned its rights, titles,
interests and claims to certain trademarks to Jupiter Wellness Marketing, Inc., as set forth in the Licensing Agreement. The Licensing
Agreement lists Jupiter Wellness Marketing, Inc. as the assignee, which is the registered doing business as name for Jupiter Sub.
The brands covered by the Distribution Agreement are &ldquo;Bella&rdquo;, &ldquo;Jack&rdquo;, &ldquo;Felix &amp; Ambrosia&rdquo;,
&ldquo;fitCBD&rdquo;, &ldquo;Black Belt CBD&rdquo; and &ldquo;Wellness CBD 1937&rdquo;, which are all topical solutions containing
CBD (collectively, the &ldquo;Brands&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> The primary products
that we started to sell pursuant to the Distribution Agreement are &ldquo;1937 Comfort Cream&rdquo;, &ldquo;Wellness 1937 Temple
Tonic&rdquo;, &ldquo;Felix and Ambrosia CBD Infused Heel Stick Crack&rdquo; and related foot cream and a line of eye creams, anti-
aging cream, anti-aging mask and &ldquo;Bella Alpha C-Serum for Day&rdquo;. The 1937 Comfort Cream is a vegan, non-comedogenic
cream. It is formulated with a blend of natural oils including arnica, camphor, peppermint, Hawaiian cramp bark and other oils.
The 8 ounce cream contains 1,000 mgs of 0% THC American grown industrial hemp derived oil. The Wellness 1937 CBD Temple Tonic
is a three ounce rollerball to apply to your temple or lower neck area. It contains an oil blend that includes jojoba oil infused
with guarana, peppermint, lavender, chamomile, eucalyptus, Hawaiian cramp bark and other oils. The three ounce roller contains
500 mgs of 0% THC American grown industrial hemp derived CBD. The Felix and ambrosia CBD Infused Heel Stick and foot cream is
a moisturizing balm for dry, cracked heels. It is made with peppermint, lemon, aloe, tea tree oil, lavender, eucalyptus and other
oils. It is infused with 0% THC American grown industrial hemp derived CBD. The anti-aging eye cream, anti-aging day cream, anti-aging
mask with AHA and the Bella alpha C-Serum for day products all contain a mixture of oils and are infused with 0% THC American
grown industrial hemp. We have recently been selling them in a package called &ldquo;Quarantine Glow Up Package&rdquo; where you
get one of each. Pursuant to the Distribution Agreement, Jupiter Sub also acquired all of Ayako&rsquo;s current inventory of the
Brands. All our current brands can be found at <FONT STYLE="color: Blue">www.CBDCaring.com</FONT>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except as disclosed
above, we have no definitive agreements in place to acquire any other entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Beginning in March
2020, we began selling masks, gloves and hand sanitizer, in order to take advantage of our supply relationships and the demand
for such products. While, this is not part of our long-term strategy, we intend to continue to pursue such opportunities in the
near term while they present themselves. We have created our own 6- ounce hand sanitizer which our sun care manufacturer produces
for us and we sell under our brand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that we
have certain competitive strengths and advantages including:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are the first to market
with a brand of CBD-infused sun care products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that we have
the management expertise to develop additional over-the-counter, or OTC, and prescription-based products which can position us
for growth;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         are currently developing unique and proprietary combination products based on CBD and
                                         other ingredients such as Aspartame; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&bull;</TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         have already begun the studies to create a research protocol to evaluate the efficacy
                                         and safety of the products containing CBD when applied as a treatment for skin irritations
                                         including eczema (atopic dermatitis) and other inflammatory skin irritations</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding: 5px">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Affecting Our Business<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is subject
to numerous risks as described in the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. You should
carefully consider these risks before making an investment. Some of these risks include:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
                                         accountant has indicated doubt about our ability to continue as a going concern.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                         will need a significant amount of capital to carry out our proposed business plan and,
                                         unless we are able to raise sufficient funds or generate sufficient revenues, we may
                                         be forced to discontinue our operations. </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
                                         ability to use our net operating loss carryforwards and other tax attributes may be limited.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
                                         we are unable to keep up with rapid technological changes, our products may become obsolete.
                                         </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
                                         we are unable to develop and maintain our brand and reputation for our product offering,
                                         our business and prospects may be materially harmed.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                         are subject to government regulation, and unfavorable changes could substantially harm
                                         our business and results of operations. </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Existing
                                         or probable governmental regulations relating to CBD products may harm or prevent our
                                         ability to sell our product offering.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                         do not have, and may never have, any approved products on the market. Our business is
                                         highly dependent upon receiving approvals from various U.S. and international governmental
                                         agencies and will be severely harmed if we are not granted approval to manufacture and
                                         sell our product candidates.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>There
                                         is currently no public market for our common shares or Warrants and none may develop
                                         following this offering.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investors
                                         may have difficulty in reselling their shares due to the lack of public market for our
                                         securities.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&bull;</TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
                                         of our stockholders hold a significant percentage of our outstanding voting securities,
                                         which could reduce the ability of minority stockholders to effect certain corporate actions.</I></FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
    business operations may be disrupted by global pandemics, including the novel coronavirus, COVID-19 pandemic</I></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Implications of Being an Emerging Growth
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a company with less
than $1.07 billion in revenue during our last completed fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified
reduced reporting requirements that are otherwise applicable generally to public companies. These reduced reporting requirements
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption
    from compliance with the auditor attestation requirement on the effectiveness of our internal control over financial reporting;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from
    compliance with any requirement that the Public Company Accounting Oversight Board may adopt regarding mandatory audit firm
    rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial
    statements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from
    the requirements to obtain a non-binding advisory vote on executive compensation or a stockholder approval of any golden parachute
    arrangements; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended transition
    periods for complying with new or revised accounting standards;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted
    to present only two years of audited financial statements and only two years of related &ldquo;Management&rsquo;s Discussion
    and Analysis of Financial Condition and Results of Operations&rdquo;, in addition to any required unaudited interim financial
    statements in this prospectus; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosures
    regarding executive compensation in our periodic reports, proxy statements and registration statements, including in this
    prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest to occur of: (i) the end of the first fiscal year in which our annual gross revenue is $1.07
billion or more; (ii) the end of the first fiscal year in which we are deemed to be a &ldquo;large accelerated filer,&rdquo; as
defined in the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;); (iii) the date on which we have,
during the previous three-year period, issued more than $1.00 billion in non-convertible debt securities; and (iv) the end of the
fiscal year during which the fifth anniversary of this offering occurs. We may choose to take advantage of some, but not all, of
the available benefits under the JOBS Act. We currently intend to take advantage of the exemptions discussed above. Accordingly,
the information contained herein may be different than the information you receive from other public companies in which you hold
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are also a &ldquo;smaller
reporting company,&rdquo; as defined under SEC Regulation S-K. As such, we also are exempt from the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act and also are subject to less extensive disclosure requirements regarding executive compensation
in our periodic reports and proxy statements. We will continue to be deemed a smaller reporting company until our public float
exceeds $75 million on the last day of our second fiscal quarter in the preceding fiscal year.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were originally
incorporated in the State of Delaware on October 24, 2018. Our principal business address is 725 N. Hwy A1A, Suite C-106, Jupiter,
FL 33477. JupiterWellnessinc.com is our primary corporate website, which will serve as the primary source of information about
us for investors and contain press releases, clinical trial pipeline, lab reports, blog posts, and additional information about
each of our brands. We anticipate that each brand will have its own front-facing website dedicated to retail sales and brand specific
information. For example, our line of sun care products, CaniSun, has its own website at CaniSun.com and allows for online retail
purchase of the entire product line. As we expand our brands (CaniSkin and CaniDermRX), we anticipate utilizing the same strategy
and dedicating a new e-commerce website to each brand moving forward. We are also building a website dedicated to servicing our
wholesale and larger distributor clients. This website will have more information about each product and provide a central location
for larger retailers to find more in-depth information about all of our brands in one place. The references to our website in
this prospectus are inactive textual references only. The information on our website is neither incorporated by reference into
this prospectus nor intended to be used in connection with this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Going Concern</B></FONT><FONT STYLE="font-size: 8pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to overcome
the circumstances that impact our ability to remain a going concern through a combination of expanding our revenues, with interim
cash flow deficiencies being addressed through additional equity and debt financing; however, we may not have commitments from
third parties for a sufficient amount of additional capital. We cannot be certain that any such financing will be available on
acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.
Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional
financing in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results
of operations and stock price and may require us to curtail or cease operations, sell off our assets, seek protection from our
creditors through bankruptcy proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders
of our common stock, and debt financing, if available, may involve restrictive covenants, and strategic relationships, if necessary,
to raise additional funds, and may require that we relinquish valuable rights. Please see&nbsp;note 1, in our financial statements,
for further information.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have a need for
additional growth capital. However, we believe that, following this offering, we will have sufficient capital to sustain our operations
for at least the next 24 months, but, there can be no assurance that sufficient funds required during the subsequent year or thereafter
will be generated from operations or that funds will be available from external sources such as debt or equity financings or other
potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise
capital from external sources would force us to substantially curtail or cease operations and would, therefore, have a material
adverse effect on our business. Furthermore, there can be no assurance that any such required funds, if available, will be available
on attractive terms or that they will not have a significant dilutive effect on our existing stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">.</P>

</DIV>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<DIV STYLE="border: Black 1pt solid">

<DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="TheOffering"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following summary of the offering
contains basic information about the offering and our securities and is not intended to be complete. It does not contain all the
information that is important to you. For a more complete understanding of our securities, please refer to the section of this
prospectus entitled &ldquo;Description of Capital Stock.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><B>Units offered</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 69%">We are offering 1,000,000 Units, each consisting of one share of common stock
    and one Warrant, each whole Warrant exercisable for one share of common stock. The Warrants included within the Units are
    exercisable immediately, have an exercise price of US$8.50 per share and expire five (5) years from the date of issuance.
    The shares of common stock and Warrants that are part of the Units are immediately separable.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Public offering price</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">The assumed public offering price is US$7.50 per Unit.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Common Stock outstanding before this offering:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">6,893,000 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Common Stock to be outstanding immediately after this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">7,893,000 shares<SUP>(1)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Option to purchase additional shares:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted the underwriters a 45-day option to purchase
    up to 150,000 additional shares of our common stock and/or Warrants to purchase up to 150,000 additional shares of our common
    stock (equal to 15% of the number of shares of common stock and Warrants underlying the Units sold in the offering), from
    us in any combination thereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to receive approximately $6,450,000&nbsp;in net proceeds
from the sale of the Units offered by us in this offering (approximately $7,485,000&nbsp;if the underwriters exercise their over-allotment
option in full), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us
of $337,500, plus a 1.5% non-accountable expense allowance of $112,500, based on the Units being offered at $7.50 per Unit. We
intend to use the net proceeds from this offering to perform clinical trials on our dermatitis, eczema treatments, acquire or establish
cash flowing retail locations and increase our proprietary product lines.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">See &ldquo;Use of Proceeds&rdquo; on page 22 for a more
        complete description of the intended use of proceeds from this offering.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Dividend Policy</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holders of common stock are entitled to receive ratably such
    dividends, if any, as may be declared by our board of directors, or the Board, out of funds legally available. We have not
    paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development
    of our business. Any future disposition of dividends will be at the discretion of our Board and will depend upon, among other
    things, our future earnings, operating and financial condition, capital requirements, and other factors.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Investing in our securities is highly speculative and involves
    a high degree of risk. You should carefully consider the information set forth in this prospectus and, in particular, the
    specific factors set forth in the &ldquo;Risk Factors&rdquo; section beginning on page 8 of this prospectus before deciding
    whether or not to invest in our securities</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Proposed Nasdaq Ticker Symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We intend to apply to list our common stock and Warrants
    on the Nasdaq Capital Market, subject to official notice of issuance, under the symbols &ldquo;JUPW&rdquo; and &ldquo;JUPWW&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Lock-ups</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We and our directors, officers and holders of 1% of our outstanding
    securities have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose
    of any of our common stock for a period of 180 days from the effectiveness of this registration statement., in the case of
    our company and our officers and directors. See &ldquo;Underwriting&rdquo; on page 44.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Based on 6,893,000 shares of common stock issued and outstanding as of March 31, 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, the information
in this prospectus assumes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                         public offering price of $7.50 per Unit;</FONT></TD></TR>                                                                                                                                                                                                                                                            <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                         exercise by the underwriters of their option to purchase 150,000 additional shares of common
                                         stock and/or 150,000 Warrants to cover over-allotments, if any;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                         exercise of the underwriters&rsquo; warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000
                                         shares of common stock included in the Units sold in this offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                         exercise of outstanding warrants to purchase 1,158,000 shares of common stock at $0.50
                                         per share which expire on November 1, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                         conversion of outstanding convertible promissory notes; and</FONT></P>


</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                         exercise of the Warrants included in the Units.</FONT></TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding: 5px">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="SummarySelectedFinancialAndOtherData"></A>SUMMARY SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The summary selected
financial data set forth below should be read together with our financial statements and the related notes to those statements,
as well as the &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo;
section of this prospectus. The balance sheet and statement of operations data for the year
ended December 31, 2019 has been derived from our audited financial statements included elsewhere in this prospectus and the balance
sheet and statement of operations data for the period ended March 31, 2020 have been derived from our unaudited financial statements
included elsewhere in this prospectus.</P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>JUPITER WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS OF MARCH 31, 2020&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    Forma <SUP>(1)(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;358,997</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,008,997</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,692</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,692</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account receivable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,060</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,060</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,375</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,375</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use
    assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,959</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,959</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Deposits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,200</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,200</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt; text-indent: 30.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    current assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">739,283</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,389,283</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt; text-indent: 30.1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transportation
    Equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,192</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,192</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">944,627</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">944,627</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">308,690</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">308,690</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt; text-indent: 30.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034,792</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,684,792</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liabilities
    and Shareholders&rsquo; Equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,186</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,186</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes
    payable to related parties</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">875,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">875,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Note payable issued in acquisition</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">956,584</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">956,584</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current portion
    of lease liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,794</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,794</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,909</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,909</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt; text-indent: 30.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    current Liabilities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,903,473</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,903,473</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term portion
    lease liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,138</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,138</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Total
    liabilities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,611</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,611</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock,
    $0.001 par value, 100,000 shares authorized of which none are issued and outstanding</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock,
    $.001 par value, 100,000,000 shares authorized, of which 6,893,000 shares issued and outstanding (actual) and 7,893,000 shares
    outstanding (pro forma)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,893</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Common
    stock payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in
    capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,236,282</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,885,282</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,466,994</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,466,994</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt; text-indent: 30.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Shareholders&rsquo; Equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,181</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,751,180</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt; text-indent: 30.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Liabilities and Shareholders&rsquo; Equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034,792</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,684,792</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma amounts reflect the sale of 1,000,000&nbsp;shares of our common stock included in the Units to be sold in this offering
    at an assumed initial public offering price of $7.50 per Unit, and after deducting the estimated underwriting discounts and
    commissions and estimated offering expenses.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>(2)</TD>
    <TD STYLE="text-align: justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $7.50 per
    Unit would increase (decrease) our pro forma amounts of each of cash, total current assets, total assets and total stockholders&rsquo;
    equity by approximately $1,000,000, assuming that the number of Units offered by us, as set forth on the cover page of this
    prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV>&nbsp;</DIV>

<DIV STYLE="border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="6" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
    WELLNESS, INC.</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="6" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Consolidated
    Statement of Operations</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="6" STYLE="vertical-align: top; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 4.5pt"><FONT STYLE="text-transform: uppercase"><B>For
                                         the Three Months Ended March 31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)&nbsp;</B></P>

</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Three Months Ended March 31, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Three Months Ended March 31, 2019</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT></TD>
    <TD STYLE="width: 25%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 21%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;117,727</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of Sales</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99,903</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross profit</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,824</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">482,253</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,541</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expense</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">482,253</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,541</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income / (expense)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
    income</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
    expense</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,215)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,369)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(481,798)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(73,541</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) per share:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0.07)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0.01</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057,556</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accompanying notes are an integral part of these unaudited financial statements</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>




<DIV STYLE="padding: 5px">

<DIV STYLE="border: Black 1pt solid">

<DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center"><B>JUPITER WELLNESS, INC.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center"><B>STATEMENT OF OPERATIONS</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>FOR THE YEAR ENDED DECEMBER 31, 2019 AND</B></P>
                    <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>FOR THE PERIOD FROM OCTOBER 24, 2018 (INCEPTION)
                    TO DECEMBER 31, 2018</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Year ended December 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">For the from October 24, 2018 (Inception) through
    December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; padding-left: 5.4pt">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-indent: 20pt; padding-left: 5.4pt">Sales</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 20pt; padding-left: 5.4pt">Cost of Sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,024</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit
    (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,569</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left; padding-left: 5.4pt">Operating expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt; padding-left: 5.4pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">908,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">Total operating expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">908,717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Other income / (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
    expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,557</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Total other income / (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net (loss)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(925,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(59,734</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 5.4pt">Net (loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 20pt; padding-left: 5.4pt">Weighted average number of shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,301,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,364,113</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</DIV>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="RiskFactors"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>An investment in
our securities is highly speculative and involves a high degree of risk. In determining whether to purchase the Company&rsquo;s
securities, an investor should carefully consider all of the material risks described below, together with the other information
contained in this Prospectus. We cannot assure you that any of the events discussed below will not occur. These events could have
a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen,
the trading price of our common stock could decline, and you could lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Risks Related to our Financial Position
and Capital Needs</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our accountant has indicated doubt about
our ability to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2020 and March 31, 2019, we had an accumulated
deficit of $1,466,994 and $133,275, respectively. The net loss for the three-month period ended March 31, 2020 was $481,798 <FONT STYLE="background-color: white">and
for the </FONT>three month period ended March 31<FONT STYLE="background-color: white">, 2019 was $73,541. </FONT>Our ability to
continue as a going concern is doubtful and if we are unable to generate significant revenue or secure financing we may be required
to cease or curtail our operations.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will need a significant amount of
capital to carry out our proposed business plan and, unless we are able to raise sufficient funds or generate sufficient revenues,
we may be forced to discontinue our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently have limited
capital on hand. We anticipate that such capital will allow us to continue operations for approximately six months at which time
we will require additional capital, either from this offering, revenues or from alternative sources, which alternative sources
may include debt or equity financing on more favorable terms than those offered pursuant to this registration statement. We believe
that the net proceeds of this offering will be sufficient for 24 months following this offering. Our ability to obtain the necessary
financing to execute our business plan is subject to a number of factors, including general market conditions and investor acceptance
of our business plan. These factors may make the timing, amount, terms and conditions of such financing unattractive or unavailable
to us. If we are unable to raise sufficient funds or generate them through revenues, we will have to significantly reduce our
spending, delay or cancel our planned activities or substantially change our current corporate structure. There is no guarantee
that we will be able to obtain any funding or that we will have sufficient resources to continue to conduct our operations as
projected, any of which could mean that we will be forced to discontinue our operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0"><B><I>Raising additional capital may cause dilution to our
existing stockholders, restrict our operations or require us to relinquish rights to our technologies or other assets.</I></B></P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may seek additional capital through a combination of private
and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that
we raise additional capital through the sale of equity or convertible debt securities, existing ownership interests will be diluted
and the terms of such financings may include liquidation or other preferences that adversely affect the rights of existing stockholders.
Debt financings may be coupled with an equity component, such as warrants to purchase shares, which could also result in dilution
of our existing stockholders&rsquo; ownership. The incurrence of indebtedness would result in increased fixed payment obligations
and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact
our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to
default on such indebtedness, we could lose such assets and intellectual property.&nbsp;</P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our potential for rapid growth and our
entry into new markets make it difficult for us to evaluate our current and future business prospects, and we may be unable to
effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm
our business, financial condition, results of operations and cash flow.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our proliferation into
new markets may place a significant strain on our resources and increase demands on our executive management, personnel and systems,
and our operational, administrative and financial resources may be inadequate. We may also not be able to effectively manage any
expanded operations, or achieve planned growth on a timely or profitable basis, particularly if the number of customers using our
technology significantly increases or their demands and needs change as our business expands. If we are unable to manage expanded
operations effectively, we may experience operating inefficiencies, the quality of our products and services could deteriorate,
and our business and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0"><B><I>Changes in tax laws and unanticipated tax liabilities
could adversely affect our effective income tax rate and ability to achieve profitability.</I></B></P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our effective income tax
rate in the future could be adversely affected by a number of factors including changes in the mix of earnings in countries with
differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws. We regularly
assess all of these matters to determine the adequacy of our tax provision which is subject to discretion. If our assessments
are incorrect, it could have an adverse effect on our business and financial condition. There can be no assurance that income
tax laws and administrative policies with respect to the income tax consequences generally applicable to us or to our subsidiaries
will not be changed in a manner which adversely affects our shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Risks Related to our Business</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to keep up with rapid
technological changes, our products may become obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market for our products
is characterized by significant and rapid change. Although we will continue to expand our product line capabilities in order to
remain competitive, research and discoveries by others may make our processes, products or brands less attractive or even obsolete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Competition could adversely affect our
business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our industry in general
is competitive. It is possible that future competitors could enter our market, thereby causing us to lose market share and revenues.
In addition, some of our current or future competitors may have significantly greater financial, technical, marketing and other
resources than we do or may have more experience or advantages in the markets in which we will compete that will allow them to
offer lower prices or higher quality products. If we do not successfully compete with these competitors, we could fail to develop
market share and our future business prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to develop and maintain
our brand and reputation for our product offerings, our business and prospects could be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business and prospects
depend, in part, on developing and then maintaining and strengthening our brand and reputation in the markets we serve. If problems
with our products cause our customers to have a negative experience or failure or delay in the delivery of our products to our
customers, our brand and reputation could be diminished. If we fail to develop, promote and maintain our brand and reputation successfully,
our business and prospects could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to government regulation,
and unfavorable changes could substantially harm our business and results of operations</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to general
business regulations and laws as well as regulations and laws specifically governing our industries in the U.S. and other countries
in which we operate. Uncertainty surrounding existing and future laws and regulations may impede our services and increase the
cost of providing such services. These regulations and laws may cover taxation, tariffs, user pricing, distribution, consumer protection
and the characteristics and quality of services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Existing or probable governmental regulations
relating to CBD products may harm or prevent our ability to sell our product offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A majority of state
governments in the United States have legalized the growing, production, and use of CBD. However, cannabis remains illegal under
federal law. In addition, in July 2017, the United States Drug Enforcement Agency issued a statement that certain CBD extractions
fall within the definition of marijuana, and are therefore a Schedule I controlled substance under the Controlled Substances Act
of 1970, as amended. Thus, the cannabis industry, including companies which sell products containing CBD, faces very uncertain
regulation by the federal government. While the federal government has for several years chosen to not intervene in the cannabis
business conducted legally within the states that have legislated such activities, there is, nonetheless, potential that the federal
government may at any time choose to begin enforcing its laws against the manufacture, possession, or use of cannabis-based products
such as CBD. Similarly, there is the possibility that the federal government may enact legislation or rules that authorize the
manufacturing, possession or use of those products under specific guidelines. Local, state and federal cannabis laws and regulations
are broad in scope and subject to evolving interpretations. In the event the federal government was to tighten its regulation
of the industry, we would likely suffer a material adverse effect on our business, including substantial losses.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Laws and regulations affecting our industry are evolving under the Farm Bill, FDA and other regulatory authorities
and changes to any regulation may materially affect our CBD products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In conjunction with
the enactment of the Agriculture Improvement Act of 2018 (the &ldquo;Farm Bill&rdquo;), the United States Food and Drug Administration
(&ldquo;FDA&rdquo;) released a statement about the status of CBD as a nutritional supplement, and the agency&rsquo;s actions in
the short term with regards to CBD will guide the industry. While our sun care products are not nutritional supplements, the statement
noted that the Farm Bill explicitly preserved the FDA&rsquo;s authority to regulate products containing cannabis or cannabis-derived
compounds under the Federal Food, Drug, and Cosmetic Act and Section 351 of the Public Health Service Act. As a company whose
sun care products contain infused CBD, we will strive to meet all FDA guidelines as the regulations evolve. Any difficulties in
compliance with future government regulation could increase our operating costs and adversely impact our results of operations
in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, as a result
of the Farm Bill&rsquo;s recent passage, we expect that there will be a constant evolution of laws and regulations affecting the
CBD industry which could affect our operations. Local, state and federal hemp laws and regulations may be broad in scope and subject
to changing interpretations. These changes may require us to incur substantial costs associated with legal and compliance fees
and ultimately require us to alter our business plan. Furthermore, violations of these laws, or alleged violations, could disrupt
our business and result in a material adverse effect on our operations. In addition, we cannot predict the nature of any future
laws, regulations, interpretations or applications, and it is possible that regulations may be enacted in the future that will
be directly applicable to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently believe
that we are required to seek FDA approval for our sun care products, and as such we do not plan to seek FDA approval. If regulation
evolves such that we are required to seek approval, we will endeavor to do so. This may require us to incur substantial costs associated
with legal and compliance fees and adversely affect our results of operations.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend heavily on key personnel, and
turnover of key senior management could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future business and
results of operations depend in significant part upon the continued contributions of our senior management personnel. If we lose
their services or if they fail to perform in their current positions, or if we are not able to attract and retain skilled personnel
as needed, our business could suffer. Significant turnover in our senior management could significantly deplete our institutional
knowledge held by our existing senior management team. We depend on the skills and abilities of these key personnel in managing
the product acquisition, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future.
We may not have written employment agreements with all of our senior management. We do not have any key person insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our products may not meet health and
safety standards or could become contaminated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have control
over all of the third parties involved in the manufacturing of our products and their compliance with&nbsp;government&nbsp;health
and safety standards. Even if our products meet these standards, they could otherwise become contaminated. A failure to meet these
standards or contamination could occur in our operations or those of our manufacturers, distributors or suppliers. This could
result in expensive production interruptions, recalls and liability claims. Moreover, negative publicity could be generated from
false, unfounded or nominal liability claims or limited recalls. Any of these failures or occurrences could negatively affect
our business and financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The sale of our products involves product
liability and related risks that could expose us to significant insurance and loss expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We face an inherent
risk of exposure to product liability claims if the use of our products results in, or is believed to have resulted in, illness
or injury. Our products contain combinations of ingredients, and there is little long-term experience with the effect of these
combinations. In addition, interactions of these products with other products, prescription medicines and over-the-counter treatments
have not been fully explored or understood and may&nbsp;have unintended consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any product liability claim
may&nbsp;increase our costs and adversely affect our revenue and operating income. Moreover, liability claims arising from a serious
adverse event may&nbsp;increase our costs through higher insurance premiums and deductibles and may&nbsp;make it more difficult
to secure adequate insurance coverage in the future. In addition, our product liability insurance may&nbsp;fail to cover future
product liability claims, which, if adversely determined, could subject us to substantial monetary damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The success of our business will depend
upon our ability to create and expand our brand awareness.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The sun care and CBD
markets we compete in, and the skin care market we intend to compete in, are highly competitive, with many well-known brands leading
the industry. Our ability to compete effectively and generate revenue will be based upon our ability to create and expand awareness
of our products distinct from those of our competitors. It is imperative that we are able to convey to consumers the benefits
of our products.&nbsp;However, advertising and packaging and labeling of such products will be limited by various regulations.&nbsp;Our
success will be dependent upon our ability to convey to consumers that our products are superior to those of our competitors.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We must develop and introduce new products
to succeed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our industry is subject
to rapid change. New products are constantly introduced to the market. Our ability to remain competitive depends in part on our
ability to enhance existing products, to develop and manufacture new products in a timely and cost-effective manner, to accurately
predict market transitions, and to effectively market our products. Our future financial results will depend to a great extent
on the successful introduction of several new products. We cannot be certain that we will be successful in selecting, developing,
manufacturing and marketing new products or in enhancing existing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The success of new product
introductions depends on various factors, including, without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
                                         sales and marketing efforts;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timely
                                         delivery of new products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability
                                         of raw materials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
                                         of raw materials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
                                         allowance of the products; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
                                         acceptance of new products</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Possible yet unanticipated changes in
federal and state law could cause any of our current products, as well as products that we intend to launch, containing hemp-derived&nbsp;CBD
oil&nbsp;to be illegal, or could otherwise prohibit, limit or restrict any of our products containing CBD.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recently launched and
commenced distribution of certain products containing hemp-derived&nbsp;CBD, and we currently intend to develop and launch additional
products containing hemp-derived CBD in the future. Until 2014, when 7 U.S. Code &sect;5940 became federal law as part of the
Agricultural Act of 2014 (the &ldquo;2014 Farm Act&rdquo;), products containing oils derived from hemp, notwithstanding a minimal
or non-existing THC content, were classified as Schedule I illegal drugs. The 2014 Farm Act expired on September 30, 2018, and
was thereafter replaced by the Farm Bill, which amended various sections of the U.S. Code, thereby removing hemp, defined as cannabis
with less than 0.3% THC, from Schedule 1 status under the Controlled Substances Act, and legalizing the cultivation and sale of
industrial-hemp at the federal level, subject to compliance with certain federal requirements and state law, amongst other things.
THC is the psychoactive component of plants in the cannabis family generally identified as marihuana or marijuana. There is no
assurance that the Farm Bill will not be repealed or amended such that our products containing hemp-derived CBD would once again
be deemed illegal under federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The  Farm Bill
delegates the authority to the states to regulate and limit the production of hemp and hemp-derived products within their
territories. Although many states have adopted laws and regulations that allow for the production and sale of hemp and
hemp-derived products under certain circumstances, no assurance can be given that such state laws may not be repealed or
amended such that our intended products containing hemp-derived CBD would once again be deemed illegal under the laws of one
or more states now permitting such products, which in turn would render such intended products illegal in those states under
federal law even if the federal law is unchanged. In the event of either repeal of federal or of state laws and regulations,
or of amendments thereto that are adverse to our intended products, we may be restricted or limited with respect to those
products that we may sell or distribute, which could adversely impact our intended business plan with respect to such
intended products.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, the FDA
has indicated its view that certain types of products containing CBD may not be permissible under the Food, Drug and Cosmetic
Act, or FDCA. The FDA&rsquo;s position is related to its approval of Epidiolex, a marijuana-derived prescription medicine to be
available in the United States. The active ingredient in Epidiolex is CBD. On December&nbsp;20, 2018, after the passage of the

Farm Bill, FDA Commissioner Scott Gottlieb issued a statement in which he reiterated the FDA&rsquo;s position that, among other
things, the FDA requires a cannabis product (hemp-derived&nbsp;or otherwise) that is marketed with a claim of therapeutic benefit,
or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into interstate commerce
and that the FDCA prohibits introducing into interstate commerce food products containing added CBD, and marketing products containing
CBD as a dietary supplement, regardless of whether the substances are hemp-derived. Our CBD product offerings must comply with
applicable federal and state laws and regulations, and legal proceedings alleging violations of such laws could have a material
adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Sources of&nbsp;hemp-derived CBD depend
upon legality of cultivation, processing, marketing and sales of products derived from those plants under state law.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Hemp-derived CBD can only
be legally produced in states that have laws and regulations that allow for such production and that comply with the Farm
Bill,&nbsp;apart from state laws legalizing and regulating medical and recreational cannabis or marijuana, which remains illegal
under federal law and regulations. We purchase all of our hemp-derived CBD from licensed growers and processors in states where
such production is legal. As described in the risk factor, possible yet unanticipated changes in federal and state law could cause
any of our current products, as well as products that we intend to launch, containing hemp-derived CBD oil to be illegal, or could
otherwise prohibit, limit or restrict any of our products containing CBD in the event of repeal or amendment of laws and regulations
which are now favorable to the cannabis/hemp industry in such states, we would be required to locate new suppliers in states with
laws and regulations that qualify under the Farm Bill. If we were to be unsuccessful in arranging new sources of supply of
our raw ingredients, or if our raw ingredients were to become legally unavailable, our intended business plan with respect to such
products could be adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because our distributors may only sell
and ship our products containing hemp-derived&nbsp;CBD&nbsp;in states that have adopted laws and regulations qualifying under the Farm Bill, a reduction in the number of states having such qualifying laws and regulations could limit, restrict or otherwise
preclude the sale of intended products containing&nbsp;hemp-derived CBD.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The interstate shipment
of hemp-derived CBD from one state to another is legal only where both states have&nbsp;laws and regulations that allow for the
production and sale of such products and that qualify under the Farm Bill. Therefore, the marketing and sale of our intended
products containing hemp-derived CBD is limited by such factors and is restricted to such states. Although we believe we may lawfully
sell any of our finished products, including those containing CBD, in a majority of states, a repeal or adverse amendment of laws
and regulations that are now favorable to the distribution, marketing and sale of finished products we intend to sell could significantly
limit, restrict or prevent us from generating revenue related to our products that contain hemp-derived CBD. Any such repeal or
adverse amendment of now favorable laws and regulations could have an adverse impact on our business plan with respect to such
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Due to recent expansion into the CBD
industry, we may have a difficult time obtaining the various insurances that are desired to operate our business, which may expose
us to additional risk and financial liability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Insurance that is otherwise
readily available, such as general liability, and directors and officer&rsquo;s insurance, may become more difficult for us to
find, and more expensive, due to our launch of products containing hemp-derived CBD. There are no guarantees that we will be able
to find such insurances in the future, or that the cost will be affordable to us. If we are forced to go without such insurances,
it may prevent us from entering into certain business sectors, may inhibit our growth, and may expose us to additional risk and
financial liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Adverse publicity associated with our
products or ingredients, or those of similar companies, could adversely affect our sales and revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Adverse publicity concerning
any actual or purported failure by us to comply with applicable laws and regulations regarding any aspect of our business could
have an adverse effect on the public perception of us. This, in turn, could negatively affect our ability to obtain financing,
endorsers and attract distributors or retailers for our products, which would have a material adverse effect on our ability to
generate sales and revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our distributors&rsquo;
and customers&rsquo; perception of the safety and quality of our products or even similar products distributed by others can be
significantly influenced by national media attention, publicized scientific research or findings, product liability claims and
other publicity concerning our products or similar products distributed by others. Adverse publicity, whether or not accurate,
that associates consumption of our products or any similar products with illness or other adverse effects, will likely diminish
the public&rsquo;s perception of our products. Claims that any products are ineffective, inappropriately labeled or have inaccurate
instructions as to their use, could have a material adverse effect on the market demand for our products, including reducing our
sales and revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We do not have and may never have any products on the
market that have been approved for the treatment of disease. Our business is highly dependent upon receiving approvals from various
U.S. and international governmental agencies and will be severely harmed if we are not granted approval to manufacture and sell
our product candidates.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order for us to commercialize
a product for the treatment of any disease, we must obtain regulatory approvals of such treatment for that indication. Satisfying
regulatory requirements is an expensive process that typically takes many years and involves compliance with requirements covering
research and development, testing, manufacturing, quality control, labeling, and promotion of drugs for human use. To obtain necessary
regulatory approvals, we must, among other requirements, complete clinical trials demonstrating that our products are safe and
effective for a particular indication. There can be no assurance that our products will prove to be safe and effective, that our
clinical trials will demonstrate the necessary safety and effectiveness of our product candidates, or that we will succeed in obtaining
regulatory approval for any treatment we develop even if such safety and effectiveness are demonstrated.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any delays or difficulties
we encounter in our clinical trials may delay or preclude regulatory approval from the FDA or from international regulatory organizations.
Any delay or preclusion of regulatory approval would be expected to delay or preclude the commercialization of our products. Examples
of delays or difficulties that we may encounter in our clinical trials include without limitation the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                         trials may not yield sufficiently conclusive results for regulatory agencies to approve
                                         the use of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         products may fail to be more effective than current therapies, or to be effective at
                                         all;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may discover that our products have adverse side effects, which could cause our products
                                         to be delayed or precluded from receiving regulatory approval or otherwise expose us
                                         to significant commercial and legal risks;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                         may take longer than expected to determine whether or not a treatment is effective;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
                                         involved in our clinical trials may suffer severe adverse side effects even up to death,
                                         whether as a result of treatment with our products, the withholding of such treatment,
                                         or other reasons (whether within or outside of our control);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may fail to be able to enroll a sufficient number of patients in our clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
                                         enrolled in our clinical trials may not have the characteristics necessary to obtain
                                         regulatory approval for a particular indication or patient population;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may be unable to produce sufficient quantities of product to complete the clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                         if we are successful in our clinical trials, any required governmental approvals may
                                         still not be obtained or, if obtained, may not be maintained;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         approval for commercialization is granted, it is possible the authorized use will be
                                         more limited than is necessary for commercial success, or that approval may be conditioned
                                         on completion of further clinical trials or other activities, which will cause a substantial
                                         increase in costs and which we might not succeed in performing or completing; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         granted, approval may be withdrawn or limited if problems with our products emerge or
                                         are suggested by the data arising from their use or if there is a change in law or regulation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any success we may achieve
at a given stage of our clinical trials does not guarantee that we will achieve success at any subsequent stage, including without
limitation final FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may encounter delays
or rejections in the regulatory approval process because of additional government regulation resulting from future legislation
or administrative action, or from changes in the policies of the FDA or other regulatory bodies during the period of product development,
clinical trials, or regulatory review. Failure to comply with applicable regulatory requirements may result in criminal prosecution,
civil penalties, recall or seizure of products, total or partial suspension of production, or an injunction preventing certain
activity, as well as other regulatory action against our product candidates or us. We have no experience in successfully
obtaining regulatory approval for a product and thus may be poorly equipped to gauge, and may prove unable to manage, risks relating
to obtaining such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Outside the U.S., our ability
to market a product is contingent upon receiving clearances from appropriate non-U.S. regulatory authorities. Non-U.S. regulatory
approval typically includes all of the risks associated with FDA clearance discussed above as well as geopolitical uncertainties
and the additional uncertainties and potential prejudices faced by U.S. pharmaceutical companies conducting business abroad. In
certain cases, pricing restrictions and practices can make achieving even limited profitability very difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have limited experience
in completing regulatory filings and any delays in regulatory filings could materially affect our financial condition.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently initiating
clinical trials of our CaniDermRX product candidates. We have not, however, demonstrated the ability to obtain marketing approvals,
manufacture product candidates at a commercial scale, or conduct sales and marketing activities necessary for the successful commercialization
of a product. Consequently, we have no historical basis as a company by which one can evaluate or predict reliably our future
success or viability.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, while our
team has experience at prior companies with regulatory filings, we have limited experience with regulatory filings
with agencies such as the FDA or the European Medicines Agency, or EMA, and will rely on third-party expertise for this. Any delay
in our regulatory filings for our product candidates, and any adverse development or perceived adverse development with respect
to the applicable regulatory authority&rsquo;s review of such filings, including, without limitation, the FDA&rsquo;s issuance
of a &ldquo;refuse to file&rdquo; letter or a request for additional information, could materially affect our financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If serious adverse or undesirable side
effects are identified during the development of our product candidates, we may abandon or limit our development or commercialization
of such product candidates.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our product candidates
are associated with undesirable side effects or have unexpected characteristics, we may need to abandon their development or limit
development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent,
less severe or more acceptable from a risk-benefit perspective.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we elect or are forced
to suspend or terminate any clinical trial with one of our product candidates, the commercial prospects of such product candidate
will be harmed, and our ability to generate revenue from such product candidate will be delayed or eliminated. Any of these occurrences
may harm our business, financial condition and prospects significantly.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With regard to our lead
product candidate, CaniDermRX, unforeseen side effects from CaniDermRX could arise either during clinical development or, if approved,
after CaniDermRX has been marketed. This could cause regulatory approvals for, or market acceptance of, CaniDermRX harder and
costlier to obtain.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The results of our planned
or any future clinical trials may show that the side effects of CaniDermRX are unacceptable or intolerable, which could interrupt,
delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA or EMA and other regulatory
authorities, or result in marketing approval from the FDA or EMA and other regulatory authorities with restrictive label warnings.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If CaniDermRX receives marketing
approval and we or others later identify undesirable or unacceptable side effects caused by the use of CaniDermRX:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         authorities may withdraw their approval of the product, which would force us to remove
                                         CaniDermRX from the market;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         authorities may require the addition of labeling statements, specific warnings, a contraindication,
                                         or field alerts to physicians and pharmacies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be required to change instructions regarding the way the product is administered,
                                         conduct additional clinical trials or change the labeling of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to limitations on how we may promote the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                         of the product may decrease significantly;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to litigation or product liability claims; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us or our potential future collaborators from achieving or maintaining market acceptance of CaniDermRX and/or could substantially
increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from
the sale of CaniDermRX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we experience delays or difficulties
in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented,
which could materially affect our financial condition.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Identifying, screening and
enrolling patients to participate in clinical trials of our product candidates is critical to our success, and we may not be able
to identify, recruit, enroll and dose a sufficient number of patients with the required or desired characteristics to complete
our clinical trials in a timely manner. The timing of our clinical trials depends on our ability to recruit patients to participate
as well as to subsequently dose these patients and complete required follow-up periods. In particular, because our planned clinical
trials of CaniDermRX are focused on indications with relatively small patient populations, our ability to enroll eligible patients
may be limited or may result in slower enrollment than we anticipate.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we may experience
enrollment delays related to increased or unforeseen regulatory, legal and logistical requirements at certain clinical trial sites.
These delays could be caused by reviews by regulatory authorities and contractual discussions with individual clinical trial sites.
Any delays in enrolling and/or dosing patients in our planned clinical trials could result in increased costs, delays in advancing
our product candidates, delays in testing the effectiveness of our product candidates or in termination of the clinical trials
altogether.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patient enrollment may be
affected if our competitors have ongoing clinical trials with products for the same indications as our product candidates, and
patients who would otherwise be eligible for our clinical trials instead enroll in our competitors&rsquo; clinical trials. Patient
enrollment may also be affected by other factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordination
                                         with clinical research organizations to enroll and administer the clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordination
                                         and recruitment of collaborators and investigators at individual sites;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
                                         of the patient population and process for identifying patients;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
                                         of the clinical trial protocol;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
                                         and exclusion criteria;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
                                         risks and benefits of the product candidates under study;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
                                         of competing commercially available therapies and other competing products&rsquo; clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">time
                                         of year in which the trials are initiated or conducted;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
                                         of the diseases under investigation;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
                                         to obtain and maintain subject consents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
                                         to enroll and treat patients in a timely manner;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk
                                         that enrolled subjects will drop out before completion of the trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
                                         and availability of clinical trial sites for prospective patients;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
                                         to monitor subjects adequately during and after treatment; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
                                         referral practices of physicians.</FONT></TD></TR></TABLE>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our inability to enroll
a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more
clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product
candidates, which could materially affect our financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we or our licensees, development collaborators,
or suppliers are unable to manufacture our products in sufficient quantities or at defined quality specifications, or are unable
to obtain regulatory approvals for the manufacturing facility, we may be unable to develop or meet demand for our products and
lose time to market and potential revenues.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Completion of our clinical
trials and commercialization of our product candidates require access to, or development of, facilities to manufacture a sufficient
supply of our product candidates. We intend to utilize third parties to manufacture CaniSun, CaniSkin and CaniDermRX.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the future we may become
unable, for various reasons, to rely on our sources for the manufacture of our product candidates, either for clinical trials or,
at some future date, for commercial distribution. We may not be successful in identifying additional or replacement third-party
manufacturers, or in negotiating acceptable terms with any we do identify. We may face competition for access to these manufacturers&rsquo;
facilities and may be subject to manufacturing delays if the manufacturers give other clients higher priority than they give to
us. Even if we are able to identify an additional or replacement third-party manufacturer, the delays and costs associated with
establishing and maintaining a relationship with such manufacturer may have a material adverse effect on us.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before we can begin to commercially
manufacture CaniDermRX or any other product candidate, we must obtain regulatory approval of the manufacturing facility and process.
Manufacturing of drugs for clinical and commercial purposes must comply with current Good Manufacturing Practices requirements,
commonly known as &ldquo;cGMP.&rdquo; The cGMP requirements govern quality control and documentation policies and procedures. Complying
with cGMP and non-U.S. regulatory requirements will require that we expend time, money, and effort in production, recordkeeping,
and quality control to ensure that the product meets applicable specifications and other requirements. We, or our contracted manufacturing
facility, must also pass a pre-approval inspection prior to FDA approval. Failure to pass a pre-approval inspection may significantly
delay or prevent FDA approval of our products. If we fail to comply with these requirements, we would be subject to possible regulatory
action and may be limited in the jurisdictions in which we are permitted to sell our products and will lose time to market and
potential revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>It is uncertain whether product liability insurance will be
adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable
terms in the future.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical research involves
the testing of new drugs on human volunteers pursuant to a clinical trial protocol. Such testing involves a risk of liability for
personal injury to or death of patients due to, among other causes, adverse side effects, improper administration of the new drug,
or improper volunteer behavior. Claims may arise from patients, clinical trial volunteers, consumers, physicians, hospitals, companies,
institutions, researchers, or others using, selling, or buying our products, as well as from governmental bodies. In addition,
product liability and related risks are likely to increase over time, in particular upon the commercialization or marketing of
any products by us or parties with which we enter into development, marketing, or distribution collaborations. Although we are
contracting for general liability insurance in connection with our ongoing business, there can be no assurance that the amount
and scope of such insurance coverage will be appropriate and sufficient in the event any claims arise, that we will be able to
secure additional coverage should we attempt to do so, or that our insurers would not contest or refuse any attempt by us to collect
on such insurance policies. Furthermore, there can be no assurance that suitable product liability insurance (at the clinical stage
and/or commercial stage) will continue to be available on terms acceptable to us or at all, or that, if obtained, the insurance
coverage will be appropriate and sufficient to cover any potential claims or liabilities.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>If the market opportunities
for our current and potential future drug candidate</I></B></FONT><FONT STYLE="font-size: 8pt">s </FONT><FONT STYLE="font-size: 10pt"><B><I>are
smaller than we believe they are, our ability to generate product revenues may be adversely affected and our business may suffer.</I></B></FONT></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our understanding of the
number of people who suffer from dermatitis or eczema, whom CaniDermRX may have the potential to treat, is based upon estimates.
These estimates may prove to be incorrect, and new studies may demonstrate or suggest a lower estimated incidence or prevalence
of this condition. The number of patients in the U.S. or elsewhere may turn out to be lower than expected, may not be otherwise
amenable to CaniDermRX treatment, or treatment-amenable patients may become increasingly difficult to identify and access, all
of which would adversely affect our business prospects and financial condition. In particular, the treatable population for CaniDermRX
may further be reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit
from CaniDermRX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to establish relationships
with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective marketing, sales,
and distribution capabilities, we will be unable to market our products successfully.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business strategy may
include out-licensing product candidates to or collaborating with larger firms with experience in marketing and selling pharmaceutical
products. There can be no assurance that we will successfully be able to establish marketing, sales, or distribution relationships
with any third-party, that such relationships, if established, will be successful, or that we will be successful in gaining market
acceptance for any products we might develop. To the extent that we enter into any marketing, sales, or distribution arrangements
with third parties, our product revenues per unit sold are expected to be lower than if we marketed, sold, and distributed our
products directly, and any revenues we receive will depend upon the efforts of such third parties.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we are unable to establish
such third-party marketing and sales relationships, or choose not to do so, we would have to establish in-house marketing and sales
capabilities. To market any products directly, we would have to establish a marketing, sales, and distribution force that has
technical expertise and could support a distribution capability. Competition in the biopharmaceutical industry for technically
proficient marketing, sales, and distribution personnel is intense and attracting and retaining such personnel may significantly
increase our costs. There can be no assurance that we will be able to establish internal marketing, sales, or distribution capabilities
or that these capabilities will be sufficient to meet our needs.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Commercial success of our non-OTC product
candidates will depend on the acceptance of these products by physicians, payers, and patients.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any non-OTC product
candidate that we may develop, such as our current CaniSkin and CaniSun product lines, may not gain market acceptance among physicians
and patients. Market acceptance of and demand for any non-OTC product that we may develop will depend on many factors, including
without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparative
                                         superiority of the effectiveness and safety in the treatment of the disease indication
                                         compared to alternative treatments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                         prevalence and severity of adverse side effects;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
                                         advantages over alternative treatments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
                                         effectiveness;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convenience
                                         and ease of administration;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sufficient
                                         third-party coverage and/or reimbursement;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strength
                                         of sales, marketing and distribution support; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to provide acceptable evidence of safety and efficacy.</FONT></TD></TR></TABLE>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any non-OTC product
candidate developed by us receives regulatory approval but does not achieve an adequate level of market acceptance by physicians,
payers, and patients, we may generate insufficient, little, or no product revenue and may not become profitable. In addition,
pandemics, including the novel coronavirus, COVID-19, could decrease consumer spending and adversely affect demand for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our non-OTC products may not be accepted
for reimbursement or properly reimbursed by third-party payers.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The successful commercialization
of any non-OTC products we might develop will depend substantially on whether the costs of our non-OTC products and related treatments
are reimbursed at acceptable levels by government authorities, private healthcare insurers, and other third-party payers, such
as health maintenance organizations. Reimbursement rates may vary, depending upon the third-party payer, the type of insurance
plan, and other similar or dissimilar factors. If our non-OTC products do not achieve adequate reimbursement, then the number of
physician prescriptions of our products may not be sufficient to make our non-OTC products profitable.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Comparative effectiveness
research demonstrating benefits of a competitor&rsquo;s non-OTC product could adversely affect the sales of our non-OTC product
candidates. If third-party payers do not consider our products to be cost-effective compared to other available therapies, they
may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us
to sell our non-OTC products on a profitable basis.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Adequate third-party reimbursement
may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in the
product development of that non-OTC product. In addition, in the U.S. there is a growing emphasis on comparative effectiveness
research, both by private payers and by government agencies. To the extent other drugs or therapies are found to be more effective
than our non-OTC products, payers may elect to cover such therapies in lieu of our products or reimburse our non-OTC products at
a lower rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The effects of economic and political
pressure to lower pharmaceutical prices are a major threat to the economic viability of new research-based pharmaceutical products,
and any development along these lines could materially and adversely affect our prospects.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Emphasis on managed care
in the U.S. has increased and we expect this will continue to increase the pressure on pharmaceutical pricing. Coverage policies
and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for
one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be
implemented in the future.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any development along these
lines could materially and adversely affect our prospects. We are unable to predict what legislative or regulatory changes relating
to the healthcare industry, including without limitation any changes affecting governmental and/or private or third-party coverage
and reimbursement, may be enacted in the future, or what effect such legislative or regulatory changes would have on our business.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we obtain FDA approval for any of
our product candidates, we will be subject to various federal and state fraud and abuse laws; these laws may impact, among other
things, our proposed sales, marketing and education programs. Fraud and abuse laws are expected to increase in breadth and in detail,
which will likely increase our operating costs and the complexity of our programs to insure compliance with such enhanced laws.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we obtain FDA approval
for any of our product candidates and begin commercializing those products in the U.S., our operations may be directly, or indirectly
through our customers, distributors, or other business partners, subject to various federal and state fraud and abuse laws, including,
without limitation, anti-kickback statutes and false claims statutes which may increase our operating costs. These laws may impact,
among other things, our proposed sales, marketing and education programs.</P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If our operations are found to be in violation of any of the
federal and state fraud and abuse laws or any other governmental regulations that apply to us, we may be subject to criminal actions
and significant civil monetary penalties, which would adversely affect our ability to operate our business and our results of operations.</I></B></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any of the federal and state fraud and abuse laws, including, without limitation, anti-kickback statutes
and false claims statutes or any other governmental regulations that apply to us, we may be subject to penalties, including criminal
and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs,
and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business
and our results of operations. To the extent that any of our product candidates are ultimately sold in a foreign country, we may
be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including
safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or
transfers of value to healthcare professionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We face business disruption and related risks resulting
from the recent pandemic of COVID-19, which could have a material adverse effect on our business plan</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our supply chain and
the development of our product candidates could be disrupted and materially adversely affected by the recent outbreak of COVID-19.
As a result of measures imposed by the governments in affected regions, businesses and schools have been suspended due to quarantines
intended to contain this outbreak. We are still assessing our business plans and the impact COVID-19 may have on our supply chain
and ability to conduct our clinical trials, but there can be no assurance that this analysis will enable us to avoid part or all
of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent
to which the COVID-19 pandemic and global efforts to contain its spread will impact our operations will depend on future developments,
which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic
and the actions taken to contain or treat the COVID-19 pandemic.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Risks Related to our Intellectual Property</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may incur substantial costs as a result
of litigation or other proceedings relating to patent and other intellectual property rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A third party may sue us
or one of our strategic collaborators for infringing its intellectual property rights. Likewise, we may need to resort to litigation
to enforce licensed rights or to determine the scope and validity of third-party intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cost to us of any litigation
or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation
would divert our efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively
than we can because they have substantially greater resources. If we do not prevail in this type of litigation, we or our strategic
collaborators may be required to pay monetary damages; stop commercial activities relating to the affected products or services;
obtain a license in order to continue manufacturing or marketing the affected products or services; or attempt to compete in the
market with a substantially similar product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Uncertainties resulting
from the initiation and continuation of any litigation could limit our ability to continue some of our operations. In addition,
a court may require that we pay expenses or damages, and litigation could disrupt our commercial activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Any inability to protect our intellectual
property rights could reduce the value of our products and brands, which could adversely affect our financial condition, results
of operations and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is partly
dependent upon our trademarks, trade secrets, copyrights and other intellectual property rights. Effective intellectual property
rights protection, however, may not be available under the laws of every country in which we and our sub-licensees may operate.
There is a risk of certain valuable trade secrets, beyond what is described publicly in patents, being exposed to potential infringers.
Regardless of our technology being protected by patents or otherwise, there is a risk that other companies may employ the technology
without authorization and without recompensing us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The efforts we have taken
to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual property rights
could harm our business or our ability to compete. In addition, protecting our intellectual property rights is costly and time
consuming. There is a risk that we may have insufficient resources to counter adequately such infringements through negotiation
or the use of legal remedies. It may not be practicable or cost effective for us to fully protect our intellectual property rights
in some countries or jurisdictions. If we are unable to successfully identify and stop unauthorized use of our intellectual property,
we could lose potential revenue and experience increased operational and enforcement costs, which could adversely affect our financial
condition, results of operations and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The intellectual property behind our
products may include unpublished know-how as well as existing and pending intellectual property protection. All intellectual property
protection eventually expires, and unpublished know-how is dependent on key individuals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 148.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The commercialization of
our licensed products is partially dependent upon know-how and trade secrets held by certain individuals working with and for us.
Because the expertise runs deep in these few individuals, if something were to happen to any or all of them, the ability to properly
manufacture our products without compromising quality and performance could be diminished greatly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Knowledge published in
the form of any future intellectual property has finite protection, as all patents and trademarks have a limited life and an expiration
date. While continuous efforts will be made to apply for patents and trademarks if appropriate, there is no guarantee that additional
patents or trademarks will be granted. The expiration of patents and trademarks relating to our products may hinder our ability
to sub-license or sell our products for a long period of time without the development of a more complex licensing strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are not able to adequately protect
our intellectual property, then we may&nbsp;not be able to compete effectively, and we may&nbsp;not be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our existing proprietary
rights may&nbsp;not afford remedies and protections necessary to prevent infringement, reformulation, theft, misappropriation and
other improper use of our products by competitors.&nbsp;We own the formulations contained in our products and we consider these
product formulations to be our critical proprietary property, which must be protected from competitors. Although trade secret,
trademark, copyright and patent laws generally provide a certain level of protection, and we attempt to protect ourselves through
contracts with manufacturers of our products, we may&nbsp;not be successful in enforcing our rights. In addition, enforcement of
our proprietary rights may&nbsp;require lengthy and expensive litigation. We have attempted to protect some of the trade names
and trademarks used for our products by registering them with the U.S. Patent and Trademark Office, but we must rely on common
law trademark rights to protect our unregistered trademarks. Common law trademark rights do not provide the same remedies as are
granted to federally registered trademarks, and the rights of a common law trademark are limited to the geographic area in which
the trademark is actually used. Our inability to protect our intellectual property could have a material adverse impact on our
ability to compete and could make it difficult for us to achieve a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Risks Related to this Offering and Our
Securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are an &ldquo;emerging growth
company&rdquo; and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make
our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company&rdquo; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; including, but
not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot
predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may
be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 16pt 0 0; text-align: justify; background-color: white"><B><I>The requirements
of being a public company may strain our resources and distract our management, which could make it difficult to manage our business,
particularly after we are no longer an &ldquo;emerging growth company.&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the
completion of this offering, we will be required to comply with various regulatory and reporting requirements, including those
required by the SEC. Complying with these reporting and other regulatory requirements will be time-consuming and will result in
increased costs to us and could have a negative effect on our results of operations, financial condition or business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a public
company, we will be subject to the reporting requirements of the Securities Exchange Act of 1934 (as amended, the &ldquo;Exchange
Act&rdquo;) and the requirements of the Sarbanes-Oxley Act. These requirements may place a strain on our systems and resources.
The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and financial condition.
The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls over financial
reporting. To maintain and improve the effectiveness of our disclosure controls and procedures, we will need to commit significant
resources, hire additional staff and provide additional management oversight. We will be implementing additional procedures and
processes for the purpose of addressing the standards and requirements applicable to public companies. Sustaining our growth also
will require us to commit additional management, operational and financial resources to identify new professionals to join our
firm and to maintain appropriate operational and financial systems to adequately support expansion. These activities may divert
management&rsquo;s attention from other business concerns, which could have a material adverse effect on our results of operations,
financial condition or business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As an &ldquo;emerging
growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain temporary exemptions from various reporting
requirements including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404
of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements. We may also delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements
are made applicable to private companies, as permitted by the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is currently no public market
for our common shares or Warrants and none may develop following this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is currently no public market for our common shares or Warrants. The offering price has been determined by negotiation among us
and the underwriters. We cannot predict the price at which our common shares and Warrants will trade <FONT STYLE="background-color: white">upon
the closing of this offering, and there can be no assurance that an active and liquid trading market will develop after this offering
or, if developed, that such a market will be sustained at the offering price. In addition, if an active public market does not
develop or is not maintained, holders of our common shares </FONT>and Warrants <FONT STYLE="background-color: white">may have
difficulty selling their shares </FONT>and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have broad discretion in the use of
the net proceeds from this offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management will have
broad discretion in the application of the net proceeds and may spend or invest these proceeds in a way with which our stockholders
disagree. The failure by our management to apply these funds effectively could harm our business and financial condition. Pending
their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investors may have difficulty in
reselling their shares and Warrants due to the lack of public market for our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is currently
no public market for our securities. While we intend to apply to list our common stock and Warrants on the Nasdaq Capital Market,
there is no guarantee that our securities will ever trade on any listed exchange or be quoted on the pink sheets, the OTCQB or
the OTCQX marketplaces. If in the future our securities do become tradeable, there is no guarantee that any significant market
for our securities will ever develop. Further, the state securities laws may make it difficult or impossible to resell our shares
in certain states. Accordingly, our securities should be considered highly illiquid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will be subject to penny stock regulations
and restrictions and you may have difficulty selling shares of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The SEC has adopted regulations
which generally define so-called &ldquo;penny stocks&rdquo; to be an equity security that has a market price less than $5.00 per
share or an exercise price of less than $5.00 per share, subject to certain exemptions. Our common stock is a &ldquo;penny stock&rdquo;,
and we are subject to Rule 15g-9 under the Exchange Act, or the &ldquo;Penny
Stock Rule&rdquo;. This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons
other than established customers. For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination
for the purchaser and have received the purchaser&rsquo;s written consent to the transaction prior to sale. As a result, this rule
may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities
in the secondary market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For any transaction involving
a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule prepared
by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the
broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required
to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in
penny stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Absent continuing listing
on the NASDAQ Capital Market, we do not anticipate that our common stock will qualify for exemption from the Penny Stock Rule.
In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the
Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if
the SEC finds that such a restriction would be in the public interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our management has limited experience
in managing the day- to-day operations of a public company and, as a result, we may incur additional expenses associated with the
management of our Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The management team is
responsible for the operations and reporting of the Company. The requirements of operating as a public company are many and sometimes
difficult to navigate. This may require us to obtain outside assistance from legal, accounting, investor relations, or other professionals
that could be more costly than planned. If we lack cash resources to cover these costs of being a public company in the future,
our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price
and adversely affect our potential results of operations, cash flow and financial condition after we commence operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Compliance with changing corporate governance
regulations and public disclosures may result in additional risks and exposures.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Changing laws, regulations
and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and new regulations
from the SEC, have created uncertainty for public companies such as ours. These laws, regulations, and standards are subject to
varying interpretations in many cases, and as a result, their application in practice may evolve over time as new guidance is provided
by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations,
and standards have resulted in, and are likely to continue to result in, increased expense and significant management time and
attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Certain of our stockholders hold a significant
percentage of our outstanding voting securities, which could reduce the ability of minority stockholders to effect certain corporate
actions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our officers and directors
are the beneficial owners of approximately 65% our outstanding voting securities. As a result, they possess significant influence
over our elections and votes. As a result, their ownership and control may have the effect of facilitating and expediting a future
change in control, merger, consolidation, takeover or other business combination, or encouraging a potential acquirer to make
a tender offer. Their ownership and control may also have the effect of delaying, impeding, or preventing a future change in control,
merger, consolidation, takeover or other business combination, or discouraging a potential acquirer from making a tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If securities or industry analysts publish
inaccurate or unfavorable research about our business, our stock price could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading market for
our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our
business. Once our common stock is quoted, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate
or unfavorable research about our business, our common stock price would likely decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Warrants are speculative in nature.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Warrants offered
hereby do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends,
but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date
of issuance, holders of the Warrants may exercise their right to acquire the common stock and pay an exercise price of $8.50,
or 113% of the public offering price of a Unit. Moreover, following this offering, the market value of the Warrants is uncertain
and there can be no assurance that the market value of the Warrants will equal or exceed their public offering price. Furthermore,
each Warrant will expire [&bull;] years from the original issuance date. In the event our common stock price does not exceed the
exercise price of the Warrants during the period when the Warrants are exercisable, the Warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Holders of the Warrants will have
no rights as a common stockholder until they acquire our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until you acquire shares
of our common stock upon exercise of your Warrants, you will have no rights with respect to shares of our common stock issuable
upon exercise of your Warrant. Upon exercise of your Warrant, you will be entitled to exercise the rights of a common stockholder
as to the security exercised only as to matters for which the record date occurs after the exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is no established market for
the Warrants to purchase shares of our common stock being offered in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no established
trading market for the Warrants and we do not expect a market to develop. Although we have applied to list the Warrants on The
NASDAQ Capital Market there can be no assurance that there will be an active trading market for the warrants. Without an active
trading market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Provisions of the Warrants offered
by this prospectus could discourage an acquisition of us by a third party.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the
discussion of the provisions of our certificate of incorporation, our bylaws, certain provisions of the Warrants offered by this
prospectus could make it more difficult or expensive for a third party to acquire us. The Warrants prohibit us from engaging in
certain transactions constituting &ldquo;fundamental transactions&rdquo; unless, among other things, the surviving entity assumes
our obligations under the Warrants. These and other provisions of the Warrants offered by this prospectus could prevent or deter
a third party from acquiring us even where the acquisition could be beneficial to you.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not intend to pay dividends for
the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently intend to
retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends
on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Purchasers of our common stock may experience
immediate dilution and/or future dilution.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Investors purchasing
shares in this offering will incur an immediate and substantial dilution in the net tangible book value per share of $6.64&nbsp;from
the initial public offering price of $7.50 per Unit (See the &ldquo;Dilution&rdquo; section of this prospectus). We are authorized
to issue up to 100,000,000 shares of common stock, of which 6,893,000 shares were issued and outstanding as of December 31, 2019.
In addition, there are 1,158,000 warrants outstanding to purchase shares of common stock at $0.50 per share which expire on November
1, 2020. Our Board has the authority to cause us to issue additional shares of common stock without consent of any of our stockholders
and there are is a class of preferred stock that may be converted to common stock. Consequently, the common stockholders may experience
dilution in their ownership of our stock in the future and as a result of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B><I>Our Second Amended and Restated Certificate of Incorporation
contains an exclusive forum provision for certain claims, which could limit our stockholders' ability to obtain a favorable judicial
forum for disputes with us or our directors, officers or employees.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Our Second Amended and Restated Certificate
of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, New York shall be the sole
and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Company, (b) any action asserting a claim
for breach of a fiduciary duty owed by any director, officer, employee, or agent of the Company to the Company or the Company&rsquo;s
shareholders or (c) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said court
having personal jurisdiction over the indispensable parties named as defendants therein. This provision may limit a shareholder's
ability to bring a claim in a judicial forum that it finds favorable for disputes with the company and its directors, officers,
or other employees and may discourage lawsuits with respect to such claims. This provision does not apply to actions arising under
the Exchange Act or Securities Act, except to the extent Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over
all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="CautionaryNote"></A><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus contains
forward-looking statements. Such statements include statements regarding our expectations, hopes, beliefs or intentions regarding
the future, including but not limited to statements regarding our market, strategy, competition, development plans (including acquisitions
and expansion), financing, revenues, operations, and compliance with applicable laws. Forward-looking statements involve certain
risks and uncertainties, and actual results may differ materially from those discussed in any such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus contains
forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections
about future events and financial trends affecting the financial condition of our business. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions, including, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Factors that might cause
these differences include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will need a significant amount of capital to carry out our proposed business plan and,
                                         unless we are able to raise sufficient funds or generate sufficient revenues, we may
                                         be forced to discontinue our operations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we are unable to keep up with rapid technological changes, our products may become obsolete.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we are unable to develop and maintain our brand and reputation for our product offerings,
                                         our business and prospects could be materially harmed.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         are subject to government regulation, and unfavorable changes could substantially harm
                                         our business and results of operations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         depend heavily on key personnel, and turnover of key senior management could harm our
                                         business.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         do not have and may never have any approved products on the market. Our business is highly
                                         dependent upon receiving approvals from various U.S. and International governmental agencies
                                         and will be severely harmed if we are not granted approval to manufacture and sell our
                                         product candidates.</FONT></TD></TR>                            <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
                                         success of our non-OTC product candidates will depend on the acceptance of these products
                                         by physicians, payers, and patients.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laws
                                         and regulations affecting the CBD industry are evolving under the Farm Bill, FDA and
                                         other regulatory authorities and changes to any regulation may materially affect our
                                         products containing hemp-derived CBD oil.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible
                                         yet unanticipated changes in federal and state law could cause any of our current products,
                                         as well as products that we intend to launch, containing hemp-derived CBD oil to be illegal,
                                         or could otherwise prohibit, limit or restrict any of our products containing CBD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible
                                         decrease in supply and demand of our products due to global pandemics, such as the novel
                                         coronavirus, COVID-19.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All forward-looking statements
in this document are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation
to update any forward-looking statement, whether as a result of new information, future events or otherwise after the date of this
prospectus, except where applicable law requires us to update these statements. Market data used throughout this prospectus is
based on published third party reports or the good faith estimates of management, which estimates are based upon their review of
internal surveys, independent industry publications and other publicly available information. In light of these risks and uncertainties,
the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially
from those anticipated or implied in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, in this prospectus,
we use words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;future,&rdquo;
&ldquo;intend,&rdquo; and similar expressions to identify forward-looking statements.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="UseOfProceeds"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect the net proceeds from this offering to be approximately
$6,450,000, or approximately $7,485,000 if the underwriters exercise their option to purchase additional shares in full, assuming
an initial public offering price of $7.50 per Unit and after deducting estimated underwriting discounts and commissions and estimated
offering expenses of approximately $337,500, in the aggregate, as well as a 1.5% non-accountable expense allowance of $112,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase
(decrease) in the assumed initial public offering price of $7.50&nbsp;per Unit would increase (decrease) the net proceeds to us
by approximately $1,000,000, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus,
remains the same, and after deducting the estimated underwriting discounts and commissions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to use the net
proceeds from this offering as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniDermRX product candidate for the treatment of eczema- $2,355,000<SUP>1</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniDermRX product candidate for the treatment of burns and skin cancer - $250,000<SUP>2</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniSun SPF 30 Lip Balm - $5,000<SUP>3</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniSun sunscreen lotions (SPF 30, 50 and 55) - $8,000<SUP>3</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniSun mineral-based sunscreen lotions (SPF 30 and 50) - $16,000<SUP>3</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniSun CBD-infused SPF 15 sunscreen lotion - $7,500<SUP>3</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of CaniSkin CBD-infused moisturizing face serum - $5,000<SUP>3</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payroll
                                         and external labor costs - $250,000</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
                                         Capital - $2,553,500</FONT></TD></TR>                                                                              <TR STYLE="vertical-align: top">
<TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition
                                         of Magical Beasts LLC - $1,000,000<SUP>4</SUP></FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
                                         </SUP>Includes the costs of performing and completing the development and testing of
                                         the CaniDermRX product candidate for the treatment of eczema. Includes preparation and
                                         testing for a pre-IND application and submission, as well as phase I and II clinical
                                         trials for the treatment of eczema. We believe that the proceeds from this offering will
                                         allow us to complete the Phase I/II clinical trial for this product candidate.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
                                         </SUP>We believe that the proceeds from this offering will allow us to establish collaborative
                                         research programs and complete preclinical development of this product candidate.</FONT></P>



</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
                                         </SUP>We believe that the proceeds from this offering will allow us to complete formulation
                                         and development of the product candidate.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="text-align: justify"> <SUP>4</SUP>As part of the consideration paid to acquire Magical
                              Beasts, LLC (see &ldquo;Recent Developments&rdquo; on page 32) we issued a non-interest bearing promissory note
                              payable at the earlier of a) the closing of any initial public offering of the Company or b) December
                              31, 2020. For financial reporting purposes, the note was discounted at an annual rate of 12% and
                              recorded as $950,427 on the closing date. </TD></TR>
</TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that the
proceeds from this offering dedicated to product development will allow us to complete our intended clinical study of its CaniDermRX
treatment for atopic dermatitis (eczema). The estimated use of proceeds is preliminary and subject to change. We cannot specify
with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering. Due to uncertainties
inherent in the development process of our OTC products and non-OTC products, it is difficult to estimate the exact amount of
net proceeds that will be used for any particular purpose. The amount, allocation and timing of our actual expenditures will depend
upon numerous factors, including the results of our research and development efforts and the timing of regulatory submissions.
Accordingly, we will have broad discretion in using these net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pending the use of the
net proceeds of this offering, we plan to invest the net proceeds from this offering in short-term, interest-bearing, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We would receive additional
gross proceeds of $8,500,000 if all of the Warrants included in the Units are exercised, assuming no exercise of the underwriters&rsquo;
over-allotment option. We intend to use any such proceeds for working capital and general corporate purposes. General corporate
purposes may include capital expenditures.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will pay all of our
own expenses and certain expenses of the underwriters related to this offering. See &ldquo;Underwriting&rdquo; on page 44.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="DividendPolicy"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Holders of common stock
are entitled to receive ratably such dividends, if any, as may be declared by the Board out of funds legally available. We have
not paid any dividends since our inception, and we presently anticipate that all earnings, if any, will be retained for development
of our business. Any future disposition of dividends will be at the discretion of our Board and will depend upon, among other
things, our future earnings, operating and financial condition, capital requirements, and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="Capitalization"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
sets forth our cash and cash equivalents as of March 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an adjusted basis after giving effect to the sale of Units
    in this offering at an assumed initial offering price of $7.50&nbsp;per Unit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should read the following
table in conjunction with the &ldquo;Use of Proceeds&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; sections of this prospectus and our consolidated financial statements and related notes
appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    of March 31, 2020</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual</FONT></P>
                                                                               <P STYLE="margin-top: 0; margin-bottom: 0">(unaudited)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)<SUP>(1)(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 58%; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">358,997</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,008,997</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,611</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,611</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock,
    par value $0.001 per share, 100,000 shares authorized, 0 outstanding</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock,
    par value $0.001 per share, 100,000,000 shares authorized, 6,893,000 shares outstanding (actual), 7,893,000 shares outstanding
    (pro forma)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,893</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Common
    stock payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in
    capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,236,282</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,885,282</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,466,994</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,466,994</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stockholder&rsquo;s
    equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,181</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,751,180</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total capitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034,792</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,684,792</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">1.</TD>
    <TD STYLE="width: 95%; text-align: justify">Pro forma amounts reflect the sale of 1,000,000&nbsp;shares of our common stock
    included in the Units to be sold in this offering at an assumed initial public offering price of $7.50 per Unit, and after
    deducting the estimated underwriting discounts and commissions and estimated offering expenses and assumes no exercise by
    the underwriters of their option to purchase 150,000 additional shares of common stock and/or 150,000 Warrants to cover over-allotments.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>2.</TD>
    <TD>Assumes no exercise of the Warrants included in the Units.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase
(decrease) in the assumed initial public offering price of $7.50&nbsp;per Unit would increase (decrease) the net proceeds to us
by approximately $1,000,000, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus,
remains the same, and after deducting the estimated underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the
underwriters exercise their option to purchase additional shares in full, pro forma cash, additional paid-in capital, total
stockholders&rsquo; (deficit) equity, total capitalization and shares of common stock outstanding as of March 31, 2020 would
be $8,021,479, $8,897,632, $7,763,681 and 8,043,000&nbsp;shares, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="Dilution"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you invest in
our Units in this offering, your interest will be diluted to the extent of the difference between the initial public offering
price per Unit and the pro forma net tangible book value per share of our common stock immediately after this offering. The
net tangible book value of our common stock as of March 31, 2020 was $125,075,&nbsp;or $0.02 per share. Net tangible book
value per share represents our total tangible assets (which were $2,052,530 at March 31, 2020 less our total liabilities,
divided by the number of shares of outstanding common stock (after adjusting for the stock split of the shares of existing
stockholders).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After giving effect to the receipt of the net proceeds from our sale
of Units in this offering, at an assumed initial public offering price of $7.50 per Unit, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses, our pro forma net tangible book value as of March 31, 2020 would have
been approximately $6,775,075 or $0.086&nbsp;per share. This amount represents an immediate increase in pro forma net tangible
book value of $0.84 per share to our existing stockholders and an immediate dilution of $6.64 per share to new investors participating
in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We determine dilution
per share to investors participating in this offering by subtracting pro forma net tangible book value per share after this offering
from the assumed initial public offering price per Unit paid by investors participating in this offering. The following table
illustrates this dilution on a per share basis to new investors:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 71%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed initial public
    offering price per Unit</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.50</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per share as of March
    31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.02</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase per share to existing stockholders
    attributable to investors in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.84</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro forma net tangible book value per share,
    to give effect to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.86</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution in net tangible book value per share
    to new investors in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.64</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase
(decrease) in the assumed initial public offering price of $7.50&nbsp;per Unit would increase (decrease) the net proceeds to us
by approximately $1,000,000, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus,
remains the same, and after deducting the estimated underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The pro forma information
discussed above is illustrative only and will change based on the actual initial public offering price, number of shares and other
terms of this offering determined at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the underwriters
exercise their option to purchase additional shares of common stock and/or Warrants to purchase additional shares of common stock
in this offering in full at the assumed initial public offering price of $7.50 per Unit and assuming the number of Units offered
by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses, the pro forma net tangible book value would be approximately $0.97 per share,
and the dilution in pro forma net tangible book value per share to investors in this offering would be approximately $6.53 per
share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The table below
summarizes as of March 31, 2020, adjusted pro forma basis described above, the number of shares of our common stock, the
total consideration and the average price per share (i) paid to us by existing stockholders and (ii) to be paid by new
investors purchasing Units in this offering at an assumed initial public offering price of $7.50 per Unit, before deducting
underwriting discounts and commissions and estimated offering expenses.</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Shares
    Purchased</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Total
    Consideration</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Number</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Percent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Amount
    </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Percent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Average
    Price Per Share</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Existing stockholders</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87.33%&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,006,500&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.83%&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.15&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">New investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.67%&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$7,500,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88.17%&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.50&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,893,000&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.00%&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$8,506,500&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;100.00%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.08&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, if the
underwriters exercise their option to purchase additional shares of common stock and/or Warrants to purchase shares of common
stock in full, the percentage of&nbsp;shares held by existing stockholders will be reduced to&nbsp;85.70% of the total number
of shares of common stock to be outstanding upon the closing of this offering, and the number of shares of common stock held by
new investors participating in this offering will be further increased by 150,000 shares, or 14.30% of the total number of shares
of common stock to be outstanding upon the closing of this offering.</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase
(decrease) in the assumed initial public offering price of $7.50&nbsp;per Unit would increase (decrease) the net proceeds to us
by approximately $1,000,000, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus,
remains the same, and after deducting the estimated underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total number of shares
of our common stock reflected in our actual and pro forma information set forth in the table above excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&bull;</TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
                                         by the underwriters of their option to purchase 150,000 additional
shares of common stock and/or 150,000 Warrants to cover over-allotments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&bull;</TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,158,000
                                         shares of common stock exercisable at $0.50 per share under outstanding warrants which
                                         expire on November 1, 2020;</FONT></TD></TR>                                                                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&bull;</TD><TD STYLE="text-align: justify">Exercise of the Warrants included in the Units; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&bull;</TD><TD STYLE="text-align: justify">Conversion of outstanding convertible promissory notes.</TD></TR>
</TABLE>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="DescriptionOfCapitalStock"></A>DESCRIPTION
OF CAPITAL STOCK<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><I>The
following description of our capital stock and the provisions of our second amended and restated certificate of incorporation
and our amended and restated bylaws are summaries and are qualified by reference to the second amended and restated
certificate of incorporation and the amended and restated bylaws. We have filed copies of these documents with the SEC as
exhibits to our registration statement of which this prospectus forms a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our authorized capital
stock consists of 100,000,000 shares of common stock, par value $0.001 per share, and 100,000 shares of preferred stock, par value
$0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Common stock outstanding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">As of March 31,
2020, there were 6,893,000 shares of our common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Voting rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Subject to the rights
granted to holders of any preferred stock issued by us, each share of common stock entitles the holder to one vote, either in
person or by proxy, at meetings of stockholders. The holders are not permitted to vote their shares cumulatively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Dividend rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Subject to the rights
granted to holders of any preferred stock issued by us, holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared by the Board out of funds legally available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rights upon liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Subject to the rights
granted to holders of any preferred stock issued by us, upon our liquidation, dissolution or winding up, the holders of our common
stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment
of all of our debts and other liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Other rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Holders of our common stock do not have any
pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Under the terms of
our second amended and restated certificate of incorporation, our Board is authorized to issue shares of preferred stock in one
or more series without stockholder approval.&nbsp;&nbsp;Our Board has the discretion to determine the rights, preferences, privileges
and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences,
of each series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The purpose of authorizing
our Board to issue preferred stock and determination its rights and preferences is to eliminate delays associated with a stockholder
vote on specific issuances.&nbsp;&nbsp;The issuance of preferred stock, while providing flexibility in connection with possible
acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party
to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2018 and 2019,
the Company conducted a private placement in which it entered into individual subscription agreements with certain investors for
the sale of units at a price per unit of $0.25, with each unit consisting of one share of common stock and one two-year warrant
to purchase one share of common stock at an exercise price of $0.50 per share. During the fourth quarter of 2018, we sold 958,000
units. During the year ended December 31, 2019, we sold 200,000 additional units. As of March 31, 2020, the total warrants outstanding was 1,158,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2019, four
of our Directors, Dr. Alila, Mr. Glynn, Mr. Melton and Mr. Young, each entered into an Independent Director&rsquo;s
Agreement. In connection with the agreements, the Directors were granted stock options to purchase a total of 141,330 shares
of the Company&rsquo;s common stock. The exercise price ranges from $0.25 to $3.00 and are exercisable for three years from
the date of grant. The fair value of these options was measured using the Black-Scholes
valuation model at the grant date. The relative fair value of the 2019 options totals $32,904.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>







<P STYLE="font: 10pt TimesNewRomanPSStd-Bold,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: TimesNewRomanPSStd-Bold,serif">During
the three months ended March 31, 2020, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">the Directors were granted
stock options to purchase a total of an additional 83,330 shares of the Company&rsquo;s common stock</FONT><FONT STYLE="font-family: TimesNewRomanPSStd-Bold,serif">.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The relative fair value of the 2020 options totals $47,159. </FONT></P>

<P STYLE="font: 10pt TimesNewRomanPSStd-Bold,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt TimesNewRomanPSStd-Bold,serif; margin: 0"><B>Anti-Takeover Effects</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our second amended
and restated certificate of incorporation and amended and restated bylaws will include a number of provisions that may have the
effect of delaying, deferring or preventing a party from acquiring control of us and encouraging persons considering unsolicited
tender offers or other unilateral takeover proposals to negotiate with our Board rather than pursue non-negotiated takeover attempts.
The provisions include the items described below.</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0"><B><I>Potential Effects of Authorized but Unissued
Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have shares
of common stock available for future issuance without stockholder approval. We may utilize these additional shares for a variety
of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or
payment as a dividend on the capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The existence of unissued
and unreserved common stock and preferred stock may enable our Board to issue shares to persons friendly to current management
or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control
of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In
addition, our Board has the discretion to determine designations, rights, preferences, privileges and restrictions, including
voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred
stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth
in our second amended and restated certificate of incorporation. The purpose of authorizing the Board to issue preferred stock
and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder
vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible
financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to
acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0"><B><I>Limitations of Director Liability and Indemnification
of Directors, Officers and Employees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular,serif">Our
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">second amended and restated certificate of incorporation </FONT><FONT STYLE="font-family: TimesNewRomanPSStd-Regular,serif">limits
the liability of directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation
will not be personally liable for monetary damages for breach of their fiduciary duties as directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended
and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify
employees and other agents. Our amended and restated bylaws also provide that we are obligated to advance expenses incurred by
a director or officer in advance of the final disposition of any action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently do not have a policy
of directors&rsquo; and officers&rsquo; liability insurance but intend to obtain such a policy in the near future.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended and
restated bylaws, subject to the provisions of Delaware Law, contain provisions which allow the corporation to indemnify any
person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated
legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he or
she reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under
the Securities Act of 1933 as amended, or the Securities Act, may be permitted to our directors, officers and controlling
persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The limitation
of liability and indemnification provisions in our amended and restated bylaws may discourage stockholders from bringing a lawsuit
against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors
and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations
and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers
pursuant to these indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At present,
there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required
or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0"><B><I>Requirements for Advance Notification of Stockholder
Nominations and Proposals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals
and nomination of candidates for election as directors.</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0; text-align: justify"><B><I>Limits on Special Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Special meetings may
be called for any purpose and at any time by the Chairman of the Board, the President (if there be one) or by any member of the
Board. Business transacted at each special meeting shall be confined to the purposes stated in the notice of such meeting.</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0; text-align: justify"><B><I>Election and Removal of
Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board is elected
annually by our stockholders. The number of directors that shall constitute the whole Board shall not be less than three (3) nor
more than seven (7) directors. Directors are elected by a plurality of the votes of shares of our capital stock present in person
or represented by proxy at a meeting and entitled to vote in the election of directors. Each director shall hold office until
a successor is duly elected and qualified or until his or her earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Newly created directorships
resulting from any increase in the number of directors or any vacancies in the Board resulting from death, resignation, retirement,
disqualification, removal from office or any other cause may be filled, so long as there is at least one remaining director, only
by the Board, provided that a quorum is then in office and present, or by a majority of the directors then in office, if less
than a quorum is then in office, or by the sole remaining director. Directors elected to fill a newly created directorship or
other vacancies shall hold office until such director&rsquo;s successor has been duly elected and qualified or until his or her
earlier death, resignation or removal as hereinafter provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any director may be
removed from office at any time for cause, at a meeting called for that purpose, but only by the affirmative vote of the holders
of at least 66-2/3% of the voting power of all outstanding shares of our capital stock entitled to vote generally in the election
of directors, voting together as a single class.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
second amended and restated certificate of incorporation and amended and restated bylaws do not provide for cumulative voting
in the election of directors.</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-BoldIt,serif; margin: 12pt 0 0; text-align: justify"><B><I>Amendments to Our Governing
Documents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The affirmative vote
of the holders of at least 66-2/3% of the voting power of all outstanding shares of our capital stock entitled to vote generally
in the election of directors, shall be required to adopt any provision inconsistent with, to amend or repeal any provision of,
or to adopt a bylaw inconsistent with,&nbsp;Articles Two,&nbsp;Seven, Eight&nbsp;and&nbsp;Nine&nbsp;of our Second Amended and
Restated Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended and restated bylaws may be amended or repealed and new bylaws may be adopted by the stockholders
and/or the Board. Any bylaws adopted, amended or repealed by the Board may be amended or repealed by the stockholders.</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Bold,serif; margin: 12pt 0 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to apply
to list our common stock and Warrants on the Nasdaq Capital Market under the symbols &ldquo;JUPW&rdquo; and &ldquo;JUPWW&rdquo;.
No assurance can be given that our application will be approved.</P>



<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Bold,serif; margin: 12pt 0 0; text-align: justify"><B>Transfer Agent, Warrant
Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The transfer agent
and registrar for our common stock and warrant agent for the Warrants offered in this offering is VSTOCK Transfer,
LLC.&nbsp;</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular,serif; margin: 8pt 0 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular,serif; margin: 8pt 0 0; text-indent: 24pt"></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B><A NAME="DescriptionOfSecuritiesWeAreOffering"></A>DESCRIPTION OF SECURITIES WE ARE
OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are offering the Units
at the initial offering price of $7.50 per Unit. Each Unit consists of one share of our common stock and a Warrant to purchase
one share of our common stock at an exercise price equal to $8.50, which is 113% of the public offering price of the Units. The
shares of common stock and Warrants may be transferred separately immediately upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The material terms and
provisions of our common stock are described under the caption &ldquo;Description of Our Capital Stock&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Warrants to Be Issued in the Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following summary of
certain terms and provisions of the Warrants offered hereby is not complete and is subject to, and qualified in its entirety by,
the provisions of the warrant agent agreement between us and VStock Transfer, LLC, as warrant agent, and the form of Warrant, both
of which are filed as exhibits to the registration statement of which this prospectus is a part. Prospective investors should carefully
review the terms and provisions set forth in the warrant agent agreement, including the annexes thereto, and form of Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Exercisability. </I>The
Warrants are exercisable at any time after their original issuance and at any time up to the date that is five years after their
original issuance. The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly
executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying
the warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration
under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the
number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares
of common stock underlying the Warrants under the Securities Act is not effective or available and an exemption from registration
under the Securities Act is not available for the issuance of such shares, the holder may, in its sole discretion, elect to exercise
the Warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of
common stock determined according to the formula set forth in the Warrant. No fractional shares of common stock will be issued
in connection with the exercise of a Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the
fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Exercise Limitation</I>.
A holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially
own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease
such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective
until 61 days following notice from the holder to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Exercise Price. </I>The
exercise price per whole share of common stock purchasable upon exercise of the Warrants is $8.50 per share, which is 113% of public
offering price of the common stock. The exercise price is subject to appropriate adjustment in the event of certain stock dividends
and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon
any distributions of assets, including cash, stock or other property to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Transferability. </I>Subject
to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Exchange Listing.
</I>We have applied list our common stock and the Warrants on The NASDAQ Capital Market under the symbols &ldquo;JUPW,&rdquo;
and &ldquo;JUPWW,&rdquo; respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Warrant Agent</I>. The
Warrants will be issued in registered form under a warrant agent agreement between VStock Transfer, LLC, as warrant agent, and
us. The Warrants shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian
on behalf of The Depository Trust Company (DTC) and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise
directed by DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Fundamental Transactions.
</I>In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common
stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock,
the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or
other property that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Rights as a Stockholder.
</I>Except as otherwise provided in the Warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the
holder of a Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until
the holder exercises the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Governing Law</I>.&nbsp;The
Warrants and the warrant agent agreement are governed by&nbsp;New York&nbsp;law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Representative&rsquo;s Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Please see &ldquo;Underwriting
&mdash; <FONT>Underwriters&rsquo;</FONT> Warrants&rdquo; for a description of the warrants we
have agreed to issue to the representative of the underwriters in this offering, subject to the completion of the offering. We
expect to enter into a warrant agreement in respect of the representative&rsquo;s warrants prior to the closing of this offering.&nbsp;</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular,serif; margin: 8pt 0 0; text-indent: 24pt"></P></DIV>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular,serif; margin: 8pt 0 0; text-indent: 24pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="MDA"></A><B>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with the section titled &ldquo;Selected
Consolidated Financial and Other Data&rdquo; and the consolidated financial statements and related notes thereto included elsewhere
in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results
could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are
not limited to, those identified below and those discussed in the section titled &ldquo;Risk Factors&rdquo; included elsewhere
in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a cutting-edge
wellness CBD consumer product development company. We are in the early stage of manufacturing, distributing, and marketing a diverse
line of consumer products infused with hemp-derived cannabidiol or CBD. We have a proprietary, trademarked line of products: CaniSun,
CaniSkin and CaniDermRX. Under the CaniSun brand name, we are marketing three proprietary CBD-infused sun care lotion formulas
containing various SPF&rsquo;s that we have developed using our own intellectual property rights. Under the CaniDermRX brand,
we are exploring formulations of CBD with over-the-counter, or OTC, consumer products that have potentially therapeutic and medical
applications. Specifically, we are exploring the use of such topical solutions for the treatment of eczema, dermatitis, and actinic
keratosis, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores, and a prescription product for the
treatment of burns. The CaniDermRX topical solution for the treatment of eczema dermatitis is the lead product candidate and will
be initially tested in humans as an investigational cosmetic ingredient followed by clinical trials subject to the regulations
of the FDA under an investigational new drug, or IND, application. In parallel, we plan to initiate the development of other products.
We are also actively seeking to acquire or license products in the OTC skin care market that can be infused with CBD and marketed
under our CaniSkin and CaniDermRX brand names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There can be no assurances
that we will acquire or enter into such partnership or licensing agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The endocannabinoid system,
which is a body system affected by CBD, plays a pivotal role in maintaining a healthy skin through modulating pain sensation,
cell proliferation and inflammation. Our strategy for treatment of skin indications is, therefore, to focus on the use of CBD
containing topical formulations and to explore potential combinations of CBD and other agents that may augment and act synergistically
with CBD. We will explore this strategy by conducting controlled clinical trials to try to ultimately gain FDA approval for specific
indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>CaniSun Brand</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We developed a CBD-infused
sunscreen with broad-spectrum SPF protection. We have completed lab testing for CBD solubility-infusing clear, colorless, odorless,
and 99.5% pure CBD isolated with three different sun care active ingredients, homosalate, octisalate and octocrylene, which have
already been approved by the FDA. The CBD-infused sun care market is fairly nascent in the United States; we believe that there
are currently no major competitors in the category. We see an opportunity to become the leading manufacturer of CBD-infused sun
care products, marketing the CaniSun brand through an extensive digital and social media awareness campaign. We announced the
launch of our CaniSun sun care line of SPF 30, SPF 50 and SPF 55 face lotion on June 6, 2019. We also sell our CBD-infused lip
balm and CBD-infused SPF 30 sunscreen spray on our website Canisun.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently have additional
CaniSun products in various stages of development as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 30 Lip Balm; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 15 sunscreen lotion; and</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Mineral-based
                                         sunscreen lotions (SPF 30 and 50).</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the products
listed above are in the developmental stage, whereby we are finalizing the formula to be used in each product, respectively. For
CBD-infused product candidates in development, such as our CBD-infused SPF 30 Lip Balm and CBD-infused SPF 15 sunscreen lotion,
we have already identified the sun care active ingredient formula (which has already been FDA approved) to be infused with CBD.
Once the respective formulas for each of our products are created, the product candidates will undergo three months of stability
testing. Provided that the product candidates pass the stability testing, we intend to sell the products on our CaniSun website.
The formula for our mineral-based sunscreen lotion (SPF 30 and 50) (product iii) above) includes certain minerals instead of chemicals
typically used in sunscreen lotions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Overall, we believe
that our currently offered sunscreen products comply with the FDA Final Rule for sunscreen products under 21 CFR 352 Sunscreen
products for Over-the-Counter Human Use. Therefore, we believe that our sunscreen products fall within the FDA monograph and that
premarket approval and testing is not required. Our products have been tested for SPF Evaluation (SPF rating), Critical Wave Length
(Broad Spectrum claim) and Water Resistance, each of which is defined within the monograph and labeled accordingly.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the test on
these products is standard testing for suncare products. Such testing protocols are not intended to test for any effects of adding
CBD. In addition to these tests that were conducted to support the claims on the package, each batch is also tested for appearance,
color, odor, pH, viscosity, specific gravity, analytical for the sunscreen active ingredients, and microbial content testing.</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are
tested each time they are manufactured. DCR Labs manufactures our products and has represented to us that it is compliant
with the FDA&rsquo;s Current Good Manufacturing Practice, or &ldquo;CGMP&rdquo;, regulations in accordance with 21 CFR
210/211 required for Over-the-Counter drug products. DCR Labs has self-imposed health and safety standards to ensure
compliance with the FDA&rsquo;s CGMPs.</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to continually
update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis. CBDBrands.net
is our primary corporate website, which will serve as the primary source of information about us for investors and contain press
releases, clinical trial pipeline, lab reports, blog posts, and additional information about each of our brands. We anticipate
that each brand will have its own front-facing website dedicated to retail sales and brand specific information. For example,
our line of sun care products, CaniSun, has its own website at CaniSun.com and allows for online retail purchase of the entire
product line. As we expand our brands (CaniSkin and CaniDermRX), we anticipate utilizing the same strategy and dedicating a new
e-commerce website to each brand moving forward. We are also building a website dedicated to servicing our wholesale and larger
distributor clients. This website will have more information about each product and provide a central location for larger retailers
to find more in-depth information about all of our brands in one place. We plan to leverage our websites with a social media presence
across multiple platforms designed to utilize product reviews to increase brand loyalty, brand recognition and sales. The references
to our website in this prospectus are inactive textual references only. The information on our website is neither incorporated
by reference into this prospectus nor intended to be used in connection with this offering. We also see growth potential in developing
retail locations. We intend to utilize cross-promotion marketing campaigns with our products and product category expansion that
leverages our existing distribution channels. We have built an e-commerce platform designed to connect us directly to consumers.
We use the platform to sell products, educate customers and build brand loyalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>CaniSkin
Brand and CaniDermRX Brand</U></I></P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently developing
other products such as CBD-infused skin care lotion under the CaniSkin brand. Specifically, a CBD-infused moisturizing face serum
is under development. We must first finalize the formula to be used in the face serum, and, once approved, the product candidate
will undergo stability testing. We intend to sell the product, provided it first passes stability testing, on our website for
CaniSkin products. Additionally, we are developing innovative dermatological treatments under the CaniDermRX brand that are specialized
to treat atopic dermatitis and other dermatological conditions such as burns, skin cancer and herpes cold sores, respectively.
Subject to obtaining FDA approval, we intend for our experimental-stage product for the treatment of atopic dermatitis to compete
with Dupixent, an FDA-approved leading treatment for atopic dermatitis, and for our experimental-stage product for the treatment
of herpes cold sores to compete with Silvadene and Abreva, FDA-approved products for treating herpes cold sores. These products
require more extensive testing to show with safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our first clinical
indication is atopic dermatitis (eczema). We have completed manufacturing of formulations containing CBD and aspartame in an FDA-approved
CGMP facility and will be initiating clinical trials of an experimental cosmetic ingredient in this indication to determine efficacy.
We expect these studies to be completed in 2020 and cost approximately $120,000. We will not make any medicinal or therapeutic
claims based on this trial. In parallel, we have initiated development studies to file an investigational new drug (&ldquo;IND&rdquo;)
application for FDA regulated clinical studies in this indication. We expect the developmental studies to be completed in the
third quarter of 2020 and the IND filing to be submitted in the fourth quarter of 2020. We originally anticipated developmental
studies to be completed in the first quarter of 2020, however, these studies were delayed due to COVID-19. The cost of the developmental
studies are estimated to be approximately $250,000.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Plan of Operation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management is focusing
its efforts on realizing its business plan o<FONT STYLE="background-color: white">f being&nbsp;<FONT STYLE="color: #2C3338">a consumer
product development company with a proprietary,&nbsp;trademarked line of CBD-infused products:&nbsp; CaniSun, CaniSkin and CaniDermRX.&nbsp;&nbsp;</FONT></FONT>&nbsp;We
are in the early stage of manufacturing, distributing, and marketing a diverse line of consumer products infused with CBD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 21, 2019, we filed a Form 1-A Regulation A Offering Statement
under the Securities Act of 1933, as amended, and subsequent amendments thereto on July 29, 2019 and August 19, 2019 (the &ldquo;Form
1-A&rdquo;). On September 5, 2019 the Form 1-A was qualified by the staff of the Securities and Exchange Commission. Pursuant to
the Form 1-A, as of December 31, 2019, we have sold 735,000 shares of its common stock, $0.001 par value per share, at a purchase
price of $1.00 per share, resulting in gross proceeds of $785,000, before deducting offerings expenses of $23,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective February
21, 2020, Jupiter Wellness Inc. (&ldquo;Jupiter Sub&rdquo;), our wholly-owned subsidiary, entered into a membership interest
purchase agreement with Magical Beasts LLC (&ldquo;Magical Beasts&rdquo;), a Nevada limited liability corporation, and Krista
Whitley, its sole interest holder, pursuant to which Jupiter Sub acquired all of the membership interests in Magical Beasts
(the &ldquo;Magical Beasts Acquisition&rdquo;) in exchange for the following consideration:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000
                                         cash at closing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                         $1,000,000 promissory note, payable by us, due upon the earlier of i) the closing of
                                         this offering or ii) December 31, 2020 (see &ldquo;Use of Proceeds&rdquo; on page 22);
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         option to purchase 250,000 restricted shares of our common stock at an exercise price
                                         of $1.00 per share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In connection
with the Magical Beasts Acquisition, Jupiter Sub shall enter into an executive employment agreement with Krista Whitley to
act as our Director of Marketing, however, until such agreement is entered into, Jupiter Sub shall pay Krista Whitley an
annual salary of $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In connection
with the Magical Beasts Acquisition, on February 21, 2020, Jupiter Sub and Magical Beasts entered into a sales agency
agreement (the &ldquo;Sales Agency Agreement&rdquo;), pursuant to which Magical Beasts and Ms. Whitley will act as a sales
agent for Jupiter Sub&rsquo;s products. The Sales Agency Agreement shall terminate on December 31, 2020. The Magical
Beasts&rsquo; Acquisition and the Sales Agency Agreement significantly expand our sales and marketing capabilities. It has
also significantly improved our web capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On February 21, 2020,  Jupiter Sub entered into a sales distributor agreement (the
&ldquo;Distribution Agreement&rdquo;) with Ayako Holdings, Inc. (&ldquo;Ayako&rdquo;), a Nevada corporation, pursuant to which
Ayako retained Jupiter Sub as its exclusive sales and distribution agent for certain of its products. The Distribution Agreement,
as extended, shall terminate on December 31, 2022. The Distribution Agreement includes an intellectual property licensing agreement
(the &ldquo;Licensing Agreement&rdquo;) with Ayako, Magical Beasts and Happy Rat Licensing, LLC, a Nevada limited liability company,
(collectively, the &ldquo;Licensor&rdquo;), dated February 18, 2020, pursuant to which the Licensor assigned its rights, titles,
interests and claims to certain trademarks to Jupiter Wellness Marketing, Inc., as set forth in the Licensing Agreement. The Licensing
Agreement lists Jupiter Wellness Marketing, Inc. as the assignee, which is the registered doing business as name for Jupiter Sub.
The brands covered by the Distribution Agreement are &ldquo;Bella&rdquo;, &ldquo;Jack&rdquo;, &ldquo;Felix &amp; Ambrosia&rdquo;,
&ldquo;fitCBD&rdquo;, &ldquo;Black Belt CBD&rdquo;, and &ldquo;Wellness CBD 1937&rdquo;, which are all topical solutions containing
CBD (collectively,
the &ldquo;Brands&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> The primary products
that we started to sell pursuant to the Distribution Agreement are &ldquo;1937 Comfort Cream&rdquo;, &ldquo;Wellness 1937 Temple
Tonic&rdquo;, &ldquo;Felix and Ambrosia CBD Infused Heel Stick Crack&rdquo; and related foot cream and a line of eye creams, anti-
aging cream, anti-aging mask and &ldquo;Bella Alpha C-Serum for Day&rdquo;. The 1937 Comfort Cream is a vegan, non-comedogenic
cream. It is formulated with a blend of natural oils including arnica, camphor, peppermint, Hawaiian cramp bark and other oils.
The 8 ounce cream contains 1,000 mgs of 0% THC American grown industrial hemp derived oil. The Wellness 1937 CBD Temple Tonic
is a three ounce rollerball to apply to your temple or lower neck area. It contains an oil blend that includes jojoba oil infused
with guarana, peppermint, lavender, chamomile, eucalyptus, Hawaiian cramp bark and other oils. The three ounce roller contains
500 mgs of 0% THC American grown industrial hemp derived CBD. The Felix and ambrosia CBD Infused Heel Stick and foot cream is
a moisturizing balm for dry, cracked heels. It is made with peppermint, lemon, aloe, tea tree oil, lavender, eucalyptus and other
oils. It is infused with 0% THC American grown industrial hemp derived CBD. The antiaging eye cream, anti-aging day cream, anti-aging
mask with AHA and the Bella alpha C-Serum for day products all contain a mixture of oils and are infused with 0% THC American
grown industrial hemp. We have recently been selling them in a package called &ldquo;Quarantine Glow Up Package&rdquo; where you
get one of each.. Pursuant to the Distribution Agreement, Jupiter Sub also acquired all of Ayako&rsquo;s current inventory of
the Brands. All our current brands can be found at <FONT STYLE="color: Blue">www.CBDCaring.com</FONT>. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Beginning in March
2020, we began selling masks, gloves and hand sanitizer, in order to take advantage of our supply relationships and the demand
for such products. While, this is not part of our long-term strategy, we intend to continue to pursue such opportunities in the
near term while they present themselves. We have created our own 6- ounce hand sanitizer which our sun care manufacturer produces
for us and we sell under our brand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Significant Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
management&rsquo;s discussion and analysis of our financial condition and results of operations is based on our audited financial
statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP,
and the rules and regulations of the Securities and Exchange Commission. The preparation of the financial statements requires
us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements (See Note 2 to the Consolidated Financial Statements for the year
ended December 31, 2019, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our estimates
are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences
may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future
performance, as these policies relate to the more significant areas involving management&rsquo;s judgments and estimates</FONT><FONT STYLE="font-size: 8pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Emerging Growth Company Status</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &ldquo;Securities Act&rdquo;),
as modified by the Jumpstart our Business Startups Act of 2012, (the &ldquo;JOBS Act&rdquo;), and we may take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies
including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, Section 102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of
such extended transition period which means that when a standard is issued or revised and it has different application dates for
public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither
an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult
or impossible because of the potential differences in accounting standards used.&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider all short-term
investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of
cash flows. There were no cash equivalents as of March 31, 2020 and December 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Property and Equipment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furniture and equipment
are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Maintenance
and repairs are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Net Loss per Common Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net income (loss)
per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income
(loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock
outstanding during the period. If applicable, diluted earnings per share assume the conversion, exercise or issuance of all
common stock instruments such as options, warrants, convertible securities and preferred stock, unless the effect is to
reduce a loss or increase earnings per share. Warrants are not considered in the calculations for the three months ended
March 31, 2020 and the year ended December 31, 2019, as the impact of the potential common shares would be to decrease the
loss per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Three Months Ended March 31, 2020</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Year Ended December 31, 2019</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Numerator:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 58%; padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (loss)</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(481,798</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925,462</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Denominator:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator
    for basic earnings per share - Weighted-average common shares issued and outstanding during the period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,301,219</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator
    for diluted earnings per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,301,219</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    (loss) per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    (loss) per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Fair Value of Financial Instruments </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of our
assets and liabilities, which qualify as financial instruments under ASC Topic 820, &ldquo;Fair Value Measurements and Disclosures,&rdquo;
approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Stock based compensation</I></B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recognize compensation
costs to employees under FASB Accounting Standards Codification 718 &ldquo;Compensation - Stock Compensation&rdquo; (&ldquo;ASC
718&rdquo;). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements
based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees
are required to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation
cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective
vesting periods of the option grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On October 24, 2018,
the inception date (&ldquo;Inception&rdquo;), we adopted ASU No. 2018-07&nbsp;&ldquo;Compensation - Stock Compensation (Topic
718): Improvements to Nonemployee Share-Based Payment Accounting.&rdquo;&nbsp;These amendments expand the scope of Topic 718,
Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments
issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees
will be substantially aligned.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> The value of common
stock issued or payable from Inception through March 31, 2020 were based upon the last sales price of our common stock to a third
party. From January through September 2019, we had multiple sales of common stock at $0.25 per share. From September through the
end of 2019, we sold our stock at $1.00 per share. Issuances and grants throughout 2019 were all based upon the last sales price
for sales of our stock for cash to third parties. If and when our shares of common stock are publicly listed, we will use the
closing share price on a exchange as a basis for valuing our stock grants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We account for income
taxes under ASC 740 Income Taxes (&ldquo;ASC 740&rdquo;). ASC 740 requires the recognition of deferred tax assets and liabilities
for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the
expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation
allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC 740 also clarifies
the accounting for uncertainty in income taxes recognized in an enterprise&rsquo;s financial statements and prescribes a recognition
threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination
by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in
interim period, disclosure and transition. Based on our evaluation, it has been concluded that there are no significant uncertain
tax positions requiring recognition in our financial statements. Since we were incorporated on October 24, 2018, the evaluation
was performed for 2018 tax year, which would be the only period subject to examination. We believe that our income tax positions
and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material changes to
our financial position. Our policy for recording interest and penalties associated with audits is to record such items as a component
of income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
deferred tax asset at December 31, 2019 consists of net operating loss carry forwards calculated using federal and state effective
tax rates equating to approximately $120,000 less a valuation allowance in the amount of approximately $120,000. Because of the
Company&rsquo;s lack of earnings history, the deferred tax asset has been fully offset by a valuation allowance in the year ended
December 31, 2019. Because of our lack of earnings history, the deferred tax asset has been fully offset by a valuation allowance
in the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B><I>Related
parties</I></B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We follow subtopic
850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to Section
850-10-20 the related parties include a. our affiliates; b. entities for which investments in their equity securities would be
required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825&ndash;10&ndash;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and
profit-sharing trusts that are managed by or under the trusteeship of management; d. our principal owners; e. our management;
f. other parties with which we may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests;
and g. other parties that can significantly influence the management or operating policies of the transacting parties or that
have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or
more of the transacting parties might be prevented from fully pursuing its own separate interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances,
and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation
of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature
of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts
were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to
an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each
of the periods for which income statements are presented and the effects of any change in the method of establishing the terms
from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented
and, if not otherwise apparent, the terms and manner of settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2018, the FASB
issued ASU 2018-07, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that
Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed
in a grantor&rsquo;s own operations by issuing share-based payment awards. The standard will be effective for us in the first
quarter of our fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The adoption
of this standard did not have a significant impact on our results of operations, financial condition, cash flows, and financial
statement disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB issued ASU No. 2014-09, &ldquo;Revenue from
Contracts with Customers&rdquo;. The new standard provides a five-step approach to be applied to all contracts with customers and
also requires expanded disclosures about revenue recognition. The ASU is effective for annual reporting periods beginning after
December 15, 2017, including interim periods and is to be retrospectively applied. The adoption of this standard did not have a
significant impact on our results of operations, financial condition, and cash flows. The adoption of this standard is expected
to result in additional financial statement disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016, Topic
842, &ldquo;Leases&rdquo; was issued to replace the leases requirements in Topic 840, &ldquo;Leases&rdquo;. The main difference
between previous GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified
as operating leases under previous GAAP. A lessee should recognize in the balance sheet a liability to make lease payments (the
lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with
a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize
lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally
on a straight-line basis over the lease term. The accounting applied by a lessor is largely unchanged from that applied under
previous GAAP. Topic 842 will be effective for annual reporting periods beginning after December 15, 2018, including interim periods
within those annual periods and is to be retrospectively applied. Earlier application is permitted. The adoption of this standard
did not have a significant impact on our results of operations, financial condition, cash flows, and financial statement disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management does not
believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect
on our financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Results of Operations</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>For the three months ended March 31, 2020 and 2019</I></B></P></DIV>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 8pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
provides selected financial data about us for the three months ended March 31, 2020 and 2019, respectively.&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify">Sales</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">117,727</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Cost of Sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;Gross Profit (Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Total expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(499,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(73,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Net Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(481,798</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(73,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B><U>Revenues</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We generated $117,727
in revenues for the three months ended March 31, 2020. There were no revenues in the prior period for comparative purposes. Revenues
were generally from the sale of our sunscreen and skin care products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Operating Expenses</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had total
operating expenses of $499,622 for the three months ended March 31, 2020 compared to $73,541 for the three months ended March
31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Operating expenses for the three months ended March 31, 2020 were in
connection with our daily operations as follows: (i) marketing expenses of $13,071; (ii) research and development of $24,350; (iii)
legal and professional expenses of $207,253, consisting of corporate advisory services, registration statement preparation fees,
general corporate governance fees; (iv) rent of $12,258; (v) depreciation and amortization of $14,701; (vi) general and administrative
expenses of $210,620, consisting of payroll and related taxes, travel, meals and entertainment, office supplies and expense and
other normal office and administration expenses and (vii) interest expense of $17,369.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Operating expenses
for the three months ended March 31, 2019 were in connection with our daily operations as follows: (i) marketing expenses of $15,030;
(ii) research and development of $33,000; (iii) legal and professional expenses of $12,150, consisting of corporate advisory services
and general corporate governance fees; (iv) rent of $4,310; and (v) general and administrative expenses of $9,051, consisting
of office supplies and expense and other normal office and administration expenses.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Income/Losses</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Net
losses were $481,798 and $73,541 for the three months ended March 31, 2020 and 2019, respectively.</FONT><FONT STYLE="font-size: 9.5pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 9.5pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>For the year ended December 31, 2019</I></B></P></DIV>
<FONT STYLE="font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>The following table
provides selected financial data about us for the year ended December 31, 2019 and for the period from October 24, 2018 (inception)
through December 31, 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">From October 24, 2018 (Inception) to</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify">Sales</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Cost of Sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,024</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;Gross Profit (Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,569</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Total expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(913,893</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(59,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Net Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(925,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(59,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>



<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Revenues</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We generated $6,455 in revenues for the year ended December 31,
2019. There is no prior period for comparative purposes. Revenues were generally from the sale of our sunscreen products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Operating Expenses</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had total
operating expenses of $913,893 for the year ended December 31, 2019. Operating expenses were in connection with our daily
operations as follows: (i) marketing expenses of $74,145 consisting of internet awareness of $14,812, website development of
$26,407, trade shows of $19,821 and promotional displays of $13,105; (ii) research and development of $108,957 consisting of
product development and formulation of $67,850 and clinical research of $41,107; (iii) legal and professional expenses of
$132,318, consisting of corporate advisory services of $35,000, registration statement preparation fees of $75,000,
intellectual property fees of $10,000 and general corporate governance fees and trademark fees of $12,318; (iv) rent of
$17,783; (v) stock based compensation of $357,904 and (vi) general and administrative expenses of $217,610, consisting of
accounting fees of $21,500, consulting fees of $5,000, payroll and related taxes of $67,206, Board of Director fees of
$26,000, patent filing expenses of $12,178, travel expenses of $22,682, charitable contributions of $5,750, meals and
entertainment of $6,046, office supplies and expense of $8,943, filing fees of $10,427 and other normal office and
administration expenses of $32,328.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Income/Losses</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net losses were $925,462 for the year ended December 31, 2019.<FONT STYLE="font-size: 9.5pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0; text-align: justify"><B><I>For the period from October
24, 2018 (inception) through December 31, 2018</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Revenues</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had no revenues for
the period from October 24, 2018 (inception) through December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Operating Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had operating expenses
of $59,734 for the period from October 24, 2018 (inception) through December 31, 2018. Operating expenses were in connection with
our daily operations as well as additional expenses, including but not limited to, research and development costs of $16,500,
marketing expenses of $10,000, legal fees of $10,000 and general and administrative expense of $23,234 which includes consulting
fees of $15,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0"><U>Income/Losses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net losses were $59,734
for the period from October 24, 2018 (inception) through December 31, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
provides selected financial data about us as of March 31, 2020 and December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Working Capital</U>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify">Cash</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">358,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">531,026</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Other Current Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">380,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">214,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">739,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">745,789</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,903,473</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(336,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Working Capital</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,164,190</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">409,345</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 35.65pt">As at
March 31, 2020, our company&rsquo;s cash balance was $358,997 and total current assets were $739,283. As at December 31, 2019
our company&rsquo;s cash balance was $531,026 and total assets were $745,789.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 35.3pt">As at March
31, 2020, our company had total current liabilities of $1,903,473, compared with total liabilities of $336,444 as at December
31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 35.3pt">As at March
31, 2020, our company had a working capital deficit of $1,164,190 compared with working
capital of $409,345 as at December 31, 2019. The decrease in working capital was primarily attributed to convertible promissory
notes totaling $875,000 and a note issued in an acquisition of $956,584 ($1,000,000 face value amount net of $43,416 discount).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flows</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the significant sources and uses of cash for the three months ended March 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Cash Flows Used in Operating Activities</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(457,638</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(107,466</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash Flows Used in Investing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(289,391</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(716</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash Flows From Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">575,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Change in Cash During the Period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(172,029</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(58,182</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flow from Operating Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.65pt">During the three months ended March 31, 2020, our company incurred
a net loss $481,798 and used an additional $24,160 from a net increase in operating assets for a total use of $457,638 in cash in
operating activities. During the three months ended March 31, 2019, we incurred a net loss of $73,541 and we used an additional
$13,925 from a net increase in operating assets for a total use of $87,466 in operating activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flow from Investing Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 35.65pt">During
the three months ended March 31, 2020, the Company purchased
two vans for $44,000 to transport products and acquired Magical Beasts, LLC for cash, issuance of a promissory note and stock options
totaling $1,357,039. The cash portion of the acquisition was $245,391 ($250,000 less $4,609 cash received in the purchase) (see &ldquo;Magical
Beast, LLC Acquisition&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flow from Financing Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 35.65pt">During
the three months ended March 31, 2020, the company issued three
convertible promissory notes totaling $575,000 from related parties. During three months ended March 31, 2019, the company received
$50,000 in net proceeds from the sale of the Company&rsquo;s common stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>Issuance of Convertible
Notes</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three months
ended March 31, 2020, the Company issued three convertible notes of $25,000, $250,000 and $300,000, effective on January 2, 2020,
January 23, 2020 and March 9, 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The $25,000 note has
a one-year term and accrues interest at an annual interest rate of eight percent (8%) non compounded and payable semi-annually.
The note is convertible into the Company&rsquo;s common stock at any time by the note holder at a conversion price of $3.00 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The $250,000 note has
a one-year term and accrues interest at an annual interest rate of eight percent (8%) non compounded and payable semi-annually.
The note is convertible into the Company&rsquo;s common stock at any time by the note holder at a conversion price of $3.00 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The $300,000 note has
a one-year term and accrues interest at an annual interest rate of eight percent (8%) non compounded and payable semi-annually.
The note is convertible into the Company&rsquo;s common stock at any time by the note holder at a conversion price of $3.00 per
share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
provides selected financial data about us as of December 31, 2019 and December 31, 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Working Capital</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
    31</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
    31,</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">531,026</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">161,316</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Current
    Assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">214,763</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Current
    Assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">745,789</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,316</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Current
    Liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(336,444</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working Capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">409,345</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,316</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 35.65pt">As at
December 31, 2019 our company&rsquo;s cash balance was $531,026 and total assets were $745,789. As at December 31, 2018, our company&rsquo;s
cash balance was $161,316 and total assets were $191,316.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 35.3pt">As at December
31, 2019, our company had total liabilities of $366,581, compared with total liabilities of $7,000 as at December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 35.3pt">As at December
31, 2019, our company had working capital of $409,345 compared with working capital of $184,316 as at December 31, 2018. The increase
in working capital was primarily attributed to a convertible promissory note of $250,000 and sale of shares of common stock of
the Company totaling $762,000, net of offering costs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 35.3pt">&nbsp;</P></DIV>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 35.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flows</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 21, 2019,
we filed the Form 1-A and subsequent amendments thereto on July 29, 2019 and August 19, 2019. On September 5, 2019 the Form
1-A was qualified by the staff of the Securities and Exchange Commission. Pursuant to the Form 1-A, as of December 31, 2019,
we have sold 735,000 shares of our common stock, $0.001 par value per share, at a purchase price of $1.00 per share,
resulting in gross proceeds of $735,000, before deducting offerings expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the significant sources and uses of cash for the year ended December 31, 2019 and for the period from October 24, 2018
(inception) through December 31, 2018, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Cash Flows Used in Operating Activities</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(692,740</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(82,734</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash Flows Used in Investing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash Flows From Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,062,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">244,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Change in Cash During the Period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">369,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">161,316</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flow from Operating Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.65pt">During the year ended December 31, 2019, our company incurred a net
loss $925,462 and provided an additional $232,722 from a net increase in operating liabilities for a total use of $692,740 in cash
in operating activities. During the period from October 24, 2028 (Inception) through December 31, 2018, we incurred a net loss
of $59,734 and we used an additional $23,000 from a net increase in operating assets for a total use of $82,734 in cash in operating activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flow from Investing Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 35.65pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Cash Flow from Financing Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 35.65pt">During
the year ended December 31, 2019, the company received a net
$1,062,450 from financing activities, consisting primarily of a $25,000 repayment to a related party promissory note, an additional
$75,000 promissory note from a related party, a $250,000 convertible promissory note and $762,000 in net proceeds from the sale
of the Company&rsquo;s common stock. During the period from October 24, 2028 (Inception) through December 31, 2018, the company
received $244,050 in net proceeds from the sale of the Company&rsquo;s common stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance of Convertible Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 10, 2019,
we issued a Twenty-Five Thousand Dollar ($25,000) convertible promissory note (the &ldquo;Caro Note&rdquo;) to Caro Partners,
LLC (&ldquo;Caro&rdquo;), a consulting firm owned by Brian S. John, our Chief Executive Officer and a member of our Board of
Directors. The term of the Caro Note was one year. The interest rate was ten percent (10%) non compounded and payable
semi-annually. The Caro Note was convertible at any time by Caro at a conversion price of $0.25 per share of common stock.
The Caro Note was paid in full in September 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 25, 2019,
we issued a Fifty Thousand Dollars ($50,000) convertible promissory note (the &quot;Wilson Note&quot;) for funds lent
by Dr. Glynn Wilson, one of our directors. The term of the Wilson Note is one year. The interest rate is ten percent (10%)
non-compounded and payable semi-annually. The Wilson Note is convertible at any time by the holder at a conversion price of
$0.25 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 31, 2019,
we issued a convertible promissory note in the principal amount of $250,000 and an interest rate of eight percent (8%) per annum
to an LLC owned by a consultant to the Company. The note has a maturity date of December 31, 2020 and the holder may, at any time,
convert the outstanding principal amount, or any portion of the outstanding principal amount, of the note, together with any accrued
but unpaid interest, at a conversion price of $3.00 per share. We may, at any time, prepay all or any part of the principal amount
at a premium equal to eight percent (8%) of the outstanding principal amount.<FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt"></FONT></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0; text-align: justify"><B><I>For the period from October
24, 2018 (inception) through December 31, 2018.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.05pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the period from
October 24, 2018 (inception) through December 31, 2018, net cash flows used in operating activities were $82,734 due primarily
to our net losses for the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no cash
flows from investing activities during the period from October 24, 2018 (inception) through December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the period from
October 24, 2018 (inception) through December 31, 2018, net cash flows provided by financing activities were $244,050, attributable
to the proceeds of $4,550 from founder shares and proceeds of $239,500 from a common stock offering at $0.25 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had cash of $161,316
on hand as of December 31, 2018, which we feel is sufficient to carry us through the completion of this offering. We will need
to raise significant capital to grow and develop our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.25pt 0 0; text-align: justify"><B>Impact of Inflation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.25pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that inflation
has had a negligible effect on operations since inception. We believe that we can offset inflationary increases in the cost of
operations by increasing sales and improving operating efficiencies.&nbsp;</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have off-balance
sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &ldquo;variable
interest entities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="DescriptionOfBusiness"></A><B>BUSINESS<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Organization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #C00000">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were originally
incorporated in the State of Delaware on October 24, 2018. Our principal business address is 725 N. Hwy A1A, Suite C-106, Jupiter,
FL 33477.</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a cutting-edge
wellness hemp-derived cannabidiol, or CBD, consumer product development company. We are in the early stage of manufacturing, distributing,
and marketing a diverse line of consumer products infused with CBD. We have a proprietary, trademarked line of products: CaniSun,
CaniSkin and CaniDermRX. Under the CaniSun brand name, we are marketing three proprietary CBD-infused sun care lotion formulas
containing various SPF&rsquo;s that we have developed using our own intellectual property rights. Under the CaniDermRX brand,
we are exploring formulations of CBD with over-the-counter, or OTC, consumer products that have potentially therapeutic and medical
applications. Specifically, we are exploring the use of such topical solutions for the treatment of eczema, dermatitis, and actinic
keratosis, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores, and a prescription product for the
treatment of burns. The CaniDermRx topical solution for the treatment of eczema dermatitis is the lead product candidate and will
be initially tested in humans as an investigational cosmetic ingredient followed by clinical trials subject to the regulations
of the FDA under an IND. In parallel, we plan to initiate the development of other products. We are also actively seeking to acquire
or license products in the OTC skin care market that can be infused with CBD and marketed under our CaniSkin and CaniDermRX brand
names. There can be no assurances that we will acquire or enter into such partnership and/or licensing agreements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The endocannabinoid
system, which is a body system affected by CBD, plays a pivotal role in maintaining a healthy skin through modulating pain sensation,
cell proliferation and inflammation. Our strategy for treatment of skin indications is, therefore, to focus on the use of CBD containing
topical formulations and to explore potential combinations of CBD and other agents that may augment and act synergistically with
CBD. We will explore this strategy by conducting controlled clinical trials to try to ultimately gain FDA approval for specific
indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our first clinical
indication is atopic dermatitis (eczema). We have completed manufacturing of topical formulations containing CBD and aspartame
in an FDA approved CGMP facility and will be initiating clinical trials of an experimental cosmetic ingredient in this indication
to determine efficacy. We expect these studies to be completed in 2020 and cost approximately $120,000. We will not make any medicinal
or therapeutic claims based on this trial. In parallel, we have initiated development studies to file an IND for FDA regulated
clinical studies in this indication. We expect the developmental studies to be completed in the third quarter of 2020 and the
IND filing to be submitted in the fourth quarter of 2020. We originally anticipated developmental studies to be completed in the
first quarter of 2020, however, these studies were delayed due to COVID-19. The cost of the developmental studies are estimated
to be approximately $250,000.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>CaniSun
Brand</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We developed a CBD-infused
sunscreen with broad-spectrum SPF protection. We have completed lab testing for CBD solubility-infusing clear, colorless, odorless,
and 99.5% pure CBD isolated with three different sun care active ingredients, homosalate, octisalate and octocrylene, which have
already been approved by the FDA. The CBD-infused sun care market is fairly nascent in the United States; we believe that there
are currently no major competitors in the category. We see an opportunity to become the leading manufacturer of CBD-infused sun
care products, marketing the CaniSun brand through an extensive digital and social media awareness campaign. We announced the
launch of our CaniSun sun care line of SPF 30, SPF 50 and SPF 55 face lotion on June 6, 2019. We also sell our CBD-infused lip
balm and CBD-infused SPF 30 sunscreen spray on our website Canisun.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently have additional
CaniSun products in various stages of development as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 30 Lip Balm; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CBD-infused
                                         SPF 15 sunscreen lotion; and</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Mineral-based
                                         sunscreen lotions (SPF 30 and 50).</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the products
listed above are in the developmental stage, whereby we are finalizing the formula to be used in each product, respectively. For
CBD-infused product candidates in development, such as CBD-infused SPF 30 Lip Balm and CBD-infused SPF 15 sunscreen lotion, we
have already identified the sun care active ingredient formula (which has already been FDA approved) to be infused with CBD. Once
the respective formulas for each of our product candidates are created, the product candidates will undergo three months of stability
testing. Provided that the product candidates pass the stability testing, we intend to sell the products on our CaniSun website.
The formula for our mineral-based sunscreen lotion (SPF 30 and 50) (product iii) above) includes certain minerals instead of chemicals
typically used in sunscreen lotions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Overall, we believe
that our currently offered sunscreen products comply with the FDA Final Rule for sunscreen products under 21 CFR 352 Sunscreen
products for Over-the-Counter Human Use. Therefore, we believe that our sunscreen products fall within the FDA monograph and that
FDA premarket approval and testing is not required. Our products have been tested for SPF Evaluation (SPF rating), Critical Wave
Length (Broad Spectrum claim) and Water Resistance, each of which is defined within the monograph and labeled accordingly.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the test on
these products is standard testing for suncare products. Such testing protocols are not intended to test for any effects of adding
CBD. In addition to these tests that were conducted to support the claims on the package, each batch is also tested for appearance,
color, odor, pH, viscosity, specific gravity, analytical for the sunscreen active ingredients, and microbial content testing.</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are
tested each time they are manufactured. Derma Care Research Laboratories, LLC (&ldquo;DCR Labs&rdquo;) manufactures our
products and has represented to us that it is compliant with the FDA&rsquo;s Current Good Manufacturing Practice
(&ldquo;CGMP&rdquo;) regulations in accordance with 21 CFR 210/211 (required for Over-the-Counter drug products). &nbsp;DCR Labs
has self-imposed health and safety standards to ensure compliance with the FDA&rsquo;s CGMPs.</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently,
consumers lack reliable resources to help them understand the benefits of CBD and choose the right formulations and products
based on their specific needs. We expect to continually update and expand upon our corporate website and further refine our
online retail strategies on an ongoing basis. CBDBrands.net is our primary corporate website, which will serve as the primary
source of information about our Company for investors and contain press releases, clinical trial pipeline, lab reports,  blog
posts, and additional information about each of our brands. We anticipate that each brand will have its own front-facing website
dedicated to retail sales and brand specific information. For example, our line of sun care products, CaniSun, has its own
website at CaniSun.com and allows for online retail purchase of the entire product line. As we expand our brands (CaniSkin
and CaniDermRX), we anticipate utilizing the same strategy and dedicating a new e-commerce website to each brand moving
forward. We are also building a website dedicated to servicing our wholesale and larger distributor clients. This website
will have more information about each product and provide a central location for larger retailers to find more in-depth
information about all of our brands in one place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We plan to leverage our website with a social media presence across
multiple platforms designed to utilize product reviews to increase brand loyalty, brand recognition and sales. The references
to our website in this prospectus are inactive textual references only. The information on our website is neither
incorporated by reference into this prospectus nor intended to be used in connection with this offering. We also see growth
potential in developing retail locations. We intend to utilize cross-promotion marketing campaigns with our products and
product category expansion that leverages our existing distribution channels.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I><U>CaniSkin
Brand and CaniDermRX Brand</U></I></P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently developing
other products such as CBD-infused skin care lotion under the CaniSkin brand. Specifically, a CBD-infused moisturizing face serum
is under development. We must first finalize the formula to be used in the face serum, and, once approved, the product candidate
will undergo stability testing. We intend to sell the product, provided it first passes stability testing, on our website for
CaniSkin products. Additionally, we are developing an innovative dermatological treatments under the CaniDermRX brand that are
specialized to treat atopic dermatitis and other dermatological conditions such as burns, skin cancer and herpes cold sores, respectively.
Subject to obtaining FDA approval, we intend for our experimental-stage product for the treatment of atopic dermatitis to compete
with Dupixent, an FDA-approved leading treatment for atopic dermatitis, and for our experimental-stage product for the treatment
of herpes cold sores to compete with Silvadene and Abreva, FDA-approved products for treating herpes cold sores.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we plan
to seek acquisition opportunities in the branded consumer products space, including but not limited to other OTC therapeutic brands
and skin care brands that can be developed manufactured, marketed, and distributed under our Caniskin and CaniDermRX brand names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We see growth potential
in developing retail locations. We intend to utilize cross-promotion marketing campaigns with our products and product category
expansion that leverages existing distribution channels. We have developed an e-commerce platform designed to connect us directly
to consumers. We utilize the platform to sell products, educate customers and build brand loyalty.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We filed Provisional Patent
(CBD Formulations and Uses Thereof: USAN: 62/884,995) on a combination of CBD and Aspartame on August 8, 2019. The patent is to
cover any products that contain a combination of CBD and Aspartame. This initially will cover the products under the CaniDermRX
Brand. The priority date starts at the time the provisional is converted into a full patent, which will occur on August 9, 2020.
If issued, the patent will give patent protection until 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We filed Provisional
Patent (CBD Sunscreen Formulations and Uses Thereof: USAN: 63/005,854) on our CBD-infused sunscreen products on August 6, 2020.
The patent is to cover any products under our CaniSun product line that contains CBD. The priority date starts at the time the
provisional is converted into a full patent, which will occur on April 6, 2021. If issued, the patent will give patent protection
until 2041.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Raw Material</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We obtain raw
materials from a variety of vendors. The availability depends on the raw material and where it comes from. There are times
when the lead times on delivery can fluctuate, which may cause us to incur varying delays in our manufacturing times. As we
grow, we hope to be able to forecast and manage growth to try and ensure we have adequate inventory on hand to meet demand.
The primary raw material that we utilize is CBD isolate. We obtain our isolate from Mile High Labs. We believe that Mile High
has sufficient capacity to provide for our isolate needs. We have no agreement with Mile High but we believe that they have
sufficient capacity to meet our needs and that we could obtain the isolate from other sources if necessary. We also import
tubes and caps from China which so far have been found to be reliable. There is typically a six to eight-week lead time for
delivery which is also effected depending on shipping air or sea. This can add to our manufacturing cost for air delivery if
needed quicker and could force delays in our ability to fill orders if we deplete our tube inventory.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market for hemp,
and for products based on extracts of hemp, is expected to grow substantially over the coming years. It is estimated by BDS Analytics
and Arcview Market Research that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024 and that there
will be a compound annual growth rate of 49 percent by 2024 across all distribution channels. We see great potential to grow and
generate revenues in this expanding market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to Grand View
Research, the U.S. sun care market size was estimated at $1.95 billion in 2016. The growing consumer awareness regarding the ill-effects
of over exposure to ultraviolet, or UV, rays on the undefended skin is expected to propel growth. The sun care market is a highly
competitive market and product differentiation in the sun care market is low. Given the relatively low amount of product differentiation,
we see an opportunity to carve out a unique market share with our CBD-infused sun care products. We cannot make any claims as
to such benefits prior to performing certain testing. We see an opportunity, although there can be no assurance that we will be
successful, to become the leading manufacturer of CBD-infused sun care products, marketing the CaniSun brand through an extensive
digital and social media awareness campaign. We announced the launch of our CaniSun sun care line of SPF 30, SPF 50 and SPF 55
face lotion on June 6, 2019. We also sell our CBD-infused lip balm and CBD-infused SPF 30 sunscreen spray on our website Canisun.com.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Growth Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We plan to
seek acquisition opportunities in the branded consumer products space, including but not limited to other non-CBD OTC therapeutic
brands and skin care brands that can be manufactured, marketed and distributed under our CaniSkin and CaniDermRX brand names.
We may market such products as they are currently comprised or may seek to add CBD to the product. In the
event we decide to add CBD to such products, we intend to first conduct FDA regulated clinical trials for safety and efficacy testing.
We have no definitive agreements in place to acquire any other entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also intend to sell
the product online directly through our own website, and other third-party marketplaces as these sites permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to
continually update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis.
CBDBrands.net is our primary corporate website, which will serve as the primary source of information about us for investors
and contain press releases, clinical trial pipeline, lab reports,  blog posts, and additional information about each of
our brands. We anticipate that each brand will have its own front-facing website dedicated to retail sales and brand specific
information. For example, our line of sun care products, CaniSun, has its own website at CaniSun.com and allows for online
retail purchase of the entire product line. As we expand our brands (CaniSkin and CaniDermRX), we anticipate utilizing the
same strategy and dedicating a new e-commerce website to each brand moving forward. We are also building a website dedicated
to servicing our wholesale and larger distributor clients. This website will have more information about each product and
provide a central location for larger retailers to find more in-depth information about all of our brands in one
place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Competition</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are several companies
developing cannabinoid therapeutics for a range of medical indications. The cannabinoid therapeutic area currently includes formulated
extracts of the Cannabis plant and synthetic formulations. These formulations include CBD and THC, or a combination of CBD/THC
as the active pharmaceutical ingredient. Certain companies such as GW Pharmaceuticals, PLC have focused on hemp-based CBD formulations;
while other companies such as Zynerba Pharmaceuticals Inc. and Insys Therapeutics Inc. have focused on synthetic CBD formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The CBD-based consumer
product industry is highly fragmented with numerous companies, consisting of publicly- and privately-owned companies. There are
also large, well-funded companies that have indicated their intention to compete in the hemp-based product category in the U.S.
We routinely evaluate internal and external opportunities to optimize value for stockholders through new product development or
by asset acquisitions or sales, and believe we are well-positioned to capitalize in the growing CBD product category. We face competition
from larger companies that are, or may be, in the process of offering similar products to ours. Many of our current and potential
competitors have longer operating histories, significantly greater financial, marketing and other resources than we have or may
be expected to have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Competitors may include
major pharmaceutical and biotechnology companies and public and private research institutions. Our management cannot be certain
that we will be able to compete against current or future competitors or that competitive pressure will not seriously harm our
business prospects. These competitors may be able to react to market changes, respond more rapidly to new regulations or allocate
greater resources to the development and promotion of their products than we can.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furthermore, some of these
competitors may make acquisitions or establish collaborative relationships among themselves to increase their ability to rapidly
gain market share. Large pharmaceutical companies may eventually enter the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Given the rapid changes
affecting the global, national, and regional economies in general and cannabis-related medical research and development in particular,
we may not be able to create and maintain a competitive advantage in the marketplace. Time-to-market is an important factor in
our industry and our success will depend on our ability to develop innovative products that will be accepted by patients as efficient
and helpful to use.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success will also depend
on our ability to respond quickly to, among other things, changes in the economy, market conditions, and competitive pressures.
Any failure to anticipate or respond adequately to such changes could have a material effect on our financial condition, operating
results, liquidity, cash flow and our operational performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Government Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since 1937, Cannabis
sativa L. has been a federally regulated Schedule I drug under the Controlled Substances Act, 21 U.S.C. &sect; 811 (the &ldquo;CSA&rdquo;),
regulated by the Drug Enforcement Agency (the &ldquo;DEA&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It was not until 2014
when a distinction between the use of Cannabis sativa L. for medical, recreational, and industrial purposes was made via Section
7606 of the Agricultural Act of 2014, which cleared a legal path for industrial hemp to be grown in three limited circumstances,
1) by researchers at an institute of higher education, 2) by state departments of agriculture, or 3) by farmers participating
in a research program permitted and overseen by a state department of agriculture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2016, the DEA,
U.S. Department of Agriculture, and the FDA issued a joint statement detailing the guidelines for growth of industrial hemp as
part of state-sanctioned research programs. Those guidelines state that hemp can only be sold in states with pilot programs, plants
and seeds can only cross state lines as part of permitted state research programs, and seeds can only be imported by individuals
registered with the DEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe the recent
passage of the Farm Bill will allow us to expand our marketplace opportunities. On December 20, 2018, President Donald J. Trump
signed into law the Agriculture Improvement Act of 2018, otherwise known as the &ldquo;Farm Bill&rdquo;. Prior to its passage,
hemp, a member of the cannabis family, and hemp-derived&nbsp;CBD&nbsp;were classified as a Schedule I controlled substances, and
so were deemed to be illegal under the CSA. With the passage of the Farm Bill, hemp cultivation is broadly permitted. The Farm
Bill explicitly allows the transfer of hemp-derived products across state lines for commercial or other purposes. It also puts
no restrictions on the sale, transport, or possession of hemp-derived products, so long as those items are produced in a manner
consistent with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Section 10113
of the Farm Bill, hemp cannot contain more than 0.3 percent THC. THC refers to the chemical compound found in cannabis that produces
the psychoactive &ldquo;high&rdquo; associated with cannabis. Any cannabis plant that contains more than 0.3 percent THC would
be considered non-hemp cannabis&mdash;or marijuana&mdash;under federal law and would thus face no legal protection under this new
legislation and would be an illegal Schedule 1 drug under the CSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally,
there will be significant, shared state-federal regulatory power over hemp cultivation and production. Under Section 10113 of the
Farm Bill, state departments of agriculture must consult with the state&rsquo;s governor and chief law enforcement officer to devise
a plan that must be submitted to the Secretary of the United States Department of Agriculture or USDA. A state&rsquo;s plan to
license and regulate hemp can only commence once the Secretary of USDA approves that state&rsquo;s plan. In states opting not to
devise a hemp regulatory program, USDA will construct a regulatory program under which hemp cultivators in those states must apply
for licenses and comply with a federally run program. This system of shared regulatory programming is similar to options states
had in other policy areas such as health insurance marketplaces under the Affordable Care Act, or workplace safety plans under
Occupational Health and Safety Act&mdash;both of which had federally-run systems for states opting not to set up their own systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Farm Bill outlines
actions that are considered violations of federal hemp law (including such activities as cultivating without a license or producing
cannabis with more than 0.3% THC). The Farm Bill details possible punishments for such violations, pathways for violators to become
compliant, and even which activities qualify as felonies under the law, such as repeated offenses.</P>

<P STYLE="font: 11pt/12.65pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">One of the goals of the
Agricultural Act of 2014 was to generate and protect research into hemp. The Farm Bill continues this effort. Section 7605 re-extends
the protections for hemp research and the conditions under which such research can and should be conducted. Further, section 7501
of the Farm Bill extends hemp research by including hemp under the Critical Agricultural Materials Act. This provision recognizes
the importance, diversity, and opportunity of the plant and the products that can be derived from it, but also recognizes that
there is still a lot to learn about hemp and its products from commercial and market perspectives.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Overall, we believe that
our sunscreen products comply with the FDA Final Rule for sunscreen products under 21 CFR 352 Sunscreen products for Over-the-Counter
Human Use. Therefore, we believe that our sunscreen products fall within the FDA monograph and that FDA premarket approval and
testing is not required. Our products have been tested for SPF Evaluation (SPF rating), Critical Wave Length (Broad Spectrum claim)
and Water Resistance, each of which is defined within the monograph and labeled accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are tested
each time they are manufactured. DCR Labs manufactures our products and is compliant with the FDA&rsquo;s Current Good Manufacturing
Practice (&ldquo;CGMP&rdquo;) regulations in accordance with 21 CFR 210/211 (required for Over-the-Counter drug products). DCR
Labs has self-imposed health and safety standards to ensure compliance with the FDA&rsquo;s CGMPs.&nbsp;</P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>FDA Regulation of Hemp Extracts</I></B></P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA is generally
responsible for protecting the public health by ensuring the safety, efficacy, and security of (1) prescription and over the counter
drugs; (2) biologics including vaccines, blood &amp; blood products, and cellular and gene therapies; (3) foodstuffs including
dietary supplements, bottled water, and baby formula; and, (4) medical devices including heart pacemakers, surgical implants, prosthetics,
and dental devices.</P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Regarding its regulation
of drugs, the FDA process requires a review that begins with the filing of an investigational new drug (IND) application, with
follow-on clinical studies and clinical trials that the FDA uses to determine whether a drug is safe and effective, and therefore
subject to approval for human use by the FDA.</P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Aside from the FDA&rsquo;s
mandate to regulate drugs, the FDA also regulates dietary supplement products and dietary ingredients under the Dietary Supplement
Health and Education Act of 1994. This law prohibits manufacturers and distributors of dietary supplements and dietary ingredients
from marketing products that are adulterated or misbranded. This means that these firms are responsible for evaluating the safety
and labeling of their products before marketing to ensure that they meet all the requirements of the law and FDA regulations, including,
but not limited to the following labeling requirements: (1) identifying the supplement; (2) nutrition labeling; (3) ingredient
labeling; (4) claims; and, (5) daily use information.</P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA has not approved
cannabis, marijuana, hemp or derivatives as a safe and effective drug for any indication. We intend to file an IND with the FDA
for our CaniDermRX products in the event the pending provisional patent on an Aspartame/CBD combination is approved. As of the
date hereof, our products containing&nbsp;CBD&nbsp;derived from industrial hemp are not marketed or sold using claims that their
use is a safe and effective treatment for any medical condition subject to the FDA&rsquo;s jurisdiction.</P>

<P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
FDA has concluded that products containing cannabis or industrial hemp derived CBD are excluded from the dietary supplement definition
under sections 201(ff)(3)(B)(i) and (ii) of the U.S. Food, Drug &amp; Cosmetic Act, respectively. The FDA&rsquo;s position is that
products containing cannabis, CBD or derivatives are Schedule 1 drugs under the Controlled Substances Act, and so are illegal.
Our products containing CBD derived from industrial hemp are not marketed or sold as dietary supplements. However, at some indeterminate
future time, the FDA may choose to generally change its position concerning products containing hemp derived CBD, and may choose
to enact regulations that are applicable to such products. In this event, our industrial hemp based products containing CBD may
be subject to regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
products contain controlled substances as defined in the Controlled Substances Act (CSA). Controlled substances that are pharmaceutical
products are subject to a high degree of regulation under the CSA, which establishes, among other things, certain registration,
manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements administered by the DEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Despite
recent approvals by the FDA and DEA for a newly approved medication which contains cannabidiol (CBD), the scheduling of these substances,
many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market our
products. <FONT STYLE="background-color: white">Any such setback in our pursuit of regulatory approval would have a material adverse
effect on our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, we had five full-time employees, including its Chief Executive Officer Brian S. John, its Chief Financial Officer, Doug
McKinnon, and its Chief Operating Officer, Richard Miller. We believe our relations with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, we do not
own any real property. We rent an office space at 725 N. Hwy A1A, Suite C-106, Jupiter, FL 33477 for $2,140 per month. This office
space is rented on a month to month lease.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are not a party
to any legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="Management"></A><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Set forth below is
certain information with respect to the individuals who are our directors and executive officers as of the date of December
 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Name</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Age</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Position(s)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; text-align: left">Brian S. John</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 26%; text-align: center">51</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: left">Chief Executive Officer and Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Douglas O. McKinnon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">68</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Richard Miller</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">52</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Operating Officer and Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dr. Glynn Wilson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">73</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Chairman, Head of Research and Development</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dr. Hector Alila</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">67</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Timothy G. Glynn</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">59</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Christopher Marc Melton</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">47</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Byron T. Young</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">45</TD><TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Director</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Brian S. John, Chief Executive Officer
and Director, </B>is one of our founders and has served as our Chief Executive Officer since October 2018. For the past 20 years,
Brian has been an investor and advisor to companies around the globe. He is the founder of Caro Partners, LLC, a financial consulting
firm specializing in assisting emerging growth companies primarily in the sub- $100 million space, and has worked with hundreds
of companies in dozens of countries over the last 25 years. Mr. John was the Chief Executive Officer of Teeka Tan Products Inc.,
a sun care company he co-founded in 2004 and later sold. He also serves on the board of directors of The Learning Center at the
Els Center of Excellence&ndash;a school for children with autism in Jupiter, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas O. McKinnon, Chief Financial
Officer, </B>has served as our Chief Financial officer since August 15, 2019. Mr. McKinnon has served as the Chief Executive Officer
of AppYea, Inc. since March 2016. Mr. McKinnon has served as a director of Surna, Inc. since March, 2014 and as Surna&rsquo;s
Executive Vice President and Chief Financial Officer since April, 2014. Prior to Surna, Inc., Mr. McKinnon served as Chief Executive
Officer of 1<SUP>st</SUP> Resource Group, Inc. for four years. Mr. McKinnon's 35+ year professional career includes financial,
advisory and operation experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis and
communications. He has served in C-level positions in both private and public sectors, including Chairman and CEO of an American-Stock-Exchange
traded company, VP - Chief Administrative Officer of a $12-billion market cap Nasdaq-traded company for which the management team
raised over $2.2 billion, CFO of several publicly-held US, Canadian and Australian companies, and CEO/CFO of various other private
enterprises. As an entrepreneur, Mr. McKinnon has been involved in organizations ranging from start-up companies using venture
capital funding to publicly traded institutional backed companies. Additionally, Mr. McKinnon has extensive merger and acquisition,
and turnaround experience.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Richard Miller, Chief Operating Officer
and Director,</B> has served as our Chief Operating Officer since October 2018 and served as our Chief Financial Officer
from November 2018 until August 2019. Since 2003, Mr. Miller has served as president of Caro Consulting, Inc. a consulting firm
that advises emerging growth companies.&nbsp;Over the last twenty years Mr. Miller has provided strategic advice&nbsp;to hundreds
of companies across diverse industries. He has assisted C Level executives with expanding, financing and other challenges emerging
companies face. Mr. Miller was co-founder of Teeka Tan Suncare Products. Prior to the company&rsquo;s sale, he was instrumental
in the design and launch a full line of boutique sun care products. He is an advocate for school safety and local schools through
his grass roots group My School Counts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dr. Glynn Wilson, Chairman, Head of
Research and Development,</B>&nbsp;has served as one of our directors since November 2018. Mr. Wilson was appointed our Chairman
and Head of Research and Development on October 15, 2019. Dr. Wilson previously served as a Director of TapImmune, Inc. from February
2005 until October, 2018 and as Chief Executive Officer from July 2009 through September 2017. Dr. Wilson also served as President
of Auriga Laboratories, Inc. from June 1, 2005 through March 13, 2006, and as Chief Scientific Officer from March 13, 2016 through
August 25, 2006. He was the Chief Scientific Officer at Tacora Corporation from 1994 to 1997 and was the Vice-President, R&amp;D,
at Access Pharmaceuticals from 1997 to 1998. Dr. Wilson was Research Area Head, Cell and Molecular Biology in Advanced Drug Delivery
at Ciba-Geigy Pharmaceuticals from 1984-1989 and Worldwide Head of Drug Delivery at SmithKline Beecham from 1989 to 1994. He was
a faculty member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Sanford Moore and William Stein,
from 1974 to 1979. Dr. Wilson is a recognized leader in the development of drug delivery systems and has been involved in taking
lead products &amp; technologies from concept to commercialization. Dr. Wilson has a Ph. D. in Biochemistry and conducted medical
research at The Rockefeller University, New York. Dr. Wilson brings an extensive background of success in corporate management
and product development with tenures in both multinational and start-up biotech organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dr. Hector Alila, Director, </B>has served
as one of our directors since February 2019. Dr. Alila brings 30 years of demonstrated scientific experience in product development
and successful management leadership in biopharmaceutical industry. He is the Founding President and Chief Executive Officer of
Esperance Pharmaceutical Inc., a clinical stage biopharmaceutical company that has successfully developed novel targeted cancer
therapeutics currently in clinical development. Dr. Alila founded Esperance Pharmaceutical, Inc. in 2006. Prior to Esperance,
Dr. Alila served as Senior Vice President of Drug Development at Protalex, Inc., where he led the development of a drug currently
in clinical trials for treatment of autoimmune diseases. He was previously Vice President of Product Development at Cell Pathways,
Inc., where he was responsible for the development cancer drugs, and a director of Biology/pharmacology at GeneMedicine, Inc.,
where he led product development of gene medicines.&nbsp; He also held several research, product development and management positions
at SmithKline Beecham Pharmaceuticals.&nbsp; He obtained his Ph.D. in physiology and immunology from Cornell University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Timothy G. Glynn, Director, </B>has
served as one of our directors since March 2019. Mr. Glynn spent nearly 25 years on Wall Street where he worked as a Senior
Vice President in Lehman Brothers&rsquo; Private Client/Middle Market Group. He also held top positions at Citigroup Global
Markets Private Client division. After retiring from Wall Street in early 2007, Mr. Glynn subsequently founded many companies
including Speed Trade Technologies, a quant-based hedge fund; Emerging Growth Advisors, a leading national advisory company
to small-and medium-size public and private enterprises; which he later sold to a public company. He has advised chief
executive officers and their companies all over the world on a myriad of subjects including: capital structure, operational
excellence and branding along with many other important corporate issues. He recently served as Chief Investment and
Innovation Officer for the Children&rsquo;s Home Society of Florida, one of the largest not-for profit ($130mm+)
Children&rsquo;s Organizations and Foundations in the nation. In addition to his position as Managing Member at TNT Capital
Advisors, LLC, he is the Founder and Managing Member for TNT Holdings Group, LLC, a consulting and investment group with
several related entities including, TNT Legacy, LLC, a land acquisition and development enterprise, and TNT Capital
Group.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Christopher Marc Melton, Director,
</B>has served as one of our directors since August 2019. Mr. Melton has served as director of SG Blocks, Inc. since November
of 2011 and currently serves as the Audit Committee Chairman. From 2000 to 2008, Mr. Melton was a Portfolio Manager for Kingdon
Capital Management (&quot;Kingdon&quot;) in New York City, where he ran in excess of $1 Billion book in media, telecom, and Japanese
investment. Mr. Melton opened Kingdon's office in Japan, where he set up a Japanese research company. From 1997 to 2000, Mr. Melton
served as a Vice President at JPMorgan Investment Management as an equity research analyst, where he helped manage $1 Billion
plus in REIT funds under management.&nbsp; Mr. Melton was a Senior Real Estate Equity Analyst at RREEF Funds in Chicago from 1995
to 1997. Mr. Melton is Principal and co-founder of Callegro Investments, a specialist land investor. He currently serves on several
Public and Private Boards as well as Chairman of the Audit Committee of a Nasdaq listed company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Byron T. Young<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">,
Director,</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;was appointed as one
of our directors in October of 2019. Additionally, Mr. Young has served as Treasurer and Chairman of the Board of Zenergy Brands,
Inc. since December 2015. Zynergy brands was a technology company engaged in the energy and utilities space. Zynergy provided
building automation systems, retail energy and energy conservation solutions to commercial and industrial users. In 2010, Mr.
Young founded&nbsp;Assist&nbsp;Wireless, a&nbsp;wireless&nbsp;communication company, and currently serves as its CEO. Mr. Young
founded a retail energy provider in 2005 under the name Young Energy, LLC, which provides electricity and natural gas services
to residential and commercial customers in Texas and where Mr. Young currently serves as a senior advisor and board member. In
2001, Mr. Young founded a competitive local exchange carrier (C-LEC) under the name of Extel Enterprises, which was ultimately
sold to publicly traded Usurf America, Inc. in 2004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among and between the issuer&rsquo;s directors, officers, persons nominated or chosen by the issuer to become directors or officers,
or beneficial owners of more than ten percent of any class of the issuer&rsquo;s equity securities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Board Composition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Director Independence</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business and affairs
are managed under the direction of our Board, which consist of six members. Under Nasdaq rules, independent directors must comprise
a majority of a listed company&rsquo;s board of directors within a specified period after completion of this offering. In addition,
Nasdaq rules require that, subject to specified exceptions, each member of a listed company&rsquo;s audit, compensation and nominating
and governance committees be independent, subject to certain phase-ins for newly-public companies. Under Nasdaq rules, a director
will only qualify as an &ldquo;independent director&rdquo; if, in the opinion of that company&rsquo;s board of directors, that
person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Audit committee members
must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent
for purposes of Rule 10A-3, a member of an audit committee may not, other than in his or her capacity as a member of the audit
committee, the board of directors, or any other board committee (1) accept, directly or indirectly, any consulting, advisory, or
other compensatory fee from the listed company or any of its subsidiaries or (2) be an affiliated person of the listed company
or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board has undertaken
a review of its composition, the composition of its committees and the independence of each director. Based upon information requested
from and provided by each director concerning his or her background, employment and affiliations, including family relationships,
our Board has determined that Messrs. Melton, Alila , Glynn and Young do not have any relationships that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &ldquo;independent&rdquo;
as that term is defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq.
In making this determination, our Board considered the current and prior relationships that each non-employee director has with
our company and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial
ownership of our capital stock by each non-employee director.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In making this determination,
our Board considered the current and prior relationships that each non-employee director has with us and all other facts and
circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock
by each non-employee director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board has established
Audit, Compensation, and Nominating and Corporative Governance Committees. Our Board may establish other committees to facilitate
the management of our business. The composition and functions of the audit committee, compensation committee and nominating and
corporate governance committee are described below. Members will serve on committees until their resignation or removal from the
Board or until otherwise determined by our Board.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our audit committee
consists of Messrs. Melton, Glynn and Alila with Mr. Melton serving as the chairman. Our Board has determined that Mr. Melton
is an &ldquo;audit committee financial expert&rdquo; within the meaning of the SEC regulations. Our Board has also determined
that each member of our audit committee can read and understand fundamental financial statements in accordance with applicable
requirements. In arriving at these determinations, the Board has examined each audit committee member&rsquo;s scope of experience
and the nature of their employment in the corporate finance sector. The functions of this committee include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping to ensure
    the independence and performance of the independent registered public accounting firm;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the scope
    and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent
    accountants, our interim and year-end operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing procedures
    for employees to submit concerns anonymously about questionable accounting or audit matters;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our policies
    on risk assessment and risk management;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing related
    party transactions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and reviewing
    a report by the independent registered public accounting firm at least annually, that describes our internal quality-control
    procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable
    law; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving (or, as
    permitted, pre-approving) all audit and all permissible non-audit services, other than de minimis non-audit services, to be
    performed by the independent registered public accounting firm.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our compensation committee
consists of Messrs. Melton, Glynn, Alila and Young with Mr. Young serving as the chairman. The functions of the compensation committee
will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving, or recommending that our Board approve, the compensation of our executive officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    that our Board approve the compensation of our directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving,
    or recommending that our Board approve, the terms of compensatory arrangements with our executive officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering our
    stock and equity incentive plans;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting independent
    compensation consultants and assessing conflict of interest compensation advisers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving,
    or recommending that our Board approve, incentive compensation and equity plans; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and establishing
    general policies relating to compensation and benefits of our employees and reviewing our overall compensation philosophy.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our nominating and
corporate governance committee consists of Messrs. Melton, Glynn and Young with Mr. Young serving as the chairman. The functions
of the nominating and governance committee will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    and recommending candidates for membership on our Board;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">including nominees
    recommended by stockholders;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    the composition of our committees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our code
    of business conduct and ethics, corporate governance guidelines and reporting; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations
    to our Board concerning governance matters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The nominating and corporate
governance committee also annually reviews the nominating and corporate governance committee charter and the committee&rsquo;s
performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board Leadership Structure and Role in Risk
Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board is primarily
responsible for overseeing our risk management processes. Our Board receives and reviews periodic reports from management, auditors,
legal counsel, and others, as considered appropriate regarding our assessment of risks. Our Board focuses on the most significant
risks we face our general risk management strategy, and also ensures that risks we undertake are consistent with our Board&rsquo;s
appetite for risk. While our Board oversees our risk management, management is responsible for day-to-day risk management processes.
We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our Board
leadership structure supports this approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended and restated
bylaws provide our Board with flexibility in its discretion to combine or separate the positions of Chairman of the Board and
Chief Executive Officer. The Board currently separates the roles of Chief Executive Officer and Chairman of the Board in recognition
of the differences between the two roles. Our Chief Executive Officer, who is also a member of our Board, is responsible for setting
the strategic direction of the Company and the day-to-day leadership and performance of the Company, while the Chairman of the
Board provides guidance to the Chief Executive Officer, sets the agenda for the Board meetings, presides over meetings of the
Board and tries to reach a consensus on Board decisions. Although these roles are currently separate, the Board believes it should
be able to freely select the Chairman of the Board based on criteria that it deems to be in the best interest of the Company and
its stockholders, and therefore one person may, in the future, serve as both the Chief Executive Officer and Chairman of the Board.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have adopted a code
of ethics and conduct applicable to all of our directors, officers, employees and all persons performing similar functions. A
copy of that code is attached as Exhibit 14.1 to the Registration Statement of which this prospectus forms a part thereof. We
expect that any amendments to the code, or any waivers of its requirements, will be disclosed in our public filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Corporate
Governance Guidelines</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have adopted a corporate
governance guidelines that serve as a flexible framework within which our Board and its committees operate. These guidelines cover
a number of areas including the size and composition of the Board, Board membership criteria and director qualifications, director
responsibilities, Board agenda, roles of the chairman of the Board and Chief Executive Officer and Chief Financial Officer, meetings
of independent directors, committee responsibilities and assignments, Board member access to management and independent advisors,
director communications with third parties, director compensation, director orientation and continuing education, evaluation of
senior management and management succession planning. A copy of our corporate governance guidelines is attached hereto as Exhibit
14.2 to the Registration Statement of which this prospectus forms a part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To our knowledge, our directors
and executive officers have not been involved in any of the following events during the past ten years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-size: 10pt">any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="ExecutiveCompensation"></A><B>EXECUTIVE
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">No
compensation was paid to our principal executive officer and our two other most highly compensated executive officers during the
fiscal years indicated below.</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name and Principal <BR> Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary<BR> ($)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus<BR> ($)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Awards ($)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards ($)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All Other Compensation ($)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Compensation ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brian
    S. John<SUP>(1)</SUP></B></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">2019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">5,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">5,000&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: justify">Chief Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richard Miller<SUP>(2)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Chief Operating Officer and former Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Dr. Glynn Wilson<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Chairman of the Board and Head of Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Mr. John was appointed
                                         as Chief Executive Officer on Oct<FONT STYLE="font-size: 10pt">ober 28, 2018.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>2.</TD><TD STYLE="text-align: justify">Mr. Miller was appointed as Chief Financial Officer on November 1,
                          2018. Mr. Miller transitioned from Chief Financial Officer to Chief Operating Officer on August 15,
                          2019.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>3.</TD><TD STYLE="text-align: justify">Dr. Wilson was appointed as a director in November 2018 and as Chairman
                          on October 15, 2019.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employment Agreements with Named Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 1,
2020, we entered into a written employment agreement with Brian John, pursuant to which Mr. John shall serve as our Chief
Executive Officer (the &ldquo;John Employment Agreement&rdquo;). The John Employment Agreement has an initial term from
February 1, 2020 through January 1, 2021, and shall automatically renew for one (1) year periods unless otherwise terminated
by either party. Mr. John shall be paid a salary of $125,000 (the &ldquo;Base Salary&rdquo;) for the period commencing
February 1, 2020 and ending January 1, 2021, with such Base Salary increasing by 10% for each renewal term. Mr. John shall
also be entitled to a quarterly cash bonus as follows: 5% of net revenues up to $1 Million; plus 4% of the second $1 Million
in net revenues; plus 3% of the third $1 Million in net revenues; plus 2% of the fourth $1 Million in net revenues; plus 1%
of all net revenues in excess of $4 Million; provided, that: (i) the bonus is subject to a cap of $2 Million; and (ii) the
bonus may be paid, at the election of Mr. John, in cash or shares of our common stock (calculated at the fair market value of
such shares as determined by the Board). In the event of Mr. John&rsquo;s death during the term of the John Employment
Agreement, his Base Salary at that time shall be paid to his designated beneficiary, or, in the absence of such designation,
to his estate or other legal representative, for three (3) months from the date of death. In addition, all granted but
unvested stock options shall immediately vest and all vested but unexercised stock options shall remain exercisable by Mr.
John&rsquo;s designated beneficiary, or, in the absence of such designation, to his estate or other legal representative,
through the term of such stock options. In the event of Mr. John&rsquo;s disability, he shall be entitled to compensation in
accordance with our disability compensation practice for senior executives, including any separate arrangement or policy
covering him, but in all events he shall continue to receive his Base Salary at the time of his disability for a for a period
of three (3) months beginning on the date the disability is deemed to have occurred. In addition, all granted but unvested
stock options shall immediately vest and all vested but unexercised stock options shall remain exercisable by Mr. John
through the term of such stock options. In the event we terminate the John Employment Agreement without cause, Mr. John shall
continue to carry out his responsibilities under the John Employment Agreement for one month and shall be paid his normal
Base Salary. In addition, upon such termination without cause, we shall pay Mr. John a lump sum equal to his entire remaining
Base Salary under the John Employment Agreement, all granted but unvested stock options shall immediately vest and all vested
but unexercised stock options shall remain exercisable by Mr. John through the term of such stock options. In the event of a
Change in Control or Attempted Change in Control, each as defined in the John Employment Agreement attached hereto as Exhibit
10.8, during the term of the John Employment Agreement, Mr. John shall have the right to terminate the John Employment
Agreement upon thirty (30) days&rsquo; written notice given at any time within one year after the occurrence of such event,
and Mr. John shall be entitled to the same compensation as if the John Employment Agreement was terminated without
cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 1, 2020,
we entered into a written employment agreement with Richard Miller, pursuant to which Mr. Miller shall serve as our Chief Operating
Officer (the &ldquo;Miller Employment Agreement&rdquo;). The Miller Employment Agreement has a term of one (1) year and shall
automatically renew for one (1) year periods unless otherwise terminated by either party. Mr. Miller shall be paid a salary of
$100,000 (the &ldquo;Miller Base Salary&rdquo;) for the period commencing February 1, 2020 and ending February 1, 2021, with such
Miller Base Salary increasing by 10% for each renewal term. Mr. Miller shall also be entitled to a quarterly cash bonus as follows:
5% of net revenues up to $1 Million; plus 4% of the second $1 Million in net revenues; plus 3% of the third $1 Million in net
revenues; plus 2% of the fourth $1 Million in net revenues; plus 1% of all net revenues in excess of $4 Million; provided, that:
(i) the bonus is subject to a cap of $2 Million; and (ii) the bonus may be paid, at the election of Mr. Miller, in cash or shares
of our common stock (calculated at the fair market value of such shares as determined by the Board). In the event of Mr. Miller&rsquo;s
death during the term of the Miller Employment Agreement, his Miller Base Salary at that time shall be paid to his designated
beneficiary, or, in the absence of such designation, to his estate or other legal representative, for three (3) months from the
date of death. In addition, all granted but unvested stock options shall immediately vest and all vested but unexercised stock
options shall remain exercisable by Mr. Miller&rsquo;s designated beneficiary, or, in the absence of such designation, to his
estate or other legal representative, through the term of such stock options. In the event of Mr. Miller&rsquo;s disability, he
shall be entitled to compensation in accordance with our disability compensation practice for senior executives, including any
separate arrangement or policy covering him, but in all events he shall continue to receive the Miller Base Salary at the time
of his disability for a for a period of three (3) months beginning on the date the disability is deemed to have occurred. In addition,
all granted but unvested stock options shall immediately vest and all vested but unexercised stock options shall remain exercisable
by Mr. Miller through the term of such stock options. In the event we terminate the Miller Employment Agreement without cause,
Mr. Miller shall continue to carry out his responsibilities under the Miller Employment Agreement for one month and shall be paid
his normal Miller Base Salary. In addition, upon such termination without cause, we shall pay Mr. Miller a lump sum equal to his
entire remaining Miller Base Salary under the John Employment Agreement, all granted but unvested stock options shall immediately
vest and all vested but unexercised stock options shall remain exercisable by Mr. Miller through the term of such stock options.
In the event of a Change in Control or Attempted Change in Control, each as defined in the Miller Employment Agreement attached
hereto as Exhibit 10.9, during the term of the Miller Employment Agreement, Mr. Miller shall have the right to terminate the
Miller Employment Agreement upon thirty (30) days&rsquo; written notice given at any time within one year after the occurrence
of such event, and Mr. Miller shall be entitled to the same compensation as if the Miller Employment Agreement was terminated
without cause.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 5, 2019 (the
&ldquo;McKinnon Execution Date&rdquo;), we entered into a written employment agreement with Douglas McKinnon, pursuant to which
Mr. McKinnon shall serve as our Chief Financial Officer (the &ldquo;McKinnon Employment Agreement&rdquo;). Pursuant to the McKinnon
Employment Agreement, we shall grant Mr. McKinnon up to 300,000 shares of our common stock, whereby 100,000 shares shall be granted
to Mr. McKinnon and vest on the McKinnon Execution Date, either i) 100,000 shares or ii) an option to purchase 100,000 shares,
issued pursuant to our contemplated equity incentive plan, shall be granted to Mr. McKinnon on the first anniversary of the McKinnon
Execution Date, and either i) 100,000 shares or ii) an option to purchase 100,000 shares, issued pursuant to our contemplated
equity incentive plan, shall be granted to Mr. McKinnon on the second anniversary of the McKinnon Execution Date. The McKinnon
Employment Agreement has a term of three (3) years and shall automatically renew for one (1) year periods unless otherwise terminated
by either party. Mr. McKinnon shall be paid a salary in an amount commensurate with his position and responsibilities at similar
companies, subject to the mutual agreement between us and Mr. McKinnon. In the event we terminate the McKinnon Employment Agreement
without cause, we shall pay to Mr. McKinnon his base salary, including participation in all benefit programs, for one (1) year
or the remainder of the then-current term, whichever is more. In the event of either i) a change of control of the Company or
ii) we change the responsibilities of Mr. McKinnon, Mr. McKinnon shall have the option to terminate the McKinnon Employment Agreement
and shall be entitled to all compensation remaining to be paid during the then-current term of the McKinnon Employment Agreement
plus an additional one-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employment Agreements with Senior Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">On October 15, 2019,
(the &ldquo;Wilson Execution Date&rdquo;), we entered into a written employment agreement with Dr. Glynn Wilson, pursuant to which
Dr. Wilson shall serve as our Chairman of the Board and Head of Research and Development (the &ldquo;Wilson Employment Agreement&rdquo;).
Pursuant to the Wilson Employment Agreement, we shall grant Dr. Wilson up to 700,000 shares of our common stock, whereby 300,000
shares shall be granted to Dr. Wilson and vest on the Wilson Execution Date, either i) 200,000 shares or ii) an option to purchase
200,000 shares, issued pursuant to our contemplated equity incentive plan, shall be granted to Dr. Wilson on the first anniversary
of the Wilson Execution Date, and either i) 200,000 shares or ii) an option to purchase 200,000 shares, issued pursuant to our
contemplated equity incentive plan, shall be granted to Dr. Wilson on the second anniversary of the Wilson Execution Date. The
Wilson Employment Agreement has a term of three (3) years and shall automatically renew for one (1) year periods unless otherwise
terminated by either party. In the event we terminate the Wilson Employment Agreement without cause, we shall pay to Dr. Wilson
his base salary, including participation in all benefit programs, for one (1) year or the remainder of the then-current term,
whichever is more. In the event of either i) a change of control of the Company or ii) we change the responsibilities of Dr. Wilson,
Dr. Wilson shall have the option to terminate the Wilson Employment Agreement and shall be entitled to all compensation remaining
to be paid during the then-current term of the Wilson Employment Agreement plus an additional one-year period.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 22, 2020,
our Board of Directors and majority shareholders approved the Jupiter Wellness, Inc. 2020 Equity Incentive Plan (the &ldquo;Plan&rdquo;),
to be administered by the our Compensation Committee. Pursuant to the Plan, we are authorized to grant options and other equity
awards to officers, directors, employees and consultants. The purchase price of each share of common stock purchasable under an
award issued pursuant to the Plan, shall be determined by our Compensation Committee, in its sole discretion, at the time of grant,
but shall not be less than 100% of the fair market of such share of common stock on the date the award is granted, subject to
adjustment. Our Compensation Committee shall also have sole authority to set the terms of all awards at the time of grant.&nbsp;Pursuant
to the Plan, a maximum of 1,183,950 shares of our common stock shall be set aside and reserved for issuance, subject to adjustments
as may be required in accordance with the terms of the Plan.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End&nbsp;</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In connection with
the Employment Agreements described above, Mr. McKinnon and Dr. Wilson were authorized a grant of 100,000 shares and 300,000 shares,
respectively, of our common stock. As of December 31, 2019 and the date hereof, these shares had not been issued. There were no
other outstanding equity awards at the end of December 31, 2019.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 12pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Director
Compensation</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">During the year ended
December 31, 2018 we did not pay any compensation to our Directors. The following table sets forth the amounts paid to Directors
during the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><B>Directors</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid"><B>Amount</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Brian John</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">5,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Richard Miller</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Glynn Wilson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Hector Alila</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tim Glynn</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Christopher Melton</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Byron Young</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Agreements with Directors</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">On February 25, 2019
(the &ldquo;Alila Execution Date&rdquo;), we entered into an independent director&rsquo;s agreement with Dr. Hector Alila, pursuant
to which Dr. Alila shall serve as one of our directors (the &ldquo;Alila Agreement&rdquo;). Pursuant to the Alila Agreement, we
shall pay Dr. Alila $1,000 per quarter, per annum. Additionally, we shall issue to Mr. Alila an option to purchase 33,330 shares
of our common stock on the Alila Execution Date and for each additional year Dr. Alila serves as a director (the &ldquo;Alila
Options&rdquo;). The Alila Options shall have a three (3) year term and an exercise price of $0.25 per share and shall be issued
on each anniversary date of his election.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">On March 13, 2019 (the
&ldquo;Glynn Execution Date&rdquo;), we entered into an independent director&rsquo;s agreement with Timothy Glynn, pursuant to
which Mr. Glynn shall serve as one of our directors (the &ldquo;Glynn Agreement&rdquo;). Pursuant to the Glynn Agreement, we shall
pay Mr. Glynn $1,000 per quarter, per annum. Additionally, we shall issue to Mr. Glynn an option to purchase 50,000 shares of
our common stock on the Glynn Execution Date and for each additional year Mr. Glynn serves as a director (the &ldquo;Glynn Options&rdquo;).
The Glynn Options shall have a three (3) year term and an exercise price of $0.25 per share and shall be issued on each anniversary
date of his election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">On July 29, 2019 (the
&ldquo;Melton Execution Date&rdquo;), we entered into an independent director&rsquo;s agreement with Christopher Melton, pursuant
to which Mr. Melton shall serve as one of our directors and our Audit Committee Chairperson (the &ldquo;Melton Agreement&rdquo;).
Pursuant to the Melton Agreement, we shall pay Mr. Melton $1,000 per quarter, per annum. Additionally, we shall issue to Mr. Melton
an option to purchase 33,000 shares of our common stock on the Melton Execution Date and for each additional year Mr. Melton serves
as a director (the &ldquo;Melton Options&rdquo;). The Melton Options shall have a three (3) year term and an exercise price of
$0.25 per share and shall be issued on each anniversary date of his election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 25, 2019
(the &ldquo;Young Execution Date&rdquo;), we entered into an independent director&rsquo;s agreement with Byron Young, pursuant
to which Mr. Young shall serve as one of our directors (the &ldquo;Young Agreement&rdquo;). Pursuant to the Young Agreement, we
shall pay Mr. Young $1,000 per quarter, per annum. Additionally, we shall issue to Mr. Young an option to purchase 25,000 shares
of our common stock on the Young Execution Date and for each additional year Mr. Young serves as a director (the &ldquo;Young
Options&rdquo;). The Young Options shall have a three (3) year term and an exercise price of $1.00 per share and shall be issued
on each anniversary date of his election.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>



<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="CertainRelationships"></A><B>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Certain Relationships and Related Party Transactions</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 20, 2019, we
issued a Twenty-Five Thousand Dollar ($25,000) convertible promissory note (the &ldquo;Caro Note&rdquo;) for funds lent by Caro
Partners, LLC, a consulting company owned by our Founder, Chief Executive Officer and director, Brian S. John. The term of the
Caro Note is one year. The interest rate is ten percent (10%) non-compounded and payable semi-annually. The Caro Note is convertible
at any time by the Note holder at a conversion price of $0.25 per share of common stock. The Caro Note was paid in full in September
2019. As a result, no value was allocated to the conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 25, 2019, we
issued a Fifty Thousand Dollars ($50,000) convertible promissory note the (&ldquo;Wilson Note&rdquo;) for funds lent by Dr. Glynn
Wilson, one of our directors. The term of the Wilson Note is one year. The interest rate is ten percent (10%) non&ndash;compounded
and payable semi-annually. The Wilson Note is convertible at any time by the holder at a conversion price of $0.25 per share of
common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 31, 2019,
the Company issued a convertible promissory note for $250,000 to an entity run by a consultant of the Company. The note has a
term of one year, an annual interest rate of eight percent (8%), payable semi-annually, and convertible into the Company&rsquo;s
common stock at any time by the holders at a conversion price of $3.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="SecurityOwnershipOfCertainBeneficialOwnersAndManagmentAndRelatedStockholderMatters"></A>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>RELATED STOCKHOLDER MATTERS</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The following table
sets forth certain information with respect to the beneficial ownership of our voting securities by (i) any person or group beneficially
owning more than 5% of any class of voting securities; (ii) our directors, and; (iii) each of our named executive officers; and
(iv) all executive officers and directors as a group as of December 31, 2019. The information presented below regarding beneficial
ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and
is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a &ldquo;beneficial
owner&rdquo; of a security if that person has or shares the power to vote or direct the voting of the security or the power to
dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person
has the right to acquire sole or shared voting or investment power within 60 days through the conversion or exercise of any convertible
security, warrant, option or other right. More than one person may be deemed to be a beneficial owner of the same securities.
Unless otherwise indicated, the address of all listed stockholders is c/o Jupiter Wellness, Inc., 725 N. Hwy A1A, Suite C-106,
Jupiter, FL 33477.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Beneficial Owner</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock Beneficially Owned</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    of<BR>
    Common Stock Before Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    of Common Stock After Offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and Officers:</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
        S. John</FONT></P>
        <P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Executive Officer and Director</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43.52</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">38.00<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Doug McKinnon</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Chief Financial Officer</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0<SUP>(2)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
        Miller</FONT></P>
        <P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Operating Officer and Director</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,150,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.68</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">14.57<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glynn
        Wilson</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
        and Head of Research and Development</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000<SUP>(3)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">1.27<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Dr. Hector Alila</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Director</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">33,330<SUP>(4)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Tim Glynn</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Director</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">50,000<SUP>(4)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Christopher Melton</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Director</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">33,000<SUP>(4)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Byron
        Young</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director&nbsp;</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">25,000<SUP>(4)</SUP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">*<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">*</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All officers and directors (8 persons)</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,391,330</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.43</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">54.66<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beneficial owners of more than 5%</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secured and Collateralized Lending LLC<SUP>(5)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">345.000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.01</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">4.37<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0pt">*represents less than
1%</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes (i) no
                                                                                                                                                      exercise by the underwriters of their option to purchase 150,000 additional shares of common stock and/or 150,000 Warrants to
                                                                                                                                                      cover over-allotments, if any; (ii) no exercise of the underwriters&rsquo; warrants; (iii) issuance and sale of 1,000,000
                                                                                                                                                      Units in this offering; and (iv) no exercise of the Warrants included in the Units.</FONT></TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                         not included 100,000 shares authorized by our Board but not yet issued.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                         not included 300,000 shares authorized by our Board but not yet issued.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                         shares issuable upon the exercise of stock options at a price of $0.25 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>5.</TD><TD STYLE="text-align: justify">Secured and Collateralized Lending LLC is located <U>at 14 Elliott Ave</U>, <U>Suite #
                                        2</U>, <U>Bryn Mawr, PA 19010</U></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="SharesEligibleForFutureResale"></A><B>SHARES ELIGIBLE FOR FUTURE RESALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Prior to this offering,
there has been no market for our common stock. Future sales of substantial amounts of our common stock in the public market or
the perception that such sales might occur could adversely affect market prices prevailing from time to time. Furthermore, because
only a limited number of shares will be available for sale shortly after this offering due to existing contractual and legal restrictions
on resale as described below, there may be sales of substantial amounts of our common stock in the public market after the restrictions
lapse. This may adversely affect the prevailing market price of our common stock and our ability to raise equity capital in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">After completion of this
offering and after giving effect to the corporate reorganization, we will have shares of common stock outstanding (or shares if
the underwriters&rsquo; option to purchase additional shares is exercised in full).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">All of the shares of common
stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, unless
the shares are purchased by our &ldquo;affiliates&rdquo; as that term is defined in Rule 144 and except certain shares that will
be subject to the lock-up period described below after completion of this offering. Any shares owned by our affiliates may not
be resold except in compliance with Rule 144 volume limitations, manner of sale and notice requirements, pursuant to another applicable
exemption from registration or pursuant to an effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Any of the shares held
by our directors, officers and holders of at least 1% of our outstanding securities will be subject to 180-day lock-up restriction
described under &ldquo;Underwriting&rdquo; on page 44. Accordingly, there will be a corresponding increase in the number of shares
that become eligible for sale after the lock-up period expires. As a result of these agreements, subject to the provisions of
Rule 144 or Rule 701, shares will be available for sale in the public market as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning on the
    date of this prospectus, all of the shares sold in this offering will be immediately available for sale in the public market
    (except as described above); </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning 180
    days after the date of this prospectus, at the expiration of the lock-up period for our officers, directors and holders of
    at least 1% of our outstanding securities, 3,202,500&nbsp;additional shares will become eligible for sale in the public market,
    all of which shares will be held by affiliates and subject to the volume and other restrictions of Rule 144 and Rule 701 as
    described below.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Pursuant to certain
&ldquo;lock-up&rdquo; agreements, we, our executive officers, directors and holders of at least 1% of outstanding shares of our
common stock and securities exercisable for or convertible into our common stock outstanding immediately upon the closing of this
offering, have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise
dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement
that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of
any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or
subsequently acquired, without the prior written consent of the underwriters, for a period of 180 days from the date of effectiveness
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The lock-up period described in the preceding
paragraph will be automatically extended if: (1) during the last 17 days of the restricted period, we issue an earnings release
or announce material news or a material event; or (2) prior to the expiration of the lock-up period, we announce that we will
release earnings results during the 16-day period beginning on the last day of the lock-up period, in which case the restrictions
described in the preceding paragraph will continue to apply until the expiration of the 18-day period beginning on the date of
the earnings release, unless the underwriters waive this extension in writing; provided, however, that this lock-up period extension
shall not apply to the extent that FINRA has amended or repealed NASD Rule 2711(f)(4), or has otherwise provided written interpretive
guidance regarding such rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member of a national
securities association from publishing or distributing any research report, with respect to the securities of an emerging growth
company (as defined in the JOBS Act) prior to or after the expiration of any agreement between the broker, dealer, or member of
a national securities association and the emerging growth company or its stockholders that restricts or prohibits the sale of
securities held by the emerging growth company or its stockholders after an initial public offering date.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In general, under Rule 144
as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is
not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale
and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior
owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation
or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person
has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other
than our affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of
Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In general, under Rule 144,
as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration
of the lock-up agreements described above, within any three-month period, a number of shares that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of
    the number of shares of our common stock then outstanding, which will equal approximately shares immediately after this offering;
    or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly
    trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect
    to that sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Sales under Rule 144 by
our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and
notice requirements and to the availability of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Rule 701 generally
allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is not
deemed to have been our affiliate during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but
without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144.
Rule 701 also permits our affiliates to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements
of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus
before selling those shares pursuant to Rule 701 and are subject to the lock-up agreements described above.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="MaterialUSFederalIncomeTaxConsiderations"></A><B>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a
general discussion of certain material U.S. federal income tax considerations with respect to the ownership and disposition of
shares of our common stock and Warrants applicable to non-U.S. holders who acquire our securities in this offering. This discussion
is based on current provisions of the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and administrative
rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this
discussion, the term &ldquo;non-U.S. holder&rdquo; means a beneficial owner of our securities that is not, for U.S. federal income
tax purposes, a partnership or any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 85%"><FONT STYLE="font-size: 10pt">a citizen or resident of the United States; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">an estate, the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">a trust if (1) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (2) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person for U.S. federal income tax purposes. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds shares of our securities, the tax treatment of a person treated
as a partner generally will depend on the status of the partner and the activities of the partnership. Persons that for U.S. federal
income tax purposes are treated as a partner in a partnership holding shares of our securities should consult their tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This discussion assumes
that a non-U.S. holder holds shares of our securities as a capital asset within the meaning of Section 1221 of the Code (generally,
property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important
to a non-U.S. holder in light of that holder&rsquo;s particular circumstances or that may be applicable to holders subject to
special treatment under U.S. federal income tax law (including, for example, financial institutions, brokers or dealers in securities,
&ldquo;controlled foreign corporations,&rdquo; &ldquo;passive foreign investment companies,&rdquo; traders in securities that
elect mark-to-market treatment, insurance companies, tax-exempt entities, holders who acquired our securities pursuant to the
exercise of employee stock options or otherwise as compensation, entities or arrangements treated as partnerships for U.S. federal
income tax purposes, holders liable for the alternative minimum tax, certain former citizens or former long-term residents of
the United States and holders who hold our securities as part of a hedge, straddle, constructive sale or conversion transaction).
In addition, this discussion does not address U.S. federal tax laws other than those pertaining to the U.S. federal income tax,
nor does it address any aspects of the unearned income Medicare contribution tax pursuant to the Health Care and Education Reconciliation
Act of 2010, any U.S. federal estate and gift taxes, or any U.S. state, local or non-U.S. taxes. Accordingly, prospective investors
should consult with their own tax advisors regarding the U.S. federal, state, local, non-U.S. income and other tax considerations
of acquiring, holding and disposing of shares of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THIS SUMMARY IS FOR GENERAL INFORMATION
ONLY AND IS NOT INTENDED TO CONSTITUTE A COMPLETE DESCRIPTION OF ALL TAX CONSEQUENCES RELATING TO THE OWNERSHIP AND DISPOSITION
OF OUR SECURITIES. WE RECOMMEND THAT PROSPECTIVE HOLDERS OF OUR SECURITIES CONSULT WITH THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES
TO THEM (INCLUDING THE APPLICATION AND EFFECT OF ANY FEDERAL, STATE, LOCAL, NON-U.S. INCOME AND OTHER TAX LAWS) OF THE OWNERSHIP
AND DISPOSITION OF OUR SECURITIES. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Allocation of Investment in Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An investor in this
offering will be required to allocate cost of the acquisition of the securities between the shares of common stock and warrants
acquired based on their relative fair market values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dividends </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In general, any distributions we make to a non-U.S. holder with
respect to its shares of our common stock that constitute dividends for U.S. federal income tax purposes will be subject to U.S.
withholding tax at a rate of 30% of the gross amount (or a reduced rate prescribed by an applicable income tax treaty) unless the
dividends are effectively connected with a trade or business carried on by the non-U.S. holder within the United States (and, if
an income tax treaty applies, are attributable to a permanent establishment of the non-U.S. holder within the United States). A
distribution will constitute a dividend for U.S. federal income tax purposes to the extent of our current or accumulated earnings
and profits as determined for U.S. federal income tax purposes. Any distribution not constituting a dividend will be treated as
first reducing the adjusted basis in the non-U.S. holder&rsquo;s shares of our common stock and, to the extent it exceeds the adjusted
basis in the non-U.S. holder&rsquo;s shares of our common stock, as gain from the sale or exchange of such shares. Any such gain
will be subject to the treatment described below under &ldquo;&mdash;Gain on Sale or Other Disposition of our Common Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
below regarding &ldquo;&mdash;Foreign Account Tax Compliance,&rdquo; dividends effectively connected with a U.S. trade or business
(and, if an income tax treaty applies, attributable to a U.S. permanent establishment) of a non-U.S. holder generally will not
be subject to U.S. withholding tax if the non-U.S. holder complies with applicable certification and disclosure requirements. Instead,
such dividends generally will be subject to U.S. federal income tax on a net income basis, in the same manner as if the non-U.S.
holder were a resident of the United States. A non-U.S. holder that is a corporation may be subject to an additional &ldquo;branch
profits tax&rdquo; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on its &ldquo;effectively
connected earnings and profits,&rdquo; subject to certain adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Gain on Sale or Other Disposition of
Our Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In general, a non-U.S.
holder will not be subject to U.S. federal income or, subject to the discussion below under the headings &ldquo;Information Reporting
and Backup Withholding&rdquo; and &ldquo;Foreign Account Tax Compliance,&rdquo; withholding tax on any gain realized upon the
sale or other disposition of our securities unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with a trade or business carried on by the non-U.S. holder within the United States and, if
    required by an applicable income tax treaty, is attributable to a U.S. permanent establishment of the non-U.S. holder; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    non-U.S. holder is an individual and is present in the United States for 183 days or more in the taxable year of disposition
    and certain other conditions are satisfied; or </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are or have been a U.S. real property holding corporation (a &ldquo;USRPHC&rdquo;) for U.S. federal income tax purposes at
    any time within the shorter of the five-year period ending on the date of the disposition and the non-U.S. holder&rsquo;s
    holding period and certain other conditions are satisfied. We believe that we currently are not and we do not anticipate becoming,
    a USRPHC. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Gain that is effectively
connected with the conduct of a trade or business in the United States generally will be subject to U.S. federal income tax, net
of certain deductions, at regular U.S. federal income tax rates. If the non-U.S. holder is a foreign corporation, the branch profits
tax described above also may apply to such effectively connected gain. An individual non-U.S. holder who is subject to U.S. federal
income tax because the non-U.S. holder was present in the United States for 183 days or more during the year of sale or other
disposition of our securities will generally be subject to a flat 30% tax on the gain derived from such sale or other disposition,
which may be offset by U.S. source capital losses, provided the Non-U.S. Holder has timely filed U.S. federal income tax returns
with respect to such losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Information Reporting and Backup Withholding
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We must report annually
to the Internal Revenue Service and to each non-U.S. holder the amount of dividends paid to and the tax withheld with respect to,
each non-U.S. holder. These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable
tax treaty. Copies of this information also may be made available under the provisions of a specific treaty or agreement with the
tax authorities in the country in which the non-U.S. holder resides or is established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">U.S. backup withholding
tax (currently, at a rate of 28%) is imposed on certain payments to persons that fail to furnish the information required under
the U.S. information reporting rules. Dividends paid to a non-U.S. holder generally will be exempt from backup withholding if the
non-U.S. holder provides a properly executed IRS Form W-8BEN or W-8BEN-E, or otherwise establishes an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under U.S. Treasury
regulations, the payment of proceeds from the disposition of our securities by a non-U.S. holder effected at a U.S. office of
a broker generally will be subject to information reporting and backup withholding, unless the beneficial owner, under penalties
of perjury, certifies, among other things, its status as a non-U.S. holder or otherwise establishes an exemption. The payment
of proceeds from the disposition of our securities by a non-U.S. holder effected at a non-U.S. office of a broker generally will
not be subject to backup withholding and information reporting, except in the case of proceeds from a disposition of our securities
by a non-U.S. holder effected at a non-U.S. office of a broker that is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    U.S. person; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    &ldquo;controlled foreign corporation&rdquo; for U.S. federal income tax purposes; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business;
    or </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    foreign partnership if at any time during its tax year (a) one or more of its partners are U.S. persons who, in the aggregate,
    hold more than 50% of the income or capital interests of the partnership, or (b) the foreign partnership is engaged in a U.S.
    trade or business. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information reporting will
apply unless the broker has documentary evidence in its files that the owner is a non-U.S. holder and certain other conditions
are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no knowledge or reason to know to
the contrary). Backup withholding will apply if the sale is subject to information reporting and the broker has actual knowledge
that the owner is a U.S. person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Backup withholding is
not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder generally can
be refunded or credited against the non-U.S. holder&rsquo;s U.S. federal income tax liability, if any, provided that the required
information is furnished to the Internal Revenue Service in a timely manner. Non-U.S. holders should consult their tax advisors
regarding the application of the information reporting and backup withholding rules to them.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Foreign Account Tax Compliance </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Sections 1471
through 1474 of the Code and the Treasury regulations and administrative guidance promulgated thereunder (collectively, &ldquo;FATCA&rdquo;),
a U.S. federal withholding tax of 30% generally is imposed on any dividends paid on our common stock and a U.S. federal withholding
tax of 30% generally will be imposed on gross proceeds from the disposition of our securities (beginning January 1, 2019) paid
to (i) a &ldquo;foreign financial institution&rdquo; (as specifically defined under FATCA) unless such institution enters into
an agreement with the U.S. tax authorities to withhold on certain payments and to collect and provide to the U.S. tax authorities
substantial information regarding U.S. account holders of such institution (which includes certain equity and debt holders of
such institution, as well as certain account holders that are foreign entities with U.S. owners) and (ii) certain other foreign
entities unless such entity provides the withholding agent with a certification identifying its direct and indirect &ldquo;substantial
U.S. owners&rdquo; (as defined under FATCA) or, alternatively, provides a certification that no such owners exist and, in either
case, complies with certain other requirements. The withholding tax described above will not apply if the foreign financial institution
or non-financial foreign entity otherwise qualifies for an exemption from the rules and properly certifies its exempt status to
a withholding agent or is deemed to be in compliance with FATCA. Application of FATCA tax does not depend on whether the payment
otherwise would be exempt from U.S. federal withholding tax under the other exemptions described above. Under certain circumstances,
a non-U.S. holder might be eligible for refunds or credits of such taxes. Foreign financial institutions and non-financial foreign
entities located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject
to different rules. Prospective non-U.S. holders should consult with their tax advisors regarding the possible implications of
FATCA on their investment in our securities.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="Underwriting"></A><B>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">WestPark Capital, Inc.
is acting as the book running manager of the offering, and we have entered into an underwriting agreement on the date of this
prospectus, with them as underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell
to the underwriters and the underwriters have agreed to purchase from us, at the public offering price per share less the underwriting
discounts set forth on the cover page of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The underwriters are
committed to purchase all the Units offered by us other than those covered by the option to purchase additional Units described
below, if they purchase any securities. The obligations of the underwriters may be terminated upon the occurrence of certain events
specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&rsquo; obligations
are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by
the underwriters of officers&rsquo; certificates and legal opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We
have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to
contribute to payments the underwriters may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The underwriters are
offering the Units, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters
by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Over-allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We have granted the
underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits
the underwriters to purchase a maximum of (i) 150,000 additional shares of common stock included in the Units, and/or (ii) Warrants
to purchase 150,000 shares of common stock included in the Units (15% of the shares of common stock and Warrants included in the
Units sold in this offering) from us in any combination thereof to cover over-allotments, if any. If the underwriters exercise
all or part of this option, they will purchase shares and/or Warrants covered by the option at the public offering price per share
and Warrant, respectively, that appears on the cover page of this prospectus, less the underwriting discount. If this option is
exercised in full, the total offering price to the public will be $8,625,000 and the total net proceeds, before expenses to us
will be $7,935,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Discount</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The
following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes
either no exercise or full exercise by the underwriters of their over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total <BR>
    Without Over-<BR>
    Allotment <BR>
    Option</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total <BR>
    With Over-<BR>
    Allotment <BR>
    Option</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">7.50</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">7,500,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right">8,625,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Underwriting discount (8%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">.60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">690,000</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">6.90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">6,500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">7.935,000</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The underwriters propose
to offer the Units offered by us to the public at the public offering price per Unit set forth on the cover of this prospectus.
In addition, the underwriters may offer some of the Units to other securities dealers at such price less a concession of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Unit. If all of the Units offered by us are not sold at the public offering price per Unit, the underwriters may change the
offering price per Unit and other selling terms by means of a supplement to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We
will pay the out-of-pocket accountable expenses of the underwriters in connection with this offering. The underwriting agreement,
however, provides that in the event the offering is terminated, any advance expense deposits paid to the underwriters will be returned
to the extent that offering expenses are not actually incurred in accordance with FINRA Rule 5110(f)(2)(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We have agreed to pay the underwriters an accountable expenses
allowance equal to 1.5% of the public offering price of the Units (excluding Units that we may sell to the underwriters to cover
over-allotments). We have also agreed to pay all expenses related to the offering, including, but not limited to: (a) all filing
fees and expenses relating to the registration of the securities with the Commission; (b) all FINRA Public Offering filing fees;
(c) all fees and expenses relating to the listing of our shares of common stock and Warrants on the Nasdaq Stock Market; (d) all
fees, expenses and disbursements relating to the registration or qualification of the securities under the &ldquo;blue sky&rdquo;
securities laws of such states and other jurisdictions as the underwriters may reasonably designate; (e) all fees, expenses and
disbursements relating to the registration, qualification or exemption of the securities under the securities laws of such foreign
jurisdictions as the underwriters may reasonably designate; (f) the costs of all mailing and printing of the offering documents;
(g) transfer and/or stamp taxes, if any, payable upon the transfer of securities from us to the underwriters; (h) the fees and
expenses of our accountants; (i) fees and expenses of Underwriters&rsquo; legal counsel not to exceed $75,000; and (i) up to an
aggregate of $75,000 for the costs associated with the use of book building, prospectus tracking and compliance software for the
offering; lucite tombstones and mementos; &ldquo;road show&rdquo; expenses; and background checks. The maximum amount of accountable
expenses to be reimbursed to the underwriters and related persons in connection with this offering (including fees and expenses
of counsel to the underwriters) is $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We have granted to
the underwriters an irrevocable right of first refusal to act as sole investment banker, sole book-runner or sole underwriter
in connection with any public underwriting or private placement of debt or equity securities for a period of one (1) year after
completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We estimate that the
total expenses of the offering payable by us, excluding underwriting discounts and commissions, will be approximately $337,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Discretionary Accounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Underwriters&rsquo; Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We have agreed to issue to the underwriters warrants to purchase
up to a total of 7% of the shares of common stock included in the Units to be sold in this offering (excluding the shares sold
through the exercise of the over-allotment option). The warrants are exercisable at $11.25&nbsp;per share (150% of the public offering
price) commencing on the effective date of the offering under this prospectus supplement and expiring five (5) years from the effective
date of the offering in compliance with FINRA Rule 5110(f)(2)(G). The warrants have been deemed compensation by FINRA and are therefore
subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. The underwriters (or their permitted assignees under the Rule)
will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it
engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition
of the warrants or the underlying securities for a period of 180 days from effectiveness. In addition, the warrants provide for
registration rights upon request, in certain cases. We will bear all fees and expenses attendant to registering the securities
issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price
and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of
a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant
exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Pursuant to certain
&ldquo;lock-up&rdquo; agreements, we, our executive officers, directors and holders of at least 1% of outstanding shares of our
common stock and securities exercisable for or convertible into our common stock outstanding immediately upon the closing of this
offering, have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise
dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement
that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of
any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or
subsequently acquired, without the prior written consent of the underwriters, for a period of 180 days from the date of effectiveness
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The lock-up period described
in the preceding paragraph will be automatically extended if: (1) during the last 17 days of the restricted period, we issue an
earnings release or announce material news or a material event; or (2) prior to the expiration of the lock-up period, we announce
that we will release earnings results during the 16-day period beginning on the last day of the lock-up period, in which case the
restrictions described in the preceding paragraph will continue to apply until the expiration of the 18-day period beginning on
the date of the earnings release, unless the underwriters waive this extension in writing; provided, however, that this lock-up
period extension shall not apply to the extent that FINRA has amended or repealed NASD Rule 2711(f)(4), or has otherwise provided
written interpretive guidance regarding such rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member
of a national securities association from publishing or distributing any research report, with respect to the securities of an
emerging growth company (as defined in the JOBS Act) prior to or after the expiration of any agreement between the broker, dealer,
or member of a national securities association and the emerging growth company or its stockholders that restricts or prohibits
the sale of securities held by the emerging growth company or its stockholders after an initial public offering date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Electronic Offer, Sale and Distribution
of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">A prospectus in electronic
format may be made available on the websites maintained by the underwriters, if any, participating in this offering and the underwriters
participating in this offering may distribute prospectuses electronically. The underwriters may agree to allocate a number of
Units for sale to its online brokerage account holders. Internet distributions will be allocated by the underwriters that will
make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information
on these websites is not part of, nor incorporated by reference into, this prospectus or the Registration Statement of which this
prospectus forms a part, has not been approved or endorsed by us or the underwriters in their capacity as underwriters, and should
not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stabilization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids and purchases to cover positions created by short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-size: 10pt">Stabilizing transactions permit bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the shares while the offering is in progress. </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Over-allotment transactions involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing shares in the open market. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-size: 10pt">Syndicate covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the over- allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering. </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Penalty bids permits the underwriters to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">These
stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market
price of our shares of common stock or preventing or retarding a decline in the market price of our shares of common stock. As
a result, the price of our common stock or warrants in the open market may be higher than it would otherwise be in the absence
of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions
described above may have on the price of our common stock. These transactions may be effected on The Nasdaq Capital Market, in
the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Passive Market Making</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In
connection with this offering, the underwriters may engage in passive market making transactions in our common stock on the Nasdaq
Capital Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers
or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid at
a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The
underwriters and their respective affiliates may, in the future provide various investment banking, commercial banking and other
financial services for us and our affiliates for which they have received, and may in the future receive, customary fees. However,
except as disclosed in this prospectus, we have no present arrangements with the underwriters for any further services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Offer Restrictions Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus
may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this
prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution
of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered
by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="DeterminationOfOfferingPrice"></A><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to this offering,
there has been no public market for our securities. The initial public offering price will be negotiated between the underwriters
and us. In determining the initial public offering price of the Units, the underwriters will consider, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prospects for our company and the industry in which we operate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our financial information;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial and operating
    information and market valuations of publicly traded companies engaged in activities similar to ours;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevailing
    conditions of U.S. securities markets at the time of this offering; including the novel coronavirus, COVID-19;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent market
    prices of, and the demand for, publicly traded shares of generally comparable companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our past and present
    financial and operating performance; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other factors deemed
    relevant by us and the underwriters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither we nor the
underwriters can assure investors that an active trading market will develop for our securities, or that our shares of common
stock and Warrants will trade in the public market at or above the initial public offering price.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="InterestOfNamedExpertsAndCounsel"></A><B>INTERESTS OF NAMED EXPERTS AND COUNSEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">No experts or counsel to
the Company have been hired on a contingent basis and none of them will receive a direct or indirect interest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="Experts"></A><B>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our financial statements
from October 24, 2018 (inception) through period ending December 31, 2018 and for the year ended December 31, 2019 have been audited
by M&amp;K CPAS, PLLC, an independent registered public accounting firm as set forth in its report and are included in reliance
upon such report given on the authority of such firm as experts in accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Magical Beasts,
LLC financial statements from December 12, 2017 (inception) through period ending December 31, 2018 and for the year ended December
31, 2019 have been audited by M&amp;K CPAS, PLLC, an independent registered public accounting firm as set forth in its report
and are included in reliance upon such report given on the authority of such firm as experts in accounting.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="LegalMatters"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sichenzia Ross Ference
LLP, New York, New York, will pass upon the validity of securities to be sold in this offering. Cozen O&rsquo;Connor P.C., Minneapolis,
Minnesota, will pass upon certain legal matters for the underwriters.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="WhereYouCanFIndAdditionalInformation"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering
to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained
in the registration statement and the exhibits, schedules and amendments to the registration statement. For further information
with respect to us and our securities, we refer you to the registration statement and to the exhibits and schedules to the registration
statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily
complete, and, in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the
registration statement. Each of these statements is qualified in all respects by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The SEC maintains a website,
which is located at <FONT STYLE="color: Blue"><U>www.sec.gov</U>,</FONT> that contains reports, proxy and information statements
and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which
this prospectus is a part at the SEC&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Upon completion of
this offering, we will be subject to the information reporting requirements of the Securities Exchange Act of 1934, and we will
file reports, proxy statements and other information with the SEC. All documents filed with the SEC are available for inspection
and copying at the public reference room and website of the SEC referred to above. We maintain a website at <FONT STYLE="color: Blue">www.jupiterwellnessinc.com</FONT>.
You may access our reports, proxy statements and other information free of charge at this website as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the SEC. The information on such website is not incorporated
by reference and is not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JUPITER WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="IndexToFinancialStatements" TITLE="Index To Financial Statements"></A>INDEX TO FINANCIAL STATEMENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Index"></A>PAGES</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ReportOfIndependentRegisteredPublicAccountingFirm">REPORT
    OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 53px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#BalanceSheet1">BALANCE
    SHEETS AS OF DECEMBER 31, 2019 and 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#IncomeStatement1">STATEMENTS
    OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER 31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#StockholdersEquity1">STATEMENT
    OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY (DEFICIT) FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM OCTOBER 24,
    2018 (INCEPTION) TO DECEMBER 31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#CashFlow1">STATEMENTS
    OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER 31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#NotesToFinancialStatements1">NOTES
    TO FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER
    31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">UNAUDITED</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#BalanceSheetJ03">BALANCE SHEETS AS OF MARCH 31, 2020 AND DECEMBER 31, 2019</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-14</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#IncomeSheetJ03">STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31,
    2020 AND 2019</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-15</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#EquityStatementJ03">STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY (DEFICIT) FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND FOR THE YEAR ENDED DECEMBER 31, 2019</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-16</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#CashFlowJ03">STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND FOR THE YEAR ENDED DECEMBER 31, 2019</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-17</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#NotesToFinancialStatementsJ03">NOTES TO FINANCIAL STATEMENTS FOR THE THREE MONTHS
    ENDED MARCH 31, 2020 AND FOR THE YEAR ENDED DECEMBER 31, 2019</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-18</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MAGICAL BEASTS, LLC&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#AcctReportMB">REPORT
    OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 53px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">F-30</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#BalanceSheetMB">BALANCE
    SHEETS AS OF DECEMBER 31, 2019 and 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">F-31</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#IncomeStatementMB">STATEMENTS
    OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM DECEMBER 12, 2017 (INCEPTION) TO DECEMBER 31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">F-32</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#EquityStatementMB">STATEMENT
    OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY (DEFICIT) FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM DECEMBER 12,
    2017 (INCEPTION) TO DECEMBER 31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">F-33</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#CashFlowMB">STATEMENTS
    OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM DECEMBER 12, 2018 (INCEPTION) TO DECEMBER 31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">F-34</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#NotesToFinancialStatementsMB">NOTES
    TO FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2019 AND FOR THE PERIOD FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER
    31, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">F-35</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 8pt"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 8pt"><B>&nbsp;<IMG SRC="image_004.jpg" ALT=""></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="ReportOfIndependentRegisteredPublicAccountingFirm"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stockholders of Jupiter Wellness, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"> We have audited the accompanying
balance sheets of Jupiter Wellness, Inc. (the Company) as of December 31, 2019 and December 31, 2018, and the related
statements of operations, stockholders&rsquo; equity (deficit), and cash flows for the year and period ending December 31,
2019 and from October 24, 2018 (Inception) through December 31, 2018 and the related notes (collectively referred to as the
financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2019 and 2018 and the results of its operations and its cash flows for the year
ended December 31, 2019 and from October 24, 2018 (Inception) through December 31, 2018 in conformity with accounting
principles generally accepted in the United States of America. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">These financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audit. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audit in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Our audit included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared assuming
the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company suffered losses from
operations which raise substantial doubt about its ability to continue as a going concern. Managements plans regarding those matters
are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; padding-right: 4.5pt; padding-left: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ M&amp;K CPAS, PLLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 83%; padding-right: 4.5pt; padding-left: 4.5pt; font: 11pt/11.75pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 17%; padding-right: 4.5pt; padding-left: 4.5pt; font: 11pt/11.75pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; padding-right: 4.5pt; padding-left: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&rsquo;s auditor since 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4.5pt; padding-left: 4.5pt; font: 11pt/11.75pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 4.5pt; font: 11pt/11.75pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt; font: 11pt/11.75pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston, TX</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/11.75pt Times New Roman, Times, Serif; padding-right: 4.5pt; padding-left: 4.5pt">June 17, 2020</TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 4.5pt; font: 11pt/11.75pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P></DIV>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="BalanceSheet1"></A>JUPITER WELLNESS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS OF DECEMBER 31, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Cash</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">531,026</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">161,316</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Due from third party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">135,478</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Account receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,911</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Right of use assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49,974</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Security Deposits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 30.1pt; padding-left: 5.4pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">745,789</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">191,316</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 30.1pt; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 30.1pt; padding-left: 5.4pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">745,789</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">191,316</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Liabilities and Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Accounts Payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Convertible notes payable to
    related parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Current portion of lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,566</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accrued liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,157</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 30.1pt; padding-left: 5.4pt">Total current Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">336,444</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Long-term portion lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30,137</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Total liabilities</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">366,581</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Preferred stock, $0.001 par value, 100,000 shares authorized of which none are issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Common stock, $.001 par value, 100,000,000 shares
    authorized, of which 6,893,000 and 5,958,000 shares issued and outstanding as of December 31, 2019 and 2018, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,893</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,958</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,032,511</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">238,542</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Subscription Receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(450</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated
    deficits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(985,196</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(59,734</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 30.1pt; padding-left: 5.4pt">Total Shareholders&rsquo; Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">379,208</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">184,316</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 30.1pt; padding-left: 5.4pt">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">745,789</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">191,316</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">The accompanying notes are an integral part of these financial statements</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P></DIV>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="IncomeStatement1"></A>JUPITER
WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STATEMENT OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEAR ENDED DECEMBER 31, 2019 AND
FOR THE PERIOD&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER
31, 2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom"><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended December 31, 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For
    the from October 24, 2018 (Inception) through December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><U>Revenue</U></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; padding-left: 5.4pt">Sales</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,455</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Cost
    of Sales</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">18,024</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross
    profit (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(11,569</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-left: 5.4pt">Operating
    expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">General
    and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">908,717</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">59,734</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Total operating expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">908,717</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,734</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Other income / (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
    income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,381</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
    expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,557</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Total other income / (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,176</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net
    (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(925,462</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(59,734</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Net (loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; padding-left: 5.4pt">Weighted average number of
    shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,301,219</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,364,113</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt">The accompanying
    notes are an integral part of these financial statements</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P></DIV>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="StockholdersEquity1"></A>JUPITER
WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEAR ENDED DECEMBER 31, 2019 AND
FOR THE PERIOD&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER
31, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common</B></FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
    Payable</B></FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid-In
    Capital</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subscription
    Receivable</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accumulated
    Deficits</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    October 24, 2018 (Inception)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">Founders shares of common stock issued for cash</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">5,000,000</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">5,000</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">4,500</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">(450</TD>
    <TD STYLE="vertical-align: bottom">)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">4,500</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">Common stock issued for cash</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">958,000</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">958</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">234,042</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">235,000</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (loss)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(59,734</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(59,734</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,958,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,958</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">238,542</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(450</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(59,734</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,316</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock issued for cash (net of offering expenses)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">935,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">935</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">761,065</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">762,000</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collection
    of subscription receivable</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">450</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">450</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock warrants issued as compensation</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,904</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,904</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock payable for services</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,000</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (loss)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925,462</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925,462</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">$</TD>
    <TD STYLE="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;325,000
    </FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,032,511</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(985,196</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">379,208</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="26" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accompanying notes are an integral part of these financial statements</FONT></TD>
    <TD STYLE="padding-bottom: 8pt; line-height: 107%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P></DIV>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="CashFlow1"></A>JUPITER WELLNESS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STATEMENT OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEAR ENDED DECEMBER 31, 2019 AND
FOR THE PERIOD&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FROM OCTOBER 24, 2018 (INCEPTION) TO DECEMBER
31, 2018 &nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Year ended December 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">For the from October 24, 2018 (Inception) through
    December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Net (loss)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(925,462</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(59,734</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt; padding-left: 5.4pt">Adjustments to reconcile net income to net cash provided
    by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of common
    stock to be issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock options issued for compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Due from third party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,911</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 40pt; padding-left: 5.4pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(135,478</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Right of use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,974</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,703</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Security deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 40pt; padding-left: 5.4pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 40pt; padding-left: 5.4pt">Accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,157</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">Net cash (used in) operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(692,740</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(82,734</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt; padding-left: 5.4pt">Repayment of notes payable &ndash; related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt; padding-left: 5.4pt">Proceeds from notes payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt; padding-left: 5.4pt">Proceeds from convertible promissory note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt; padding-left: 5.4pt">Collection of subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt; padding-left: 5.4pt">Proceeds from sales of common
    stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">762,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">244,050</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,062,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net increase in cash and cash
    equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">369,710</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">161,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Cash and cash equivalents at
    the beginning of the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">161,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Cash and cash equivalents at
    the end of the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">531,026</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">161,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Cash paid for income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center; padding-left: 5.4pt">The accompanying notes are an integral part of these financial
    statements</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></DIV>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="NotesToFinancialStatements1"></A>JUPITER
WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Year Ended December 31, 2019
and &nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>For the Period
From October 24, 2018 (Inception) through December 31, 2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 1 - Organization and Business
Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jupiter Wellness, Inc. (the &ldquo;Company&rdquo;)
was formed on October 24, 2018 under the laws of the State of Delaware, and is headquartered in Jupiter, Florida. The Company
is a leading cutting-edge wellness brand dedicated to exploring and developing multiple therapeutic and medical use for Cannabidiol
(CBD) in the treatment of various ailment and diseases such as cancer, arthritis, anxiety, insomnia, psoriasis, chronic pain amongst
others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2018, the Company had
not yet commenced any operations. During the year ended December 31, 2019, the Company generated revenue of $6,455. The Company&rsquo;s
activities through December 31, 2019 are primarily related to the Company&rsquo;s formation and the offering of its common stock
pursuant to the Form 1-A (as described in Note 6 below). The Company has selected December 31 as its fiscal year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Going Concern Consideration </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2019, the Company an accumulated deficit of $985,196, and the cash flow used in operations during the year ended
December 31, 2019 was $692,740. The Company has incurred and expects to continue to incur significant costs in pursuit of its
exploring and developing plans. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going
concern. Management has taken certain action and continues to implement changes designed to improve the Company&rsquo;s financial
results and operating cash flows.&nbsp;&nbsp;The actions involve certain cost-saving initiatives and growing strategies, including
(a) engage in very limited activities without incurring any liabilities that must be satisfied in cash until a source of funding
is secured; and (b) offer noncash consideration and seek for equity lines as a means of financing its operations. If the Company
is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to
cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities
through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 2 - Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements are presented
in conformity with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;) and pursuant to
the rules and regulations of US Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Emerging Growth Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is an &ldquo;emerging growth company,&rdquo;
as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &ldquo;Securities Act&rdquo;), as modified by the Jumpstart
our Business Startups Act of 2012, (the &ldquo;JOBS Act&rdquo;), and it may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to,
not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure
obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, Section 102(b)(1) of the JOBS Act
exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of
securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such
extended transition period which means that when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard. This may make comparison of the Company&rsquo;s financial statements with another public company
which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition
period difficult or impossible because of the potential differences in accounting standards used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all short-term investments
with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of cash flows.
There were no cash equivalents as of December 31, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Inventory</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Inventories are stated at the lower of
cost or market. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory
based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Inventory is based
upon the average cost method of accounting. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Net Loss per Common Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net income (loss) per common share is computed
pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per share is computed by
dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. If applicable,
diluted earnings per share assume the conversion, exercise or issuance of all common stock instruments such as options, warrants,
convertible securities and preferred stock, unless the effect is to reduce a loss or increase earnings per share. As such, options,
warrants, convertible securities and preferred stock are not considered in the calculations, as the impact of the potential common
shares would be to decrease the loss per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For
    the Year Ended December 31, 2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For
    the period from October 24, 2018 (Inception) to December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net
    (loss)</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(925,462</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(59,734</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Denominator
    for basic earnings per share - Weighted-average common shares issued and outstanding during the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,301,219</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,364,113</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Denominator
    for diluted earnings per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,301,219</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,364,113</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Basic
    (loss) per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Diluted
    (loss) per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Fair Value of Financial Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&rsquo;s assets
and liabilities, which qualify as financial instruments under ASC Topic 820, &ldquo;Fair Value Measurements and Disclosures,&rdquo;
approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates its revenue from the
sale of its products directly to the end user or distributor (collectively the &ldquo;customer&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenues by applying
the following steps in accordance with FASB Accounting Standards Codification 606 &ldquo;Revenue from Contracts with Customers&rdquo;
(&ldquo;ASC 606&rdquo;). Under ASC 606, revenues are recognized when control of the promised goods or services are transferred
to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or
services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized
as it fulfills its obligations under each of its agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
                                         the contract with a customer;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
                                         the performance obligations in the contract;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
                                         the transaction price;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
                                         the transaction price to performance obligations in the contract; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
                                         revenue as the performance obligation is satisfied.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company&rsquo;s performance obligations
are satisfied when goods or products are shipped on a FOB shipping point basis as title passes when shipped. Our product is generally
paid in advance of shipment or standard net 30 days and we offer no specific right of return, refund or warranty related to our
products except for cases of defective products of which there have been none to date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our revenue currently is generated from
one general product category of health care products with one performance obligation and geographically there are no specific
concentrations of our customer base to disaggregate our revenue stream. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV></DIV>



<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Accounts Receivable and Credit Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are generated from sales
of the Company&rsquo;s products. The Company provides an allowance for doubtful collections, which is based upon a review of outstanding
receivables, historical collection information, and existing economic conditions. As of December 31, 2019, the Company has not
recognized any allowance for doubtful collections.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock based compensation</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes compensation costs to
employees under FASB Accounting Standards Codification 718 &ldquo;Compensation - Stock Compensation&rdquo; (&ldquo;ASC 718&rdquo;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of
grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2018, the inception date, the
Company adopted ASU No. 2018-07&nbsp;&ldquo;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting.&rdquo;&nbsp;These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently
only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services.
Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under
ASC 740 Income Taxes (&ldquo;ASC 740&rdquo;). ASC 740 requires the recognition of deferred tax assets and liabilities for both
the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected
future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance
to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 also clarifies the accounting for uncertainty in income
taxes recognized in an enterprise&rsquo;s financial statements and prescribes a recognition threshold and measurement process for
financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also
provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
Based on the Company&rsquo;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring
recognition in the Company&rsquo;s financial statements. Since the Company was incorporated on October 24, 2018, the evaluation
was performed for 2018 and 2019 tax year which would be subject to examination. The Company believes that its income tax positions
and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material changes to its
financial position. The Company&rsquo;s policy for recording interest and penalties associated with audits is to record such items
as a component of income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s deferred tax asset at December 31, 2019 consists of net operating
loss carry forwards calculated using federal and state effective tax rates equating to approximately $120,000 less a valuation
allowance in the amount of approximately $120,000. Because of the Company&rsquo;s lack of earnings history, the deferred tax asset
has been fully offset by a valuation allowance in the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below reconciles the US federal
income tax rate to the effective rate for the years ended December 31, 2019 and 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2019</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Income Tax at Statutory Rate</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(21</TD><TD STYLE="width: 1%; text-align: left">%)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(21</TD><TD STYLE="width: 1%; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Effect of Operating Losses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>Related
parties</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows subtopic 850-10 of the
FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Section 850-10-20 the related parties
include a. affiliates of the Company; b. entities for which investments in their equity securities would be required, absent the
election of the fair value option under the Fair Value Option Subsection of Section 825&ndash;10&ndash;15, to be accounted for
by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts
that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f.
other parties with which the Company may deal if one party controls or can significantly influence the management or operating
policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate
interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties
or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that
one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements shall include disclosures
of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the
ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined
financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved;
b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of
the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income
statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding
period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent,
the terms and manner of settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies
to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s
own operations by issuing share-based payment awards. The standard will be effective for us in the first quarter of our fiscal
year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The adoption of this standard
is not expected to have a significant impact on the Company&rsquo;s results of operations, financial condition, cash flows, and
financial statement disclosures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #1C1A1C">In
May 2014, the FASB issued ASU No. 2014-09, <I>Revenue from Contracts with Customers (Topic 606) </I>(&quot;ASU 2014-09&quot;).
ASU 2014-09 will supersede virtually all existing revenue guidance. Under this update, an entity is required to recognize revenue
upon transfer of promised goods or services to customers</FONT><FONT STYLE="color: #444444">, </FONT><FONT STYLE="color: #1C1A1C">in
an amount that reflects the expected consideration received in exchange for those goods or services. As such, an entity will need
to use more judgment and make more estimates than under the current guidance. ASU 2014-09 is to be applied retrospectively either
to each prior reporting period presented in the financial statements, or only to the most current reporting period presented in
the financial statements with a cumulative effect adjustment to retained earnings. The Company has elected to apply the impact
(if any) of applying ASU 2014-09 to the most current reporting period presented in the financial statements with a cumulative
effect adjustment to retained earnings.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, Topic 842, &ldquo;Leases&rdquo;
was issued to replace the leases requirements in Topic 840, &ldquo;Leases&rdquo;. The main difference between previous GAAP and
Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases
under previous GAAP. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and
a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months
or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets
and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line
basis over the lease term. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. Topic
842 will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual
periods and is to be retrospectively applied. The Company has adopted this standard beginning January 1, 2019. The adoption of
this standard has not had a significant impact on the Company&rsquo;s results of operations, financial condition, cash flows,
and financial statement disclosures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 3 - Prepaid Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2019, the Company had prepaid
expenses of $25,000, consisting of offering expenses in connection with a pending fund raise.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 4 - Inventory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2019, the Company had inventory
of $135,478, consisting of finished goods, raw materials and packaging supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 5 - Convertible Notes Payable
&ndash; Related Parties&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 10, 2019, the Company entered
into a Twenty-Five Thousand Dollar ($25,000) Convertible Promissory Note (the &ldquo;Caro Note&rdquo;) with Caro Partners,
LLC (&ldquo;Caro&rdquo;), a consulting firm owned by Brian S. John, our Chief Executive Officer and a member of our Board of
Directors,. The term of the Caro Note was one year. The interest rate was ten percent (10%) non compounded and payable
semi-annually. The Caro Note was convertible at any time by Caro at a conversion price of $0.25 per share of common stock.
The Caro Note was paid in full in September 2019. As a result, no value was allocated to the conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2019, the aggregate
outstanding balance of notes payable to related parties (the &ldquo;Convertible Promissory Notes&rdquo;) was $300,000, net of
repayments of $25,000 in September 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the Convertible Promissory
Notes are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Convertible Promissory Note
for $50,000, dated July 2019, has a term of one year, an annual interest rate of ten percent (10%), which is non compounded
and payable semi-annually, and convertible into the Company&rsquo;s common stock at any time by the holder at a conversion
price of $0.25 per share, which is considered as the fair value of the Company&rsquo;s common stock based on the arm&rsquo;s
length equity transactions since there is no open market for the Company&rsquo;s common stock yet. As a result, the Company
determined that the conversion features contained in this Convertible Promissory Note should carry neither beneficial
conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The second Convertible Promissory Note
for $250,000, dated December 31, 2019, has a term of one year, an annual interest rate of eight percent (8%), effective on
December 31, 2019, which is non compounded and payable semi-annually, and convertible into the Company&rsquo;s common stock
at any time by the holders at a conversion price of $3.00 per share, which is considered as the fair value of the
Company&rsquo;s common stock based on the arm&rsquo;s length equity transactions since there is no open market for the
Company&rsquo;s common stock yet. As a result, the Company determined that the conversion features contained in the Note
should carry neither beneficial conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of
$2,181 related to the Convertible Promissory Notes during the year ended December 31, 2019, and the accrued interest payable of
$2,181 was included into accrued liabilities as of December 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 6 - Capital Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Common Stock</I></B> - The Company is
authorized to issue a total of 100,000,000 shares of common stock with par value of $0.001 and 100,000 shares of preferred stock
with par value of $0.001. As of December 31, 2019, 6,893,000 shares of common stock were issued and outstanding and no shares of
preferred stock were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Founder Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2018, 5,000,000 shares of
the Company&rsquo;s common stock were issued to the Founders of the Company (&ldquo;Founder Shares&rdquo;) for an aggregate amount
of $5,000 to the management of the Company, of which $4,550 was collected as of December 31, 2018 and $450 was collected during
the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Subscription Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2018 and 2019, approximately 14
investors submitted subscription agreements to the Company regarding the purchase of total 1,158,000 shares of the Company&rsquo;s
Common Stock by cash payment of total $289,500, or $0.25 per share, of which $239,500 was collected as of December 31, 2018 and
$50,000 was collected in 2019. The transaction was independently negotiated between the Company and the investors. The proceeds
from the subscription agreements mitigated the Company&rsquo;s cash pressure in short term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Regulation A Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2019, the Company filed a Form 1-A Regulation A Offering
Statement Under the Securities Act of 1933, as amended, and subsequent amendments thereto on July 29, 2019 and August 19, 2019
(the &ldquo;Form 1-A&rdquo;). On September 5, 2019, the Form 1-A was qualified by the Securities and Exchange Commission. Pursuant
to the Form 1-A, as of December 31, 2019, the Company has sold 735,000 shares of its common stock, $0.001 par value per share,
at a purchase price of $1.00 per share, resulting in gross proceeds of $785,000, before deducting offering expenses of $23,000.<B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Common Stock to be Issued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> During 2019, the Company granted 100,000
shares of its common stock to its Chief Financial Officer and 300,000 shares to its Chairman. The shares were valued at $0.25
and $1.00 per share, respectively, and the Company recognized a total of $325,000 as compensation expense for the year ended December
31, 2019. The shares had not been issued as of December 31, 2019. The shares were valued based upon the last price paid by third
parties for shares of our common stock. </P>



<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P></DIV>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 7 - Warrants and Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the subscription agreements
discussed in Note 6, during the years ended December 31, 2019 and 2018, the Company granted the subscribers a total of 1,158,000
warrants to purchase up to 1,158,000 shares of common stock at an exercise price of $0.50 per share, with a term of two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of these warrants was measured
using the Black-Scholes valuation model at the grant date. The table below sets forth the assumptions for Black-Scholes valuation
model on the respective reporting date.</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Reporting <BR> Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Relative Fair <BR> Value</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term <BR> (Years)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise <BR> Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Market <BR> Price on <BR>
    Grant Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Volatility <BR> Percentage</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Risk-free <BR> Rate</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">11/26/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">108,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0286</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: center">2/18/2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">30,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">0.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">0.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">717</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">0.0227</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4/3/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0233</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp; &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables summarize all warrant
outstanding as of December 31, 2019, and the related changes during this period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of <BR> Warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exercise <BR> Price</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Stock Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2018</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">958,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">200,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Expired</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance at December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,158,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants Exercisable at December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,158,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;In connection with four of our Directors,
Dr. Alila, Mr. Glynn, Mr. Meltion and Mr. Young, each entering into an Independent Director&rsquo;s Agreement, the Directors were
granted stock options to purchase a total of 141,330 shares of the Company&rsquo;s common stock. The options have a three-year
term with an exercise price between $0.25 and $3.00, and vest immediately. The Agreements call for an annual grant
of additional options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of these options was measured
using the Black-Scholes valuation model at the grant date. The table below sets forth the assumptions for Black-Scholes valuation
model on the respective reporting date.</P>

<P STYLE="font: 11pt/106% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reporting
    <BR>
    Date</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Options Granted</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    <BR>
    (Years)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    <BR>
    Price</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
    <BR>
    Price on <BR>
    Grant Date</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Volatility
    <BR>
    Percentage</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
    Value</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 43%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/25/19
    &ndash; 7/29/19</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,330</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">194-281</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,955</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/25/19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;25,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">193</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11,949</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company recognized $32,904 as compensation
expense in the financial statements for the year ended December 31, 2019. The market price was valued based upon the last price
paid by third parties for shares of our common stock. </P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 8 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an office lease dated
April 1, 2019 with a primary term of one-year plus two one-year extension at the Company&rsquo;s option. The base lease rate during
the primary term is $2,000 per month, and the monthly rate during the optional extension will be increased to $2,080 and $2,163,
respectively. The Company paid a total of $21,430 in rent and related fees during the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the new standard for lease reporting,
the company recorded a Right of Use Asset (&ldquo;ROU&rdquo;) and an offsetting lease liability of $64,327 representing the present
value of the future payments under the lease calculated using a 10% discount rate (the current borrowing rate of the company).
The ROU and lease liability are amortized over the three year life of the lease. The unamortized balances at December 31, 2019
were ROU of $49,974, current lease liability of $20,566 and non-current lease liability of $30,137. Additionally, the Company
recognized accreted interest expense of $4,376.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><I>Legal Proceedings</I></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">The Company may be subject to legal proceedings and
claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of
any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its
financial position, results of operations or liquidity.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P></DIV>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 9 - Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first quarter of 2020, the Company
issued three convertible notes of $25,000,$250,000 and $300,000 effective on January 2, 2020, January 23, 2020 and March 9, 2020,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $25,000 note has a one year term and accrues interest at an
annual interest rate of eight percent (8%) non compounded and payable semi-annually. The note is convertible into the Company&rsquo;s
common stock at any time by the note holder at a conversion price of $3.00 per share, which is considered as the fair value of
the Company&rsquo;s common stock based on the arm&rsquo;s length equity transactions since there is no open market for the Company&rsquo;s
common stock yet. As a result, the Company determined that the conversion features contained in the note should carry neither beneficial
conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $250,000 note has a one year term and accrues interest at an
annual interest rate of eight percent (8%) non compounded and payable semi-annually. The note is convertible into the Company&rsquo;s
common stock at any time by the note holder at a conversion price of $3.00 per share, which is considered as the fair value of
the Company&rsquo;s common stock based on the arm&rsquo;s length equity transactions since there is no open market for the Company&rsquo;s
common stock yet. As a result, the Company determined that the conversion features contained in the note should carry neither beneficial
conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $300,000 note has a one-year term and
accrues interest at an annual interest rate of eight percent (8%) non compounded and payable semi-annually. The note is convertible
into the Company&rsquo;s common stock at any time by the Note holder at a conversion price of $3.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 21, 2020, Jupiter Wellness
Inc. (&ldquo;Jupiter Sub&rdquo;), our wholly-owned subsidiary, entered into a membership interest purchase agreement with Magical
Beasts LLC (&ldquo;Magical Beasts&rdquo;), a Nevada limited liability corporation, and Krista Whitley, its sole interest holder,
pursuant to which Jupiter Sub acquired all of the membership interests in Magical Beasts (the &ldquo;Magical Beasts Acquisition&rdquo;)
in exchange for the following consideration:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000
                                         cash at closing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                         $1,000,000 promissory note, non-interest bearing, payable by us, due upon the earlier of i) the closing of
                                         this offering or ii) December 31, 2020; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         option to purchase 250,000 restricted shares of our common stock at an exercise price
                                         of $1.00 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Magical Beasts Acquisition,
Jupiter Sub shall enter into an executive employment agreement with Krista Whitley to act as our Director of Marketing, however,
until such agreement is entered into, Jupiter Sub shall pay Krista Whitley an annual salary of $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Magical Beasts Acquisition, on February
21, 2020, Jupiter Sub and Magical Beasts entered into a sales agency agreement (the &ldquo;Sales Agency Agreement&rdquo;), pursuant
to which Magical Beasts and Ms. Whitley will act as a sales agent for Jupiter Sub&rsquo;s products. The Sales Agency Agreement
shall terminate on December 31, 2020. The Magical Beasts&rsquo; Acquisition and the Sales Agency Agreement significantly expand
our sales and marketing capabilities. It has also significantly improved our web capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 21, 2020, Jupiter Sub entered into a sales distributor agreement (the
&ldquo;Distribution Agreement&rdquo;) with Ayako Holdings, Inc. (&ldquo;Ayako&rdquo;), a Nevada corporation, pursuant to which
Ayako retained Jupiter Sub as its exclusive sales and distribution agent for certain of its products. The Distribution Agreement,
as extended, shall terminate on December 31, 2022. The Distribution Agreement includes an intellectual property licensing agreement
(the &ldquo;Licensing Agreement&rdquo;) with Ayako, Magical Beasts and Happy Rat Licensing, LLC, a Nevada limited liability company,
(collectively, the &ldquo;Licensor&rdquo;), dated February 18, 2020, pursuant to which the Licensor assigned its rights, titles,
interests and claims to certain trademarks to Jupiter Wellness Marketing, Inc., as set forth in the Licensing Agreement. The Licensing
Agreement lists Jupiter Wellness Marketing, Inc. as the assignee, which is the registered doing business as name for Jupiter Sub.
The brands covered by the Distribution Agreement are &ldquo;Bella&rdquo;, &ldquo;Jack&rdquo;, &ldquo;Felix &amp; Ambrosia&rdquo;,
&ldquo;fitCBD&rdquo;, &ldquo;Black Belt CBD&rdquo;, and &ldquo;Wellness CBD 1937&rdquo;, which are all topical solutions containing
CBD
(collectively, the &ldquo;Brands&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The primary products that we started to
sell pursuant to the Distribution Agreement are &ldquo;1937 Comfort Cream&rdquo;, &ldquo;Wellness 1937 Temple Tonic&rdquo;, &ldquo;Felix
and Ambrosia CBD Infused Heel Stick Crack&rdquo; and related foot cream and a line of eye creams, anti- aging cream, anti-aging
mask and &ldquo;Bella Alpha C-Serum for Day&rdquo;. The 1937 Comfort Cream is a vegan, non-comedogenic cream. It is formulated
with a blend of natural oils including arnica, camphor, peppermint, Hawaiian cramp bark and other oils. The 8 ounce cream contains
1,000 mgs of 0% THC American grown industrial hemp derived oil. The Wellness 1937 CBD Temple Tonic is a three ounce rollerball
to apply to your temple or lower neck area. It contains an oil blend that includes jojoba oil infused with guarana, peppermint,
lavender, chamomile, eucalyptus, Hawaiian cramp bark and other oils. The three ounce roller contains 500 mgs of 0% THC American
grown industrial hemp derived CBD. The Felix and ambrosia CBD Infused Heel Stick and foot cream is a moisturizing balm for dry,
cracked heels. It is made with peppermint, lemon, aloe, tea tree oil, lavender, eucalyptus and other oils. It is infused with
0% THC American grown industrial hemp derived CBD. The antiaging eye cream, anti-aging day cream, anti-aging mask with AHA and
the Bella alpha C-Serum for day products all contain a mixture of oils and are infused with 0% THC American grown industrial hemp.
We have recently been selling them in a package called &ldquo;Quarantine Glow Up Package&rdquo; where you get one of each. All
our current brands can be found at <FONT STYLE="color: Blue">www.CBDCaring.com</FONT>. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020,
the Directors were granted an additional 83,330 options.&nbsp; The options have a three-year term with an exercise price between
$0.25 and $3.00.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P></DIV>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center"><A NAME="BalanceSheetJ03"></A>Jupiter Wellness, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">Condensed Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center; border-bottom: Black 2.5pt double">As of March 31, 2020 and
    December 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31, 2019</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 4.5pt">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-left: 4.5pt">Cash</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">358,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">531,026</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Due from third party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 4.5pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164,692</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,478</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Account receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,911</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Right of use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,974</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left; padding-left: 4.5pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">745,789</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Fixed assets, net of accumulated depreciation of $1,808</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Intangible assets, net of accumulated amortization of $12,898</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">944,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left; padding-left: 4.5pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">308,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 4.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,034,792</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">745,789</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Liabilities and Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Accounts Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,721</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Convertible notes payable to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">875,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Note payable issued in acquisition, net of discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">956,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Current portion of lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,566</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left; padding-left: 4.5pt">Accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,909</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,517</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,903,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">336,444</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Long-term portion lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,137</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,933,611</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">366,581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Preferred stock, $0.001 par value, 100,000 shares authorized of which
    none are issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 4.5pt">Common stock, $.001 par value, 100,000,000 shares authorized, of which 6,893,000 shares
    issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,893</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,893</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,236,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,032,511</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Common stock payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 4.5pt">Accumulated deficits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">(1,466,994</P>


</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(985,196</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 4.5pt">Total Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">101,181</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">379,208</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 4.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 4.5pt">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">2,034,792&nbsp;</P>


<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">745,789</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="9" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="text-align: center">The accompanying notes are an integral part of these unaudited financial statements</TD>
    </TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P></DIV>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV>&nbsp;</DIV>

<DIV><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom"><TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><A NAME="IncomeSheetJ03"></A>Jupiter
                                   Wellness, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Condensed Consolidated Statement
    of Operations</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 2.5pt double"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 4.5pt"><B>For
                                         the Three Months Ended March 31, 2020 and 2019</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Three Months Ended March 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For
    the Three Months Ended March 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenue</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%">Sales</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$&nbsp;</TD><TD STYLE="text-align: right; width: 12%">117,727&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cost of Sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative
    expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">482,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">73,541</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total operating expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">482,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,541</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income/(expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">846</TD><TD STYLE="text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,215</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net (loss)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(481,798</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(73,541</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net (loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.07</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Weighted average number of shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,893,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,057,556</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">The accompanying notes are an integral
    part of these unaudited financial statements</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></DIV>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="29" STYLE="font-weight: bold; text-align: center"><A NAME="EquityStatementJ03"></A>Jupiter Wellness, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="29" STYLE="font-weight: bold; text-align: center">Condensed Consolidated Statement of Changes in Stockholders' Equity</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="29" STYLE="text-align: center; border-bottom: Black 2.5pt double"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Three Months Ended March 31, 2020 and Year Ended December 31, 2019</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">Common</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Common</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Additional</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">Stock</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Stock</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Paid-In</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Subscription</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Accumulated</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Receivable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Deficits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%">Balance, December 31, 2018</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">5,958,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">5,958</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">238,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(450</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(59,734</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">184,316</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock issued for cash (net of offering expenses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">761,065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">762,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Collection of subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock warrants issued as compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,904</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,904</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net (loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(925,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(925,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance, December 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,893,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,893</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">325,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,032,511</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(985,196</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">379,208</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Acquisition consolidation - stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock options issued as compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,159</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(481,798</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(481,798</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance, March 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,893,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,893</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">325,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,236,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,466,994</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">101,181</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="29" STYLE="text-align: center; padding-left: 10pt">The accompanying notes are an integral part of these unaudited financial statements</TD></TR>
</TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></DIV>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center"><A NAME="CashFlowJ03"></A>Jupiter Wellness, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">Consolidated Statement of Cash Flows</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center; border-bottom: Black 2.5pt double"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 31.5pt"><B>For
                                         the Three Months Ended March 31, 2020 and 2019</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 31.5pt"><B>(Unaudited)&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended March 31, 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended March 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Net (loss)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(481,798</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(73,541</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net income to net cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,858</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in current operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt; text-align: left">Due from third party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(110,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63,463</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt; text-align: left">Right of Entry asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,149</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt; text-align: left">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,006</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; text-align: left">Security deposits and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,200</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,465</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,538</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; text-align: left">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt; text-align: left">Lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,771</TD><TD STYLE="text-align: left">)&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash (used in) operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(457,638</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(107,466</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Purchase of fixed assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(44,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(716</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash paid in acquisition</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(245,391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash (used in) investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(289,391</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(716</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from convertible debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">575,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Proceeds from sales of common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">575,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net increase (decrease) in cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(172,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(58,182</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at the beginning of the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">531,026</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">161,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at the end of the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">358,997</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">103,134</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,111,648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center">The accompanying notes are an integral part of these unaudited financial statements</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P></DIV>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="NotesToFinancialStatementsJ03"></A>JUPITER WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Three Months Ended March 31,
2020 and 2019</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 1 - Organization and Business
Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jupiter Wellness, Inc. (the
&ldquo;Company&rdquo;) was formed on October 24, 2018 as CBD Brands, Inc. under the laws of the State of Delaware, and is
headquartered in Jupiter, Florida. The Company is a leading cutting-edge wellness brand dedicated to exploring and developing
multiple therapeutic and medical use for Cannabidiol (CBD) in the treatment of various ailment and diseases such as cancer,
arthritis, anxiety, insomnia, psoriasis, chronic pain amongst others.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Going Concern Consideration </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, the Company had $358,997 in cash, accumulated
deficit of $1,466,994, and the cash flow used in operation during the period ended March 31, 2020 was $457,638. The Company has
incurred and expects to continue to incur significant costs in pursuit of its exploring and developing plans. These conditions
raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management has taken certain action and
continues to implement changes designed to improve the Company&rsquo;s financial results and operating cash flows.&nbsp;&nbsp;The
actions involve certain cost-saving initiatives and growing strategies, including (a) engage in very limited activities without
incurring any liabilities that must be satisfied in cash until a source of funding is secured; and (b) offer noncash consideration
and seek for equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts
or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially
curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements
that may dilute the interests of existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 2 - Significant Accounting
Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial
statements are presented in conformity with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
and pursuant to the rules and regulations of US Securities and Exchange Commission (&ldquo;SEC&rdquo;). The consolidated financial
statements include the accounts of the Company and its wholly-owned subsidiaries, Jupiter Wellness, Inc., a Florida corporation,
and Magical Beasts, LLC, a Nevada limited liability company. All intercompany accounts and transactions have been eliminated.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Emerging Growth Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is an &ldquo;emerging growth
company,&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &ldquo;Securities Act&rdquo;), as modified
by the Jumpstart our Business Startups Act of 2012, (the &ldquo;JOBS Act&rdquo;), and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that
apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of the Company&rsquo;s financial statements with
another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using
the extended transition period difficult or impossible because of the potential differences in accounting standards used.&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P></DIV>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company considers all short-term
investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of
cash flows. There were no cash equivalents as of March 31, 2020.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Inventory</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Inventories are stated at the lower of
cost or market. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory
based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Inventory is based
upon the average cost method of accounting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Net Loss per Common Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net income (loss) per common share is computed
pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per share is computed by
dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. If applicable,
diluted earnings per share assume the conversion, exercise or issuance of all common stock instruments such as options, warrants,
convertible securities and preferred stock, unless the effect is to reduce a loss or increase earnings per share. As such, options,
warrants, convertible securities and preferred stock are not considered in the calculations, as the impact of the potential common
shares would be to decrease the loss per share.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Three Months Ended March 31, 2020</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Three Months Ended March 31, 2019</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Numerator:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 60%; padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (loss)</FONT></TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(481,798</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73,541</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Denominator:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator
    for basic earnings per share - Weighted-average common shares issued and outstanding during the period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057,556</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator
    for diluted earnings per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057,556</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    (loss) per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
    (loss) per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>Fair Value of Financial Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&rsquo;s assets
and liabilities, which qualify as financial instruments under ASC Topic 820, &ldquo;Fair Value Measurements and Disclosures,&rdquo;
approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates its revenue from
the sale of its products directly to the end user or distributor (collectively the &ldquo;customer&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenues by applying
the following steps in accordance with FASB Accounting Standards Codification 606 &ldquo;Revenue from Contracts with Customers&rdquo;
(&ldquo;ASC 606&rdquo;). Under ASC 606, revenues are recognized when control of the promised goods or services are transferred
to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or
services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized
as it fulfills its obligations under each of its agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract with a customer;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to performance obligations in the contract; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue as the performance obligation is satisfied.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company&rsquo;s performance obligations
are satisfied when goods or products are shipped on a FOB shipping point basis as title passes when shipped. Our product is generally
paid in advance of shipment or standard net 30 days and we offer no specific right of return, refund or warranty related to our
products except for cases of defective products of which there have been none to date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our revenue currently is generated from
one general product category of health care products with one performance obligation and geographically there are no specific
concentrations of our customer base to disaggregate our revenue stream. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;Accounts Receivable and Credit
Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are generated from
sales of the Company&rsquo;s products. The Company provides an allowance for doubtful collections, which is based upon a review
of outstanding receivables, historical collection information, and existing economic conditions. As of March 31, 2020 and December
31, 2019, the Company has not recognized any allowance for doubtful collections.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock based compensation</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes compensation costs
to employees under FASB Accounting Standards Codification 718 &ldquo;Compensation - Stock Compensation&rdquo; (&ldquo;ASC 718&rdquo;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the
grant-date fair value and recognize the costs in the financial statements over the period during which employees are required
to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods
of the option grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2018, the inception date,
the Company adopted ASU No. 2018-07&nbsp;&ldquo;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting.&rdquo;&nbsp;These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently
only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services.
Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under
ASC 740 Income Taxes (&ldquo;ASC 740&rdquo;). ASC 740 requires the recognition of deferred tax assets and liabilities for both
the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected
future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance
to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 also clarifies the accounting for
uncertainty in income taxes recognized in an enterprise&rsquo;s financial statements and prescribes a recognition threshold and
measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing
authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period,
disclosure and transition. Based on the Company&rsquo;s evaluation, it has been concluded that there are no significant uncertain
tax positions requiring recognition in the Company&rsquo;s financial statements. Since the Company was incorporated on October
24, 2018, the evaluation was performed for 2018 tax year which would be the only period subject to examination. The Company believes
that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result
in a material changes to its financial position. The Company&rsquo;s policy for recording interest and penalties associated with
audits is to record such items as a component of income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>Related
parties</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows subtopic 850-10 of
the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Section 850-10-20 the related
parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required,
absent the election of the fair value option under the Fair Value Option Subsection of Section 825&ndash;10&ndash;15, to be accounted
for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts
that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating
policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate
interests; and g. Other parties that can significantly influence the management or operating policies of the transacting parties
or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that
one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements shall
include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other
similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of
consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature
of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts
were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary
to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for
each of the periods for which income statements are presented and the effects of any change in the method of establishing the
terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet
presented and, if not otherwise apparent, the terms and manner of settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies
to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s
own operations by issuing share-based payment awards. The standard will be effective for us in the first quarter of our fiscal
year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The adoption of this standard
is not expected to have a significant impact on the Company&rsquo;s results of operations, financial condition, cash flows, and
financial statement disclosures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
<I>Revenue from Contracts with Customers (Topic 606) </I>(&ldquo;ASU 2014-09&rdquo;). ASU 2014-09 will supersede virtually all existing
revenue guidance. Under this update, an entity is required to recognize revenue upon transfer of promised goods or services to
customers, in an amount that reflects the expected consideration received in exchange for those goods or services. As such, an
entity will need to use more judgment and make more estimates than under the current guidance. ASU 2014-09 is to be applied retrospectively
either to each prior reporting period presented in the financial statements, or only to the most current reporting period presented
in the financial statements with a cumulative effect adjustment to retained earnings. The Company has elected to apply the impact
(if any) of applying ASU 2014-09 to the most current reporting period presented in the financial statements with a cumulative
effect adjustment to retained earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, Topic 842, &ldquo;Leases&rdquo;
was issued to replace the leases requirements in Topic 840, &ldquo;Leases&rdquo;. The main difference between previous GAAP and
Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases
under previous GAAP. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and
a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months
or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets
and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line
basis over the lease term. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. Topic
842 will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual
periods and is to be retrospectively applied. The Company has adopted this standard beginning January 1, 2019. The adoption of
this standard has not had a significant impact on the Company&rsquo;s results of operations, financial condition, cash flows,
and financial statement disclosures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 3 - Accounts Receivable </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">As of March 31, 2020 and December 31, 2019, the Company had
accounts receivable of $32,060 and $1,911, respectively consisting of sales of the Company&rsquo;s sunscreen products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 4 - Prepaid Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020 and December 31, 2019,
the Company had prepaid expenses of $135,375 and $25,000, respectively consisting of prepaid inventory items and offering expenses
in connection with a pending fund raise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 5 - Inventory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020 and December 31, 2019, the Company had inventory of $ 164,692 and
$135,478, consisting of finished goods, raw materials and packaging supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 6 </B>- <B>Intangible Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In connection with the acquisition of Magical
Beasts (see Note 11 below), the Company allocated the purchase price to intangible assets as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Tradenames &amp; trademarks</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">151,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer base</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">651,220</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Non-compete</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,266,210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Non-compete has an estimated life of
two years, the Customer base has an estimated life of fifteen years and the Tradenames &amp; trademarks and Goodwill have indefinite
life and will be reviewed at each subsequent reporting period to determine if the assets have been impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization for the three months ended
March 31, 2020 totaled $12,893.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 7 - Convertible Notes Payable
&ndash; Related Parties&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The 2019 Notes:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 10, 2019, the Company entered into
a Twenty-Five Thousand Dollar ($25,000) Convertible Promissory Note (the &ldquo;Caro Note&rdquo;) with Caro Partners, LLC (&ldquo;Caro&rdquo;),
a consulting firm owned by Brian S. John, our Chief Executive Officer and a member of our Board of Directors. The term of the
Caro Note was one year. The interest rate was ten percent (10%) non compounded and payable semi-annually. The Caro Note was convertible
at any time by Caro at a conversion price of $0.25 per share of common stock. The Caro Note was paid in full in September 2019.
As a result, no value was allocated to the conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, the
aggregate outstanding balance of notes payable to related parties (the &ldquo;Convertible Promissory Notes&rdquo;) was
$300,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the Convertible Promissory
Notes are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Convertible Promissory Note
for $50,000, dated July 2019, has a term of one year, an annual interest rate of ten percent (10%), which is non compounded
and payable semi-annually, and convertible into the Company&rsquo;s common stock at any time by the holder at a conversion
price of $0.25 per share, which is considered as the fair value of the Company&rsquo;s common stock based on the arm&rsquo;s
length equity transactions since there is no open market for the Company&rsquo;s common stock yet. As a result, the Company
determined that the conversion features contained in this Convertible Promissory Note should carry neither beneficial
conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The second Convertible Promissory Note
for $250,000, dated December 31, 2019, has a term of one year, an annual interest rate of eight percent (8%), effective on
December 31, 2019, which is non compounded and payable semi-annually, and convertible into the Company&rsquo;s common stock
at any time by the holders at a conversion price of $3.00 per share, which is considered as the fair value of the
Company&rsquo;s common stock based on the arm&rsquo;s length equity transactions since there is no open market for the
Company&rsquo;s common stock yet. As a result, the Company determined that the conversion features contained in the Note
should carry neither beneficial conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The 2020 Notes:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020, the Company issued three
convertible notes of $25,000, $250,000 and $300,000, effective on January 2, 2020, January 23, 2020 and March 9, 2020 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $25,000 note has a one-year term and accrues interest at an annual
interest rate of eight percent (8%) non compounded and payable semi-annually. The note is convertible into the Company&rsquo;s
common stock at any time by the note holder at a conversion price of $3.00 per share, which is considered as the fair value of
the Company&rsquo;s common stock based on the arm&rsquo;s length equity transactions since there is no open market for the Company&rsquo;s
common stock yet. As a result, the Company determined that the conversion features contained in the note should carry neither beneficial
conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $250,000 note has a one-year term and accrues interest at an annual
interest rate of eight percent (8%) non compounded and payable semi-annually. The note is convertible into the Company&rsquo;s
common stock at any time by the note holder at a conversion price of $3.00 per share, which is considered as the fair value of
the Company&rsquo;s common stock based on the arm&rsquo;s length equity transactions since there is no open market for the Company&rsquo;s
common stock yet. As a result, the Company determined that the conversion features contained in the note should carry neither beneficial
conversion feature nor derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $300,000 note has a one-year term and
accrues interest at an annual interest rate of eight percent (8%) non compounded and payable semi-annually. The note is convertible
into the Company&rsquo;s common stock at any time by the Note holder at a conversion price of $3.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of
$12,058 and $2,181 related to the Convertible Promissory Notes during the three months ended March 31, 2020 and year ended December
31, 2019. At March 31, 2020, the Company had accrued interest payable of $14,239.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 8 - Note payable issued in acquisition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Acquisition of Magical
Beasts, LLC (see Note 11) the Company issued a non-interest bearing $1,000,000 promissory note, due upon the earlier of i) the
closing of a public offering or ii) December 31, 2020. The note has been valued its discounted amount of $950,427. During the three
moths ended March 31, 2020, the company recognized $6,157 of interest expense for the accretion of the discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 9 - Capital Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Common Stock</I></B> - The Company
is authorized to issue a total of 100,000,000 shares of common stock with par value of $0.001 and 100,000 shares of preferred
stock with par value of $0.001. As of December 31, 2019, 6,893,000 shares of common stock were issued and outstanding and no shares
of preferred stock were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Founder Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2018, 5,000,000 shares of the Company&rsquo;s
common stock were issued to the Founders of the Company (&ldquo;Founder Shares&rdquo;) for an aggregate amount of $5,000 to the
management of the Company, of which $4,550 was collected as of December 31, 2018 and $450 was collected during the year ended
December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Subscription Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2018 and 2019, approximately 14
investors submitted subscription agreements to the Company regarding the purchase of total 1,158,000 shares of the Company&rsquo;s
Common Stock by cash payment of total $289,500, or $0.25 per share, of which $239,500 was collected as of December 31, 2018 and
$50,000 was collected in 2019. The transaction was independently negotiated between the Company and the investors. The proceeds
from the subscription agreements mitigated the Company&rsquo;s cash pressure in short term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Regulation A Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2019, the Company filed a Form 1-A Regulation A Offering
Statement Under the Securities Act of 1933, as amended, and subsequent amendments thereto on July 29, 2019 and August 19, 2019
(the &ldquo;Form 1-A&rdquo;). On September 5, 2019, the Form 1-A was qualified by the Securities and Exchange Commission. Pursuant
to the Form 1-A, as of December 31, 2019, the Company has sold 735,000 shares of its common stock, $0.001 par value per share,
at a purchase price of $1.00 per share, resulting in gross proceeds of $785,000, before deducting offering expenses of $23,000.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2019, the Company sold 200,000 shares of its Subscription
Shares and 735,000 Regulation Shares for a total of $785,000 less expenses of $23,000 (net $762,000).&nbsp; No
additional shares were sold during three months ended March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Common Stock to be issued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> During 2019 the Company granted 100,000
shares of its common stock to the Chief Financial Officer and 300,000 shares to its Chairman. The shares were valued at $0.25
and $1.00 per share, respectively and the Company recognized a total of $325,000 as compensation expense for the year ended December
31, 2019. The shares had not been issued as of December 31, 2019.&nbsp;The shares were valued based upon the last price paid by
third parties for shares of our common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 10 - Warrants and Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the subscription agreements
discussed in Note 6, during the years ended December 31, 2019 and 2018, the Company granted the subscribers a total of 1,158,000
warrants to purchase up to 1,158,000 shares of common stock at an exercise price of $0.50 per share, with a term of two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of these warrants was measured
using the Black-Scholes valuation model at the grant date. The table below sets forth the assumptions for Black-Scholes valuation
model on the respective reporting date.</P>

<P STYLE="font: 11pt/106% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reporting
    <BR>
    Date</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relative
    Fair <BR>
    Value</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    <BR>
    (Years)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    <BR>
    Price</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
    <BR>
    Price on <BR>
    Grant Date</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Volatility
    <BR>
    Percentage</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk-free
    <BR>
    Rate</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,163</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">717</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0286</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 46%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2019</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">717</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0227</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/3/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">717</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0233</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp; &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables summarize all warrant
outstanding as of March 31, 2020 and December 31, 2019, and the related changes during this period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of <BR>
    Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    <BR>
    Price</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31,
    2018</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">958,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,158,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at March 31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,158,000</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants Exercisable at March 31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,158,000</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2019, in connection with four
of our Directors, Dr. Alila, Mr. Glynn, Mr. Melton and Mr. Young, each entering into an Independent Director&rsquo;s
Agreement, the Directors were granted stock options to purchase a total of 141,330 shares of the Company&rsquo;s common
stock. The options have a three-year term with an exercise price between $0.25 and $3.00. Additionally, the Agreements call for the grant of additional options in a like amount annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31,
2020 the Directors were granted an additional 83,330 options. The options have a three-year term with an exercise price between
$0.25 and $3.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of these warrants was measured
using the Black-Scholes valuation model at the grant date. The table below sets forth the assumptions for Black-Scholes valuation
model on the respective reporting date.</P>

<P STYLE="font: 11pt/106% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Reporting <BR> Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Options Granted</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term <BR> (Years)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise <BR> Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Market <BR> Price on <BR> Grant Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Volatility <BR> Percentage</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: center">2/25/19 &ndash; 7/29/19</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">116,330</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">0.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">0.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 9pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font-size: 9pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">194-281</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 9pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font-size: 9pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">%</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">20,955</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">10/25/19</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">193</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;2/25/20</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">.025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28,180</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3/19/20</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,979</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company recognized $47,159 and $32,904
as compensation expense in the financial statements for the three months ended March 31, 2020 and the year ended December 31,
2019, respectively. The market price was valued based upon the last price paid by third parties for shares of our common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 11 - Acquisition of Magical Beasts,
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 21, 2020, Jupiter
Wellness Inc. (&ldquo;Jupiter Sub&rdquo;), our wholly-owned subsidiary, entered into a membership interest purchase agreement
with Magical Beasts LLC (&ldquo;Magical Beasts&rdquo;), a Nevada limited liability corporation, and Krista Whitley, its sole
interest holder, pursuant to which Jupiter Sub acquired all of the membership interests in Magical Beasts (the &ldquo;Magical
Beasts Acquisition&rdquo;) in exchange for the following consideration:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000 cash
    at closing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    $1,000,000 promissory note, non-interest bearing payable by us, due upon the earlier of i) the closing of this offering or ii)
    December 31, 2020 valued at its discounted amount of $950,427; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 3%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT> </TD>
    <TD STYLE="text-align: justify; width: 94%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    option to purchase 250,000 restricted shares of our common stock at an exercise price of $1.00 per share valued at $156,612.
    The fair value of these options was measured using the Black-Scholes valuation model at the grant date. The table below sets
    forth the assumptions for Black-Scholes valuation model on the reporting date. The market price was valued based upon the last price paid by third parties for shares of our common stock.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Reporting <BR>
    Date</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Number of Options
    Granted</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Term <BR>
    (Years)</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Exercise <BR>
    Price</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Market <BR>
    Price on <BR>
    Grant Date</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Volatility
    <BR>
    Percentage</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Fair Value</B></FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 44%; text-align: center"> <FONT STYLE="font-size: 10pt">2/21/20</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-size: 10pt">250,000</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-size: 10pt">5</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-size: 10pt">1.00</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-size: 10pt">1.00</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 5%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 9pt">&nbsp;77</FONT> </TD>
    <TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-size: 9pt">%</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-size: 10pt">156,612</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Magical Beasts
Acquisition, Jupiter Sub shall enter into an executive employment agreement with Krista Whitley to act as our Director of
Marketing, however, until such agreement is entered into, Jupiter Sub shall pay Krista Whitley an annual salary of
$150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Valuation and Purchase Price Allocation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to ASC 805, the standard of value
to be used in the application of purchase accounting rules is fair value. The Company utilized fair value defined in Statement
of Financial Accounting Standard No. 820&ndash;10&ndash;35&ndash;37 <I>Fair Value Measurements and Disclosures. </I>The determination
of the fair value of the consideration and related allocation of the purchase price was determined by management of the Company
with the assistance of a qualified professional valuation firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the consideration is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Cash</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Promissory Note, net of discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950,427</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Stock Options&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">156,612</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">Total Consideration paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,357,039</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price allocation is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Tangible assets</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">4,609</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">86,220</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total tangible assets</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">90,829</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Intangible assets</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"></P>


</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tradename-Trademarks</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">151,800</P>


</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer base</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">651,220</P>


</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-compete</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">154,500</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Intangibles</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">957,520</P>


</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">308,690</P>


</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif">1,357,039</P>


</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the promissory note above, the Company recognized
amortization of the discount on the note as interest expense of $6,157 from the date of closing through March 31, 2020.</P>



<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Supplemental proforma financial information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following shows the proforma results of operations as if the transaction had occurred effective January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JUPITER WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROFORMA BALANCE SHEETS</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Magical Beasts, LLC</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Jupiter Wellness, I.nc</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Consolidated Balance&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Adjustments&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Notes</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Balance</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">358,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">358,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">380,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">164,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739,283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">944,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,860</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(a)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">927,767</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,192</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,192</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,034,792</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,860</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,017,932</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">977,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,187</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Note payable issued in acquisition</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">956,584</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,613</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;(b)&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">965,197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,933,611</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,942,224</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,893</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,236,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,236,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Common stock payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Accumulated deficits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,466,994</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,473</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;(c)&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,492,467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">101,181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,473</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,708</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,034,792</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,860</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,017,932</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="18" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December
                                         31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Magical Beasts, LLC</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Reported Balance</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Reported Balance</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Adjustments&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Notes</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Balance</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">531,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">849</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(250,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;(d)&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">281,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current Assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">135,478</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">119,550</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">255,028</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">745,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">616,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907,270</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;(e)&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907,270</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;(e)&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">745,789</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">120,399</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,832,148</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">61,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Note payable issued in acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;(e)&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950,427</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">366,581</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,367,854</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,893</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,032,511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;(e)&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,273,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Common stock payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Accumulated deficits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(985,196</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;(f)&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,140,844</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">379,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">69,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">464,294</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">745,789</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">120,399</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,832,148</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Notes to Proforma Balance Sheets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="21" STYLE="text-align: left">(a) Additional amortization of the intangible assets</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="21" STYLE="text-align: left">(b) Additional amortization of debt discount on acquisition note</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="21" STYLE="text-align: left">(c) Income statement effects of notes (a) and (b) above</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(d) $250,000 paid at closing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="21" STYLE="text-align: left">(e) Allocation of the purchase price to respective assets and paid in capital
    (net of related amortization</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="21" STYLE="text-align: left">(f) Income statement effects of additional amortization of intangibles and acquisition
    note</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></DIV>

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></DIV>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JUPITER WELLNESS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROFORMA STATEMENT OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; text-align: center">Three Months Ended March 31, 2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Magical Beasts, LLC</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">Consolidated Balance&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Adjustments&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Notes</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Balance</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Sales</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">117,727</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">105,404</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;(a)&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: right">223,131</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;(a)&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">183,331</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">39,801</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">499,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74,804</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;(a)(b)&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">574,426</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Income (loss)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(481,798</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(52,827</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(534,426)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; text-align: center">Year
                                         Ended December 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">Magical Beasts, LLC</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Jupiter Wellness, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Reported Balance</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Reported Balance</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Adjustments&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Notes</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Proforma Balance</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">127,703</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,024</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">109,766</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">127,790</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,569</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,482</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(87)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">913,893</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">116,880</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">50,250</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,081,023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Income (loss)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(925,462</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">(50,250</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,081,110)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><B>Notes to Proforma Balance Sheets</B></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19" STYLE="text-align: left; padding-bottom: 2.5pt">(a) Magical Beasts income and cost of sales prior to closing date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="19" STYLE="text-align: left; padding-bottom: 2.5pt">(b) Includes additional amortization of intangibles plus expenses of Magical Beasts prior to closing</TD></TR>
</TABLE>


<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 12 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an office lease
dated April 1, 2019 with a primary term of one-year, plus two one-year extension at the Company&rsquo;s option. The base lease
rate during the primary term is $2,000 per month, and the monthly rate during the optional extension will be increased to $2,080
and $2,163, respectively. The Company paid a total of $12,258 and $21,430 in rent and related fees during the three months ended
March 31, 2020 and the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the new standard for lease reporting, the company recorded
a Right of Use Asset (&ldquo;ROU&rdquo;) and an offsetting lease liability of $64,327 representing the present value of the future
payments under the lease calculated using a 10% discount rate (the current borrowing rate of the company). The ROU and lease liability
are amortized over the three year life of the lease. The unamortized balances at March 31, 2020 and December 31, 2019 were ROU
of $44,959 and $49,974, respectively, current lease liability of $14,792 and $20,566, respectively, and non-current lease liability
of $30,138 and $30,138, respectively. Additionally, the Company recognized accreted interest expense of $4,377.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt"><I>Legal Proceedings</I></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">The Company may be subject to legal proceedings and
claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of
any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its
financial position, results of operations or liquidity.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 13 - Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with ASC Topic 855-10, the Company has analyzed
its operations subsequent to March 31, 2020 to the date these financial statements were issued, and has determined that it does
not have any material subsequent events to disclose in these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></DIV>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="AcctReportMB"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Member of Magical Beasts, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"> We have audited the accompanying
balance sheets of Magical Beasts, LLC. (the Company) as of December 31, 2019 and 2018, and the related statements of
operations, members&rsquo; equity (deficit), and cash flows for each of the years in the two-year period ended December 31,
2019 and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018 and the
results of its operations and its cash flows for each year in the two year period ended December 31, 2019 and December 31, 2018
in conformity with accounting principles generally accepted in the United States of America. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">These financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audit. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to
obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Our audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared assuming
the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company suffered losses from
operations which raise substantial doubt about its ability to continue as a going concern. Managements plans regarding those matters
are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the accompanying balance sheets of Magical Beasts,
LLC. (the Company) as of December 31, 2019 and 2018, and the related statements of operations, members&rsquo; equity (deficit),
and cash flows for each of the years in the two-year period ended December 31, 2019 and the related notes (collectively referred
to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2019 and 2018 and the results of its operations and its cash flows, in conformity with
accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">These financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audit. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to
obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Our audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared assuming
the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company suffered losses from
operations which raise substantial doubt about its ability to continue as a going concern. Managements plans regarding those matters
are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    M&amp;K CPAS, PLLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 84%; padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt">&nbsp;</TD>
    <TD STYLE="width: 16%; padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&rsquo;s auditor since 2020.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
    TX</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 4.5pt; padding-left: 4.5pt; line-height: 11.75pt">June 17, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B></B></P></DIV>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="BalanceSheetMB"></A>MAGICAL BEASTS, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS OF DECEMBER 31, 2019 and 2018</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December
    31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December
    31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Cash</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">849</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,550</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 30.1pt; padding-left: 5.4pt">Total
    current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">120,399</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 30.1pt; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 30.1pt; padding-left: 5.4pt">Total
    assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">120,399</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Liabilities and Member&rsquo;s
    Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Accounts Payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,846</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 30.1pt; padding-left: 5.4pt">Total
    current Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,846</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Member&rsquo;s capital account</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174,951</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated
    deficits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 30.1pt; padding-left: 5.4pt">Total
    Shareholders&rsquo; Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,553</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 30.1pt; padding-left: 5.4pt">Total
    Liabilities and Member&rsquo;s Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">120,399</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">The accompanying
    notes are an integral part of these financial statements</TD></TR>
</TABLE>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B></B></P></DIV>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0; font: 10pt/106% Times New Roman, Times, Serif; text-align: center"><B><A NAME="IncomeStatementMB"></A>MAGICAL
BEASTS, LLC</B></P>

<P STYLE="margin: 0; font: 10pt/106% Times New Roman, Times, Serif; text-align: center"><B>STATEMENT OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018 </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; padding-left: 5.4pt">Sales</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">121,248</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">Cost
    of Sales</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">109,766</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross
    profit (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,482</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-left: 5.4pt">Operating
    expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 20pt; padding-left: 5.4pt">General
    and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">116,880</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Total operating expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">116,880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net
    (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt">The accompanying
    notes are an integral part of these financial statements</TD></TR>
</TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P></DIV>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="EquityStatementMB"></A>MAGICAL
BEASTS, LLC.</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STATEMENT OF CHANGES IN MEMBERS&rsquo;
EQUITY FOR THE YEAR ENDED DECEMBER 31, 2019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital
    Contributions</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Accumulated
    Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif">Balance, December 12, 2017 (Inception)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Balance, December 31,
    2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Capital Contributions</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174,951</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174,951</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Balance, December 31,
    2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">174,951</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(105,398</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">69,553</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="13" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">The
    accompanying notes are an integral part of these financial statements</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></DIV>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="CashFlowMB"></A>MAGICAL BEASTS,
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STATEMENT OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018 &nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> December 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt; width: 56%">Cash flows
    from operating activities:</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Net (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(105,398</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Adjustments
    to reconcile net income to net cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;provided
    by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change
    in operating assets and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; padding-left: 5.4pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(119,550</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 40pt; padding-left: 5.4pt">Accounts
    payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">50,846</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Net cash (used in) operating
    activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(174,102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Cash flows from financing
    activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 20pt; padding-left: 5.4pt">Proceeds
    (net) from member capital contributions</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">174,951</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Net cash provided by financing
    activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174,951</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net
    increase in cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">849</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Cash
    and cash equivalents at the beginning of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Cash
    and cash equivalents at the end of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">849</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">The accompanying
    notes are an integral part of these financial statements</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></DIV>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="NotesToFinancialStatementsMB"></A>Magical
Beasts, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Years
    Ended December 31, 2019 and 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 1 - Organization and Business
Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Magical Beasts, LLC (the &ldquo;Company&rdquo;)
was formed on December 12, 2017 under the laws of the State of Nevada, and is headquartered in Las Vegas, Nevada. Magical Beasts,
LLC formulates, manufactures, and distributes CBD based products worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the year ended December
31, 2019, the Company generated revenue of $121,248. The activities through December 31, 2019 primarily related to the Company&rsquo;s
formation and distribution channels for sales of its products. The Company has selected December 31 as its fiscal year end.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Going Concern Consideration </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2019, the Company had
accumulated deficit of $105,398, and the cash flow used in operation during the year ended December 31, 2019 was $174,102 and
no operations during the period from inception (December 12, 2017) through December 31, 2018. The Company has incurred and expects
to continue to incur significant costs in pursuit of its marketing and expansion plans. These conditions raise substantial doubt
about the Company&rsquo;s ability to continue as a going concern. Management has taken certain action and continues to implement
changes designed to improve the Company&rsquo;s financial results and operating cash flows.&nbsp;&nbsp;The actions involve certain
cost-saving initiatives and growing strategies, including (a) engage in very limited activities without incurring any liabilities
that must be satisfied in cash until a source of funding is secured; and (b) offer noncash consideration and seek for equity lines
as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the
revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or
terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements
that may dilute the interests of existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 2 - Significant Accounting
Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements are
presented in conformity with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;) and
pursuant to the rules and regulations of US Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Emerging Growth Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is an &ldquo;emerging growth
company,&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended, (the &ldquo;Securities Act&rdquo;), as modified
by the Jumpstart our Business Startups Act of 2012, (the &ldquo;JOBS Act&rdquo;), and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that
apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of the Company&rsquo;s financial statements with
another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using
the extended transition period difficult or impossible because of the potential differences in accounting standards used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></DIV>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company considers all short-term
investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of
cash flows. There were no cash equivalents as of December 31, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Inventory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Inventories are stated at the lower of
cost or market. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory
based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Inventory is based
upon the average cost method of accounting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Fair Value of Financial Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&rsquo;s assets
and liabilities, which qualify as financial instruments under ASC Topic 820, &ldquo;Fair Value Measurements and Disclosures,&rdquo;
approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates its revenue from
the sale of its products directly to the end user or distributor (collectively the &ldquo;customer&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenues by applying
the following steps in accordance with FASB Accounting Standards Codification 606 &ldquo;Revenue from Contracts with Customers&rdquo;
(&ldquo;ASC 606&rdquo;). Under ASC 606, revenues are recognized when control of the promised goods or services are transferred
to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or
services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized
as it fulfills its obligations under each of its agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
                                         the contract with a customer;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
                                         the performance obligations in the contract;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
                                         the transaction price;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
                                         the transaction price to performance obligations in the contract; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
                                         revenue as the performance obligation is satisfied.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company&rsquo;s performance obligations
are satisfied when goods or products are shipped on a FOB shipping point basis as title passes when shipped. Our product is generally
paid in advance of shipment or standard net 30 days and we offer no specific right of return, refund or warranty related to our
products except for cases of defective products of which there have been none to date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our revenue currently is generated from
one general product category of health care products with one performance obligation and geographically there are no specific
concentrations of our customer base to disaggregate our revenue stream. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Accounts Receivable and Credit Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of the Company&rsquo;s products are
generated by the receipt of cash or cash equivalents at or before the sale. As such the Company does not carry any accounts receivable
and has no credit risk at this time. If the Company does begin generating accounts receivable in the course of its selling activities,
the Company will provide an allowance for doubtful collections based upon a review of outstanding receivables, historical collection
information, and existing economic conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a limited liability company
treated as a partnership for federal and state income tax purposes with all income tax liabilities and/or benefits of the Company
being passed through to the member. As such, no recognition of federal or state income taxes for the Company or its subsidiaries
that are organized as limited liability companies have been provided for in the accompanying consolidated financial statements.
Any uncertain tax position taken by the member is not an uncertain position of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the Company&rsquo;s
operating agreement, to the extent possible without impairing the Company&rsquo;s ability to continue to conduct its business
and activities, and in order to permit its member to pay taxes on the taxable income of the Company, the Company would be required
to make distributions to the member in the amount equal to the estimated tax liability of the member computed as if the member
paid income tax at the highest marginal federal and state rate applicable to an individual resident of Nevada, in the event that
taxable income is generated for the member. There was no taxable income and therefore no distributions in 2018 or 2019.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>Related
parties</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows subtopic 850-10 of
the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Pursuant to Section 850-10-20 the
related parties include (a) affiliates of the Company; (b) Entities for which investments in their equity securities would be
required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825&ndash;10&ndash;15,
to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and
profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management
of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management
or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its
own separate interests; and (g) Other parties that can significantly influence the management or operating policies of the transacting
parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent
that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements shall include
disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar
items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated
or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s)
involved; (b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed,
for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding
of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods
for which income statements are presented and the effects of any change in the method of establishing the terms from that used
in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if
not otherwise apparent, the terms and manner of settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies
to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s
own operations by issuing share-based payment awards. The standard will be effective for us in the first quarter of our fiscal
year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The adoption of this standard
is not expected to have a significant impact on the Company&rsquo;s results of operations, financial condition, cash flows, and
financial statement disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&ldquo;Revenue from Contracts with Customers&rdquo; (Topic 606) (&ldquo;ASU 2014-09&rdquo;). ASU 2014-09 will supersede virtually
all existing revenue guidance. Under this update, an entity is required to recognize revenue upon transfer of promised goods or
services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services.
As such, an entity will need to use more judgement and make more estimates than under the current guidance. ASU 2014-09 is to
be applied retrospectively either to each prior reporting period presented in the financial statement, or only to the most current
reporting period presented in the financial statements with a cumulative effect adjustment to retained earnings. The Company has
elected to apply the impact (if any) of applying ASU 2014-09 to the most current reporting period presented in the financial statements
with a cumulative effect adjustment to retained earnings. The adoption of this standard has had no impact on the Company&rsquo;s
results of operations, financial condition, cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, Topic 842, &ldquo;Leases&rdquo;
was issued to replace the leases requirements in Topic 840, &ldquo;Leases&rdquo;. The main difference between previous GAAP and
Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases
under previous GAAP. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and
a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months
or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets
and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line
basis over the lease term. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. Topic
842 will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual
periods and is to be retrospectively applied. The Company has adopted this standard beginning January 1, 2019. The adoption of
this standard has not had an impact on the Company&rsquo;s results of operations, financial condition, cash flows, and financial
statement disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 3 - Inventory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2019, the Company had
inventory of $119,550, consisting of finished goods, raw materials and packaging supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 4 - Member&rsquo;s Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue one
class of Membership Interests. The Membership Interests are not represented by certificates. The Company has only one member.
The initial contribution by the member was made by transferring
inventory to the Company valued at $ $204,467.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 5 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2019, the Company entered into an
office lease and a storage facility lease, each of which are on a month to month basis at the monthly rate of $1,250 and $400
respectively. The Company does not intend to use these facilities for more than a year and has elected not to recognize lease
assets and lease liabilities under ASC 842, the new standard for lease reporting. The Company paid a total of $3,505 in rent and
related fees during the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 6 - Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 21, 2020 the
Company and its sole member interest holder entered into a membership interest purchase agreement with Jupiter Wellness Inc.
(&ldquo;Jupiter&rdquo;), a Florida corporation and a wholly owned subsidiary of the Company, pursuant to which Jupiter
Sub acquired all of the membership interests in the Company in exchange for the following consideration:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000
                                         cash at closing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                         $1,000,000 promissory note, non-interest bearing, payable by Jupiter, due upon the earlier of i) the closing of
                                         a public  offering of Jupiter or ii) December 31, 2020; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         option to purchase 250,000 restricted shares of Jupiter common stock at an exercise price
                                         of $1.00 per share</FONT></TD></TR></TABLE>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#Index" TITLE="Index" STYLE="font-style: italic">Index</A></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_004.gif" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font: 16pt Times New Roman, Times, Serif"><B>WestPark
    Capital, Inc.</B></FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="text-align: center; font: 14pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><B>KINGSWOOD CAPITAL MARKETS</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;&nbsp; Division of Benchmark Investments, Inc.</P>

<P STYLE="margin: 0">&nbsp;</P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center; width: 100%"><IMG SRC="image_002.gif" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">Until</FONT> ,
all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver
a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 60 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II - INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 13. Other Expenses of Issuances and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table indicates
the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts
and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration
fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and The Nasdaq Capital Market application and listing
fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 84%"><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Capital Stock Market Application &amp; Listing Fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Legal fees and expenses*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Accounting fees and expenses*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Transfer Agent&rsquo;s fees and expenses*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Printer and engraving expenses*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Estimated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Item 14. Indemnification
of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jupiter Wellness, Inc.
is incorporated under the laws of the State of Delaware. Reference is made to Section 102(b)(7) of the General Corporation Law
of the State of Delaware, as amended (the &ldquo;DGCL&rdquo;), which enables a corporation in its original certificate of incorporation
or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director&rsquo;s fiduciary
duty, except (1) for any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (2) for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) pursuant to Section 174
of the DGCL, which provides for liability of directors for unlawful payments of dividends or unlawful stock purchase or redemptions
or (4) for any transaction from which the director derived an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 145(a) of the DGCL
provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other
than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if
he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the
corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 145(b) of the DGCL
provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because
the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with the defense or settlement
of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to
the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter
as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the adjudicating
court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is
fairly and reasonably entitled to indemnity for such expenses which the adjudicating court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 145(g) of the DGCL
provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such
person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation
would have the power to indemnify the person against such liability under Section 145 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our bylaws, subject to
the provisions of the DGCL, contain provisions which allow the corporation to indemnify any person against liabilities and other
expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service
to us if it is determined that person acted in good faith and in a manner which he reasonably believed was in the best interest
of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our
directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission,
such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As permitted by
the DGCL, the registrant has entered into separate indemnification agreements with each of the registrant&rsquo;s directors and
certain of the registrant&rsquo;s&nbsp;officers&nbsp;which require the registrant, among other things, to indemnify them against
certain liabilities which may arise by reason of their status as directors,&nbsp;officers&nbsp;or certain other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The registrant
expects to obtain and maintain insurance policies under which its directors and&nbsp;officers&nbsp;are insured, within the limits
and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities
which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been
directors or&nbsp;officers. The coverage provided by these policies may apply whether or not the registrant would have the power
to indemnify such person against such liability under the provisions of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These indemnification
provisions and the indemnification agreements entered into between the registrant and the registrant&rsquo;s&nbsp;officers and
directors may be sufficiently broad to permit indemnification of the registrant&rsquo;s&nbsp;officers&nbsp;and directors for liabilities
(including reimbursement of expenses incurred) arising under the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The underwriting
agreement between the registrant, the selling stockholders and the underwriters to be filed as Exhibit&nbsp;1.1 to this registration
statement provides for the indemnification by the underwriters of the registrant&rsquo;s directors and&nbsp;officers&nbsp;and certain
controlling persons against specified liabilities, including liabilities under the Securities Act with respect to information provided
by the underwriters specifically for inclusion in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 30.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 30.85pt"></P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 30.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Founder Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2019, 5,000,000 shares of our common stock
were issued to our founders (&ldquo;Founder Shares&rdquo;) for an aggregate amount of $5,000 to our management, of which $4,550
was collected as of December 31, 2018 and $450 was collected during the year ended December 31, 2019. The Founders Shares were
offered pursuant to Rule 506(b) of Regulation D under the Securities Act.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Subscription Shares and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, we received subscription agreements from 14 investors regarding the purchase of an aggregate of 1,158,000 shares of our
common stock by cash payment of a total of $289,500, or $0.25 per share, of which $239,500 was collected as of December 31,
2018 and $50,000 was collected during the year ended December 31, 2019. The transaction was independently negotiated between
us and the investors. The proceeds from the subscription agreements mitigated our cash pressure in short term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
the subscription agreements discussed, we granted the subscribers warrants to purchase up to 1,158,000 shares of our common stock
at an exercise price of $0.50 per share, with a term of two years. The 1,158,000 shares and warrants to purchase up to 1,158,000
shares of common stock were offered pursuant to Rule 506(b) of Regulation D under the Securities Act.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Regulation A Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 21, 2019, we
filed the Form 1-A and subsequent amendments thereto on July 29, 2019 and August 19, 2019. On September 5, 2019, the Form 1-A
was qualified by the Securities and Exchange Commission. Pursuant to the Form 1-A, as of December 31, 2019, we have sold 735,000
shares of its common stock, $0.001 par value per share, at a purchase price of $1.00 per share, resulting in gross proceeds of
$735,000, before deducting offerings expenses.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 16. Exhibits and Financial Statement
Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The exhibits to the registration
statement are listed in the Exhibit Index to this registration statement and are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Financial Statement Schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All financial statement
schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require
submission of the schedule, or because the information required is included in the financial statements and notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned registrant
hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements certificates in such denominations
and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned registrant hereby undertakes
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1) For purposes of determining
any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1)
or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(2) For the purpose of
determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1) To file, during any
period in which offers, or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) To include any prospectus
required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii) To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in
the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iii) To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(2) That, for the purpose
of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(4) That, for the purpose
of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part
of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first
used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-1 to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Jupiter, State of Florida on the 14th day of July,
2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>JUPITER WELLNESS, INC.</B> <BR>
(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>&nbsp;/s/ Brian S. John</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Brian S. John</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian S. John and Richard
Miller, and each of them (with full power to each of them to act alone), his true and lawful attorneys-in-fact and agents, with
full power of substitution and re-substitution, for him and on his behalf and in his name, place and stead, in any and all capacities,
to sign, execute and file this registration statement under the Securities Act of 1933, as amended, and any or all amendments (including,
without limitation, post-effective amendments) to this registration statement, with all exhibits and any and all documents required
to be filed with respect thereto, with the Securities and Exchange Commission or any other regulatory authority, granting unto
such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing appropriate
or necessary to be done in order to effectuate the same, as fully to all intents and purposes as he himself might or could do in
person, hereby ratifying and confirming all that such attorneys-in-fact and agents, or any of them, or their substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant
to the requirements of the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons
in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT> </TD>
    <TD STYLE="width: 1%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 53%; border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="width: 1%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 15%; border-bottom: Black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    <I>Brian S. John</I></FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                    Executive Officer</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Executive Officer) and Director</FONT> </P></TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian S. John</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> /s/ <I>Douglas McKinnon</I> </TD>
    <TD> &nbsp; </TD>
    <TD> Chief Financial Officer (Principal Financial Officer) </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"> Douglas McKinnon </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"></TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    <I>Richard Miller</I></FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating
    Officer and Director</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Miller</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    <I>Tim Glynn</I></FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tim Glynn</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    <I>Glynn Wilson</I></FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> Chairman and Head of Research and <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glynn Wilson</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/
    <I>Dr. Hector Alila</I></FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Hector Alila</FONT> </TD>

    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ <I>Christopher Melton</I></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Melton</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ <I>Byron Young</I></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2020</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Byron
    Young</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT INDEX<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">

    <TD STYLE="width: 72px; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No. &nbsp;</FONT></TD>
    <TD STYLE="width: 19px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting
    Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1760903/000126493119000132/ex2_1.htm">Amended and Restated Certificate of Incorporation, incorporated herein by reference to Exhibit 2.1 to Jupiter Wellness, Inc.&rsquo;s Form 1-A filed with the Securities and Exchange Commission on June 21, 2019</A>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1760903/000126493119000132/ex2_2.htm">Bylaws, incorporated herein by reference to Exhibit 2.2 to Jupiter Wellness, Inc.&rsquo;s Form 1-A filed with the Securities and Exchange Commission on June 21, 2019</A>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex3_3.htm">Amended and Restated Bylaws</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Certificate of Amendment of Certificate of Incorporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: justify"> <A HREF="ex3_5.htm">Second Amended and Restated Certificate of Incorporation</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4_1.htm">Common Stock Purchase Warrant</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s
    Warrant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.3</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Form of Warrant included in Unit</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.4</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Form of Warrant Agent Agreement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Sichenzia
    Ross Ference LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_1s.htm">Common Stock and Warrant Subscription Agreement</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.2</TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: justify"><A HREF="ex10_2.htm">Independent Director&rsquo;s Contract between the Company and Dr. Hector Alila, dated February 25, 2019</A>.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_3.htm">Independent Director&rsquo;s Contract between the Company and Timothy G. Glynn, dated March 13, 2019</A>.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_4.htm">Independent Director&rsquo;s Contract between the Company and Christopher Melton, dated July 29, 2019.</A>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_5.htm">Employment Agreement with Douglas O. McKinnon, dated August 5, 2019</A>.&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1760903/000126493119000148/ex4_1.htm">Form
    of Regulation A Subscription Agreement, incorporated herein by reference to Exhibit 4.1 to Jupiter Wellness, Inc.&rsquo;s
    Form 1-A/A filed with the Securities and Exchange Commission on August 19, 2019.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_7.htm">Employment Agreement with Dr. Glynn Wilson, dated October 15, 2019</A>.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.8</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Employment Agreement with Brian John, dated February 1, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.9</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Employment Agreement with Richard Miller, dated February 1, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.10</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">2020 Equity Incentive Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.11</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Confidential Membership Interest Purchase Agreement dated February 20,
    2020 by and between Jupiter Wellness, Inc., Magical Beasts LLC. and Krista Whitley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.12</TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify">Sales Distribution Agreement dated February 20, 2020 between Jupiter
    Wellness Inc. and Ayako Holdings, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>14.1</TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: justify"><A HREF="ex14_1.htm">Code of Ethics</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>14.2</TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: justify"><A HREF="ex14_2.htm">Corporate Governance Guidelines</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="text-align: center"></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23_1.htm">Consent of M&amp;K CPAS PLLC, an independent registered public accounting firm</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sichenzia
    Ross Ference LLP (included in exhibit 5.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="text-align: center">*</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney
    (included in signature page to this registration statement)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Previously
    filed</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><A HREF="#toc" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.gif
M1TE&.#EAF@ [ /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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G;)@[.^;_2IG,$MYL>LM\$I(D\1&M<&8R]N),9Y$D9,MUGDQ    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EAZ0 _ /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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MAOUKHICR$KENXSUE-6B''.P9%@ULBCQCWH,$(',JV!8[)Q* ABU'J=[>%K5
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4B[S8B[[XB\ 8C,(XC,1H%@$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 :H# 2(  A$! Q$!_\0
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MSUT'/2EKS;P[XEN(=42*\N7DAFPF7.=A[&O2%.5S7-6HRHRY6=^%Q<,3#FB
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M7L(=N6<< =^M2\*K-J:+CF4FTG3>IWJ:9;AM\FZ9_60YJTJI&,(JJ/84JY"
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M'WKY^;DW[VY]=2C",4J>WD.Q2445)J(>AKQ#4I<:M>C/_+=_YU[?V-> ZK<
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M7AGL9L?,DL1(S[$51U_Q3X)UJW*2B6\EQA&MH&\P'V.*[^2QM93NDMH7/JR
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MS>A/%7XXHX5VQHJCT J2BD 4444 %%%% !1110 4444 %%%% !1110 4444
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<4X6>X _WZEBL4#JYEF8J<C<]%% %ZBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 :H# 2(  A$! Q$!_\0
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M0;7&?$B5H/!UQM5BTCHF%!)ZUVE,95<88 CT-53ER24NQG5ASP<.Y\R;IO\
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M7H<5IVW-M$3UVBLO7O\ EC^-:=K_ ,>L7^X*.@$]4=6)&GN02#D=*O50U?\
MY![_ %'\Z0#='):RR22=QZFM&L[1?^/'_@9K1H8%._OELH@<;G;[JU5@M[N]
M02W%PT:-R$3CBF:U;N^R902JC#8[5<L;R*X@0!@'4 %:8A!I5KW#M[ES0FFP
M1R*Z&12ISC><&KU%(84444 %%%% !1110 4444 %%%% "8!ZBF;$;JB_E110
M >1">L2?]\BF^1#_ ,\D_P"^1110 [R(1TB3_OD4;$7HB_E110 _ '04M%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0
MS*'MV5NC#FH[6SBM%;RMWS=<G-%% %FEHHH J75G%=E?-W?+TP<5'_9D2A0)
M9P/^NE%% !_9L?\ SVN/^_E37%NDUMY3EBO'?FBB@"L=-BC^5))E'H'J3^S8
M_P#GM<?]_*** )H(A%;A S,/5CDU'+IEK*=YCVMZJ<444 56M!'PLTX'^_4T
4%D@=6,LS%3D;GHHH T**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.gif
M1TE&.#EAF@ [ /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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G;)@[.^;_2IG,$MYL>LM\$I(D\1&M<&8R]N),9Y$D9,MUGDQ    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
M1TE&.#EAZ0 _ /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
M,\P  )G__YG_S)G_F9G_9IG_,YG_ )G,_YG,S)G,F9G,9IG,,YG, )F9_YF9
MS)F9F9F99IF9,YF9 )EF_YEFS)EFF9EF9IEF,YEF )DS_YDSS)DSF9DS9IDS
M,YDS )D _YD S)D F9D 9ID ,YD  &;__V;_S&;_F6;_9F;_,V;_ &;,_V;,
MS&;,F6;,9F;,,V;, &:9_V:9S&:9F6:99F:9,V:9 &9F_V9FS&9FF69F9F9F
M,V9F &8S_V8SS&8SF68S9F8S,V8S &8 _V8 S&8 F68 9F8 ,V8  #/__S/_
MS#/_F3/_9C/_,S/_ #/,_S/,S#/,F3/,9C/,,S/, #.9_S.9S#.9F3.99C.9
M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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MAOUKHICR$KENXSUE-6B''.P9%@ULBCQCWH,$(',JV!8[)Q* ABU'J=[>%K5
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4B[S8B[[XB\ 8C,(XC,1H%@$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3
<SEQUENCE>8
<FILENAME>ex3_3.htm
<DESCRIPTION>AMENDED AND RESTATED BYLAWS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Exhibit 3.3</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>AMENDED AND RESTATED BY-LAWS</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>CBD BRANDS, INC.</B></P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE I</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">MEETINGS OF STOCKHOLDERS</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.1 &nbsp;&nbsp;&nbsp;<U>Place
of Meetings.</U>&nbsp;Meetings of the stockholders of CBD Brands, Inc. (the &ldquo;<U>Corporation</U>&rdquo;) shall be held at
such place in or outside the State of Delaware as shall be designated by the board of directors of the Corporation (the &ldquo;Board&rdquo;)
or the authorized person or persons calling the meeting.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.2 &nbsp;&nbsp;&nbsp;<U>Annual
Meetings.</U>&nbsp; The annual meeting of the stockholders for the election of directors and the transaction of such other business
as may properly come before the meeting shall be held after the close of the Corporation&rsquo;s fiscal year on such date and at
such time as shall be designated by the Board. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.3 &nbsp;&nbsp;&nbsp;<U>Special
Meetings.</U>&nbsp; Special meetings may be called for any purpose and at any time by the Chairman of the Board (the &ldquo;<U>Chairman</U>&rdquo;),
the President (if there be one) or by any three members of the Board. Business transacted at each special meeting shall be confined
to the purposes stated in the notice of such meeting.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.4 &nbsp;&nbsp;&nbsp;<U>Notice
of Meetings.</U>&nbsp; A written notice stating the place, date and hour of each meeting and the purpose or purposes for which
the meeting is called shall be given by, or at the direction of, the Secretary or the person or persons authorized to call the
meeting to each stockholder of record entitled to vote at such meeting not less than ten (10) days nor more than sixty (60) days
before the date of the meeting, unless a different period of time is required by applicable law in a particular case.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.5 &nbsp;&nbsp;&nbsp;<U>Record
Date.</U>&nbsp; In order to determine the stockholders entitled to notice of, and to vote at, any meeting of stockholders or any
adjournment thereof, or to express consent to corporate action in writing without a meeting, the Board may fix, in advance, a record
date that shall not be more than sixty (60) nor less than ten (10) days before the scheduled date of such meeting and nor more
than sixty (60) days prior to any other action. If no record date is fixed: (x) the record date for determining stockholders entitled
to notice of, and to vote at, a meeting of stockholders shall be at the close of business on the day next preceding the day on
which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting
is held and (y) the record date for determining stockholders entitled to express consent to corporate action in writing without
a meeting, when no prior action by the Board is necessary, shall be the day on which the first written consent is delivered to
the Corporation. A determination of stockholders of record entitled to notice of, and to vote at, a meeting of stockholders shall
apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.6 &nbsp;&nbsp;&nbsp;<U>Action
Without a Meeting.</U>&nbsp; Unless otherwise provided in the Certificate of Incorporation, any action required to be taken at
any annual or special meeting of stockholders, or any action that may be taken at any annual or special meeting of the stockholders,
may be taken without a meeting, without prior notice and without a vote, in accordance with the provisions of the General Corporation
Law of the State of Delaware (the &ldquo;Delaware Code&rdquo;), only if a consent or consents in writing, setting forth the action
so taken, shall be signed by the holders of the Corporation&rsquo;s outstanding stock having not less than the minimum number of
votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present
and voted.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 1in">Section 1.7 &nbsp;&nbsp;&nbsp;<U>Nomination
of Directors.&nbsp;</U></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in"><I>(a)</I>&nbsp;&nbsp;&nbsp;<I>General</I>.
Nominations for the election of directors may be made by the Board or a committee appointed by the Board or by any stockholder
entitled to vote in the election of directors generally. However, any stockholder entitled to vote in the election of directors
generally may nominate one or more persons for election as directors at a meeting only if written notice (a &ldquo;<U>Stockholder
Nomination Notice</U>&rdquo;) of such stockholder&rsquo;s intent to make such nomination or nominations has been delivered personally
to, or been mailed to and received by the Secretary of the Corporation at, the principal executive offices of the Corporation,
not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first
anniversary of the preceding year&rsquo;s annual meeting;&nbsp;<I>provided, however</I>&nbsp;, that in the event that the date
of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding
year&rsquo;s annual meeting, notice by the stockholder must be so delivered not earlier than the close of business on the 120th
day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting
or the 10th day following the day on which public announcement of the date of such meeting is first made. In no event shall the
public announcement of an adjournment of an annual meeting commence a new time period for the giving of a stockholder&rsquo;s notice
as described above. The presiding officer of the meeting may refuse to acknowledge the nomination of any person not made in compliance
with the procedure set forth in this Section 1.7(a).&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in"><I>(b)</I>&nbsp;&nbsp;&nbsp;<I>Stockholder
Nomination</I>&nbsp;<I>Notice</I>. Each Stockholder Nomination Notice shall set forth: (i) the name and address of the stockholder
who or that intends to make the nomination and of the person or persons to be nominated; (ii) the class(es) and number(s) of shares
of stock held of record, owned beneficially and represented by proxy by such stockholder as of the record date for the meeting
(if such date shall then have been made publicly available), the date of stockholder&rsquo;s acquisition of an interest in such
shares of such and of the date of the Stockholder Nomination Notice; (iii) a representation that the stockholder intends to appear
in person or by proxy at the meeting to nominate the person or persons specified in the notice, (iv) a description of all arrangements
or understandings between such stockholder and each nominee and any other person or persons (naming such person or persons) pursuant
to which the nomination or nominations are to be made by such stockholder; (v) such other information regarding each nominee proposed
by such stockholder as would be required to be included in a proxy statement filed pursuant to the proxy rules of the United States
Securities and Exchange Commission; and (vi) the consent of each nominee to serve as a director of the Corporation if so elected.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.8 &nbsp;&nbsp;&nbsp;<U>Quorum
and Voting.</U>&nbsp; The holders of a majority of the shares of capital stock issued and outstanding and entitled to vote thereat,
present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of
business, except as otherwise expressly provided by the Delaware Code, the Certificate of Incorporation or these By-laws. If, however,
such majority shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat,
present in person or by proxy, shall have the power, by the vote of the holders of a majority of the capital stock thereon, to
adjourn the meeting from time to time, without notice other than announcement at the meeting (except as otherwise provided by the
Delaware Code) At such adjourned meeting at which the requisite amount of shares of voting stock shall be represented, any business
may be transacted that might have been transacted at the meeting as originally scheduled. At all meetings of the stockholders,
each stockholder having the right to vote shall be entitled to vote in person, or by proxy appointed by an instrument in writing
subscribed by such stockholder and hearing a date not more than three years prior to said meeting, unless such instrument lawfully
provides for a longer period. At each meeting of the stockholders, each stockholder shall have one vote for each share of capital
stock having voting power, registered in his or her name on the books of the Corporation at the record date fixed or otherwise
determined in accordance with these By-laws. Except as otherwise expressly provided by the Delaware Code, the Certificate of Incorporation
or these By-laws, all matters coming before any meeting of the stockholders shall be decided by the vote of a majority of the number
of shares of stock present in person or represented by proxy at such meeting and entitled to vote thereat; provided, however, that
a quorum shall be present. The directors shall be elected by the stockholders at the annual meeting or any special meeting called
for such purpose.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 1.9&nbsp;&nbsp;&nbsp;<U>Conduct
of Meeting.</U>&nbsp;The Board, or, if the Board shall not have made the appointment, the Chairman presiding at any meeting of
stockholders, shall have the power to appoint two or more persons to act as inspectors or tellers, to receive, canvass and report
the votes cast by the stockholders at such meeting; provided, that no candidate for the office of director shall be appointed as
inspector or teller at any meeting for the election of directors. The Chairman or, in his or her absence, the President, a Vice
President or such other person as designated by the Board (the &ldquo;Meeting Chair&rdquo;) shall preside at all meetings of the
stockholders, and the Secretary, or in his or her absence, the person whom the Meeting Chair&nbsp;may appoint, shall act as Secretary
of the meeting and keep the minutes thereof.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE II</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">DIRECTORS</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.1 &nbsp;&nbsp;&nbsp;<U>Powers
of Directors.</U>&nbsp; The business and affairs of the Corporation shall be managed by or under the direction of the Board, which
shall exercise all powers that may be exercised or performed by the Corporation and that are not, by the Delaware Code, the Certificate
of Incorporation or these By-laws, directed to be exercised or performed by the stockholders.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.2 &nbsp;&nbsp;&nbsp;<U>Number,
Election and Term of Office.</U>&nbsp; The number of directors that shall constitute the whole Board shall not be less than three
(3) nor more than seven (7) directors. Subject to the foregoing, the actual number of directors shall be determined from time to
time by resolution of the Board. Directors need not be stockholders of the Corporation. The directors shall be elected by the vote
of a majority of the shares held by the stockholders (in person or represented by proxy) at the annual meeting or any special meeting
called for such purpose. Each director shall hold office until his or her successor shall be duly elected and qualified or until
his or her earlier resignation or removal. A director may resign at any time upon written notice to the Corporation.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.3 &nbsp;&nbsp;&nbsp;<U>Vacancies.</U>&nbsp;
Vacancies and newly-created directorships resulting from any increase in the authorized number of directors may be filled by a
majority vote of only those directors who were directors of the Corporation immediately prior to such vacancies or newly-created
directorships, even though such directors may constitute less than a quorum, or by a sole remaining director. The occurrence of
a vacancy that is not filled by action of the Board shall constitute a determination by the Board that the number of directors
is reduced so as to eliminate such vacancy, unless the Board shall otherwise specify. When one or more directors shall resign from
the Board, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall
have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become
effective. Any director so chosen to fill a vacancy or a newly-created directorship shall hold office until the next election of
the class for which such director shall have been chosen and until his/her successor shall be elected and qualified.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.4 &nbsp;&nbsp;&nbsp;<U>Meetings
of Directors.</U>&nbsp; Regular meetings of the Board shall be held immediately following the annual meeting of stockholders for
the purposes of appointing officers and at such time and place as the Board shall from time to time by resolution appoint, and
no notice shall be required to be given of any such regular meeting. A special meeting of the Board may be called for any purpose
by the Chairman or by any three directors by giving two (2) days&rsquo; notice to each director by overnight courier, electronic
mail, telegram, telefacsimile, telephone or other oral message, or by giving three (3) days&rsquo; notice if given by depositing
the notice in the United States mail, postage pre-paid. Such notice shall specify the time and place of the meeting, which may
be by means of conference, telephone or any other means of communication by which all persons participating in the meeting are
able to hear each other.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.5 &nbsp;&nbsp;&nbsp;<U>Conduct
of Meetings; Quorum; Voting.</U>&nbsp; At meetings of the Board, the Chairman or, in his or her absence, the President or a designated
Vice President, shall preside. Except as otherwise provided by these By-laws, a majority of the total number of directors determined
by resolution of the Board shall constitute a quorum for the transaction of business, and the vote of a majority of the directors
present at any meeting at which a quorum is present shall be the act of the Board. Any business may be transacted at any meeting
at which every director shall be present, even though the directors may not have had any advance notice of such meeting.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.6 &nbsp;&nbsp;&nbsp;<U>Action
Without Meeting.</U>&nbsp; Any action required or permitted to be taken at any meeting of the Board, or of any committee thereof,
may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing, and the
writing or writings are filed with the minutes of proceedings of the Board or committee.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.7 &nbsp;&nbsp;&nbsp;<U>Telephone
Participation in Meetings.</U>&nbsp; Members of the Board, or any committee thereof, may participate in a meeting of the Board
or such committee by means of conference, telephone or similar communications equipment by means of which all persons participating
in the meeting can hear each other, and participation in a meeting pursuant to this Section shall constitute presence in person
at such meeting.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.8 &nbsp;&nbsp;&nbsp;<U>Committees
of Directors.</U>&nbsp; By resolutions adopted by a majority of the entire Board, the Board may designate an Executive Committee
and one or more other committees, each such committee to consist of one or more directors of the Corporation (other than the Audit
Committee, which shall consist of at least three independent directors, and the Nominations and Governance Committee and the Compensation
Committee, each of which shall consist entirely of independent directors, as such term is defined in the NASDAQ Rules). Notwithstanding
the foregoing, the Executive Committee shall have no more than three directors and such directors may exercise all the powers and
authority of the entire Board in the management of the business and day-to-day affairs of the Corporation without the necessity
of a meeting or approval of the entire Board (except as otherwise expressly limited by applicable law). Each such committee shall
have such powers and authority of the Board as may be provided from time to time in resolutions adopted by a majority of the entire
Board. The requirements with respect to the manner in which the Executive Committee and each such other committee shall hold meetings
and take actions shall be set forth in the resolutions of the Board designating the Executive Committee or such other committee.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.9 &nbsp;&nbsp;&nbsp;<U>Removal.</U>&nbsp;
A director may be removed by the holders of a majority of the shares of capital stock entitled to vote for the election of directors
with &ldquo;cause&rdquo; only, as such term is generally used and defined under the Delaware Code. Directors may not be removed,
with or without &ldquo;cause,&rdquo; by action of the Board.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.10 &nbsp;&nbsp;&nbsp;<U>Compensation.</U>&nbsp;
The directors shall receive such compensation for their services as may be authorized by resolution of the Board and shall be reimbursed
by the Corporation for ordinary and reasonable expenses incurred in the performance of their duties as such. Subject to applicable
law, nothing contained herein shall be construed to preclude any director from serving the Corporation in any other capacity and
receiving compensation therefor.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 2.11 &nbsp;&nbsp;&nbsp;<U>Manifestation
of Dissent.</U>&nbsp; A director of the Company who is present at a meeting of the Board or committee thereof at which action on
any corporate matter is taken shall be presumed to have assented to the action taken unless his of her dissent shall be entered
in the minutes of the meeting or unless he shall file his or her written dissent to such action.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE III</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">OFFICERS</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.1 &nbsp;&nbsp;&nbsp;<U>Enumeration.</U>&nbsp;
The officers of the Corporation that the Board shall seek to appoint at its regular meeting following each annual stockholders&rsquo;
meeting may consist of a president, such number of vice presidents (if any) as the Board shall from time to time appoint, a secretary,
a treasurer, and such other officers (if any) as the Board shall from time to time appoint. The Board may at any time elect one
of its members as Chairman of the Board, who shall preside at meetings of the Board and of the stockholders and shall have such
powers and perform such duties as shall from time to time be prescribed by the Board. Any two or more offices may be held by the
same person.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.2 &nbsp;&nbsp;&nbsp;<U>President.</U>&nbsp;
The President shall be the chief executive officer of the Corporation. Subject only to the authority of the Board, he or she shall
have general charge and supervision over, and responsibility for, the business and affairs of the Corporation. Unless otherwise
directed by the Board, all other officers shall be subject to the authority and supervision of the President. The President may
enter into and execute in the name of the Corporation contracts or other instruments in the regular course of business or contracts
or other instruments not in the regular course of business that are authorized, either generally or specifically, by the Board.
The President shall also have such other powers and perform such other duties as are incident to the office of the president of
a corporation or as shall from time to time be prescribed by the Board. In the event that there is no President, the Board may
allocate the duties and powers set forth in this Section 3.2 among such other officers as the Board in its discretion shall determine.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.3 &nbsp;&nbsp;&nbsp;<U>Vice
President(s).</U>&nbsp; The Vice President or, if there shall be more than one, the Vice Presidents, in the order of their seniority
unless otherwise specified by the Board, shall have such powers and perform such duties as shall from time to time be prescribed
by the Board and/or the President or by such other person or persons as may be designated by the Board.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.4 &nbsp;&nbsp;&nbsp;<U>Secretary.</U>&nbsp;
The Secretary shall record the proceedings of the meetings of the stockholders and the Board in a book to be kept for that purpose,
and shall give notice as required by applicable law or these By-laws of all such meetings. The Secretary shall have custody of
the seal of the Corporation and custody of all books, records and papers of the Corporation, except such as shall be in the charge
of the Treasurer or of some other person authorized or directed to have custody and possession thereof by resolution of the Board.
The Secretary may, together with the President or such other person as may be designated by the Board, execute on behalf of the
Corporation any contract that has been approved by the Board. The Secretary shall also have such other powers and perform such
other duties as are incident to the office of the secretary of a corporation or as shall from time to time be prescribed by the
Board or the President or by such other person or persons as may be designated by the Board.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.5 &nbsp;&nbsp;&nbsp;<U>Treasurer.</U>&nbsp;
The Treasurer shall keep, or cause to be kept, full and accurate accounts of the receipts and disbursements of the Corporation
in books belonging to the Corporation, shall have custody of the funds of the Corporation and shall deposit all moneys and other
valuable effects of the Corporation in the name and to the credit of the Corporation in such depositories as may be designated
by the Board, and shall also have such other powers and perform such other duties as are incident to the office of the treasurer
of a corporation or as shall from time to time be prescribed by the Board or the President or by such other person or persons as
may be designated by the Board.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.6 &nbsp;&nbsp;&nbsp;<U>Other
Officers and Assistant Officers.</U>&nbsp; The powers and duties of each other officer or assistant officer who may from time to
time be chosen by the Board shall be as specified by, or pursuant to authority delegated by, the Board at the time of the appointment
of such other officer or assistant officer or from time to time thereafter. In addition, each officer designated as an assistant
officer shall assist in the performance of the duties of the officer to which he or she is assistant, and shall have the powers
and perform the duties of such officer during the absence or inability to act of such officer.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.7 &nbsp;&nbsp;&nbsp;<U>Term
and Compensation.</U>&nbsp; Officers shall be appointed by the Board from time to time, to serve at the pleasure of the Board and
subject to any employment or similar agreements. Each officer shall hold office until his or her successor is duly appointed and
qualified, or until his or her earlier death, resignation or removal. The compensation of all officers shall be fixed by, or pursuant
to authority delegated by, the Board from time to time.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.8 &nbsp;&nbsp;&nbsp;<U>Vacancies.</U>&nbsp;
In case any office shall become vacant, the Board may fill such vacancy. In case of the absence or disability of any officer, the
Board may delegate the powers or duties of any officer to another officer or a director for such time to be determined by the Board.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 3.9 &nbsp;&nbsp;&nbsp;<U>Exercise
of Rights as Stockholder.</U>&nbsp; Unless otherwise ordered by the Board, the President or a Vice President thereunto duly authorized
by the President or the Board, shall have full power and authority on behalf of the Corporation to attend and to vote at any meeting
of stockholders of any corporation in which this Corporation may hold stock, and may exercise on behalf of this Corporation any
and all of the rights and powers incident to the ownership of such stock at any such meeting, and shall have power and authority
to execute and deliver proxies and consents on behalf of this Corporation in connection with the exercise by this Corporation of
the rights and powers incident to the ownership of such stock. The Board, from time to time, may confer like powers upon any other
person or persons.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE IV</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">WAIVERS OF NOTICE</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 4.1 &nbsp;&nbsp;&nbsp;<U>Waivers
of Notice.</U>&nbsp;Any notice required to be sent by these By-laws, the Certificate of Incorporation or the Delaware Code may
be waived in writing by any person entitled to notice. The waiver or waivers may be executed either before or after the event with
respect to which notice is waived. Each director or stockholder attending a meeting without protesting the lack of proper notice,
prior to its conclusion, shall be deemed conclusively to have waived notice of the meeting.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE V &nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">INDEMNIFICATION OF DIRECTORS, OFFICERS
AND OTHERS</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 5.1 &nbsp;&nbsp;&nbsp;<U>Mandatory
Indemnification.</U>&nbsp; The Corporation shall indemnify and hold harmless, to the fullest extent now or hereafter permitted
by applicable law, each director or officer of the Corporation who was or is, or is threatened to be made, a party to or otherwise
involved in any Proceeding (hereinafter defined) by reason of the fact that such person is or was an Authorized Representative
(hereinafter defined), against all expenses (including attorneys&rsquo; fees and disbursements), liabilities, judgments, fines
(including excise taxes and penalties) and amounts paid in settlement actually and reasonably incurred by such person in connection
with such Proceeding, whether the basis of such person&rsquo;s involvement in the Proceeding is an alleged act or omission in such
person&rsquo;s capacity as an Authorized Representative or in another capacity while serving in such capacity, or both. The Corporation
shall be required to indemnify an incumbent or former director or officer in connection with a Proceeding initiated by such person
only if and to the extent that such Proceeding was authorized by the Board or it is a civil suit by such person to enforce rights
to indemnification or advancement of expenses.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 5.2 &nbsp;&nbsp;&nbsp;<U>Advancement
of Expenses.</U>&nbsp; The Corporation shall promptly pay all expenses (including attorneys&rsquo; fees and disbursements) actually
and reasonably incurred by an incumbent or former director or officer of the Corporation in defending or appearing (otherwise than
as a plaintiff) in any Proceeding described in Section 5.1 hereof in advance of the final disposition of such Proceeding upon receipt
of an undertaking by or on behalf of such person to repay all amounts so advanced if it shall ultimately be determined by a final,
unappealable judicial decision that such person is not entitled to be indemnified for such expenses under this Article or otherwise.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 5.3 &nbsp;&nbsp;&nbsp;<U>Permissive
Indemnification and Advancement of Expenses.</U>&nbsp; The Corporation may, as determined by the Board in its discretion, from
time to time indemnify any person who was or is, or is threatened to be made, a party to or otherwise involved in any Proceeding
by reason of the fact that such person is or was an Authorized Representative, against all expenses (including attorneys&rsquo;
fees and disbursements), judgments, fines (including excise taxes and penalties) and amounts paid in settlement actually and reasonably
incurred by such person in connection with such Proceeding, whether the basis of such person&rsquo;s involvement in the Proceeding
is an alleged act or omission in such person&rsquo;s capacity as an Authorized Representative or in another capacity while serving
in such capacity or both. The Corporation may, as determined by the Board in its discretion from time to time, pay expenses actually
and reasonably incurred by any such person by reason of such person&rsquo;s involvement in such a Proceeding in advance of the
final disposition of the Proceeding.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 5.4 &nbsp;&nbsp;&nbsp;<U>Basis
of Rights, Other Rights.</U>&nbsp; The rights to indemnification and advancement of expenses provided by or granted pursuant to
this Article shall be presumed to have been relied upon by Authorized Representatives in serving or continuing to serve the Corporation,
shall continue as to a person who ceases to be an Authorized Representative, shall inure to the benefit of the heirs, executors
and administrators of such person, and shall be enforceable as contract rights. Such rights shall not be deemed exclusive of any
other rights to which a person seeking indemnification or advancement of expenses may be entitled under the Delaware Code, agreement,
vote of stockholders or disinterested directors, or otherwise, both as to action in such person&rsquo;s official capacity and as
to action in another capacity while holding such office or position. Any amendment, modification or repeal of this Article shall
not adversely affect any right or protection of an Authorized Representative with respect to any act or omission occurring prior
to the time of such amendment, modification or repeal.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 5.5 &nbsp;&nbsp;&nbsp;<U>Insurance.</U>&nbsp;
The Corporation may purchase and maintain insurance on behalf of each incumbent or former director and officer against any liability
asserted against or incurred by such person in any capacity, or arising out of such person&rsquo;s status as an Authorized Representative,
whether or not the Corporation would have the power to indemnify such person against such liability under the provisions of this
Article. The Corporation shall not be required to maintain such insurance if it is not available on terms satisfactory to the Board
or if, in the business judgment of the Board, either (i) the premium cost for such insurance is substantially disproportionate
to the amount of coverage or (ii) the coverage provided by such insurance is so limited by exclusions and/or limitations that there
is insufficient benefit from such insurance. The Corporation may purchase and maintain insurance on behalf of any person referred
to in Section 5.3 hereof against any liability asserted against or incurred by such person in any capacity, or arising out of such
person&rsquo;s status as an Authorized Representative, whether or not the Corporation would have the power to indemnify such person
against such liability under the provisions of this Article. The Corporation may purchase such insurance from, or such insurance
may be reinsured in whole or in part by, an insurer owned by or otherwise affiliated with the Corporation.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 5.6 &nbsp;&nbsp;&nbsp;<U>Powers
of the Board.</U>&nbsp; The Corporation may enter into contracts to provide any Authorized Representatives with specific rights
to indemnification and advancement of expenses, which contracts may confer rights and protections to the maximum extent permitted
by applicable law. The Board, without approval of the stockholders, shall have the power to borrow money on behalf of the Corporation,
including the power to create trust funds, pledge, mortgage or create security interests in the assets of the Corporation, obtain
letters of credit or use other means, from time to time, to ensure payment of such amounts as may be necessary to perform the Corporation&rsquo;s
obligations under this Article or any such contract.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 1in">Section 5.7 &nbsp;&nbsp;&nbsp;<U>Definitions.</U>&nbsp;
For the purposes of this Article:&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">(a) &nbsp;&nbsp;
Proceeding. &ldquo;Proceeding&rdquo; means a threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">(b) &nbsp;&nbsp;
Corporation. References to &ldquo;the Corporation&rdquo; include, in addition to the resulting or surviving corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger, which, if its separate existence
had continued, would have had power and authority to indemnify its Authorized Representatives, so that any person who is or was
an Authorized Representative of such constituent corporation shall stand in the same position under this Article with respect to
the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence
had continued.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">(c) &nbsp;&nbsp;
Authorized Representative. &ldquo;Authorized Representative&rdquo; means a director, officer, employee or agent of the Corporation,
or a trustee, custodian, administrator, committeeman or fiduciary of any employee benefit plan, or a person serving another corporation,
partnership, joint venture, trust, other enterprise or non-profit entity in any of the foregoing capacities at the request of the
Corporation.</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE VI</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">CAPITAL STOCK</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.1 &nbsp;&nbsp;&nbsp;<U>Issuance
of Stock.</U>&nbsp; Shares of capital stock of any class now or hereafter authorized, securities convertible into or exchangeable
for such stock, or options or other rights to purchase such stock or securities may be issued or granted in accordance with authority
granted by resolution of the Board.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.2 &nbsp;&nbsp;&nbsp;<U>Stock
Certificates.</U>&nbsp; The Board shall adopt a form of stock certificate for shares of the capital stock of the Corporation, which
shall be signed by the President or a Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant
Secretary and may be sealed with the seal of the Corporation. All such certificates shall be numbered consecutively, and the name
of the person owning the shares represented thereby, with the number of such shares and the date of issue, shall be entered on
the books of the Corporation. If certificates are signed by a transfer agent, acting on behalf of the Corporation or registrar,
the signatures of the officers of the Corporation may be by facsimile.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.3 &nbsp;&nbsp;&nbsp;<U>Transfer
of Stock.</U>&nbsp; Shares of capital stock of the Corporation shall be transferred only on the books of the Corporation, by the
holder of record in person or by the holder&rsquo;s duly authorized representative, upon surrender to the Corporation of the certificate
for such shares duly endorsed for transfer, together with such other documents (if any) as may be required to effect such transfer.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.4 &nbsp;&nbsp;&nbsp;<U>Lost,
Stolen, Destroyed, or Mutilated Certificates.</U>&nbsp; New stock certificates may be issued to replace certificates alleged to
have been lost, stolen, destroyed or mutilated, upon such terms and conditions, including proof of loss or destruction, and the
giving of a satisfactory bond or other form of indemnity, as the Board from time to time may determine.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.5 &nbsp;&nbsp;&nbsp;<U>Regulations.</U>&nbsp;
The Board shall have the power and authority to make all such rules and regulations not inconsistent with these By-laws as it may
deem expedient concerning the issue, transfer and registration of shares of capital stock of the Corporation.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.6 &nbsp;&nbsp;&nbsp;<U>Holders
of Record.</U>&nbsp; The Corporation shall be entitled to treat the holder of record of any share or shares of capital stock of
the Corporation as the holder and owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other
claim to, or right, title or interest in, such share or shares on the part of any other person, whether or not the Corporation
shall have express or other notice thereof, except as otherwise provided by applicable law.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.7 &nbsp;&nbsp;&nbsp;<U>Restriction
on Transfer.</U>&nbsp; A restriction on the hypothecation, transfer or registration of the shares of the Corporation may be imposed
either by these By-laws or by an agreement among any number of stockholders or such holders and the Corporation. No restriction
so imposed shall be binding with respect to those securities issued prior to the adoption of the restriction unless the holders
of such securities are parties to an agreement or voted in favor of the restriction.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.8 &nbsp;&nbsp;&nbsp;<U>Transfer
Agent and Registrars.</U>&nbsp; The Board shall have the power to appoint one or more transfer agents and registrars for the transfer
and registration of certificates of stock of any class, and may require that stock certificates be countersigned and registered
by one or more of such transfer agents and registrars.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 6.9 &nbsp;&nbsp;&nbsp;<U>Closing
of Books.</U>&nbsp; The Board shall have the power to close the stock transfer books of the Corporation for a period not exceeding
sixty (60) days preceding the date of any meeting of stockholders or the date for payment of any dividend or the date for allotment
of rights or the date when any change or conversion or exchange of capital stock shall go into effect; provided, that, in lieu
of closing the stock transfer books, the Board may fix in advance a date, not exceeding sixty (60) days preceding the date of any
meeting of stockholders, or the date for payment of any dividend of the date for allotment of rights, or the date when any change
or conversion or exchange of capital stock shall go into effect, as a record date for the determination of stockholders entitled
to notice of, and to vote at, any such meeting, or entitled to receive payment of any such dividends, or any such allotment of
rights, or to exercise the rights in respect of any such change, conversion or exchange of capital stock, and in such case only
stockholders of record on the date so fixed shall be entitled to such notice of, and to vote at, such meeting, or to receive payment
of such dividend, or allotment of rights, or exercise such rights, as the case may be, and notwithstanding any transfer of any
stock on the books of the Corporation after any such record date fixed as herein provided.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE VII &nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">GENERAL PROVISIONS</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 7.1 &nbsp;&nbsp;&nbsp;<U>Corporate
Seal.</U>&nbsp; The Corporation may adopt a seal in such form as the Board shall from time to time determine.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 7.2 &nbsp;&nbsp;&nbsp;<U>Fiscal
Year.</U>&nbsp; The fiscal year of the Corporation shall be as designated by the Board from time to time.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 7.3 &nbsp;&nbsp;&nbsp;<U>Authorization.</U>&nbsp;
All checks, notes, vouchers, warrants, drafts, acceptances and other orders for the payment of moneys of the Corporation shall
be signed by such officer or officers or such other person or persons as the Board may from time to time designate.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 7.4 &nbsp;&nbsp;&nbsp;<U>Financial
Reports.</U>&nbsp; Subject to applicable law, financial statements or reports shall not be required to be sent to the stockholders
of the Corporation, but may be so sent in the discretion of the Board, in which event the scope of such statements or reports shall
be within the discretion of the Board, and such statements or reports shall not be required to have been examined by or to be accompanied
by an opinion of an accountant or firm of accountants.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 7.5 &nbsp;&nbsp;&nbsp;<U>Effect
of By-laws.</U>&nbsp; No provision in these By-laws shall vest any property right in any stockholder.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE VIII &nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">QUALIFICATIONS OF DIRECTORS AND OFFICERS</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 8.1 &nbsp;&nbsp;&nbsp;<U>Definitions.</U>&nbsp;
For purposes of this Article VIII, the following terms shall have the following meanings:&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">(a) &nbsp;&nbsp;
&ldquo;Affiliate,&rdquo; &ldquo;Associate&rdquo; and &ldquo;control&rdquo; shall have the respective meanings ascribed to such
terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
Act</U>&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">(b) &nbsp;&nbsp;
&ldquo;Principal Party&rdquo; shall mean any person or entity that, pursuant to an agreement, understanding or otherwise, is represented
by another person.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">(c) &nbsp;&nbsp;
&ldquo;Regulatory Approvals&rdquo; shall mean any governmental or regulatory approvals, agreements, permits, licenses or registrations
of the Corporation or any of its subsidiaries necessary to the conduct of its business.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 8.2 &nbsp;&nbsp;&nbsp;<U>Qualifications.</U>&nbsp;
No person shall serve as a director or officer of the Corporation or shall be elected or appointed to serve in any such capacity
if, in the good faith judgment of the Board (by majority vote), there is a reasonable likelihood that service by such person as
a director or officer (whether based on the qualifications of such person or on the qualifications of any Affiliate, Associate
or Principal Party of such person) will result in (i) the loss of any existing Regulatory Approvals, (ii) the inability of the
Corporation or any subsidiary to renew any Regulatory Approvals or (iii) the inability of the Corporation or any subsidiary to
obtain new Regulatory Approvals.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 8.3 &nbsp;&nbsp;&nbsp;<U>Determinations
of the Board of Directors.</U>&nbsp; Any determination by the Board with respect to the qualifications of any persons to serve
as a director or officer of the Corporation pursuant to this Article VIII, whether based on the qualifications of such person or
the qualifications of any Affiliate, Associate or Principal Party of such Person, shall, among other things, take into account
the involvement of any of such persons in legal actions or proceedings or governmental investigations. Persons, or their Affiliates,
Associates or Principal Parties, covered by Section 8.2 herein shall include, but shall not be limited to, any (i) directors, officers
or employees of the Corporation or its subsidiaries whose actions the Board has determined in good faith were detrimental to the
maintenance, renewal or acquisition of the Regulatory Approvals, whether they resigned or were dismissed for cause, (ii) persons
or entities who were convicted in criminal proceedings or are named defendants of pending criminal proceedings (excluding minor
offenses) regulated by any federal, state or local governmental agency or (iii) persons or entities who are subject to any order,
judgment, decree or debarment, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or governmental
or regulatory authority, permanently or temporarily enjoining them from, or otherwise limiting such person or entity from engaging
in, any type of business practice relating to any other business regulated by any federal, state or local governmental agency.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">ARTICLE IX &nbsp;&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">AMENDMENTS TO AND EFFECT OF BY-LAWS</P>

<P STYLE="font: 11pt/107% -webkit-standard; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 9.1 &nbsp;&nbsp;&nbsp;<U>Force
and Effect of By-laws.</U>&nbsp; These By-laws are subject to the provisions of the Delaware Code and the Corporation&rsquo;s Certificate
of Incorporation, as it may be amended from time to time. If any provision in these By-laws is inconsistent with a provision in
the Delaware Code or the Certificate of Incorporation, the provision of the Delaware Code or the Certificate of Incorporation shall
govern.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 1in">Section 9.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
to By-laws.</U>&nbsp; These By-laws may be amended or repealed and new By-laws may be adopted by the stockholders and/or the Board.
Any By-laws adopted, amended or repealed by the Board may be amended or repealed by the stockholders.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>9
<FILENAME>ex3_5.htm
<DESCRIPTION>SECOND AMENDED AND RESTATED, CERTIFICATE OF INCORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">Exhibit 3.5</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">SECOND AMENDED AND RESTATED<BR>
CERTIFICATE OF INCORPORATION<BR>
OF<BR>
JUPITER WELLNESS, INC.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Jupiter Wellness,
Inc. (the &ldquo;<U>Corporation</U>&rdquo;), a corporation organized and existing under the laws of the State of Delaware, does
hereby certify that:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The name of the Corporation is Jupiter Wellness, Inc. The Corporation&rsquo;s original Certificate of Incorporation was
filed with the Secretary of State of Delaware on October 24, 2018 and amended and restated on November 29, 2018. </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Second Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections 242 and 245 of
the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;), and has been duly approved by the written
consent of the stockholders of the Corporation in accordance with Section 228 of the DGCL, and restates, integrates and further
amends the provisions of the Corporation&rsquo;s Certificate of Incorporation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The text of the Certificate of Incorporation of this Corporation is hereby amended and restated in its entirety to read
as follows:</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
One</FONT><BR>
NAME</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The name of the
Corporation is Jupiter Wellness, Inc. (the &ldquo;<U>Corporation</U>&rdquo;).</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Two</FONT><BR>
REGISTERED OFFICE AND AGENT</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> The address
of the Corporation&rsquo;s registered office in the State of Delaware is 8 The Green, Ste. R, in the City of Dover, County of
Kent, 19901. The name of its registered agent at such address is Resident Agents Inc. </P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Three</FONT><BR>
PURPOSE</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The purpose of the
Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation
Law (the &ldquo;<U>DGCL</U>&rdquo;).</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Four</FONT><BR>
CAPITAL STOCK</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Authorized Shares</U>. The total number of shares of stock of all classes of capital stock that the Corporation
is authorized to issue is 101,000,000, of which 100,000,000 shares shall be common stock having a par value of $0.001 (&ldquo;Common
Stock&rdquo;) and 1,000,000 shares shall be shares of preferred stock having a par value of $0.001 (&ldquo;Preferred Stock&rdquo;).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Common Stock</U>. Except as otherwise required by law, as provided in this Second Amended and Restated Certificate
of Incorporation, and as otherwise provided in the resolution or resolutions, if any, adopted by the board of directors of the
Corporation (the &ldquo;Board of Directors&rdquo;) with respect to any series of the Preferred Stock, the holders of the Common
Stock shall exclusively possess all voting power. Each holder of shares of Common Stock shall be entitled to one vote for each
share held by him. Subject to the rights of holders of any series of outstanding Preferred Stock, holders of shares of Common
Stock shall have equal rights of participation in the dividends and other distributions in cash, stock, or property of the Corporation
when, as and if declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally
available therefor and shall have equal rights to receive the assets and funds of the Corporation available for distribution to
stockholders in the event of any liquidation, dissolution, or winding up of the affairs of the Corporation, whether voluntary
or involuntary.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Preferred Stock</U>. The Board of Directors is hereby authorized to provide, out of the unissued shares of Preferred
Stock, for one or more series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting
such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and
relative, participating, optional, or other special rights, if any, and any qualifications, limitations, or restrictions thereof,
of the shares of such series, as shall be stated in the resolution or resolutions providing for the issuance of such series adopted
by the Board of Directors. The authority of the Board with respect to each series of Preferred Stock shall include, but not be
limited to, determination of the following:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>the designation of the series;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>the number of shares of the series;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>the dividend rate or rates on the shares of that series, whether dividends will be cumulative, and if so, from which
date or dates, and the relative rights of priority, if any, of payment of dividends on shares of that series;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>whether the series will have voting rights in addition to the voting rights provided by law, and, if so, the terms
of such voting rights;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>whether the series will have conversion privileges, and, if so, the terms and conditions of such conversion, including
provision for adjustment of the conversion rate in such events as the Board of Directors shall determine;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>whether or not the shares of that series shall be redeemable, in whole or in part, at the option of the Corporation
or the holder thereof, and if made subject to such redemption, the terms and conditions of such redemption, including the date
or dates upon or after which they shall be redeemable, and the amount per share payable in case of redemptions, which amount may
vary under different conditions and at different redemption rates;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>the terms and amount of any sinking fund provided for the purchase or redemption of the shares of such series;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution, or winding
up of the Corporation, and the relative rights of priority, if any, of payment of shares of that series;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>the restrictions, if any, on the issue or reissue of any additional Preferred Stock; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>any other relative rights, preferences, and limitations of that series.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Five</FONT><BR>
BOARD OF DIRECTORS</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>General Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of
the Board of Directors.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Number of Directors</U>. The number of directors which shall constitute the Board of Directors shall be fixed
from time to time by resolution adopted by the affirmative vote of a majority of the total number of directors then in office.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Election and Term of Office</U>. The directors shall be elected by a plurality of the votes of the shares of
capital stock of the Corporation present in person or represented by proxy at the meeting and entitled to vote in the election
of directors. The directors shall be elected and shall hold office only in this manner, except as provided in this Article Five.
Each director shall hold office until a successor is duly elected and qualified or until his or her earlier death, resignation
or removal. Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Newly-Created Directorships and Vacancies</U>. Newly created directorships resulting from any increase in the
number of directors or any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification,
removal from office or any other cause may be filled, so long as there is at least one remaining director, only by the Board of
Directors, provided that a quorum is then in office and present, or by a majority of the directors then in office, if less than
a quorum is then in office, or by the sole remaining director. Directors elected to fill a newly created directorship or other
vacancies shall hold office until such director&rsquo;s successor has been duly elected and qualified or until his or her earlier
death, resignation or removal as hereinafter provided.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Six</FONT><BR>
LIMITATION OF LIABILITY AND INDEMNIFICATION</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Limitation of Liability</U>. To the fullest extent permitted by law, no director of the Corporation shall be
personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Without
limiting the effect of the preceding sentence, if the DGCL is hereafter amended to authorize the further elimination or limitation
of the liability of a director, then the liability of a director of the Corporation shall be eliminated or limited to the fullest
extent permitted by the DGCL, as so amended.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Amendment or Repeal</U>. Neither any amendment nor repeal of this Article Six, nor the adoption of any provision
of this Second Amended and Restated Certificate of Incorporation inconsistent with this Article Six, shall eliminate, reduce or
otherwise adversely affect any limitation on the personal liability of a director of the Corporation existing at the time of such
amendment, repeal or adoption of such an inconsistent provision.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Seven</FONT><BR>
STOCKHOLDER ACTION</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Stockholder Consent Prohibition</U>. Subject to the rights of the holders of any series of Preferred Stock, any
action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special
meeting of the stockholders of the Corporation and may not be effected by any consent by such stockholders.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Special Meetings of Stockholders</U>. Except as otherwise required by law and subject to the rights of the holders
of any series of Preferred Stock, special meetings of the stockholders of the Corporation shall be called only by: (i) the Board
of Directors; or (ii) the Secretary of the Corporation, following receipt of one or more written demands to call a special meeting
of the stockholders from stockholders of record who own, in the aggregate, at least 25% of the voting power of the outstanding
shares of the Corporation then entitled to vote on the matter or matters to be brought before the proposed special meeting that
complies with the procedures for calling a special meeting of the stockholders as may be set forth in the By-Laws.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Eight</FONT><BR>
BYLAWS</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Board of Directors</U>. In furtherance and not in limitation of the powers conferred by law, the Board of Directors
is expressly authorized and empowered to adopt, amend, alter, or repeal the Bylaws of the Corporation without any action on the
part of the stockholders.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">Section
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Stockholders</U>. The stockholders shall also have the power to adopt, amend, alter, or repeal the Bylaws of
the Corporation; provided that, in addition to any affirmative vote of the holders of any particular class or series of capital
stock of the Corporation required by applicable law or this Second Amended and Restated Certificate of Incorporation, such adoption,
amendment, alteration, or repeal shall be approved by the affirmative vote of the holders of at least two-thirds (2/3) of the
voting power of the shares of the then outstanding voting stock of the Corporation entitled to vote generally in the election
of directors, voting together as a single class.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Nine</FONT><BR>
SECTION 203 OF THE DELAWARE GENERAL CORPORATION LAW</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Corporation
expressly elects to not be governed by Section 203 of the DGCL.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
Ten</FONT><BR>
FORUM SELECTION</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Unless the corporation
consents in writing to the selection of an alternative forum, New York shall be the sole and exclusive forum for (a) any derivative
action or proceeding brought on behalf of the corporation, (b) any action asserting a claim for breach of a fiduciary duty owed
by any director, officer, employee, or agent of the corporation to the corporation or the corporation's shareholders or (c) any
action asserting a claim governed by the internal affairs doctrine, in each case subject to said court having personal jurisdiction
over the indispensable parties named as defendants therein. This Article Ten shall not apply to actions arising under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934. </P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0in"> <FONT STYLE="text-transform: uppercase">Article
Eleven</FONT>&nbsp; </P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"> AMENDMENT </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: justify; text-indent: 24.5pt">The Corporation
reserves the right to amend, alter, change or repeal any provision contained in this Second Amended and Restated Certificate of
Incorporation, in the manner now or hereafter prescribed herein and by the laws of the State of Delaware, and all rights conferred
upon stockholders herein are granted subject to this reservation. Notwithstanding any other provision of this Second Amended and
Restated Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage or
separate class vote may be specified by law, this Second Amended and Restated Certificate of Incorporation, the Bylaws of the Corporation
or otherwise, the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the shares of the then outstanding
voting stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall
be required to adopt any provision inconsistent with, to amend or repeal any provision of, or to adopt a bylaw inconsistent with,
<U>Articles Five</U>, <U>Seven</U> and <U>Eight</U> of this Second Amended and Restated Certificate of Incorporation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">* * * * * *</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> IN WITNESS WHEREOF,
the Corporation has caused this Second Amended and Restated Certificate of Incorporation to be signed by the undersigned, a duly
authorized officer of the Corporation, on July 10, 2020. </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%"> By: <I>Brian John</I> </TD>
    <TD STYLE="width: 33%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD> &nbsp; </TD>
    <TD> Brian John </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD> &nbsp; </TD>
    <TD> President and Chief Executive Officer </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><BR> </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 238.5pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 238.5pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 238.5pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>10
<FILENAME>ex4_1.htm
<DESCRIPTION>COMMON STOCK PURCHASE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 5.65pt 0 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 5.65pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 5.65pt 0 0; text-align: justify"><B>NEITHER THE ISSUANCE AND
SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND REASONABLY
APPROVED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD
PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="margin: 0; font: 9pt Sans-Serif; color: Red"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 129.5pt 0 129.35pt; text-align: center"><B>COMMON STOCK PURCHASE
WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.55pt 0 0 5.85pt"><B>Number of shares: <U>&#9;</U>&#9;Holder: <U>&#9;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.55pt 0 0 5.85pt"><B>Exercise Price per Share: $0.50&#9;Warrant No.
2018-00</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 5.85pt; text-align: justify"><B>Expiration Date: November
<FONT STYLE="letter-spacing: -0.15pt">1,</FONT> 2020&#9;Issue Date: November , 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 5.85pt; text-align: justify"><B>FOR VALUE RECEIVED,</B>
CBD Brands, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), hereby certifies that <FONT STYLE="text-underline-style: double"><U>&#9;</U></FONT><B>,
</B>or its designated assigns (the &ldquo;<U>Warrant Holder</U>&rdquo;), is entitled to purchase the securities set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.85pt; text-align: justify">This Warrant entitles the Warrant
Holder to purchase from the Company at any time after the Issue Date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 5.85pt">and before the Expiration Date, <U>&#9;</U>shares
(the &ldquo;<U>Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.8pt 0 5.85pt; text-align: justify"><U>Shares</U>&rdquo;) of
common stock (the &ldquo;<U>Common Stock</U>&rdquo;) of the Company at an exercise price of <B>$0.50 per share </B>(as adjusted
from time to time as provided in Section 7 hereof, the &ldquo;<U>Exercise Price</U>&rdquo;), at any time and from time to time
from and after the Issue Date and through and including 5:00 p.m. New York time on the Expiration Date, as such date may be accelerated
as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify">This Warrant is being
issued pursuant to that certain Common Stock and Warrant Subscription Agreement, dated as of November , 2018 by and between the
Company and the Warrant Holder, (the &ldquo;<U>Subscription Agreement</U>&rdquo;). Capitalized terms used herein but not otherwise
defined herein, shall have the meanings given to them in the Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.7pt 0 5.85pt; text-align: justify; text-indent: 35.95pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-size: 10pt"><U>Investment
Representation</U>. The Warrant Holder by accepting this Warrant represents that the Warrant Holder is acquiring this Warrant
for its own account or the account of an affiliate for investment purposes and not with the view to any offering or
distribution and that the Warrant Holder will not sell or otherwise dispose of this Warrant or the underlying Warrant Shares
in violation of applicable securities laws. The Warrant Holder acknowledges that the certificates representing any Warrant
Shares will bear a legend indicating that they have not been registered under the United States Securities Act of 1933, as
amended (the &ldquo;<U>1933 Act</U>&rdquo;) and may not be sold by the Warrant Holder except pursuant to an
effective registration statement or pursuant to an exemption <FONT STYLE="letter-spacing: -0.15pt">from </FONT>registration
requirements of the 1933 Act and in accordance with federal and state securities laws. If this Warrant was acquired <FONT STYLE="letter-spacing: -0.15pt">by </FONT>the
Warrant Holder pursuant to the exemption from the registration requirements of the 1933 Act afforded by Regulation
S thereunder, the Warrant Holder acknowledges and covenants that this Warrant may not be exercised by or on behalf of a
Person during the one year distribution compliance period (as defined in Regulation S) following the date hereof.
&ldquo;<U>Person</U>&rdquo; means an individual, partnership, firm, limited liability company, trust, joint venture,
association, corporation, or any other legal entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Validity of Warrant and Issue of Shares</U>. The Company represents and warrants that this
Warrant has been duly authorized and validly issued <FONT STYLE="letter-spacing: -0.15pt">and</FONT> warrants and agrees that all
of Warrant Shares that may be issued upon the due exercise of the rights represented by this Warrant will, when issued upon such
exercise, be duly authorized, validly issued, fully paid <FONT STYLE="letter-spacing: -0.15pt">and </FONT>nonassessable and free
from all taxes, liens and charges with respect to the issue thereof. The Company further warrants and agrees that during the period
within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved
a sufficient number of shares <FONT STYLE="letter-spacing: -0.15pt">of </FONT>Common Stock to provide for the exercise of the rights
represented by this Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt; text-align: right">Initials: _____</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.8pt"></TD><TD STYLE="width: 36.05pt">3.</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>Registration of Transfers and Exchange of Warrants</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Subject to compliance with the legend set forth on the face of this Warrant, the Company
shall register the transfer of this Warrant, or any portion of this Warrant, in the Warrant Register, upon delivery by the Warrant
Holder to the Company, pursuant to Section 10 of (i) this Warrant, and (ii) a duly completed and executed written assignment. Upon
any such registration or transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such
new warrant, a &ldquo;<U>New Warrant</U>&rdquo;), evidencing the portion of this Warrant so transferred shall be issued to the
transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the
transferring Warrant Holder. The acceptance of the <FONT STYLE="letter-spacing: -0.15pt">New</FONT> Warrant by the transferee thereof
shall be deemed the acceptance of such transferee of all of the rights and obligations of a Warrant Holder of a Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder to the
office of the Company specified in or pursuant to Section 10 for one or more New Warrants, evidencing in the aggregate the right
to purchase the number of Warrant Shares which may then be purchased hereunder. Any such New Warrant will be dated the date of
such exchange, and will have the same Expiration Date as the original Warrant for which the New Warrant was exchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.8pt"></TD><TD STYLE="width: 36.05pt">4.</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>Exercise of Warrants</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Exercise of this Warrant shall be made upon delivery to the Company pursuant to Section
10, of (i) this Warrant; (ii) a duly completed and executed election notice, in the form attached hereto (the &ldquo;Election Notice&rdquo;)
and (iii) payment of the Exercise Price. Payment of the Exercise Price may be made at the option of the Warrant Holder either (a)
in cash, wire transfer or by certified or official bank check payable to the order of the Company equal to Exercise Price per share
in effect at the time of exercise. The Company shall promptly (but in <FONT STYLE="letter-spacing: -0.15pt">no</FONT> event later
than five (5) business days after the &ldquo;Date of Exercise,&rdquo; as defined herein) issue or cause to be issued and cause
to be delivered to the Warrant Holder in such name or names as the Warrant Holder may designate in the Election Notice, a certificate
for the Warrant Shares issuable upon such exercise, with such restrictive legend as required by the 1933 Act, as applicable. Any
person so designated by the Warrant Holder to receive Warrant Shares shall be deemed to have become holder of record of such Warrant
Shares as of the Date of Exercise of this Warrant. All Warrant Shares delivered to the Warrant Holder the Company covenants, shall
upon due exercise of this Warrant, be duly authorized, validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.85pt; text-align: justify">For purposes of Rule 144 promulgated
under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction
in the manner described above shall be deemed to have been acquired by the Warrant Holder, and the holding period for the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt/98% Times New Roman, Times, Serif; margin: 0.05pt 6pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp; </FONT></FONT><FONT STYLE="font-size: 10pt; line-height: 98%">A
&ldquo;<U>Date of Exercise</U>&rdquo; means the date on which the Company shall have received (i) this Warrant (or any New
Warrant, as applicable), (ii) the Election Notice (or attached to such New Warrant) appropriately completed and duly signed,
and (iii) payment of the Exercise Price (if this Warrant is exercised on a cash basis) for the number of Warrant Shares so
indicated by the Warrant Holder to be purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.9pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">This Warrant shall be exercisable at any time and <FONT STYLE="letter-spacing: -0.15pt">from
</FONT>time to time for such number of Warrant Shares as is indicated in the attached Form of Election to Purchase. If less than
all of the Warrant Shares which may be purchased under this Warrant are exercised at any time, the Company shall issue or cause
to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares for which no
exercise has been evidenced by this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">e.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise
this Warrant if such exercise would cause Warrant Holder&rsquo;s beneficial ownership (as defined by Section 13(d) of the Securities
Exchange Act of 1934, <FONT STYLE="letter-spacing: -0.2pt">as </FONT>amended) of the Common Stock of the Company to exceed 4.9%
of its total issued and outstanding Common Stock or voting shares. Upon not less than sixty-one (61) days advance written notice,
at any time or from time to time, the Warrant Holder at its sole discretion, may waive this provision of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">f.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise
this Warrant if such exercise would cause Warrant Holder&rsquo;s beneficial ownership (as defined by Section 13(d) of the Securities
Exchange Act of 1934, <FONT STYLE="letter-spacing: -0.2pt">as </FONT>amended) of the Common Stock of the Company to exceed 9.9%
of its total issued and outstanding Common Stock or voting shares. Any common shares exercised under this Warrant need to be delivered
to the Warrant Holder within three (3) business days of the receipt of Exercise Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">g.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Notwithstanding any other provision of this Warrant, if the Common Stock, or any securities
into which the Common Stock have been converted or exchanged, are traded in the United States on the OTC Markets or any national
securities exchange in the United States, or in Canada on any Canadian stock exchange, including without limitation, the CNQ, Montreal
Exchange (Bourse de Montr&eacute;al), NASDAQ Canada and the Toronto Stock Exchange (TSX), at a per share price of $1.00 or more
for ten</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">(10) consecutive trading
days, then the Expiration Date of this Warrant shall be accelerated to the next business day that is at least thirty (30) days
after such ten (10) day trading period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt; text-align: right">Initials: _____</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 5.9pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 74.85pt">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Common Share Issuance.</U> Upon receipt by the Company of a written request from Warrant
Holder to exercise any portion of any Warrant, subject to any limitations on exercise contained in any Warrant, the Company shall
have three (3) business days (&ldquo;Delivery Date&rdquo;) to issue the shares of Common Stock rightfully listed in such request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.85pt"></TD><TD STYLE="width: 36pt">6.</TD><TD STYLE="text-align: justify; padding-right: 5.9pt"><FONT STYLE="font-size: 10pt"><U>Adjustment of Exercise Price and Number
of Shares</U>. The character of the shares of stock or other securities at the time issuable upon exercise of this Warrant and
the Exercise Price therefor, are subject to adjustment upon the occurrence of the following events:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Adjustment for Reorganization, Consolidation, Merger, Etc.</U> In case of any consolidation
or merger of the Company with or into any other corporation, entity or person, or any other corporate reorganization, in which
the Company shall not be the continuing or surviving entity of such consolidation, merger or reorganization (any such transaction
being hereinafter referred to as a &ldquo;<U>Reorganization</U>&rdquo;), then, in each case, the Holder of this Warrant, on exercise
hereof at any time after the consummation or effective date of such Reorganization (the &ldquo;<U>Effective Date</U>&rdquo;), shall
receive, in lieu of the shares of stock or other securities at any time issuable upon the exercise of the Warrant issuable on such
exercise prior to the Effective Date, the stock and other securities and property (including cash) to which such Holder would have
been entitled upon the Effective Date if such holder had exercised this Warrant immediately prior thereto (all subject to further
adjustment as provided in this Warrant). The Company shall ensure that the surviving entity in any Reorganization specifically
assumes the Company&rsquo;s obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt/98% Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp; </FONT></FONT><FONT STYLE="font-size: 10pt; line-height: 98%"><U>Exercise
Price Adjustment</U>. If at any time the Company grants, issues or sells any Common Stock, options to purchase Common Stock,
securities convertible into Common Stock or rights relating to Common Stock (the &ldquo;Purchase Rights&rdquo;) to any
person, entity, association, or other organization other than the Holder, at a price per share less than the Exercise Price,
then the Exercise Price hereof shall be proportionately reduced to match the price per share of the Purchase Rights. For
purposes of clarification, if the exercise price of the Warrant Shares is $0.20 per share, and if the Company sells Common
Stock at $0.08 per share at any time after the date hereof, then the Exercise Price of Holder&rsquo;s Warrant Shares would be
adjusted to $0.08 per share. Notwithstanding, the Exercise Price may not exceed $0.20 per share in any case.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: left; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Adjustments for Stock Dividends; Combinations, Etc</U>. In case the Company shall
do any of the following (an &ldquo;Event&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: left; text-indent: 142.55pt"><FONT>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">declare a dividend or other distribution on its Common Stock payable in Common Stock
of the Company,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 4.6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 148.4pt"></TD><TD STYLE="width: 28.6pt"><FONT>(ii)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">subdivide the outstanding Common Stock pursuant to a stock split</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 5.85pt">or otherwise, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 4.6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 148.4pt"></TD><TD STYLE="width: 28.6pt"><FONT>(iii)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">reclassify its Common Stock,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 5.65pt 0 5.85pt; text-align: justify">then the number of shares
of Common Stock or other securities at the time issuable upon exercise of this Warrant shall be appropriately adjusted to reflect
any such Event; however, there shall be no adjustment to the Exercise Price or issuable Warrant Shares in the event of a reverse
stock split or other reduction in the authorized Common Stock of the Company. Not-with-standing the above, the adjustment to the
Exercise Number of issuable Warrant Shares in the event of a reverse stock split or other reduction in the authorized Common Stock
of the Company shall not exceed a reduction of greater than 1 for 20 regardless of the amount of the reduction of Common Stock
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Certificate as to Adjustments</U>. In case of any adjustment or readjustment in
the price or kind of securities issuable <FONT STYLE="letter-spacing: -0.15pt">on </FONT>the exercise of this Warrant, the Company
will promptly give written notice thereof to the holder of this Warrant in the form of a certificate, certified and confirmed by
the Board of Directors of the Company, setting forth such adjustment or readjustment and showing in reasonable detail the facts
upon which such adjustment or readjustment is based.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Fractional Shares</U>. The Company shall not be required to issue or cause to be issued
fractional Warrant Shares on the exercise of this Warrant. The number of full Warrant Shares that shall be issuable upon the exercise
of this Warrant shall be computed on the basis of the aggregate number of Warrants Shares purchasable on exercise of this Warrant
so presented. If any fraction of a Warrant Share would, except for the provisions of this Section <FONT STYLE="letter-spacing: -0.15pt">9,</FONT>
be issuable on the exercise of this Warrant, the Company shall, at its option, (i) pay an amount in cash equal to the Exercise
Price multiplied by such fraction or (ii) round the number of Warrant Shares issuable, <FONT STYLE="letter-spacing: -0.15pt">up
</FONT>to the next whole number.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt; text-align: right">Initials: _____</P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.65pt 0 5.85pt; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Notice</U>. All notices and other communications hereunder shall be in writing and shall
be deemed to have been given (i) on the date they are (a) delivered if delivered in person or (b) sent, if sent by email; (ii)
on the date initially received if delivered <FONT STYLE="letter-spacing: -0.15pt">by </FONT>facsimile transmission followed by
registered or certified mail confirmation; (iii) on the date delivered by an overnight courier service; or (iv) on the third business
day after it is mailed by registered or certified mail, return receipt requested with postage and other fees prepaid as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 77.85pt">If to the Company:</P>

<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 113.85pt">CBD Brands, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 113.85pt">1005 W. Indiantown Road Suite 202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 113.85pt">Jupiter, FL. 33458</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 113.85pt">Attn: Brian S. John, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.8pt"></TD><TD STYLE="width: 36.05pt">9.</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 3.65pt 5.5pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 3.65pt 5.5pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">This Warrants is being granted pursuant to the terms of the Subscription Agreement
by and between the Company and the Warrant Holder. If not otherwise defined herein, <FONT STYLE="letter-spacing: -0.1pt">all </FONT>capitalized
terms herein shall have the meanings given to them in the Subscription Agreement. Further, all of the terms, representations, warranties,
agreements, covenants and conditions set forth in the Agreement are incorporated herein by reference. To the extent that there
is a conflict between any condition, term or provision of this Warrant and the Subscription Agreement, the conditions, terms, and
provisions set forth herein shall specifically supersede the conflicting conditions, provisions and/or terms in the Subscription
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">This Warrant shall be binding on and inure to the benefit of the parties hereto and
their respective successors and permitted assigns. This Warrant may be amended only in writing and signed by the Company and the
Warrant Holder. Warrant Holder may assign this Warrant without consent from the Company but in accordance with the restrictions
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Nothing in this Warrant shall be construed to give to any person or corporation other
than the Company and the Warrant Holder any legal or equitable right, remedy or cause of action under this Warrant; this Warrant
shall be for the sole and exclusive benefit of the Company and the Warrant Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">This Warrant shall be governed by and construed in accordance with the laws of the
State of Delaware, without regard to conflict of laws provisions. All disputes arising out of or in connection with this Warrant,
or in respect of any legal relationship associated with or derived from this Warrant, shall only be heard in any competent court
residing in Palm Beach County, Florida. The <FONT STYLE="letter-spacing: -0.25pt">Company </FONT><FONT STYLE="letter-spacing: -0.3pt">agrees
</FONT><FONT STYLE="letter-spacing: -0.2pt">that </FONT>a <FONT STYLE="letter-spacing: -0.25pt">final </FONT><FONT STYLE="letter-spacing: 0.15pt">judgment
</FONT><FONT STYLE="letter-spacing: 0.1pt">in any such action </FONT>or <FONT STYLE="letter-spacing: 0.1pt">proceeding shall </FONT>be
<FONT STYLE="letter-spacing: 0.1pt">conclusive and may </FONT>be <FONT STYLE="letter-spacing: 0.1pt">enforced in other jurisdictions
</FONT>by <FONT STYLE="letter-spacing: 0.1pt">suit </FONT>on <FONT STYLE="letter-spacing: 0.15pt">the </FONT><FONT STYLE="letter-spacing: 0.1pt">judgment
</FONT>or <FONT STYLE="letter-spacing: 0.1pt">in any </FONT>manner <FONT STYLE="letter-spacing: 0.1pt">provided </FONT>by <FONT STYLE="letter-spacing: 0.1pt">law.
</FONT>The Company further waives any objection to venue in any such action or proceeding on the <FONT STYLE="letter-spacing: 0.1pt">basis
</FONT>of <FONT STYLE="letter-spacing: 0.15pt">inconvenient</FONT> <FONT STYLE="letter-spacing: 0.1pt">forum. The Company agrees
that </FONT>any <FONT STYLE="letter-spacing: 0.1pt">action </FONT>on or <FONT STYLE="letter-spacing: 0.1pt">proceeding </FONT>brought
against the Warrant Holder shall only be brought in such courts.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">e.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">In the event the Warrant Holder hereof shall refer this Warrant Agreement to an attorney
to enforce the terms hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting the enforcement
of the Warrant Holder's rights, including reasonable attorney's fees, whether or not suit is instituted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 6.05pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">f.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">The headings herein are for convenience only, do not constitute a part of this Warrant
and shall not be deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.65pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">g.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">In case any one or more of the provisions of this Warrant shall be invalid or unenforceable
in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected
or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a
commercially reasonably substitute therefore, and upon <FONT STYLE="letter-spacing: -0.15pt">so </FONT>agreeing, shall incorporate
such substitute provision in this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">h.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">The Warrant Holder shall not, by virtue hereof, be entitled to any voting or other
rights of a shareholder of the Company, either at law or equity, and the rights of the Warrant Holder are limited to those expressed
in this Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 5.85pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt; text-align: right">Initials: _____</P>


<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.65pt Times New Roman, Times, Serif; margin: 0 129.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3.95pt 0 0 5.85pt; text-indent: 74.85pt">IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by the authorized officer as of the date first above stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>CBD Brands Inc.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">By:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Brian John</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title: President/CEO</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 293.85pt">&nbsp;</P>

<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 293.85pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt; text-align: right">Initials: _____</P>




<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 293.85pt">&nbsp;</P>

<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 293.85pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.55pt Times New Roman, Times, Serif; margin: 0 0 0 293.85pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.95pt 129.35pt 0; text-align: center">FORM OF ELECTION TO PURCHASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 5.9pt 0 5.85pt; text-align: justify">(To be executed by the
Warrant Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.85pt; text-align: justify"><FONT STYLE="font-weight: normal">To:
</FONT>The CBD Brands Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 5.75pt 0 5.85pt; text-align: justify">The undersigned, pursuant
to the provisions set forth in the attached Warrant, hereby irrevocably elects to purchase (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.8pt"></TD><TD STYLE="width: 36.05pt"><FONT STYLE="font: 20pt Times New Roman, Times, Serif">&#9744;</FONT></TD><TD STYLE="text-align: left; vertical-align: middle"><FONT STYLE="font-size: 10pt">shares of the Common Stock covered by such Warrant; or</FONT></TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><FONT STYLE="font-size: 20pt">&#9744;</FONT></TD><TD STYLE="text-align: left; vertical-align: middle">the maximum number of shares of Common Stock covered by such Warrant pursuant to the exercise procedure set
forth therein.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 11pt/98% Times New Roman, Times, Serif; margin: 12.75pt 0 0 41.85pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.7pt 0 5.85pt; text-align: justify">The undersigned herewith makes
payment of the full purchase price for such shares at the price per share provided for in such Warrant, which is $.50. Such payment
takes the form of (check applicable box or boxes):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 5.8pt"></TD><TD STYLE="width: 36.05pt"><FONT STYLE="font: 20pt Times New Roman, Times, Serif">&#9744;</FONT></TD><TD STYLE="text-align: left; vertical-align: middle"><FONT STYLE="font-size: 10pt">$______ in lawful money of the United States.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12.6pt 5.8pt 0 5.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12.6pt 5.8pt 0 5.85pt; text-align: justify">The undersigned
represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant
shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), or pursuant to an exemption from registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Name of Warrant Holder:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(Print)___________________________________________ </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(By:)____________________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(Name:)__________________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(Title:)___________________________________________ </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Signatures must conform
in all respects to the name of the Warrant Holder on the face of the Warrant.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 255.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 255.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: right">Initials: _____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.55pt 5.65pt 0 255.7pt; text-align: justify"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>11
<FILENAME>ex10_1s.htm
<DESCRIPTION>COMMON STOCK AND WARRANT SUBSCRIPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.5pt 5.1pt 0 11.45pt; text-align: right; color: #06082C">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.5pt 5.1pt 0 11.45pt; text-align: justify; color: #06082C">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.5pt 5.1pt 0 11.45pt; text-align: justify; color: #06082C">THESE
SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT <FONT STYLE="letter-spacing: -0.15pt">AS
</FONT>PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION
OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT <FONT STYLE="letter-spacing: -0.2pt">FOR
</FONT>AN INDEFINITE PERIOD OF TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 11.45pt; text-align: justify; color: #06082C"><B>IN MAKING
AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY CREATING THE SECURITIES AND THE TERMS
OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES
COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY
OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;<IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/185% Times New Roman, Times, Serif; margin: 0 172pt 0 178pt; text-align: center"><B>1005 W. Indiantown Road
Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 172pt 0 177.9pt; text-align: center"><B>Jupiter, FL. 33458</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 123.6pt 0 129.8pt; text-align: center">COMMON STOCK AND
WARRANT SUBSCRIPTION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 16.9pt 0 22.7pt; text-align: center">THIS COMMON STOCK AND WARRANT
SUBSCRIPTION AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 5.3pt 0 11.45pt; text-align: justify">dated as of November 12,
2018 (the &ldquo;<U>Effective Date</U>), is by and among CBD Brands, Inc., a Delaware corporation whose address is <FONT STYLE="color: #06082C">1005
W. Indiantown Road, Suite 202. Jupiter, FL. 33458 </FONT>(the &ldquo;<U>Company</U>&rdquo;), the undersigned investor (the &ldquo;<U>Investor</U>&rdquo;),
and each other investor that becomes a party to this Agreement pursuant to Section 1(c) hereto (each a &ldquo;<U>Subsequent Investor</U>&rdquo;
and together with the Investor, the &ldquo;<U>Investors</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 5.2pt 0 11.45pt; text-align: justify; text-indent: 0.5in">WHEREAS,
the Investor desires to subscribe for and purchase, and the Company desires to sell and issue, (i) up to 2,000,000 shares of the
Company&rsquo;s common stock, $0.001 par value (the &ldquo;<U>Common Stock</U>&rdquo;) and (ii) certain warrants to purchase shares
of the Company&rsquo;s common stock, all as provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
in consideration of the foregoing and the mutual and dependent covenants hereinafter set forth, the parties hereto hereby agree
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 3.5pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.4pt"></TD><TD STYLE="width: 36.05pt">1.</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>Subscription for Common Stock and Warrants; Closings</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.1pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Subject to the terms and conditions of this Agreement, each Investor hereby irrevocably subscribes
for and agrees to purchase (1) that number of shares of Common Stock set forth next to such Investor&rsquo;s name <FONT STYLE="letter-spacing: -0.15pt">on
</FONT><U>Exhibit A</U> attached hereto (as to each such Investor, the &ldquo;<U>Subscription Shares</U>&rdquo;), together with
(2) a warrant to purchase a number of shares of Common Stock equal to the Subscription Shares (the &ldquo;<U>Warrant Stock</U>&rdquo;),
at $0.50 <FONT STYLE="letter-spacing: -0.15pt">per </FONT>share, in the form attached hereto as <U>Exhibit A</U> (the &ldquo;<U>Warrant</U>&rdquo;,
and together with the Subscription Shares, the &ldquo;<U>Units</U>&rdquo;), at a price per Unit of $0.25, for the aggregate subscription
amount set forth next to such Investor&rsquo;s name on the signature page hereto (as to each such Investor, the &ldquo;<U>Subscription
Amount</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.3pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The purchase of Units by the Investor shall occur at a closing (the &ldquo;<U>Initial Closing</U>&rdquo;),
on the Effective Date. At the Initial Closing (i) the Company shall issue and sell the respective Units to the Investors, (ii)
the Investors shall pay his, her or its Subscription Amount by wire transfer of immediately available funds to the account set
forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #06082C"><B><I><U>Wire
instructions;</U></I></B></P>

<P STYLE="font: bold 10pt/12.55pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: center; color: #06082C">CBD
Brands, Inc.</P>

<P STYLE="font: 10pt/98% Times New Roman, Times, Serif; margin-top: 0.2pt; margin-bottom: 0; text-align: center; color: #06082C"><B>_______</B></P>

<P STYLE="font: 10pt/98% Times New Roman, Times, Serif; margin-top: 0.2pt; margin-bottom: 0; text-align: center; color: #06082C">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: center; color: #06082C"><B>Routing
number; ___________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: center; color: #06082C"><B>Account
number: ______________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">At any time, and from time to time, after the Initial Closing, the Company may sell and issue
additional Units to Subsequent Investors on the terms and conditions set forth in this Agreement, provided that (i) the aggregate
Subscription Amount of all Investors under this Agreement does not exceed $500,000, and (ii) each Subsequent Investor executes
and delivers a counterpart to this Agreement. Each purchase of Subscription Shares by a Subsequent Closing Investor under this
Section 1(c) shall be referred to herein as a &ldquo;<U>Subsequent Closing</U>&rdquo; (and each Subsequent Closing, together with
the Initial Closing, shall be referred to herein as a &ldquo;<U>Closing</U>&rdquo;). At each Subsequent Closing, (i) the Company
shall issue and sell the respective Units to the applicable Subsequent Investor, and (ii) the applicable Subsequent Investor shall
pay his, her or its Subscription Amount by wire transfer of immediately available funds to the account designated by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.3pt 0 11.45pt; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Representations and Warranties of Investors</U>. Each Investor, severally and not jointly,
represents and warrants to the Company that each of the following statements is true and correct as of the date hereof and as of
the applicable Closing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 11.45pt; text-align: justify; text-indent: 1in">Such Investor
is an &ldquo;accredited investor&rdquo; within the meaning of Rule 501 promulgated under the Securities Act of 1933, as amended
(the &ldquo;<U>Securities Act</U>&rdquo;), as amended by Section 413(a) of the Dodd-Frank Wall Street Reform and Consumer Protection
Act, and agrees that such Investor not take any action that could have an adverse effect on the availability of the exemption from
registration provided by Rule 501 promulgated under the Securities Act with respect to the offer and sale of the Subscription Shares.
Without limiting the foregoing, such Investor acknowledges and agrees that Investor has delivered an Investor Questionnaire to
the Company, in the form attached hereto as <U>Exhibit B</U> (the &ldquo;<U>Investor Questionnaire</U>&rdquo;), and that all statements
in the Investor Questionnaire are true and correct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 11.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 3.5pt 5.3pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Subscription Shares, Warrants and Warrant Shares (collectively, the &ldquo;<U>Securities</U>&rdquo;)
are being acquired for such Investor&rsquo;s own account solely for investment and not with a view to resale or distribution thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.1pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Such Investor has conducted Investor&rsquo;s own independent review and analysis of the business,
operations, assets, liabilities, results of operations, financial condition and prospects of the Company, and Investor acknowledges
that Investor <FONT STYLE="letter-spacing: -0.15pt">has </FONT>been provided adequate access to the personnel, properties, premises
and records of the Company for such purpose;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.1pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The determination of such Investor to acquire the Securities has been made by such Investor
independent of any other stockholder of the Company and any agent, representative or employee of any other stockholder of the Company
(i.e., such Investor is not relying on any other stockholder of the Company for investment advice) and independent of any statements
or opinions as to the advisability of such purchase or as to the business, operations, assets, liabilities, results of operations,
financial condition and prospects of the Company that may have been made or given by any other stockholder of the Company or by
any agent, representative or employee of any other stockholder of the Company, other than the representations and warranties set
forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.4pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Such Investor has such knowledge and experience in financial and business matters and is capable
of evaluating the merits and <FONT STYLE="letter-spacing: -0.15pt">risks </FONT>of an investment in the Company and making an informed
decision with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Such Investor is able to bear the economic and financial risk of an investment in the Company
for an indefinite period of time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The execution, delivery and performance of this Agreement have been duly authorized by such
Investor and do not require such Investor to obtain any consent or approval that has not been obtained and do not contravene or
result in a default in any material respect under any provision of any law or regulation applicable to Investor or other governing
documents or any agreement or instrument to which such Investor is a party or by which such Investor or its assets is bound;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Such Investor, if other than an individual person, is duly organized or formed, validly existing
in good standing under the laws of the jurisdiction of its incorporation or formation and has all requisite power and authority
to execute and deliver this Agreement and to perform its obligations hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Such Investor, if not a United States person (as defined by Section 7701(a)(30) of the Internal
Revenue Code of 1986, as amended), has satisfied itself as to the full observance of the laws of its jurisdiction in connection
with any invitation to subscribe for the Securities or any use of this Agreement, including (i) the legal requirements within its
jurisdiction for the purchase of the Securities</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.2pt 0 11.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">any foreign exchange restrictions applicable to such purchase, (iii) any governmental
or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant
to the purchase, holding, redemption, sale, or transfer of the Subscription Shares. Such Investor&rsquo;s subscription and payment
for and continued beneficial ownership of the Securities will not violate any applicable securities or other laws of such Investor&rsquo;s
jurisdiction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">This Agreement has been duly executed and delivered by such Investor, and this Agreement
constitutes legal, valid and binding obligations of such Investor, enforceable against such Investor in accordance with its terms,
except as <FONT STYLE="letter-spacing: -0.15pt">such </FONT>enforceability may be limited by bankruptcy, insolvency or other laws
affecting generally the enforceability of creditors&rsquo; rights, by general principles of equity and <FONT STYLE="letter-spacing: -0.15pt">by
</FONT>limitations on the availability of equitable remedies;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 3.5pt 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">The execution and delivery by such Investor of this Agreement does not and the consummation
by such Investor of the transactions contemplated hereby will not (with or without the giving of notice or the lapse of time or
both), contravene, conflict with or result in a breach or violation of, or a default under, (i) such Investor&rsquo;s articles
or certificate of incorporation or formation or by-laws (or similar constitutive documents), if such Investor is not an individual
person, (ii) any judgment, order, decree, statute, rule, regulation or other law applicable to such Investor or (iii) any contract,
agreement or instrument by which such Investor or such Investor&rsquo;s assets are bound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.1pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">To such Investor&rsquo;s knowledge, no consent, approval, order or authorization <FONT STYLE="letter-spacing: -0.15pt">of,
</FONT>or registration, declaration or filing with, any court, administrative agency or commission or other governmental authority
or instrumentality, domestic or foreign, is required by or with respect to such Investor in connection with the execution and delivery
by such Investor of this Agreement or the consummation by such Investor of the transactions contemplated hereby; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="letter-spacing: -0.1pt">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Neither the issuance of any Securities to such Investor nor any provision contained
herein will entitle such Investor to remain in the employment of the Company or affect the right of the Company to terminate such
Investor&rsquo;s employment at any time for any reason, other than as otherwise provided in such Investor&rsquo;s employment agreement
or other similar agreement with the Company, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 11.45pt; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Representations and Warranties of the Company</U>. The Company represents and warrants
to the Investors that each of the following statements is true and correct as of the date hereof and as of the date of the applicable
Closing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware, and the Company has full corporate power and authority to enter into this Agreement and to carry
out the provisions hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The execution, delivery and performance of this Agreement by the Company has been duly authorized
by all necessary corporate action on the part of the Company and this Agreement constitutes the valid and legally binding obligation
of the Company, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency or other laws affecting generally the enforceability of creditors&rsquo; rights, by general principles of equity and
by limitations on the availability of equitable remedies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">None of (i) the execution and delivery of this Agreement by the Company, (ii) compliance by
the Company with the provisions hereof, or (iii) consummation by the Company of the transactions contemplated by this Agreement,
violates any provision of the Company&rsquo;s Articles of Incorporation, By-laws or any law, statute, ordinance, regulation, order,
judgment or decree of any court or governmental authority or instrumentality, or conflicts with or will result in any breach of
the terms of or constitute a default under or result in the termination of or the creation of any lien or encumbrance pursuant
to the terms of any agreement or instrument to which the Company is a party or by which it or any of its assets is bound. No consent,
approval, order, authorization, registration, declaration or filing with, any court, administrative agency, or commission or other
governmental authority or instrumentality, domestic or foreign, is required by or with respect to the Company in connection with
the execution and delivery by the Company of this Agreement or the consummation by the Company of the transactions contemplated
hereby;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.4pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-size: 10pt">The
issuance, sale and delivery of the Subscription Shares in accordance with this Agreement have been duly authorized by all
necessary corporate action on the part of the Company. Assuming (i) due authorization, execution and delivery to the Company
of this Agreement by each Investor and (ii) the payment by each Investor to the Company, as the case may be, of the full
Subscription Amount then due from such Investor in respect of the Subscription Shares subscribed to by him, her or it, the
Subscription Shares to be acquired <FONT STYLE="letter-spacing: -0.15pt">by </FONT>such Investor pursuant to this Agreement
will be duly and validly issued, fully paid, non-assessable, will not be subject to any Lien (as defined below), other than
any Lien under securities laws and/or created by the holder of such Subscription Shares, and will not conflict with any
provision of any agreement <FONT STYLE="letter-spacing: -0.15pt">or </FONT>instrument to which the Company is a party or by
which it or its property is bound. For purposes hereof, &ldquo;<U>Lien</U>&rdquo; means, any mortgage, pledge, assessment,
securities interest, encumbrance, lien, lease, levy, claim or charge of any kind, including, without limitation, any
conditional sale or other title retention agreement, any lease in the nature thereof and the filing of or agreement to give
any financing statement under the Uniform Commercial Code of any jurisdiction and including any lien or charge arising by
statute or other law; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.4pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.4pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.4pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.1pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Immediately prior to the Initial Closing, the authorized capital of the Company will consist
of: (i) 100,000,000 shares of common stock, $0.001 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;), of which 5,000,000
shares shall be issued <FONT STYLE="letter-spacing: -0.15pt">and </FONT>outstanding; and (ii) 10,000 shares of preferred stock,
$0.001 par value per share, none of which shall be issued and outstanding. Immediately prior to the Initial Closing, there will
not be outstanding any options, warrants, subscriptions, rights (including conversion or preemptive rights or first refusal rights)
or agreements for the purchase or acquisition from the Company, or to the Company&rsquo;s knowledge, from any person and/or entity,
of any shares of the Company&rsquo;s capital stock or securities convertible into its capital stock other than subscriptions for
Common Stock and Warrant pursuant to this Agreement. In addition, the Company anticipates that it will reserve up to 5,000,000
shares of Common Stock for the purpose of granting options pursuant to a stock option plan or other equity incentive plan. The
Company is not a party or subject to any agreement or understanding, and, to the Company&rsquo;s knowledge, there is no agreement
or understanding between any persons and/or entities, which affects or relates to the voting or giving of written consents with
respect to any security of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.45pt 0 11.45pt; text-align: left; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Acknowledgements of Investor</U>. Each Investor hereby acknowledges to the Company as follows
as of each Closing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">No market for the resale of any of the Securities currently exists, and no such market may
ever exist; accordingly, such Investor must bear the economic and financial risk of an investment in the Securities for an indefinite
period of time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Securities have not been registered under the Securities Act or the securities laws of
any other jurisdiction, and the offer and sale of the Securities are being made in reliance on one or more exemptions for private
offerings under Section 4(a)(2) of the Securities Act and applicable securities laws; accordingly, no transfer, sale or other disposition
(whether with or without consideration and whether voluntarily or involuntarily or by operation <FONT STYLE="letter-spacing: -0.15pt">of
</FONT>law) of any of the Securities is permitted unless such transfer, sale or other disposition is registered under the Securities
Act and other applicable securities laws, or an exemption from such registration is available;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0.05pt 5.3pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The certificates evidencing the Subscription Shares and Warrant Shares to be purchased hereunder
may bear substantially the following legends:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 42.75pt 0 86.35pt; text-align: justify">THE SHARES
EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT <FONT STYLE="letter-spacing: -0.15pt">OF </FONT>1933,
AS AMENDED (THE &quot;ACT&quot;), OR ANY APPLICABLE STATE SECURITIES <FONT STYLE="letter-spacing: -0.15pt">LAW, </FONT>AND NO
INTEREST THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (i) THERE IS AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS COVERING ANY SUCH TRANSACTION INVOLVING
SAID SHARES, (ii) THIS COMPANY RECEIVES AN OPINION OF LEGAL COUNSEL FOR THE HOLDER OF THESE SHARES SATISFACTORY TO THIS
COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION, OR (iii) THIS COMPANY OTHERWISE SATISFIES ITSELF THAT SUCH
TRANSACTION IS EXEMPT FROM REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">The Securities are subject to restrictions on transfer as set forth in this Agreement; accordingly,
no transfer, sale, or other disposition of any of the Securities is permitted unless such transfer, sale, or other disposition
complies with the applicable provisions hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Other than the representations and warranties of the Company set forth in Section 3 of this
Agreement, neither the Company nor any <FONT STYLE="letter-spacing: -0.15pt">other </FONT>Person makes any representation or warranty,
expressed or implied, as to the accuracy or completeness of the information provided or to be provided to such Investor by or on
behalf of the Company or related to the transactions contemplated hereby, and nothing contained in any other documents provided
or other statements made <FONT STYLE="letter-spacing: -0.15pt">by </FONT>or on behalf of the Company to such Investor is, or shall
be relied upon <FONT STYLE="letter-spacing: -0.15pt">as, </FONT>a promise or representation by the Company or any other Person
that any such information is accurate or complete; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt">Such Investor acknowledges that such Investor&rsquo;s representations, warranties, acknowledgments
and agreements in this Agreement will be relied upon by the Company in entering into this Agreement and issuing the Subscription
Shares to such Investor at the applicable Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Resale Restrictions</U>. Investor <FONT STYLE="letter-spacing: -0.25pt">hereby </FONT><FONT STYLE="letter-spacing: -0.2pt">agrees
</FONT><FONT STYLE="letter-spacing: -0.15pt">that for </FONT>the <FONT STYLE="letter-spacing: -0.15pt">period </FONT><FONT STYLE="letter-spacing: -0.2pt">beginning
</FONT><FONT STYLE="letter-spacing: -0.15pt">on </FONT>the <FONT STYLE="letter-spacing: -0.15pt">date hereof </FONT><FONT STYLE="letter-spacing: -0.2pt">and
</FONT><FONT STYLE="letter-spacing: -0.15pt">ending </FONT><FONT STYLE="letter-spacing: -0.2pt">twelve </FONT><FONT STYLE="letter-spacing: -0.15pt">(12)
</FONT><FONT STYLE="letter-spacing: -0.2pt">months after </FONT><FONT STYLE="letter-spacing: -0.15pt">the </FONT><FONT STYLE="letter-spacing: -0.2pt">consummation
</FONT>of <FONT STYLE="letter-spacing: -0.15pt">the </FONT><FONT STYLE="letter-spacing: -0.2pt">Business Combination </FONT><FONT STYLE="letter-spacing: -0.15pt">(the
</FONT><FONT STYLE="letter-spacing: -0.2pt">&ldquo;Restricted Period&rdquo;), Investor will </FONT>not <FONT STYLE="letter-spacing: -0.15pt">offer,
</FONT><FONT STYLE="letter-spacing: -0.2pt">pledge, </FONT><FONT STYLE="letter-spacing: -0.15pt">sell, </FONT><FONT STYLE="letter-spacing: -0.2pt">contract
</FONT>to <FONT STYLE="letter-spacing: -0.15pt">sell, sell any option </FONT>or <FONT STYLE="letter-spacing: -0.2pt">contract </FONT>to
<FONT STYLE="letter-spacing: -0.2pt">purchase, lend, </FONT><FONT STYLE="letter-spacing: -0.15pt">transfer </FONT>or <FONT STYLE="letter-spacing: -0.15pt">otherwise
dispose </FONT>of <FONT STYLE="letter-spacing: -0.15pt">any </FONT>shares <FONT STYLE="letter-spacing: -0.15pt">or any </FONT><FONT STYLE="letter-spacing: -0.2pt">options,
warrants </FONT>or <FONT STYLE="letter-spacing: -0.15pt">other </FONT><FONT STYLE="letter-spacing: -0.2pt">rights </FONT>to <FONT STYLE="letter-spacing: -0.15pt">purchase
</FONT><FONT STYLE="letter-spacing: -0.2pt">shares </FONT><FONT STYLE="letter-spacing: -0.15pt">or any </FONT><FONT STYLE="letter-spacing: -0.2pt">other
</FONT><FONT STYLE="letter-spacing: -0.15pt">security of the Company </FONT><FONT STYLE="letter-spacing: -0.2pt">which Investor
</FONT><FONT STYLE="letter-spacing: -0.15pt">owns or </FONT><FONT STYLE="letter-spacing: -0.2pt">has </FONT>a <FONT STYLE="letter-spacing: -0.25pt">right
</FONT>to <FONT STYLE="letter-spacing: -0.15pt">acquire </FONT><FONT STYLE="letter-spacing: -0.2pt">as </FONT>of <FONT STYLE="letter-spacing: -0.15pt">the
</FONT>date <FONT STYLE="letter-spacing: -0.2pt">hereof (collectively, </FONT>the <FONT STYLE="letter-spacing: -0.2pt">&ldquo;<U>Lockup
Shares</U>&rdquo;). Any subsequent </FONT><FONT STYLE="letter-spacing: -0.15pt">issuance </FONT>to <FONT STYLE="letter-spacing: -0.15pt">and/or
</FONT><FONT STYLE="letter-spacing: -0.2pt">acquisition </FONT><FONT STYLE="letter-spacing: -0.15pt">by </FONT><FONT STYLE="letter-spacing: -0.2pt">Investor
</FONT>of <FONT STYLE="letter-spacing: -0.2pt">shares </FONT><FONT STYLE="letter-spacing: -0.15pt">or </FONT><FONT STYLE="letter-spacing: -0.2pt">options
</FONT><FONT STYLE="letter-spacing: -0.15pt">or </FONT><FONT STYLE="letter-spacing: -0.2pt">instruments convertible into </FONT><FONT STYLE="letter-spacing: -0.15pt">shares
</FONT><FONT STYLE="letter-spacing: -0.2pt">will </FONT><FONT STYLE="letter-spacing: -0.15pt">be </FONT><FONT STYLE="letter-spacing: -0.2pt">subject
</FONT>to <FONT STYLE="letter-spacing: -0.15pt">the </FONT><FONT STYLE="letter-spacing: -0.2pt">provisions </FONT>of <FONT STYLE="letter-spacing: -0.2pt">this
Agreement. </FONT>Notwithstanding the foregoing restrictions on transfer, the Investor may, at any time and from time to time during
the Restricted Period, transfer the shares <FONT STYLE="letter-spacing: -0.1pt">(i) </FONT>as bona fide gifts or transfers by will
or intestacy,</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.1pt 0 11.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">to any trust for the direct or indirect benefit of the undersigned or the immediate
family of the Investor, provided that any such transfer shall not involve a disposition for value, (iii) to a partnership which
is the general partner of a partnership of which the Investor is a general partner, provided, that, in the case of any gift or
transfer described in clauses (i), (ii) or (iii), each donee or transferee agrees in writing to be bound by the terms and conditions
contained herein in the same manner as such terms and conditions apply to the undersigned. For purposes hereof, &ldquo;immediate
family&rdquo; means any relationship by blood, marriage or adoption, not more remote than first cousin. During the Restricted Period,
the Investor shall retain all rights of ownership in the Lockup Shares, including, without limitation, voting rights and the right
to receive any dividends that may be declared in respect thereof. The Company is hereby authorized and required to disclose the
existence of this Agreement to its transfer agent. The Company and its transfer agent are hereby authorized and required to decline
to make any transfer of the common stock if such transfer would constitute a violation <FONT STYLE="letter-spacing: -0.15pt">or
</FONT>breach of this Agreement and/or the Purchase Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.1pt 0 11.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.1pt 0 11.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.1pt 0 11.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.4pt"></TD><TD STYLE="width: 36.05pt">5.</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.2pt 0 11.45pt; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Headings</U>. The headings in this Agreement are for reference only and shall not affect
the interpretation of this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.6pt 5.2pt 0 11.45pt; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 3.5pt 5.1pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Governing Law; Submission to Jurisdiction</U>. This Agreement shall be governed by and
construed and enforced in accordance with the laws of the State of Delaware without regard to principles of conflict of laws (except
insofar as affected by the securities or &ldquo;blue sky&rdquo; laws of the state or similar jurisdiction in which the offering
described herein has been made to Investor). Any claim, action, suit or proceeding seeking to enforce any provision of, or based
on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be heard and determined
in any state or federal court sitting in Palm Beach County, Florida and each of the parties hereto hereby consents to the exclusive
jurisdiction of such courts (and of the appropriate appellate courts therefrom in any such claim, action, suit or proceeding) and
irrevocably waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying
of venue of any such claim, action, suit or proceeding in any such court or that any such claim, action, suit or proceeding that
is brought in any such court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Successor and Assigns</U>. This Agreement shall be binding upon and shall inure to the
benefit of the parties hereto and their respective successors and permitted assigns. However, neither this Agreement nor any of
the rights of the parties hereunder may otherwise be transferred or assigned by any party hereto without the prior written consent
of the other party; <U>provided</U>, <U>however</U>, that the Company may assign this Agreement to any Affiliate, to its financing
sources as collateral security, or to any purchaser of the Company (whether pursuant to a stock sale, a sale of all or substantially
all of the Company&rsquo;s assets, by operation of law, or otherwise). Any attempted transfer or assignment in violation of this
Section 5(c) shall be void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Third-Party Beneficiaries</U>. This Agreement is <FONT STYLE="letter-spacing: -0.15pt">for
</FONT>the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express
or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature
whatsoever, under or by reason <FONT STYLE="letter-spacing: -0.15pt">of </FONT>this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.3pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Amendment and Modification; Waiver</U>. This Agreement may only be amended, modified or
supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall
be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or
be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether
of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising,
any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall
any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof
or the exercise of any other right, remedy, power or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>Severability</U>. If any term or provision of this Agreement is invalid, illegal or unenforceable
in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement
or invalidate or render unenforceable such term or provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; font-weight: normal; letter-spacing: -0.1pt">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; font-weight: normal; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt; font-weight: normal"><U>Waiver of Jury Trial</U>. </FONT><FONT STYLE="font-size: 10pt">EACH
PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT <FONT STYLE="letter-spacing: -0.15pt">IT </FONT>MAY HAVE TO A TRIAL BY JURY
IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be
deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of
electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 5.35pt 0 11.45pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt; letter-spacing: -0.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"><U>No Strict Construction</U>. This Agreement shall be construed without regard to any presumption
or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 172pt 0 178pt; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 172pt 0 178pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 172pt 0 178pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 172pt 0 178pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 172pt 0 178pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3.5pt 1.05pt 0 11.45pt; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties have executed this Common Stock and Warrant Subscription Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 263.45pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B>COMPANY:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>CBD BRANDS, INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">By:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Brian John</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title: President</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 263.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; text-align: center; margin-bottom: 0"><I>[Signature Page
to Common Stock and Warrant Subscription Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-right: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-right: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 11pt/12.2pt Times New Roman, Times, Serif; margin: 0"></P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-right: 0; margin-bottom: 0"><B>SUBSCRIBER:</B></P>

</DIV>



<DIV STYLE="border: Black 1pt solid">

<P STYLE="font: 11pt/12.2pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt/12.2pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt/12.2pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">Name of Subscriber:</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Fax No: ______________________________________________________________</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Taxpayer ID# (if applicable): ______________________________________________</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-top: Black 1pt solid">(Signature)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>By: _________________________________________________________________</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Dated: ______________, 2019</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Purchase Price:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>_____________ US Dollars</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Number of Subscription Shares: ________________________</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Number of Warrant Shares: ___________________________</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>[EQUAL TO SUBSCRIPTION SHARES]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Aggregate Purchase Price:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>_____________ US Dollars</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>[EQUAL TO $0.25 TIMES NUMBER OF SUBSCRIPTION SHARES]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 11pt/12.2pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt"></P>
</div>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 263.45pt">&nbsp;</P>

<P STYLE="font: 9pt Sans-Serif; margin: 0.15pt 0 0; color: Red"><B></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 5.7pt">&nbsp;</P>

<P STYLE="font: 10pt/195% Times New Roman, Times, Serif; margin-top: 3.5pt; text-align: center; margin-bottom: 0">EXHIBIT A</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM OF WARRANT</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ 24# 2(  A$! Q$!_\0
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M+B[@@.0)9%0D=1D@4 >H?\(GX4_N1?\ @2?_ (JC_A$_"G]R+_P)/_Q54/\
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5</%86R..C+$H(_2KE% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>13
<FILENAME>ex10_2.htm
<DESCRIPTION>INDEPENDENT DIRECTORS CONTRACT BETWEEN THE COMPANY AND DR. HECTOR ALILA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_007.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_008.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_009.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .I M@# 2(  A$! Q$!_\0
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MB&))SN)W'DD\DUN44 9UYI"7MND,EU<JBMN^5^3UZD]1S3;;1Q9HZPWMU\P
M.YE;IG&,CCK6G10!0GTUYX1'_:%U'R"6C*@G'_ :KV&BW-A;+;C6K^=%SAYR
MCR')[L5Y_*M>B@"E]BERA%[-A%(P0IW9(Y/'7C]327EG=W4+1QWOV<-&R%TC
MRX)[J<X!'T-7J* ,A-+U""TB@M]5^=!@S30>8[C)(SR.F:LQ6^H)#MDOXY)/
M[_D8_3=5ZB@#.GM=5D$9BU&"-E.6S:[E;VQNS^1J![+76O+>4:M9") 1)"+
M_.<]0?,RO'U_I6Q10!F3PZPU]'+!=V:6RKAH7MV9F;U#[Q@>VW\:M2"\:!A$
MT,<Q7AF0NH/NH(S^8JS10!E_9=8%Q%*=0MV 0+(GV<A2>[ ;LCMP2?K5@Q72
M >2+="QR_P IY/\ GO5RB@#.@@U*.ZD:2>%K?""./8=PX^8EL\G/L*;!97MK
M#=+%=>9)+(\D<D_SB+=R% X^4>F:TZ* ,41>(DMHE^T:<]QYR^;(T+ -%W
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M4 %%%% !2$9Q[4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-8D8PN<
MGGGI3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW?AW2_$U[>1A8_#*V$4$*8_=[ =S,3R>.F,56^%4XM?AQI,NKRVPT58]UMN
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M3[#-&OE@>6X4D%<#CE%/X5H>(V-UXH\-Z7)_QZS237,B]G:)04!]MS!OJHH
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M7Q)>:3%:%1:M(KR&5=P*%1\T?WE#;B5/0@9H Z.BN=U7Q4NGW=[##8SW:Z?
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M0@9Q*[$HIX!R3G'0>@XZ5&W@S0GFNY&M9C]LD,MRGVN79,WJZ;MK>F",8XK
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MW$$", #AFZG('0X?9>*-0F\;RZ)=PP6B*[^5'*C!YX@N1)')G:W/!3&0/QH
MV]9\.Z3KRQ?VG9K,T))CD#LCIG@X92",_6H)/".AS')L0JFW6V9(Y&1'B7[J
M,H(# 9/4'J?6N<\63W]S>>*]-DGC.FQ^'_/6'R_F#MYXSG/7,8/3M[<L'C:_
MTJS9+BSMI1]ALI[18G*_Z]_*VN6P"01NSQGIQ0!LZ_X12[TCQ&NE )J.M6QA
ME:XN'\LMLV!B/FQ@>@[ 5-#X-T9]/FCNK(F6ZAB2=GNI)F7R^5".YW#:Q)!&
M.>>M6/#NH:MJ$%TNKZ<;.2*79%(,*)TQD,%W,5[C!)Z?E@3>'M;LM#N!J.N+
M>6L6D36\L*P[-\F699 <Y!VD*?4J#Q0!M2>#])D5 ?/\Q;I+PRF4L[RH,(S,
M<DXQP.E1W7@?1KR]N+MC=I)/<QW;B*Z=%\Y,;7"@XS\HKD[^V70/A]HOB;2G
MG@OXDLFDCCD;9=B1D5U=,X8G>3G&<CK6G#XB?2UUA[328?/'B&.QD1KMB)#+
MY067)4[<^8OR@8&#C/< WF\'Z:TB/YEV FH?VDJ"8[1-SG\"6)(]Z=#X1TJ"
MZ29$FVQ7;WL4)D)CCF<$,RK_ ,"8^@))&,UC+XYU$ZF]DOARXN&MIX[>\>U9
MY!&[*K-M.P!@H<=2I/84Z3QCJ5[X=GU73=(/V9[6ZEMYWE!VM$2%WKC(# $C
M&>F#C.: -+3O!NGZ7=Z;<6]Q=EM/CEBA5W4@K(VYPWRY/.#U[#WS%<^$UGOM
M=C69HM.URW"W0B;$B2A=A9<@K\R8!XZKGG/%>+Q9J!TZW,&F?;;I-+AU"Y E
M\OA\[53Y3ECL?C@<=>:A/B2Z\3RSZ5IMA=1P36D%Q]NCNUA>.*97*L."0P*8
MQSZT 6M0\"6>I2O)<W]ZY:RBL\[E4CRWWI("%!#A^<CCVJ2W\'M'+IUQ<:WJ
M5U=65RUR)IF0^8Q0QX(VX V,1A<<G/)IESHFJV-I=7MMKM])<Q62"..9U>,R
MQJ?F(Q_%SN]<Y&,"MS1=2CUG0[#5(E9([RWCG56Z@,H;!_.@#+@\)+::Q/>V
MNJZA#;33-<M8K(/),S?>;INP3R5# $\XJII_@==-FT>6+4[AWTN*XBC,B*=X
MF.YB>.H(7'T]ZZVB@#@&^%UM_9;V$6L7D<;V,-F3LC8XA8LA!*\>X&,XK5N_
M!?\ :#:T+S5)Y(M5M8K>1515,9C'#*?4DDD8[^U=510!S/\ PB4RZJ]]%KE]
M%]H\MKV.,(!<,@PK9VY3@ ';C( 'O5[0=%DT2"\B:\-S]INY;H%DV[#(VXKP
M>@).*V** .0'@F<Z)!:'694O;;49-1M[R*$*4DD9V8%<G<I\UQC(X/M4_P#P
MB^H'4M&O)-:,[6$DLDIFM\F<R J0"& 0 '@ '&!G/.>HHH Y"Q\#O8V5WI<>
MMWC:/+#-'#9LB$Q>9G/SXRP&3@'IGDGBKMIX9FM;K091J&Y=*M'M"GE?ZY65
M1G.?E/[M3W[^O'144 <;'X$D&FWNC2ZY=2:)<),D=KY:!XQ)G(,F,L 6)''I
MDG'-[1?#NJ6&NMJ>HZVM^QLDM-@M1%]ULAR=QR3EL]N>W2NDHH Y*Y\%RS7U
MS>1ZH4E;44U&US "() @1@><NK*,$9'M6I9Z"UM::J&O&-[J;M)-<Q+Y95B@
M1=@R<;55<<GD9[ULT4 <)8> M1T^*X1-:M)%FM(+5HI--4Q,(W9OF7=E@P>0
M'G.6SGM6FO@Y1X%O/#+7C!+E)D#HN%A$A)"HISA%S@#/0=:ZBB@#C=2\$7&K
M6NL1W6JKYFK64-I.Z6^-OEER&4;N_F-P?;TYL6GA2_L-9N+FSUQH["YN?M4]
MH;=68OP6"R$Y56(R1@]3@C-=510 5YRJ:[IGB74;W0M#U2*WOI=]U;3PVS1-
M(,*98S]H4J6 &<@YZ\5Z-10!YW?VNN&[N;VTT_7!<W=B+.X$D=H^<%BKKB=5
M5AO;U'3CUJ7'A[4Y=/UBTM-)U.&"^M;6WC61;<M$L/&,^?\ ,2,\\#ZUZ?10
M!YGXDAULMJU_!HFJ^;=R:>L*1I"YC$,X<D[96)SN;/   &3WJ:^T[7[O4?[2
MCL;^WN7NO,EB>.&2%HA&45"HG!8C)8$\;CTX%>C44 >80Z3JNGVP4V&LSLFF
M3:>BK! >'?*N?WX!8#''&?:EQ=WD^@PCPGXC,NB*BR2-]GA$ZA1M&3-M8;T1
MR-QP4 [UZ=10!#%.S627$L$L+&,.T+ ,Z'&2IVD@D=."?;-8NA:;<_:-:U*Z
M62W?5+A72+/S11K&L:Y]&.W=[9 [5T%% 'G\/PXN8["6W;7 SRV/V-V^R@!O
MG#;SALECSN))))SQTK3U'P;<7VJ76HQZL;>Y>XM[FV*P9$+Q(R'()^=65V!'
M&,]>*ZVB@#$\.Z)<Z*-0-UJ'VV2\NC<LPA$85B , 9/&%%;=%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>_MY+O3[BWAE6*26-D5
MV3<%)&,XR,_G5BB@#E)/"E^_A[1-+75XE?2I8I!.;3/F^5]P%=_''7U[8I;?
MP=-;RWMJNL3'1+LS.]@8E)!E!W@2'D+EF; YR>N.#U5% '&2>"M1N/#]UI%S
MXDGGB,<<5FS6R#R1&X92^,>8W"@GC('0$DU(_@8227B/J+M:ZDT4NHP^4!YT
MJ;<LI!^3?M 88/ XQUKKZ* ,G1M%;2+G4Y?M1F2^NC<["@'EL0 0#W&%'XY]
M:C@\/Q+K&H:C=-'=R7058_-B!,**#\@/IDD_4GKVVJ* .-TWP-/IUEHEHNMS
MR1:1=-<0!HEY4HR>6?\ 9 =P.X!'I4]MX)%N-/\ ^)M=.;/49M1!*)\[R[MR
MGC[O[Q_?YNO%=710!R.A>!$T+4+&ZCUB^G%G%-!''*(\&*1@Y5B%R3N4'=G)
MQ]<W;CP_*-?U"]M'6*/4[(6UR1]Y)%W;) ._#D'IT6NAHH Y*3P#8W$=M#=7
MEU/;PZ8=,,3;0'C)!R2 #N!5,$8^[[U/'X+A%A%;7&M:Q=O%<Q7*3W%PKN&C
M.4'W=N,\GC)[DXKIJ* ,+_A%+-==?5(;N_@,L@FGMH;@K#-(  '9?7 7." <
M#(-5;/P/86,]E-#>7NZSNI[I 63#/-]_(V=.6P!CJ?;'3T4 <A'\.-'2*.)K
MB_9%CN(642A/,BG;>\;;%'R[B6 &.?;BKMMX+TRW8EI+J=6T\::Z3R[@\'/R
MGC.>3S[FNBHH Y=_ .CNEJ!-J,;V\(MO-BO9%>6$'(C<@_,OMVR<8S6QIVC6
MNEW-_/;F3=?3">8,V1OVA<@=OE51^ K0HH QSX9TQ[_4[N6%ICJ<:QW<4K;H
MY%48'RG@<?SJHO@;05TJ?3/(N3:SA%=7O)F.Q?NH&+$JH_N@@5T=% &%-X1T
MJ?5?[2=;D7+>7YFRZD5)MGW?,0-A\>X/2F2>#M,ETJXTUWO#!/=?;'_TEMWF
M[@^0<\?, V.F17044 <_>>#-%OM;35YX9?M@"B1DF=%GV_=\Q5(#XP,9':H_
M^$#\/B^CNQ;3AXKHWD2+=RB..8G)94#;1DDYX[FNDHH SM0T2RU.]L+NY23S
M[&0R0.DC(02,$'!&01U!X-5M/\+:7IES;S6T<H%LKI;1-*S) '(+;%)XS@?0
M<# K:HH Y_6/!FCZ[>RW5\EP9)H5@E6.X>-9%4DKN52 2"Q()Z9J>V\+Z7:W
MT-VB7#20NTD8EN9)%5V4JS@,Q^8J2,^Y[DULT4 8NI>%M-U349+Z?[0L\MH;
M.0Q3LBO$=W#*#@XWMC(XS],4KCP%HMXKQW0N)HGLDL6C>3(\I"63G&=P)R&S
MG-=/10!FZ/HEMHL$D<$MS.\K!I)KJ9I9'(  RQ[  <4:_:WE]H=W:6'D^?/&
M8_WSE%VGAN0"0<9QP>:TJ* ."MO"FMPPV"W$=C?)IX46EO<WKF*(J,*<+$-Q
M '!8$BFMX2U<RW<HL[+?=7\.H2 :H^#-$05QFW.!E5R/;ZY[^B@#@[GP[KTV
MN-JT5A:VLLK1M=1VNN2HER4&%WC[-V  X(R!@Y%4['PSK-A)=*NAHUE.96%@
M-;/V>+S 0X51".#DG!R!DXQ7I%% 'E]GH/BFU$<46C>4R67V$W UE&:6('Y
MP^SXRH+ $ =3UK:T#1-7T?7FN4TZWM[&2V@L_L\5YY@BCBSL(R@)QN;OSGVK
MMJ* ,[7/MIT>XBT^$2W<R&*/<0%0MQO;/\(SDXY..*KZ)H<NB);6T>H2RV-M
M8PVD5LR+A3&,;\]<D8&.G%;-% !1110 4444 %%%% !1110 4444 %%%% !1
M110 @ '2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLG@J2" 1P30!MT5QOB7Q[IUCX5O-1TB_M[BY2WEFM\0O-&QCX.[9]T$_+N)
MR>]=5#<K_9L=U<,D:^2))&)PJ\9)]A0!8HK!/B[29+*ZGMIVE>&U-V(C$Z-)
M'SAU! +*2,;AD5%X1OM4U72X]5OKB)[>]@BG@A6W:-H2RY=23]Y<XVG R/7B
M@#HZ*X?3-8\4:G8:M<VMUI4LFGWT]L+=[21/-$;=-XE.TD=]I^AJ;2_&]EJ1
MM=2-^L-E+I!OGLS;LSIA@&?>."%SM*@9SS0!V5%<\GC?P_+:FYAO))HP"W[J
MVE=MH"L6VA2=H#+\V,<]:FG\7Z#;B)GU*(I(D<@>,%T5'.$9V4$(&)X+$ T
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M%/B[PZ+4W0UJQ:W686[2K.K*)",A20< UI07UK<W-Q;0SH\UL569%.3&6&X
M^F00: +%%<YK_BN#2-2TVPA>TFNKJ\BMY(&GVR(CG&X* <_0XXK6&KZ<UU+:
MB^MS/"I>2/S1N11U)&> /ZT 7:*Q9?$-I/';/I=]IETLETD,A-XH #=0N,[G
MZ87C-6AKFDL\R#4K/? A>5?/7,:@X);G@ \9- &A16>VO:0EG%>/JEDMM,Q6
M.9KA CD9R V<$\'\JEOM3LM,TV74;RYCALXD\QYF/RA?7W_K0!;HJDFL::]O
M;3B^MQ%<@&%FD \S/IGKU%7"0H))  Y)- "T53AU;3KF(RP7]K+&'\LNDRL
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MD8..": -^BJ&FZA)>69GNK;[$WF.GEO*CG ) .5)'.,XSQWJX)HC(T8D0R*
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M>+/#Z2&,ZS9%P77:LRL<IG<.#U&#Q[4Q_%_A^.UM[F35K9(K@NL)9\%RIPP
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M1Z-%J=M#-#%(\B>7. '4H[(V<$CJI[UJ9H \RU;3[2Z\8^)A>Z9K<EM?VEM
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MK<IYJ>3&I(8@!AO63OWSWR>IHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:SWMQ"TT5C-C]Z%(QU&.N,9]..AJ#1[S1?%7A[3VFL[%P]K#<FPD"R_9]R9
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MF)0AL'HPQGFJ.B>"+_3[W28[FS23R=%DM6NPR,MO,9-Z;58Y^49 ('I7I=%
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MLDOAJ8:;%9W4;Q76V?R6>3>@?D@<;S@9"[L9Z5!I?AV-4\+FY\.NOD:E>M>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R.02H'"LH/9A@_E3Z
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJI::G9WUU>VUM.LDUE
M((IU'\#%0P'Y,*S)?%^EKJ-Q8P&XNY;7 N3:P-*L!.>&*CKP>!D^U &]17-R
M^.] B&EM]IFD75039&*UE?S<=0,+P?8\U/;>,="N]+OM0@O=\-@2+M1$_F0$
M9R'CQN&,'MV/I0!NT5S^F^,](U66W2U-X5N<_9Y)+*9(Y@%+Y1RNT_*"1SSB
MJ]K\0?#E];-<VUS=26ZS>0\PL)]B29 VLVS Y(Z^M '445C6?BK1K_7[K0H+
MS.J6J[IK9XW1E''(W  CYAR,]:B_X3+06O-0M(K\37&G(SW:11._DA>N=JGG
MV'/!]#0!O45S5IX]\.7\ELMM>RR)<RB&";[),(9'SC:)"FPG/'6IM-\9Z'JQ
MU)+*YDDGTTD75OY$@EC(S_ 5R>G8&@#?HKF+CX@^&[.$S7-W/#"L4<KR/9S!
M45_N;CLPI/8'!K6TK6['63<BS>4O:R"*9)87B9&*AL%7 /0@_C0!HT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11UHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *HZSJ(TG1[J_,<DODQEECC0NS'H  .>N*O44 >
M/Z&NI>"OB#'=7]N'LO$%N#=SVC23(MRISYKY1=@8L1CH,^@JQX5O;CP7H7BJ
MQOO+M]72^N+Z#[4#MO%;!4H<C>3MQ@'()&17K%% 'C>MZG=:A_P@%U-$-+O?
M-EN)EBMB19JZE59E/1<G!)QGGIVCT^8Z7H?Q M=;AGB\375M.TL[ B.]4(ZQ
M&'C ^^!MY//X#VBB@#RKX9:K#8Z!I,&I:FL\LEO%%;613,EJRF4.2 ,J"N/F
M;'IZ5A?#VZ@T&WUZ35-246T&H7CR:84S)<[A$$=%ZL#M('&.?>O<J,"@#R+Q
M-:7<7BF?Q'X? N-6L=9C@DAR2K13V\$1W8Y #+^'S>E0Z;:6FG?$CQA9_:&,
M9T5$,K?Q,$&\^[<[C[DU[%@9S@4M 'C/PKNH]*\(Z6FJ7^Z-2;9-*>+]Y'.U
MR71@O4]=V3TQQ[2:GH<LD5UXS\(2*VOZ=>W:7<,9XNX?.8[& ZD(5(/4C'?&
M/8J* /*/BFT3_!%G;;]HN(K3;SAI&W(<>YP"?PKT^T:UGB%W:M%(EPJR>;'@
MB08&#D=>,58Q10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445GZSK-MH=D+N[29HC(D
M7[J,N=S$*O ]20/QH T**!R** "BBB@ HH/ JC!J:3Z0VHBVND0([^3)"5E(
M7/&P\Y..![B@"]15/2M3M]9TJUU*T+&WN8Q+&77:<$=QVJY0 44UY$C +NJ@
MD*"QQDG@"JUE?K>O=*MO<P_9YC"3-$4$F #N3/WEYQGU!H MT44'@4 %%9%A
MXCL=2U V=NMR24=XY6@812!6VMM?&.#Q[]1D5KT %%-:1$*AF +'"@GK]*J:
M3JMKK6GK>V;.86=T'F1LC;D8HP(8 C!4B@"[1110 454TW4K75K(7=E(9(2S
MIDH5(96*L"" 0001^%6Z "BBB@ HHHH **I1:M9S:G=Z>DC?:;14:93&P"AQ
ME<,1@]#T)QWJ[0 453FU6RM]3M=-EN%2[NE=H8B#EPHRV.W JY0 4444 %%%
M58-0M;F]NK2&XCDFM2HGC4\QEAD _4<T 6J*** "BBB@ HJO-?VEO=VUI-<1
MI<7)80QL?FDVC+8'L*FDD2&-I)'5$0%F9C@ #J30 ZBHK:Y@O+6*YMIDF@E0
M/')&V5=2,@@]Q4M !1110 44=Z* "BJMWJ-G8RV\5U<QQ27,@BA1FP9'/8#O
M5J@ HHHH ***@%[:F_-B+B/[6(O.,.X;PF<;L=<9&,T 3T444 %%%% !1110
M 456;4+1-1CT]KB,7DD;2I#GYBBD MCTR1^=6: "BCH,FJ<&K:==:<VHP7UM
M)9*&+7"2@Q@+D,2W3 P<_2@"Y14-K=6]]:Q75I-'/;RJ&CEC8,K ]"".HJ:@
M HHJK8:C9ZG;FXL;F.XA#M'YD;97<IP1GO@@T 6J*** "BBB@ HHHH ****
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M^TK;0B?;L\T(-VWTSUQP*HVEIH-[;7,=G!IT\#2&.X6)$92ZGE6QQD$]#T-
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MK(A\,Z3;7UC=6ME!;&R5UAC@B1%7>,'H/3/?')Z\8UZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R&]6QMKG4HSJKP3'Q5;$B2
M;>Z A"& ;(Y.<$C&%QVQ5B?Q#>VN-+N_$2PV4.JW-I+J<AY4*B/$DD@P%/SL
M,GJ4QZY](@DTO4)+CR#:7+PR^7-LVN4D '#>A (_.I_L-H4=/LL&R1MSKY8P
MQSG)]3GF@#GQJDEG\.9=3FU4W3Q63R?VA':E2^ <2"(GGL<9 /L#7$6_C*[5
MKNVFUA7LQ/8F:YCG65K>"16$C%E4 ?,J@D9"^9P?3UW8I385&W&-N.,51@.E
M33W-C!]D>6!%CG@0*2BD':K = 1G - 'EL>OIIUE?0V?B"..S;Q$T=QJ);S_
M "HFA#)N*D'!<!-V>Q!-6_\ A)?+CMK74O%$CVKV-Q)9ZA$GV874R.0!DD[L
M#;M&</U(->GO9VLENT#VT+0M]Z,H"I^HIMQ8PSV#V@58T,9C4J@^0$8X!&./
MI0!Y?/XKO;;10][K3VT]SX3AO+>1PHWW>&+%1CEL[,J/7I4-UXZF75+*XCUV
M-%6YT])H9G6-1%*J&1@N#N4B3/F,1M(P/?T[1M(CTG1++33(;E;2!8%DD50Q
M4  #@ = !^%7#;0,23#&20!DJ.W2@#SW0M9;7KK[/<^(KFUU>26YMKK3(U&Z
M(#=L=1U0!0I#\AB<'DXJUX-NM5U#4EL=2FO%N-"C>WO&)/EW4S-\KDD\_( X
M'0>9VQBNTN;-+BWN(XW:WEFC*>?" )%R,9!(/([9S5;1='CT:R,(N)KJ>1M\
M]U.09)GP!N8@ =  ..@% ' _$7Q7<Z-J5XMGJC6]Q96$=S' \@0.QD.=J\F4
ME5P0<!0,YYX;>:_>V^JZE>1^))9+2RUNRA2/,7EF&81;PQ"Y( =\<\8[UZ<]
MO#*VZ2&-VVE<LH)P>H^E1O8V<GF;[6!O-_UF8P=_U]>IH \K&NQ:EXD\.SZC
MJK1ZK#KT]M+IKLJB%?+E"87J01Y?S<Y+_0#J/'NHZC8&P^P7J1 I,\ML)EAE
MF"A3F-V4KE<D[3C.>HQ70G4]&BUH6/VFT&IS?\LP1YC[03^@S]!4FHG2I)+:
MTU+[([W#[8(K@*3(P^;"@]2,9X]* /,M1\7W5CH6L3MKDRS_ -DV-W9?:%2&
M5W._S"J'CG8,J,@9-:#FQ'BOQQ=#4WBC;2[65GCG49RLW()'&!MP??WKO8&T
MK5"\L!M+LP,UNSIM?8>-R9[=LBITL+..4R):0+(0%+", D#'&<>P_*@#S;3M
M9N=-M?#$>DZJ]Y!-H-S,EK(4?S)8TC*#( ;/SL,9Z+TR":AO?%4DG@W4]2TK
MQ>+B[72TN3"(8V>WF'WMW!";L@;",C!(/6O4A;0!PXACW DAMHR*:;*T:.2-
MK6$I(<NIC&&/J1WH \]U;Q/J'_"6WMG'KUAIRV<]N8+>X/\ Q]0.BEBJ[29"
MS,R@JW!4<>L-OKVM1:E'</K,ES%'XAFTS[(\<2AX]C;<LJ@[@P&#Q[@UZ/\
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M!>AW9Y"GC->D1^']&AE66+2;%)$<R*RVZ ACU8''7WJ5](TU_M&_3[5OM/\
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M+I%@()B&EC%L@60CH6&,$T <==^(]?M=1OM,&JZ4MWIJ02-)>KY"7*N2S-M
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M<6XP5!SCN..N>ZJG!I.GVVH2W\-E!'>3($DG6,!V4<!2>N!@<>U7* "BBB@
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MC<OJ* %HI-P]:7(]: "BC(I,CUH 6BBB@ HI,CUI: "BBB@ HHR#10 4444
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M.7NR\NH#47/GD?O@  >,<8 X]JSM \'[+>==:A#L-0NKF&);EI(L2LQW;2
MP#D=/4CDT 9Y^(E]#I]_<2:7!+);6,-^%CF(38[E67?@ABNTX9?E;U%6;[QG
MJ^G#4#=:798L)K<W#17+.J6\N1YGW1RI!)& ,<U:?X;: ]H]J3?^5):+9N#>
MR-NA4Y5.2>!DX],FG:KX9NX1=OHQBFGU-([6\.H2%HUA5&4,J 8)&[IP#DT
M;NDWT^H1W4LL BC2YDBA().]$.W<?3)#?A@]ZYJ[\9:K87VNFXTBV_L_2" T
MB71,DI=%:/"[,#[PSD\9XSCGK;"R@TVPM[*UC$<%O&L<:#HJ@8 K-;PMITQU
M<77G746K8^U0S/E#A0HVC'R\ =/0'K0!EQ>*M6^VQ6-SHOD3W-V(+:1Y-L<J
M"-I'?!&X;=C#&.<C\&Z9XQN[VZL;::Q@1Y]4NM-E:.<L$:%'8,..0?+Z'&,B
MK"^!-$6PBM6:]=HIEGCN9+R1IT9<A=LA.X  D8'&"?4U3T3P<1930:I')"T.
MJSWMG+;W;^8JN3U?A@2K,&'.<GF@"K8^($UG4/#^JG2A]MN(+Y(B+Q]D31-M
M9" ,-NQU(R,=*2S^(.IWECIDB^'PESJELUW:1"X:0&-0I.XK'D$EU &.AR2.
ME;=GX&T;3UM5M?M<8M#.8,7+G9YWW^I[GGZ\T/X(T@Z5IM@C7<(TP%;.>&X9
M)H5(P5#CG&,#!SD 4 4X?&MP^N:?IMSI:V$EW$C[+R?RY"6SN"#!5RN!D;@>
M>E:/BW5+[2=.L9;#R=\VHVMLYES]R254./?G'XT2^$=.G>V\R:\DAMY(94@>
M<NF^+[C<Y.<X)YY(YS5_6M&MM=T[['=-,BB1)4DA?8Z.C!E8'L00* .&L]1E
M\+^(_$TL=KY]F^JVBSLTQW1^>D:_("#D!Y,D9& >/;3D\<7;7LMC%IL8F87:
MQ/YQ=4>'H'(7;\PYP&)7(! K2F\$:9/]J,DUZ6NIX;B9C-DM)%C8>G;:OUQ4
M</@'1(;B&6/[8%ADF>.+[4^Q?-_UB@9^Z22<?TXH T_#=[>:CX8TR]O5B%W<
M6L<L@C;*[F4'C@>OX>_6N!?6M5OM2\-:G<0(UXNM7UC'!#<NL3*J3(-V1C@J
M#NVDX&0,\5Z-I&EPZ+I5OIT$L\L-N@1&G?>^T= 3[#C\*Q5\#:;'>0W$5U?1
MB"^>_CB$H*+*^[=@%3@'<W'^U[# !F2?$&Y>T06>BR7&I!)FEM$,C[3%*8F5
M62-LDLC %@H]<5UMC<-J>C0SSVTUJ;B$,\$ORR1Y'*G'0BL"+P!ID'DO#?:E
M%=1/.PN8K@)(PE;>ZDJH!4M\V,<'I7216B6]@MI!))&J1[%?=N<<8SELY/?)
MSD]<T >66,,UO\*G\3V.I:A'JNGBYE\R:[ED2;R974I(C,5((7'J.HQ6RGBU
M=-E\2:A%HTK3PM8R3(UV?WGG(H& 1A-O3 ZGGBM?3_A_I-EI<6ERW.H7NGQ2
M&46UU/F-G+ER6"@;\L<X;(SVJSJ'@W3M2DU-IKB[4ZEY/GJDB@?NCE,<<<_G
MF@#.E\;:A#J$ME_PCT\\]JT:W2VK/+LW\_*=@5L*0W)4\X[<Z-CXBO=4/F6>
MDE[-WN(H[AIP,/$Q3YUQD*S*P!&XC R.:=>^#].O=8&I^??6\[[1<K;7+1I=
M!>%$JCAL?AQQTXHLO!^G:?JSW]O->JK3/<"U^T-Y"ROG<P3U.2<=,G@"@#%T
M/QGJ^I:-IH32K>XUBXL#?20_:3$@3(4<[20Q.<#&.#S5O2?&MQKFJ6=MI^E*
MUO/:17DDLEQM:)'9D(V[3E@R'@'&.XZ59M_!&GV2V9LKN^MIK.%[>&:.1=XA
M8Y\LY4@J" 1D9&.M6--\)Z?I.J17UE)<1>59I9+#N4IY2DL,Y&XG+$YSDD\T
M 4?&S303^';JV$CW":HB+$)BBR;HWX;MC(')!(QP*I2?$.97:R30KAM6B>99
MK0%W"^7L)PR(Q(82H5)4#GDBNIU?1[?68;=)Y)HVMIUN(9(6PR2+G!Y!!ZG@
MC%9,_@;2YQ#()[Z&]BEDF%[#/MG8R??!;&"#A>,8&T8QB@#<LKQKO2X;QK6>
M!Y(A(;>50)$)&=I&>HZ5QL'Q'DN8M16+1C)=6EC]O6".Y#;XP<,F[;@2+Z#<
M.V[-=E'I]O%I@TY5;[,(O)P7).W&/O=<X[]:P]&\$:?HFH07EO>ZC+)!:"R1
M9YPR^4/NJ1@=.WZY/- $=QXPD$3SV=C%<6@>W07)N0D8,JALL2.%"LAR,D[A
MQUQGVFOVWB#5_#MU)8SQ274=]"I6Y91&T;;) 5P"V2O!(!'H*U6\#:2NBV>E
MVKW-G#9W0NX'@<!T<9QU!! #8 (/ 'H*BM/ =C97-C/!J.I!K*:YGAW2(WS3
M_?!)0DC)R,\Y[F@#GM,\6S>&?!&G?Z$UZ([2XF9GN3O81N1M489F..<G"@#E
MAQ3$\17.A^)/%6K)87%WIPAL[N;-R,PQ&,EBBDD$]3@8''6M^/X<Z2EE#:F\
MU-@EM):/)]HVM-$[ERKE0.Y.,8ZD<BISX#THF96GO6BN;:*VNHFF!6Y2/(4-
MQD<$@[2,@X- &/;Z^=&U7Q$\:7%Y]IU6WBLXB[L/WEM&YQ@,0OWS\H/H!75Z
M!JT^LZ:;FYTVYT^99&C:&X0@G'\2Y )4]B0#["L^\\$:9?/?O+->*]W<170:
M*4(8)8E"(T9 X. !SGI6OI6F)I5GY"W%S<LS%Y)KJ3?(['N3TZ #  ''2@#E
M;#Q=JRW%_!>V$+7#:T=.LHQ*54CRP^6;;D (&;.#G./>MWPWXA_MZ*^22V-K
M>6%TUI<P[MZAP <JV!N4@@@X!]JJS>"=-GN[JY%S>QR37B7R>7*,03J N] 1
MW P0<@Y/'-:NDZ-;:/'<B!I9)+J=KB>65@6DD( ).  . !@  8H YG5?'=YI
MFI:U"-",]IHR137=PET WE.I;<J$<D $XR.AYJS%XRN+O5VM;+1+J>V%Q-;?
M: K@!XR5))V;-A967(8D<<<\4D\+7>I^-/$5QJ4$T.D7\5O&JQS)BX$>0RR#
MD@'/;'&0>N*V8?!]A:ZC/>6MUJ%N)IFN&MXKDB'S6ZOLZ9SSCIGG% '+WOB?
M6O$'A_1;N#1UL[/4KVW3$EZ0TL3C)'R*< X(/MVY(&EIWB2'1M-MH[:PF?0X
MKTZ:MTUT9I$?S/+!((SLW_*#NSC'&*TAX+LH]#TK28[^_2WTR5);=@T9;*'*
M9)3! ^GUS4T?A#3X[IY%EN1;O=B^:TWCRC.#G?C&?O8;&<;AG% &&/'6L-";
MI/#!^R?;A8*[7BAFD\\P' P> 0#^?IRX^.]1@E=;O0H4CM]3CTVZDCOMVQY-
MFQD!0%Q^\7.=N.V:T?\ A![7^RI-/&JZD(WU#^T=X:+>)?,\SC]W@#?\V,=>
M.G%)J'@6RU#[:'U+48OM=]%J#^4\8VRQA0NW*'CY$R#G[H]\@%SQEJUYH?A+
M4M4L8X7FMH6D_>L0 !U/ .<>E<G<>(=0\-Z_XGU&;3OM$45M97-TB79*Q*0Z
ML8]R_,<#.,+G;UKO-5TNVUG2+K3+U6>VNHC%* V"5(YY'2L6X\#6%U!J4,][
MJ#KJ5M%:W):5272/..=O4Y;)]^W& !B^+KJ;7C9VNBW%Q8I=&TDNXRQ,;CJQ
M7;MV \9W9[XQ755ST?@_3X=;?5$N;Y7E=9I;<7!6"64# D9!@%N![<#CBNAH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //O'>J
M7>H:1XETVSMX#%IMK'+,TV=SLWSC8.G 7//4\<=:OZGXPO=,_M+-E Z6.H6E
MJ6WD;DF*#/L5\P>QK3UKP;I&OW4EQ>I<!IK?[-,(;AXA-'G(#A2-V"3C/J:B
MU'P+H>JS327:7;><(O-1;N55<Q_=9@&Y8  ;CSQZ\T <Y/K-[>6VH/K=A;W,
M-AXB@M(1'*\9C#-&JN,?>QYH.,\G/3 %:UKXOU.^U!EL=!DN-/2ZFM&G64!E
M:/*EB#Q@LI''U]JT)?!>DR&[^:[07=W%>RJEPP'G1X*L/0Y52<==HIH\#Z*F
MJ3W\:W4;3NTLD,=RZPF0C!D\L';NY/..O/6@"IX+\677B22ZCO([:WF@CC,E
MJ Z3P2'.Y'1QG P,,.#D^E0:IXTO;5M>N;.RMY[+0F"W<;N5F<;%=F0=,!6X
MS]X@]*WM+\.6.DWLEY"UQ+<R0I;^;<3&1A$A)5 3V!8^Y[DU'>>%-)O]0GO9
MX9/,N4C2X1966.<(<KO4'#8Z<]N.E '.6-BOB'X@ZR^HQ0SPZ?\ 8YK-MS!X
M#AG7;Z9Y+#OP.15SQ-XRN= U1H([6&>")(&D&XM(1))L/"YV <'+X#=!TK=L
MM!LK'6;W5('G^U7NWS]TQ*MMX7Y>@P.!BJ.K>"-$UN\NKJ[2Z$MRD:3"&ZDC
M#^6<H2%(!*DY![4 9;^-M0BOYUETVV%G;ZTFE2NMP3)^\$>QP-N,9D7(S6CX
M]EAA\)327&GQ7]N)H/,@DE:/K(H# @9R&VG''3K1-X%TB;S\R7B^?>17SXG)
MS-& %;)R?X5/N5&:T]>T.T\1Z/+I=\91;2E2_E/M8X((Y^H% ',WOC'6;'4-
M35].LC9:?J%K:NXF8O(DYC (&, @R G/H1[U6U+5KG5M5T#4!'"FG1:]):(0
MQ,A*++'N;M@NIXZ_=/?%;T_@G3+LZB;BXO9#?RPS3_O]OSPXV$;0,8PO_?(H
M;P+H;:B]Z8[L.UV+WRDO)4B$_P#ST"*P7<>_'- &,GCK5YM(O-:M]!\S2TLI
M[J"5I0G^KR0K<DG< >@X(QSUI]UXYU/2Y?(U+1H!-<6\=Q9+;W1??OECBVN2
MJ[2&E0\9!R<5?F\":-!;:M]B@F22_MYHO)%PWEH9 0Q1"2J$GJ0*6Q\$Z;+H
M"6>K0-<RRV45K.))FDV*@!V(W! #<YZDX/88 *ESXMU^T:VCET"%'GOTLT>6
MZVJX="5<;0Q !4@@CTQG/#K?Q7?:KY>E1Z?:_P!I3&\25996\E4@?RRV=N6W
M,R\8'!/IS?A\$:1#!;1%KV8V]TEVLL]W))(TB<*68G) '0=/:D;P-HQ9'7[9
M'/'<2W*3QW+K(KR?ZS# YPW<=* .5\,^)-3L/"VB:7I>E"^NQI1NV4SJ.C[5
M3)(ZG(SSCCK6I=^.-5M9-3E?1X$MM,:U-RK7&9@DP4D  ;=R[C_%@[>.N:OM
M\./#9M;"W$%T@L=X@=+R59 KDEE+ALE23G!/]:L7'@;1+@:@IBN$2_6))TCN
M'52L> @ !X   XH /#&H:M?:GXA34'MGM[74#!;>4""J^7&V#_WUGZD]L5S7
MC_5;G5-(\165M:H+;26A$LS3,DC2,%;Y !T56!R>N<=LUVVG:#8Z5J%]>VOG
MK+>LKSJTS%"P4+N"DX#$ 9.,G%9^L>"-#UR\N+J[CN0]S&L=RL%U)$LX7E=X
M4@,1V)H R+S7SH%UK]Y:Z,LT\=_:P3?Z8P\T2*BHX!4A<%P"!@<$Y-3?\)CJ
MW]H262Z"T\]I-%#>+;.SA2X#$HQ4#"JR-\V,Y([9-ZY\#:5>-?F6>^87TD,L
MP^T'EHL>61],#ZX&<U8N?"&E76M#56^TI<G9YPAN&C2XV?<\U5(#X]_H<B@#
M&3Q;K.HZ)+J^FV-I]@DANFBFD<[H3$6"EUXW;BIX'W?4]:9HWBK6+ZVM+"**
MUNM2CTB&_N&D8QB4R9VJH'0G:<GH"1QSQLVW@G1;6_N+J**;9-YA-J9F,"M(
M,.RQ_=!89SCU/J:2/P3I$,5FD1O(WM;<VJRK<N)'A/6-FSEE]/[O;% &=H_C
M/4-?U>TAT_2H18S6-M?M--<$.L4N\$;0I&X%#QG! )R*U-9UZ[M=6ATG2[.*
MZOY+66[VS3>6NQ"HQG!.2S =,#DFK-AX<T[3-3:_M$>.0VR6@0.?+6)"2JA>
M@QD_F?6F:YX8TSQ"]M)>K.DUL6\J>VG:&10PPR[U(.T]QGM0!BW?C>[LH=:>
M;24$FFVUK<F(W'+"7<"I(4C*E&Z9!HOO&%__ &KJ6DVEE;P7<$<K0&[E96D"
MH")%3;\Z$Y'RL3QSC/%W4? >@ZF"LL,\436R6CQ6]P\2O&A)0,%(SM).,^M3
MKX/TL7L=S(UU/Y32/%'-,75&D4JY&>>0QSSCG/7F@#!TOQ=K=SI=C#':6MWJ
M T6+4[AWE,:R;\[54 '#'8Q)Z#CKFH;CXD71M;N_L=*@FL;?2X-5W27)5S$^
MX,N I&\%&[XK<3P+I$4%M%%+>HT%F;#S%N#O>W/_ "S8]P.W<=L5)<^!]"N4
MNT:WDCBNK-+&6.*9D3R4^ZH .!C)Z>I]: *+>+]0@;5;>YTZV6[LY;8*B7.5
M\N<X4DD EAAOE4$L0 N2:@MO&VK7R6<5GH<4EW//<6["6X:)5>%N3@IN"E>F
M1D$@$8YK4N? ^CW=Q<7$WVPS3F M(+IU*M#S&RD'Y2.>1ZGUI+'P+H^FWMO=
M6CWT<D%Q+<(#=NR[I!A\AB<@^_UH Y>:Z^TFV:*WGM)(O%BPSHMX\HE.W).6
MQ\IX.W&!C@5N67B_4I]4NM)N-,@M]2AOD@6$S,1) REO/!V]-JO@8ZK@D$U<
M;P5IA)VW-ZA_M#^TOEF'^O\ 7D=/;I3],TR^G\1W.M:O964-Q%&;6S:WD9V,
M)8L2Q(&"<+P.F#SS0 _Q/KE_HO\ 9HLK&"Z:]NA:CS9S'L9E)4\*<CY3GT]#
M69IGB[4-7O\ [,NBM]G2ZDLKMXY#^Y=!AF#8 *AP5P#NQ@XZ@;^K:);ZR]BU
MQ+.ALKE;J+RG"_.N0,\<C!/'O55?".CIK+ZHD4R3/*)WC2X=86EQCS#&#M+8
M[D=L]>: ..TCQ/<>&?!MFB6WVL1K?RDS3DR.(9W&P !F)Q_$1M&.3R*U)/&6
MH6FKZFTUM#)8HEDEI&K$.9+ABJ@G!&"2,GMC@&M)? &B+;P08NS'%%- 0;EO
MWD<K;G5_[P+<\_RXJ1O VB/;S6\L4\D4UK%:R*\['<L9RC'G[X[-UX% %>+Q
M5J9:&SN-#,&HW%TT%NDDQ6*1%0N9-VW<!@8QMSG Z<T?#R:ZF\&J]QYC3K=W
M:8EF:3&VXD 7>>6 QC)]*M#P7I?DQJTVH//'/]HCNI+R1YD?!7AR2<8)&WIR
M>*T=%T6TT#3_ +#9&8P^8\O[Z4N=SL6;D^I)/XF@#D_#_BW7+RSL;2YM[&;5
M[Q[QU'G,D:1PR%#D[2?O%5& <@9S72:'KDFN^'S?PVOD7:M)#);RL<1S1L49
M2P'(W \@=.U5(_!.FPF)X+B]AF@N);B"59LM"922ZKD$;"3G!!YYK9TW3K;2
M=.BL;4$0Q X+'+,2<EB>Y)))/<DT >>:7J^LZC=>$]6:.*74+ZQNMR+<,D!
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MD9KDK(KP;MS,NTX!"G'/IZ\6T\$62RF9KZ]:=[V*^DD_=*9)(QA<A4"XQUP
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MLVE2Z8,[J2L@,8 #)N4KDD_=)QBNRU_6QHUO;!(Q+=7EPEK;1DX#2-G&3V
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M;Z!</JX,_P!HT\LQ,7E$*P#HC!B2R[> #GJ._3ZUHJZN+)Q<RV\]E<K<PR(
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M^8[1@$\XSS^6OHW@P:3JEG?OK6H7CV=HUE DWEA1"2IP=J DY1>2<\5H:QH
MU6^L;^*^N+*[LA(L4D(1OED # A@0>@(^E &#;_$*.>:(M8&&VN--EOH)9I=
MI=XCB2$KCAE/7D\<C-;>JZMJ%EX-N=7CL(UOXK0SFUEFP$(7)!;';GMSC''6
ML>X\/,^HZ+HT.BD:5ICI=)J3W W;QNRFW[Q9B1N)X(+=ZZJ_LH]0TZYLI21'
M<1-$Q7KA@0<?G0!YT?%^H:7J]SJUU975Q#_8-K>SVT-QF.$>9+O=0Q SM"G
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M<P+XA72[:PN+I1<_9)9(>2C[<YV_W ?E+$C!]1S5/3OB#-J<-I)%H<\2WJ7
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M53CA6WD#Z'/M4>M:MJ,E]H0FAN=-E37$M9%28F*YC,3MD'C<O Z@8((J]<^
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M[R\'UKG[_P #V^IP3_:]4OY;F:&&$W!\L.$C?> !LQRW)XS73Q*R1*KN78
MN1C<?6@#E[GQHMKXECTB6QV^9<BVC9I@)&)3<'"=X\_+NSG/;BJ47C?5KU=-
MEM=!6&WO+_[)YEU<@;L>8&VA02"#'WXYX]:OS>!K66_FNTU74X3+?+J'EQO'
MM68*%R,H200,8)(],4X>"H$T:TTZ/5=03[)>F]@N 8_,5R6)'W-I7YVX([T
M5=*\0I#-=6D4=[/>3ZO/;1Q7<X(1E02-AAG;&!T')Y [U#<^(;B#Q#I%_=F[
ML+.32[Z>[LIL80PM%\V/7#-SGD8JW-X"M)GDG_M._CN_[0;4(;F(QAX)&4*P
M7Y2"I48(8&IKCP9!>3V;WFI7MVD%M<6LBW!5C.D^/,W$ 8^ZN-N ,<4 4_\
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M9<ER"%W'EF(!8@$YQTPEUX'BO+&:&?5+MYY+%;!;A@A9(@VXGIC<W&3[#&*
M()?&VIPSS6S^$=2^U1VYNO+$T)!C#$9W!L9('"]>U#_$&U:RGU*ULY9]+M(8
M)KNXSM:-94$@PF/FVHRLW(X;C)R*+[2=4O/'*R)+?6]A_91M9+J(Q;6D+YQM
M;)S@Y! P#QSFII/A_I?D7-K;7%Y:V-U!%;W-K$X*2I&H1>H)!V*%)!&0!0 Y
MO&;?:M2ABT/495T^012R1B,C<RJZ8 ;<05<'...<XJI'X\:^NM.AL+..43:L
M^F7+";(4K$9"R,.&7&#S@\$8STO7/@JWNK?7('U"\V:M-'.^-@\ID" !?EY&
M(U!!R"!CN:KIX#$<IF37=1\_^T!J"R$1';*8C$V!LQ@J>A''&.^0!NF^)D@W
M6J1ZA<WUWJEU!#!=2(&79EFP0<"-0,#J>0*?'X\ANHM/^PZ3?W,UXTT0B7RU
M,<L6=Z.688P1UZ>]/7P1%',MU#J%PEY'J$M_%-M4[3*,2(1CE2/QZ>E%MX+^
MQ7.G3P:@_F6DMQ<.SQ F>:;.YFZ8Z\ >E &WH>K0Z]H=EJMNKI%=1+*JN,%<
M]C]*RO'UY=:?X)U&]LKB6"X@571XL9^\..?K3-#\/:KH<^F6J:N9]+M+5X9(
MGC53(Q;*-P,Y XZ_A6QKFD0Z]HMUI=Q)+'%<)M9XB R\Y!&01U% '-W/C\V4
M=Q]IT*^AFM;B"*YB<IF**4D)-E204R"#@\$'TJ2_URYG\2:"EL\L%HVIW%G*
M,C;<!;>1L_0.A';E31J>C75I97@33WUV\U91;7;RND2+&%95R,_=&YN%R?F)
MJ\OA2.&WT&&"ZDC72)?.!8!VF8HR,6)[D2.2?4YH H0?$"">:>W&E7RW4=K-
M=);-M$K)$^T@H3E"<@@-C(-68/'%A/=K;)!,7DTU=2APR'S4.!M'S?>R1[<]
M:KZ#X$70KZQN(M8NYDLUN(XXI$CP4E96(8A<DY4$MG)Q]<R6GP]T:R^P^0UP
M#9WC7<9,G7.?W9_Z9@[2%_V1[Y )]*\81:OKUQIEO83@6TLD,\K.G[IU[,@.
MX ]B1@]JV-6OSI>ESWHMIKDQ+GRH5W,W../ZGL*QX_"0_P"$G@UNYOC-);/*
MT/[E5D"R CRW<??10?E!'&!DFM+Q#HD7B'1)],FGF@24J?,AQN!5@PX(((R.
M01@B@##MO'MM<P1M%I\\\AU#^SF%M)'(JR[ X.[< 5((Y'3OBI[7Q@M_#!!#
M87*ZE/)<0FUW(#&86VNQ8G! )7!&<[A[XCM_ R07)N&UF^E<ZC'J+;TBYD6/
MRR,!!@$8^F.*0>!Q#=1WEKK%[!>1W=Q<),JH<+.09(]I&"I*J>>010!<\#7M
MUJ'@W3[J^F>:Y<2"1WQNR)&&#CC(QCCCCBJ'B+Q!)HNJ:I<1+>RRV6C27BVS
M.BVT@5LEN,OO[<\8Z=:W/#NBKX?T2#3$NIKE82Y$LP4,=S%N=H [^E4-9\)I
MK.I7=S->2)%=:9)IKQ*HX1^K ^OX4 5[7QJLMWI]A+I\WVZXMH;B:.-E_=K(
M<!E!.7 Y+;<[175UR$O@J6ZCTV*\U9[B*P,+QEK=%D5XVSE'&-H8 *1@Y ]3
MFNOH **** "BBB@ /2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%>6][]N<72ZBVI7#K&,2R&(Q;0"3M4(Q &2?>BT\%):#2BNJ76_3[FYNEPJ
M.\Y<L",=!YC8^M &=9_$.ZOQIWD>'IMVI6LEQ:J]P@SY9 <.?X1\PP><^@I4
M\6)>7MIJ5K!>;KC09-0MX9)]MNP!4L&4 X<;E^;'0FM#3_ \.G/I#1:I>,=+
MMI[>'<$^82D$EOEZC:N,8Z4VQ\"P64>G0C4[N2&QTZ73D1E3YHY-N2<#K\B<
MCTH SK+QU?*UE+J=E!#9G0/[5N9(W)8-\O"@]N>F2?F'IS9/Q"MXEE6YL)8Y
M=T(@*MNCE\S/\>  5VMN'H,C.:DC\ PF"T@N]3N;F"+3FTV:-XXP)X3C ) R
MN,=1S[T'P-++I"65SXCU.>:W>*2SN3L#VQCSM( 7#'!();.0: -KP[KJ>(-*
M%Z+:6V99'B>*0=&4X)!Z,IZ@CJ#7.:IXJN-1\.WLEK8WD-I<Z9=7-IJ$3D;3
M&#@MC[A;AEY.1UQTKJM)TZ73K'R;G4+B_G9B\D\^ 6)]%  4>@ KG[/P,]E8
M7&FQZ[?/IK12Q6]I(%*PB3((S@%P 3M#$@>^!0!5TOQO=G2Y!<Z/<>?#8VUW
M%^]#F>.4[=[8SLP02V<X'/K2M\09WCM!9Z')?3W%S-:J+>ZC*-)&C/\ *Q(R
M"JYS@<'UXJ:?X?17$,<3:O>*(K."TCVJG A<.I(QALD<@@@YZ=*DL_ B66KQ
M:@NL7LKQWK7VV94(,CQF-^BC@J3QT!QC XH BM_&MQ%]K_M*UM8'_M%K"U07
M!P2J%R9"5^4  \C/7&.Y;;?$![R33X;;P_J$LMXLI(!0*GE2*DARS#(&\$''
M(([YQ9O? T=U)<RIJUY!,]\-0MI(]N;:;;M;;D?,K+P5;(JS!X7N(]5LK^;6
M)[B6VMI8&:2-=S^:RLS9'W>43  P ".<T 1^&/&">)Y-UO9E+9HO,$HF5RC9
MP8Y%'*2#^[ST/-:FO:W;^']+:^N59E\Q(E52!N=V"J,D@ 9(Y/2N<F\%:A;Q
M7-Y8:TZZR;06T5X($5GPX;=+V=N-N<# +=S70ZYHBZ]HCZ?/<20R$HZ7$'RM
M'*C!E=<YZ, <?A0!SD?Q'@GTV:[@L&(@EFCE=Y0L.8U#?+* 0Q8,-O3)!Z8J
M^/&D=S''-IVG7-[#Y-K/*8A\Z+.?EPO\1 ^9N1@<\U#<>"KF_>QEO_$-[-/
MLR32".-?,6554A1MPF-HP1SRW/.:98_#]=--F+/7=2A2.UBM+E8RB_:HX\A,
MG&4(!(RN"1WSS0!1T#Q-=V6IRZ?=VU[<VMQK5Q917TDH8(WS,J!<[MH"D9P
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M99G" A@^"0>JY!Y7L<U;N?&=G:2.TEK=&UAN5M+FY55*02L%P&&<D?.H+ $
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MG8O/&,GK6?KNC:CI5W%+'*EPU]XCBOT"6SL(0(_+(?;GY<*GS<8W'VH W/\
MA8&EFP-RMM?&2-YHY[<Q!9(#$ 7W[F"C 92.3G<,9I;SXA:+9^8Q2]EBBMH;
MQY8[<E!!+G;)DXX&.>_7@X.*-UX'U"[N#=2:G;F:YFEENXWMMT66C6-&1=P^
M9%0*"<_>8X[573P%JHT&ZTV74[9S<:)#I/F")AMV%_GQDY^5SQQR.V: .D;Q
M58K/?P&&Z\^QGA@DC\L99I2 A7GD'/7Z^AK=KB[>T&L>/EOQ:WMO]@A\J[:2
M$I#<2*3Y>PL/G"[Y3N'J/6M_0I-6E@NCJRQ!Q=2+ 8T*;H<_*2"3SU'O@'O0
M!CMXJL])N=8:ZEU.X$&H0VS1FW#>2TJH$"!>2I+ Y.3EJMQ^,M/DQ$+>[^V&
M[:S%GY8\TR*@D/?;C80V<XP1G!XK/U'P?J-Y=ZK/#JL,0O;ZSO$5K8MY?V?8
M=OWQG)C7GC'-1WG@O49-2N-3L]6A@OO[2%_:LUN65,PK"\;C?\RE$'3!!H <
M?%9&OK?&6Y71QHLUY);O"%9'CD 8X(SG!(QG'''7)UIO%^E0,ZNTP86D=XH\
MLGS$=MJA?5BQ QZD51N/"=_?70FOM628R:7/83E;;:6,K EEPV% P  0>.I)
MYK*/@#5I(8A+KD'FV^GV]K;O':%=DD$BR1R'+G=\R\CH<]NX D.OWDE]K:7V
MH:C9PV^KV<,(\F(O&LBQ_NVV@C:6?&[).".<YK>7QMI+:F+'%T&%X;!IFMV$
M:SXR$+>I[?AZBLF?P;K5RVK2RZK9>;J%U9W.%M6"QF J2/OY.=B_KZT7/@O5
M)5N=E[9AI-<CU9"T1. @7"'GK\B\^YXH VT\7Z=)JD%A&EP[7%Q):PRJ@,;R
M1@F0 Y_AP<Y_NG&<5?U75H-*B@\Q)99KB4000Q %Y'()P,D#@ DDD  $UYYH
M46HCQ@TPM$)&J7#BWFM+F)H$=B&D5B?*)*@'(Z[CW)SV_B31+K53IUUI]VEK
M?Z?<BXA>2/>C95D967(."KD<$&@#(\)>)WN+:*UOWO);NXO+V*%IXU5@(I&P
MC!< ,%QVQP>:E@\:1ZK<VT%E:7BP76G37GVD(N^+:P7 CR23DGL03C&1G%*+
MP1J\#V5XNKVCZA:ZG<WZEK5A$1.K!EV[\\;B1S_C4FE^#]7T:;3KB#4;.XFM
MK2YMI3);E!())!(",-P=R@$]QGC- $MOX[T6PT+3Y;K4I;IY+%;MY9(U20PX
MP967@#)!X7)ZX!P:UK3Q7IU_J7V2T$TZ>9Y7VB)-T0?9OVD@Y'RXY(QSC.>*
MY73_  !K.E6VE-9ZCI[7-M8KI]P+FV,L4D:LS(ZC((<;VXZ'-:@\)7S>++?6
M6GM89(9?GN;<,DMS#MP(I5'RL,X.>VT8'>@#H=5UFWT@VR2QS2S74ACABA3<
MSD*6/H!A5)Y-9J^-]&E%F;=KBX%U"DX\F(L8T=]BLXZ@;@0>.,'.*7Q5HFHZ
MR=/^Q3VWDP3%[BUNU8Q3C:0-VTY.T\@'@]^@KFXO 6K1VFE0>=IR7%@ L-_;
MAXI8 )"QV@<.K*<%&P,\\T =SJVJ0:/ILE]<+*\:%5V1)O=F9@J@#U)(%1:)
MKEIKUE)<VGF+Y4SP2QR+AHY%.&4XR/Q!(J#Q/I5YK.B/965VMM*TD;$NI*R*
MK LC8(.U@,'!'!JGX/\ #U[X<M[^WN9K)XI[IKB);2W,2IN R,;B,9' ].YH
M 2[\>:)8W]W:7+7<;6DZ07$GV60I&S@;,L!C#;ABI#XWT5;.2X>6:-DN?LI@
MEB,<OF[=^W:V,?+\V3QBLK7/!NI:G)KWDWEK&NHW-G/$61LQ^05)!]<[!TQU
M-1ZEX+U:?4;[4[2\LA>'41>VJSQ%XR/(6%HY!Z%5!R.0: -)/B'X>FM8[BVF
MNKF-[=[D>1:R/B-&VN3@<;3U'T]1FIK?C6VG\.:Q)HMU+#?6>G-J$+36Y421
M@$AEWCYE)4C/N/:G/X9UNXNUN[JZL6D;2KBRD2)&C022N&!4<_* H')R>M4I
MO VIW-G]FDNK9%;PXVC,068"0@#S ,#C@?Y% &Y'XXT(QW#/<RQ/ L;&.:W=
M)'60X0HI&6!/ P.M56^(N@I''DWCSO+)#]GAM7ED61,%E(0'D @_3D51U?P1
M?Z_%]INY[6WOX(H5MD0&:$M&^_,FX LK' QC@9Y.:MVWAO5DOM%O9?[*A>RF
ME>:&TB9(]CIL"I].O/?C@4 ='?ZM9Z9I,FIW<C16R*&)9"&Y( &W&=Q)  QG
M)QUKG-=\;PVV@ZK+81SC4;%HXI8)(?G@,A 5R"<%>>""0<?6MCQ1HA\0^'Y]
M/2?R)F:.6&7&0DB.'4D=QE1GVKG=5\(:QJUOK,\DUC'?ZBEM -I;RXXX6+Y)
MQEF)8CV&.>* .BL8M1AT*X:XU&:>9U:2&:>!(Y(E*Y575<*2#["N>\'>/K+4
M?#E@^K7;I?-IYO)II8#'%(J_ZQD;&T[<C..GYUV026:RV3A$E>/#A"64$CG!
MP,C\JX*U^'M]<>&[30]4NK98;"PGL[>:WR6=I!M$C @;=H ^4$Y)Y/J =,/&
M.C>5</)-+"]N(RT4T+)(PD.(RJD98,>!COQ4$WCS0+:&.2>>Y3?/);[/L<K,
M)44LR$!20<#('<=,UD7?A7Q%?I-?R7EE#JQL[>S'DNXCD1)-\A+8#+OY P,K
MV.3Q!IW@[7=/U&UD$>E?98=8;4?+CED4A7@,3#E#D@L3U^;'.,\ &CK'BP_V
MMI%OIDLWE2:FMI<2>0#$^5)9-QY## _'(ZC%=E7GT7@[Q!;W<5K'<Z:VEP:L
M=3BED#F<[F9BA4 +P7;#;O3BO0: "BBB@ HHHH **** "BBB@ HHHH ****
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M7-LMI>_8EWQDM-)L#84#OR>/09..P_C_ ,.)90W0O6D25)9-L43.RK&<2%E
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MG:RG8/EP.IYI;_P=JE_/-?/?6?\ :$US9RL?(;RU2V<R*JC=G)8G)ST..V:
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MI--MK658PV1)#O *YXP0_P!>!5+6?">KWE[KLEI<68AU*2SF3S2P:-X60D'
M/!"?F?;D W(_%NBRV;7*74A59_LQC^SR>;YN-VSR]N\G;\W3ISTYJ>'Q#IMU
MH3:S:SM<62JS%H8V9N#@C8!NR""",9'>N7U3P;J]YJ=[J5M/8+.=3COK:*X5
MI(F MU@99!@8)"Y!&<5TEEI=ROAZ:RN!9PW,ZR;A:1;8D+$]!U/49)ZG)XSB
M@#*L/&-O>RV=Z]W%;6$^D'4'M9H'$R#<OS[NA4 XP!DD@C(-61X^\,&$RC5%
MV"%9\^5)_JFZ/]WE>#EN@[D5B6?@[6X+/3H))-/;[+X?ET@D._+D(%;[OW?W
M:Y^IZXY<O@S54T];0/9,%\.?V1N+,/WN,;ON_<Q^- '4W'B/2+2Z6VGOHTD9
MD7."54O]P,P&U2W;)&>*U*\]A\$ZG;ZZ]YY&BW4-[Y+7)O(?->V=$56$1P-R
MD*,9Q@\\UZ%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 9FK^(-*T%8FU2]2V$Q*Q[@3O(&2!@=<=N]0)XMT22[@MEO?GN&V1,T
M3B-VQG8'(V[L?PYS[5%XCT[4+V_T&>QA@D2RU 7$_FR;2$\MXSM^4Y(\PGMT
MKGK?P1J%MK]Z3!I$]A=7<ETM[+"#>0!R6,:G;S\QX;.0,^V #H4\::%(S!+J
M5@()+A6%K+MDC3&YD.W#@9'W<]14.K>+M-BTJ\:TU**"Y33_ +='+/;R-&L3
M<+(0!\PSV'/M7'VNEZK::MH>A:Y+IL,HT6\TZT>VE+&4_N@&9"!CY%Z#/(//
M( L+X0\47$,XN(=+B9O#K:.H2X9@9/X7Y3A>I(YQQU[ '7-XPT.UU!=+NM4B
M&H!8]\8C89WCY6Z$!3ZYP,@$U)#XNT*>.X=;[:+=%D<21.C%&.%90P!=6/ *
MY!/ S6$GA/5KF_U5KI[2&"^T.+30\;EGCD56RV-H&W+GO_"/7C,C\'>(GTE8
MS9>'[*^LC#)!+:H<7<D;JP,GR#:IV]!G!.>PH Z7PIX@FUV^UY'EC>&ROO(@
MQ \3!?+1L.K\[@6(Z#ITJGK7BB\3Q2^B:?/!:/;VBW<LUY:R-$PW'(+C 50J
MM\V<9XZ@BK?AC3-7M-9UW4-5M[. :C+%+$EO<-*5VQA"&RB\_*#D9SGVYH:]
MX6U/7M<UK<T%OI]]I"Z>DHD+2*P9F+;-N,?/C&>WO0!K_P#":: ME=W;W_EQ
M6B(\YDA=617^ZVTKDJ>S 8K1TO5[+6K-KJPE:2$.4W-&R<CK@, 2/?H:XS6?
M"?B'7K:]N+H:9'J$FE?V=&$E<QN6<,[L=F0/E&%P>IYKO(?--LGG(BS;!O5&
MW*&QR <#(SWP/I0!PNG:UXNNM!U+58I],NFL+NYA^R?970SI"Y7APYVNVTX^
M4CD<=ZO6'C2TO)4U-M2CCTMM)^WM:M:.98QN&9#(,@@9(*@9XS5+2M!\8Z=H
M6I:9&=*BDO;VXG6\^U22- LK%C\GE+N89/\ $!GGVIESX'U"VMY=/TM+1K)?
M#TFDPM/.RN9&(RS (0!U/'?L* .@'CCP\]F;N*^:6$9):*WD<A0%)? 7.P!E
M._[O/6IY?%FB17=O;&^5WG:-4:-&=,R#,8+J"JENP)&<C'6N:U3PEK-S/I6H
MPV>BW=Q#IZV=S9:AEXA@[@Z/L)R#D8VC(^@J?3O#?B+2=8N$M)=,.EWDD$\C
M&,J]NZ1K&ZQQX*D%8UQDC;GH<4 :6G>.=*O[6>X9+NW1+UK*-);6422N,YVI
MMW$\-D $@#G%/N?'GAJSMH+B?4MJ3^9Y8$$A8E,[U*A<AEP<@@$>E8*>$=;M
M;R.\@^S&2RUN>_@42D?:(9]V]&&W"L-_!YSCMFGV/A#5[3Q!IVIK]DV"_N[V
M[C,S#;YZA0J84ABH4$DXR<^M '2^(O$=MX=T4:G-#//&TD<:K"A))=@JY]!D
MC^77 J.Y\7Z/9W0@N)Y(R'CCD<PMLA=P"BR-C"$Y'!/<9ZBCQEHUSK_A:[TZ
MS:$7+F-X_.R$W(ZN 2.1G;C(Z5SMUX,UBZCU>P::S_L_6+N&\N'+L9(6 3S%
M0;<,#Y8 )(QGIQ0!VNH:C:Z79/>7DOE0)@%L$DDG   Y))(  Y)-9/\ PF>C
M%#B2<SB<V_V46[^=Y@3>5V8S]SYOI3_%VAW'B#P])96=T+6]26*XMIR,A)(W
M#J2.XR/UK$N=#\7:C%9RW\VCM()BUS9H)! R^65!W8W.=W)4X4C [9(!IMX]
M\/*UHJW<TK7<23PB&UEDW1L2 WRJ<#(P?0X!QFH[3XA^&[U[807=PRW4J0PR
M&SF5'D?.U=Q7&?E(YZ8-4_"GAG6=!735N#92+::4;-MDK?,X?<I'R<#&<_R.
M*S=4LQI/P[L/#.HS(NN2C9IQ@5Y0;A&WHP.W@ [220,#/6@#O+#4K;4HYY+8
MR%(9G@8O&R993AL9 R,Y&1QP:H+XMT5]1BL5NV\V61X8F\E_+DD3[R+)C:S#
M!& <Y!'45>TNP33-+M[)&+>4@4NW5V[L?<G)/UKC[#P1J$<.F:?=W-N;#3-6
MDU""2//FR*2S(K#& 0TC9(SD*.F: -UO&&E-;VLELT]PUY%-+;1I"RM+Y7WU
M 8##>QQ5CPWK8\2>&K+5D@>V-U")/+?)VY'J0,CWKE-,\$Z[:7FD+/>Z>UGI
M<EWY>R)O,=)MV">P(W#CH<=:Z?PGI5YH7A33]*NW@DGLX! &B)VL%X4\C/(Q
MF@#"\)>-$U/1K>WO[R0ZO*MSMD^QN$D\MV'R8&'(7:=JDGK5VQ\8Z=#I&G27
M.HO?M-:K</=06C*#&6"B1D&2@)./P/3!K-T7PCKFF0^'5FEL)6TJ6[DD99&'
MF>;NVX^7C&_GZ53;P#JPT'1[*)[".^TVTCAAU&.61)H'5OF(('SHRX^0X&<]
M<YH [_4=1M=*L9+V\D\N"/&2%+$DD    DDD@  9)-<QHGBXRZCJT6IR/'$F
MIQ6-HKVS(ZL\2L$;KW8@-T/'/(K4\5:+=ZUHJPV-Q'%?6]Q#=6[2@E#)&X<!
M@.QQCCIUKGKCPGXAN6U"\:;3UO)M5M=1AB#.8P(E13&S;<C(3J!^ H VG\9Z
M>VI:?96L5Q<-=WTUB[K&5$,D2%FW9'L.G8D]J;IOBBSCTH7-WJ9O3)-.(S'9
M/$VV-CN4Q\GY,8)[D#N1618>$_$%M>VM_-<:?)<QZS-?2(A<)Y4L1C('&=RY
M..Q]14!\#ZWY5G?1S::NIVUW>S>1.AGMY$N93(RD[58$';\P';T.* .BB\:Z
M/=7%K'9R2W:7"1.)H(RR()21'N[C)![<8YQ6IJNK6VD6\4MSO)FE6&*.-2S2
M.W11_P#7XKD[GP?J]UK.G7DDVGI+9O"5OK</#,$4YDBV*,-&W( +?*"3R:VO
M%VD:EK.FVT&F7$$;QW*2S1W&[RYXP"#&VWG!)!]\8/!- $;>-](^RV]Q']HE
M66-Y66.(LT2(P1V<=1M8X/7H>PK:U'4;;2K&2\NY-D*8R0"222   .222 !W
M)KSR3P!KLFAPZ<\NEF>"2>2UO8-]O)9N\A=7C"@Y&&(*9 .!SQFNP\5:+=:Y
MH0MK.Y2"]AGAN;>1URGF1NKKN'IE: ,K1O%K2:AKJ7\DK)#J"6MG"+8K)S"K
ME=HY)'S'/H,\"KX\<Z$]O'-%<2RJRNSK'"S/$%?8Q=0,KAN.??L":YZ;P9XD
MN9[O4I+O2TU(ZG!J%M&$=X<I"(61R>>5Z,!D$9XS@/O_  =KE_:6X8Z5!>1_
M/%=6FZ!K*0N23'A3O7;M!5B-Q!)Q0!TK^+M&2_6S-Q(9&DDA5EA=D:1 2T88
M#!8 '@>A'48K.B\8:?K-WI!TC5BD-S<%/WEA+BX'E,X56( &,9S_ +)'6H-(
M\.>(=%NY[2WO;*71S=S7D7F(1.ID)8Q="H7<Q^;DX)&!UI-.\+:M::=X/@EE
MM&ET20M<,';$@,3Q?+\O7#D\XY&.^: &^&/'=I<VT%IJ]VPOFDN4^T-;-%#(
M8G?(#8VY"*"1GUK57QOHA6<M/*K1"-A&T+!Y%D.V,HN,MN;CCN.<5BKX$N[G
M3?[&O[J'^S4N;RX22#/FN9_, 4@C VB9^<G.%Z57C\#ZZ^CB&XNM'2^LIK>>
MQDMK4QB5X6)#3<Y.X'! Z<GF@#?\):U<ZS<Z]]H>0I::B8(%DA\ID3RHVP1U
MSESR>O7IBL^W\8II_BC7-/U>[9H8+NWBM_+MF(A65%QYC*"%!9L L?\ ZVEX
M7TG5].NM8N=6DLV?4+E;D):[L1D1K&5R>O$:\X'>LC5?!^J75YXEGM9;1?[5
MELGBWNPV^006W87J<<8S0!N3>,=#M[M[:6[=742X/DN58Q#,BJ0,,RX/ R>#
MZ&H8_'GAV:Q6\CO)6A==Z$6LN77:&+*-N2 &&2. 2 >>*S=,\+:WIFJWQ2;2
MGL&GGN;=VMS]H!D+-Y;-T"JSL<CDCCO5:?P=K46E>')+2739=1TBT:REANU9
MH)T*H"<]0V8U/3U% &J/%VG17FH7LFL12:5;Z?#>;([9V9$8M^\W '<I ' !
MQ@YQ6OI6OZ=K4MS%93.TEMM\U)(7C(##*G#@$@CH1QQ7(:IX)UB[74ECEL7-
MYH":67),0$@=B6V!2 F'. .>,=\CH=(T6_LO$^I:E<26[07=K;0JJ9WAH@^2
M>,8)<_E0!9O/$-C;ZB=-,DHN/D1G2%G6)Y#B,,0, D],_CC(SA^&/'%G<Z1:
MKJU[MOVAGF>1X&CC=8F._:V-IVC&<$XJ35O#&H7WBNWU6W:UA\F6)EN8W9)C
M$OWX7 7$BM[GY<Y%9H\&>(!INCQ+>6,=Y8P7T;7"[CM:92$9<CG!()!QTH T
M-6\8I+HKW>D3-'-;WMG'*D\!!:*:5%! ., JY(/L1P:T=!U.^N_$/B*RNY8W
MBL;B-( J;2JO$KX///WL9]JY5/ NOQVVI*G]DJ]Y]A?"R2#]Y;R!R68J2V['
M4C//?&3UFBZ3?6/B/7K^Y%OY&H2121>7(S,NR-4(8%0/X<\&@#)/C:#2?$^N
M6.M7.RUMFA,#QVKL(T=<DR,H(4;B/F; YK>?Q/I,>J)I[W)$SRB!7\MO+,I7
M<(_,QMW8YQG-8&I>&=:FU;Q(]K)9M::W;Q0;I9&#6VU&1F"[2'R&SC*_=]ZK
M6?@K4--\3O+;VVC3Z;)=1W0NKF+?>0X W(IQ@Y*@AL@C<>#0!V&IZQ9:0D+7
MDC@S/Y<21QM(\C;2V%502>%)_"LBZ\?>';1(G:ZFD6:U^V1F&UE?=#QEQA>@
MSD^G?%/\4Z3JFJRZ8+!K=K>&=GNH9G9/,4HP4AE!/#$$KQN'&17&Z78:KH7B
M'1M&4:5+J<6AW4!!E*1%?-C*8&TG/#';CH#SP: .NN?B!X;M7*RWLNT)%*TJ
MVTAC6.7[DA?;@(?[V<9XJR_C/08[JYMI+QU>VW><3!)MCVJ&Y;;CD$$?WNV:
MX.VT2YBU;6_".F-8W &@V-E-)=2D,@'FJ7"!3NP'S@D=5YYK=G\%ZC=67B>P
M+6MO'J$L$UE.DC.RF)(U42#:.\0)P3]XCZ@&])XTT*"&YEFNI8OLLL<4Z/:R
MAXFD^YN7;D*<_>^[[U7U7Q+"5LS8:DEL#JJ64KW%E*RRG)5HT. ,D\!\E<@C
M-9MYX<UK4KN_OKJVL4DU"VM]/F@6<NJVX=FE?<4&YSYC  C P#D]*B3P[XBA
MT"TT?RK2:*PU6&6UE:X(9K2.0.H?Y>9,#;[]<YS0!NMXX\.K.\)OVWK,]N<6
M\I'FKG,8.W!?@X4<GL#4@\9:"VG07ZWVZWG61T*PN6Q'_K"5"[EV]\@8KGX?
M#>MQW5N[6UL43Q#+J+8GY\ED=1V^]\^<>W6J3>$_$3I+ ;:R^RRSZ@WE&Y9,
M"=]\;$JOS  L#'D G!STP =4/&6E?VY<:8SRJ+>T2\>Z,9\CRVS@[^G09ST/
M0'((&;KOC$Q_81HTR&0:Q:V%[%<6[JZ+*1_"VT@X((."#6._@C6[JV^SR+:0
M"XT&WT^642[_ "IX69E.W;\ZDLN1QP#UXJS)X7UZ\TVU:;3]#L[R+4[2\D2Q
MW*KI"03N;;DL<8 Q@#N: .K@\3:3<C]S<2,1>&Q(\B0$3 9*XV]@,YZ8[U6\
M6:^^@6-HT4;M+=W<5LK+ \H3<V"VU1R0,X'<UCZ)!8:KX]U+5=-F,EC H29=
MA"?;1NC9E)'WA& IQ_>'6M7Q=IFHZG:Z<-.B@D>UU""[<2RE,K&X8@<'D].>
M* *FD^)#86MY_P )#K%I<20WRV@>VLY(Q&S ;%<'/)R#GI\P&:V[G7]-M))8
MIK@^;%((FC6-G8N5WA5 !+';S@9XK"/AJ\OW\76]]'%';:O*DEM)'*69"L*1
M@D8&"&C##!/7VK.O/"6N_P!CZ+=C[!J&N65T]Q=I<?+#<F12K8.WY2 5VG'\
M- ';V.HVFI6$=]9SI-;2 E9%Z<'!^F""#Z8KD[KQK./"*:_#%'!#>3;;1YX9
M)%CBY_>2^7D@$*3V W*">IK:TG2'B\*_V9=6UG9O*DBO#8+MBB#LQPO Z!N3
M@9.3CFL;PU=ZS;^$=+L8]+@GO+%?L5];O/Y10H-JLN5(96 !^C C- %\:]=V
M-KHUU?2V-Q:WT@ADN+3(C5WSY3+DG*L<+]6!Z=.EK@[S1'@\.:/X5B9'NFO(
MKF41+A(HTG$SD?W5R-B_4>]=Y0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <_XHUV;P^VE7!-LMC/>+;W<DQ(,:L#AAVZ@9SZU<
M'B31FL(;X:C;FVF9DCD#?>9<[@.^1@Y],&JOB?3KS43HXM((Y5M]2AGGWL!M
MC7.2/4\BN;T[P[XAT[6X=5^RVTJI>WVZU\\#$,[HX=3C&X%><]B: .N.KZ)(
MT<_VRTD;[,;N-E8,?)&,N,<[>1R/6F_\)1H/FV\1UFQ$EPB20H9U!D5^5(&>
M0>WK7(6OA'6M&.C26-O:S-;V]]#)$9MB0^>ZR(H;:2R)MV],]Z70O"NJV+Q?
M;=)LI3%X=@TT,TH(:6/=E3WVG*\^WTH [;3M9TW5_-_L^]AN?*QO\ML[<]#]
M".0>XZ54;Q9X?6_6Q_MBR-RTWV?RUE!(D_N''0^Q[\5D^#= U/1+N^^U+''9
M21Q+;Q-/Y\L>W.5\TJ"4&1M#9(YY&:YZ+3;CQ!K7C#2X4LWAEU>W>6X68%XE
M2*$G"X^]\I .>&W>G(!W4GB?1(9I8I=3MXVB#ES(VT83[^">#MSSCIWJ;3=<
MTO6()I].O[>ZAA;9))"X95. >OT(-<+9>#]7L1/ ^CZ3<>3]J^SZ@)2)Y!*&
MVC:1A#\^&;<<@=.<UV'AFRNM,\)Z?:75M&E[;VL<4J1$;69%"Y!Z8.T8H AC
M\<>%Y03'KED^(C-\LF<J#@D>O/;KR/6KLWB+1X+.VNY-0A\BY3S(7!R'3 )8
M8_A (R>@SS7%Z#X9UNPD\,-=:9#G3_MIN&2925,S$KM]>V:9X?\ #7B308-%
MNOL4-Q/;6$VG7-J9U VE]\<B$\=MK#W[XH [*\\6>'K#;]JUJQB+1B90TRY*
M'HP'H?6L?Q)XWBTZSUB/30LM_IL$<["=&$15FQUXSQSU[CWQ@0^"=:T^UGM8
MK>*XQX;ETV-_,"J9G<M@ \A!D >RT^_\+>(9=+UJRBL8)!J>DVL"LUP%\F:,
M%"".X&=V[VQ@T =[IFM:9K*S'3;^WNQ"VR0PN&VG\*O<^M<E%I^OV/B+5]1M
M;*S=;S[$B[YR/E3(E. .,!CCUQ77=J .-O\ 6?$MIXATO36?2X!J;W(B#6\D
MAC$8W+E@X#%EYZ#'/7%-L?&4UEX@O],\33Z;9^1%;&)HBPWO(7#<D_=RJ]AC
M< 2>M7]=TS4KSQ7X;O;6"%[2PEFDN':3:XWQF,!1CG[V3R.E8_B3POK.I2^*
M6LXK-O[3M+6"V:64@@QLQ;<,'CYB?P]Z .LDU[2XK]+&2^B6Y>00A"?^6A7<
M$STW8YQUK+\3:OJNFZIH5KIWV3;J-V;:1IXF;9\C/N&&'9",>XYKG[3P9JEO
MXLN)IM.TFZL9[\:@EW.S-+;-G<T:IC!.<[6R,9SS@"M[Q1I>J7^L>'KK3[:"
M:/3[MKB82SF,\QL@ PI_OD_A[T 51XIU&TO-2TC5DL;348+%KVUNMS&WE09!
M9A]Y=K8R,G@Y!K3@\5Z1'%I\-]K%@+Z[AB=%C? EWX"LBDYVD]*R;CP[J^H:
MO>^(+N*U6^33Y++3[2.0LJ;SDN\A R2<< 8 SU)JIIWA+6(Y[2.Z6VCA7PZN
MDO-%,6D23NRC:..!W]* .J3Q+HLB7#KJ=MLMXQ+*Q< *AZ/D]5X/(XJG/XTT
M:.>QABG:X>\NS:*(8V;9(%+$-Q\O Z'GG/3-<NO@36)-!DLS;Z%:7\$,*6]]
M"C,T[12I(OF @;%)C&5!;DY[8.I=:%XDOI]*U"9=)CO;34?M+P1.XC*&%HC\
M^W+-\V>5'IGC- '0KXCTAKH6PO4,K&0(,'#F/[X4XPQ7N!D\4:/XBTC7UD;2
MKZ.Z6,*7,><#.<=1['\JY2Q\(:U:VVE:=,;&:STB]DO+><2L)9N'V(R[<*<R
M<L">G3FN@\%Z3>Z'X3L=,U!;<7-NI1C;N61OF)R"0#SGTH L)XGT:18F6^3$
MMT;-,JPS,.J<C@U5GUTSZK]FT_4;+Y;:X8PR0NSF2-@F1R 55LAAUZ<BL36?
M 5S?:AJL]E>BWAF*7MI#D@1Z@O\ RU..V%3COECC.*MOX;U.WUC2KBW6UN(;
M/3;FWE>6=HY)9I2C%R A&"R9)S_&3CCD A\-^+-3U6^\-QW8M$CU71GOI%2-
M@PE4Q\*2Q^7$G3&>.M=%J?B;1='G\C4=1AMY?+,NQR<[!P6QZ"N9T'PSK6G7
M/A(W5O8E=(TV6RN'BG8DEO+"E05&1B(9SC[Q].5\07<T?Q'T^&QCL;B\?2+I
M?(N9_+W R1$=CG[IXP. W7&* .CG\4:);&/S=2@"NB2!P2RA'.$9F'"@GH20
M#6=K'CS1=.TW4I[:[CO+JR@EE-O!ECE,9!P#MY*YST!STKEK7X8WE@D=NJZ/
M?0364%O.]["Q:)XUV[D49#@C'#$?=')YK8E\,ZY-X8\5Z<8M.^T:Q<2R0[KA
M]B+(BK\QV9R-N< '/M0!I6WB5--CE.OZG;Y(69#'9RPF*(\;I5;<4&X,-S8'
M%3WGCCPWI]Q<P76JQ1RVP)F4HQV8&><#T!QZX..E9%[X9UZ[DU.7?8%M8TZ.
MTO%D=F%NZAEW1_+\ZD.QVG;R!SR:CG\'ZD=.\66,0M3%JMG';VC-,V05A$7[
MSY>/7@F@#:D\<^&XFD634U0QLJMNB<8#?=;[OW#_ '_N^];-[?6VG6K7-U)Y
M<2D+G:6)).  !R220 !R2:X;6?">O:DFM%%L!+J&C6^GH3<-\LJLY=B=F<?O
M#CN=HZ9XZCQ'I<FM: ]FUG:7+NT9:&Y9@A =2V& R&P#M8#@X- !%XJT:9@J
M74F\QRR[#;R!L1$+)\I7.5)&5Z\CBFOXOT%(+><ZBGDW$23)($8JJ.<(SD#"
M G@%L=#Z5S5KX3\0VBZ;.L]M//;B\@\NZG9S%#,5*?O N9&7RUSD#.<9XR8M
M*\(^)]%@M8+6;29(IM.M[.\68,PB>%=HD3Y?GR/X3CGO0!LZ+XP@GUC4-*U.
M\MDO$U*2UM8T1EWHJ!@#R1NQN],XX%;^HZG:Z;''Y\I629BD*+&TC.V">%4$
MG !)QV%<FGA/5OMS3.;(#_A(1J@(D;_5>5Y>,;>'[XZ>_>MC7](U*XUC2M6T
MF6V^T6/FQM#=9"21R!=QR 2&&P$<>H[T 4?"7C6'5_#UA=:G-"E]=)<RJD$+
MA7CBD925!SS@*2N<\]*FG\;:;+,]K:32+OTQM0CO6MI&A6/'RL>.1WQD=,=:
MQM*\&:[I=GHB>=ITT]B]\DN=X1DN'+[AQG*G'R]_[PZTFD^"M:TJTM8E;3G9
M=%?3)<,ZC<&9D9?E/'S<YZ=LT =*GBG2K.PM&U#5(6=[>*62=(F6/#\*[=?+
M5CG&X]CSP:NP:]IMSJ/V"&YWW'S@ 1MM)0@. V-I() (!R*XI? VL6TEJT46
MA7BRV%M:78OX6E$3PJ0'C&/F!S]TXY'6M?2_#>H6/C&;4HDM[.RE,IGC@G9D
MN2<;&,9&$< ?,P/S?R )_&OBM/#NAZE):3PG4[6U^TI#)"\B[<X&X*1M!((!
M)'/KC%::>(-.1[>"XNXDN91&"H!P'<?*I/0$]@3D\>M<WXG\+:W?7FNG2O[/
M>WUO3ULY_M4C(T+J'4.NU6W#:_W3CD9S5>#P3J,&NM=-::%=07;P3W$UU$9)
M[>2-%5A$2OS*=@VDE=I).#TH ZI/%&B/'-(NHQ>7"N]G((4KNVY4XPWS<<9Y
MJ&X\9^';6W2:?5841W>-1@EBZ_>7;C.1W&,BN4/@+5F%S]FDLM.7S4NH;=)&
MG@,Z3+(&VLH,88+A@I().<<<ZC^'-<N-7T/4KG^S/-L;Z6YE2'<B[7B,9 ^4
MEFY+;CCGCWH ;?\ BZ:S:WN$U"RFM'UH6,NVV<-'&4SMY;EP1U ((88%;P\4
MZ*]FEU'>B6)V=0(8WD?*'#Y106&WOD<=ZYZ7PKK+3W-PGV'S/[<3584,S;64
M1B,HQV?*<#.<-R<50G\ :C]H_M1;;1+N]FO+F>XL;U"]OMF$8^5MI.X>2G.W
MG<W XH V/%GC>STKPU/?Z7?6TUPL"7,?[MID,;-@,2O"@\X)/4'KBM'Q?K5Q
MH7AT:G;20 )<VZ2-,I*^7)*D;$8(P0'SGD<=*Y75O!&OR:3J>F:?'H?V;5+%
M(94 >W6VE4$?NU56RG(X)&,9YR172^*M(U/7/"2V%NEI]N:6VED$DK+&#'*D
MC ,%)_@P..] %^'Q)I$]@U[%>J\*RF [5;?Y@&=@3&XMCD #)!!%0CQAX<+6
MZC6K+=<A3"OFC+Y;:,#_ 'N/8]:Y34/!NO7>J:E>HFEL&U2+4+:WN7:2.4"#
MR663Y/E.!D$;L'UJ]IGA74+/7;"XDLM,@M%L+FWGCLF*"-Y9$?*@K\V-F"QP
M23G Z4 ;6H^)K 6-^MEJUA%>06[3*UTQ\I1R YZ90,,$@\'CK3YO%FAV*^7>
MZO9K/&D9E"O]W?T..< \G)Z#GI7%V'@/5K+1[K33INAL\6F2Z?;7Z[A-<*PV
MJ6X_=@#EL;LD\58U+P9KMXFME(].4ZAH<.FQK]H?Y)%R&8_)]WYSCN=HZ9X
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M@WQ9..A\O((/.0#5OQ!8:NGBBQU?3;&*^C6RGM)8FD6-D+%65@3VRN#WQZT
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M(CR75F1@JD,3@X<YP. *Z'PII^I:?;:I'J4<*>?J5Q<0".3?^[D;<,\#G)-
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MTOQ!H^L:A>6NGV$_GZ7;11B.;R46:$2#8%QPIW\'C &* .UHIJ%C&I<;6QR
M<X-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &O&DJ%)$5U/56&0:$1(T"(JJHZ!1@"G44 %%%% !1110
M4444 %%%% !1110 R.*.+=Y<:IO8LVT8R?4T^BB@ ILD:2QM'(H=&&"K#((I
MU%  !@4444 %%%% !111GGI0 4444 %%%% !1110 4444 1I!#&[/'$BLWWB
MJ@$_6I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH BN+6WNXO*N8(YH\YVR*&&?H:D    & *6B@ HHHH **** "BBB@
M HHHH *.]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU!A<;8EE1MY<';\V<=\<XZ50\!^&]>\(Z390#1)6U(A+:ZN)+R,VZPB9G+*
MQ;(5V& !R._4@&G+\1KV"#6YY/#^Z#0Y_*OFBN\MTR6C!0;@!R<E:N:[\0X-
M"30[V33Y9='U79B^5\" /MVEU(X!##OV/X\CJ?PWUK5KKQ7<+$;6:ZO8[RP\
MV97BFV]4E0$@AB!U!QQ[BNIU31+WQ9X9.BZGH26+2::\?F+,C1P3@KL50ISM
MR@;Z "@"QK'CK^SO&^E>&;?3S<27S;6N3,$2(@;F&,$E@N#CC[R\\UV->4S>
M#/$%OJO@2]2&2\N=->2;5;CS8P6>545L9(S@)MX'W0*]+L+FZN4F:ZL6M"DS
MHBM(K^8@/ROQTSUP>10!;KE?$OB75]!E#QZ/:S6;W4%K'++?&-G>5@N=HC;"
MJ2,Y/8\5U5<UXXL;[4="AM]/L6O)A?6TQ0,BX2.59&/SD#HN/J1VS0!!'XKO
M[+7+;3M?L;/3TEAGE-RMYNCQ&8@""RKP?-QSCE3]:Z&74[""6"*:]MXY+C_4
MJ\H!D_W0>O4=*YCQ'H]SJ7BFRO&T4WMI!IEW$=SQ<2N4* !F'.$89Z?,.>I'
M,V?@[5WM+2UUC0Y+^VFTJTM)(_[1\DV\L(P=^Q\,F[YP1DC)XH ]79@JEF(
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M9;B<!99 CIGZ^4P^I [US\GAN\EFV'028!XJ^V!6$>W[.8]IDQGH6'3KSTH
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M"DT5V\T]A)J#2R3;XRAD,C_+O&?4_+WYP"[\*:M<6[6UEIUGI:76C7%D!;R
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MU_LV>(:M)<QJQ=2(C#NX..N=AZ<5U)(4$DX [UYAHD%W"W@X2:=J"-:ZI?\
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M?L]M)=01WT$EW;Q+N:6 ."XV_P 78[>X!&#0!I:UKEOHVGI<MMD::6."! X
MDD=@JC/89.2>PS4FCWUW?Z:MQ?Z>^GW 9E>%Y X&TD9##JIQD$@'':O-=2T8
MIYC#1;E]+?Q';W%K;+8LYBA4)YS[ I*JSAC@@9Z@<UZM$D?V=$1 L6T )MP
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M=M;P*+U9'FD";-T2A22> ,C'/<BL'Q/<-?77BGQ+ILUS;6$&AK:17L1>(S7
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M0 THI!!48/48ZTNT   # ]J6B@!,#T%! (P0,>E+10 @50,  ?A1@9S@4M%
M!BC ]*** $P/048'H*6B@!,#T% 51T 'X4M% !C%&!Z444 &*3 '84M% !@>
ME&!Z444 &*3:/0?E2T4 %&!Z444 &*,#THHH 3 ]*P1X-T4:C->^3/NFF^T/
M!]JD\AI,@[_*W;,Y&<XZUOT4 )@8QBEQ110 8'I1@>E%% "8'H*6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6:3GYTZ,AP>G.#@=C6=K5Q?W>D^!]>UI%AO4UFUM/*D[+"S!W/IN<,3VQMH
M]@NO'/AVQU"XL;N_,$]NRK/YD$@6+<,J6;;M4'L2<&EO/''AVPU,Z;<7["\\
ML2B)+>1RR$9#+M4[E]QQ7!WVD/XB^*/C#1+?4(+9+W3+9;HM%YKX''RC< "
M1R<XR.*KZE;7&E?%O3]*T&:VCEM/#"P))<?,VU9#QG(&_:HP6R!G.* /1?\
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MP9AIU]!<M#@2K&X)CSTW#MG!ZUS'B*5(OB1X8;47$>FB*X\AI#B/[60H4'/
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MJWU":\LI8U@5,-!YFV3(.=Q\HY[?,.!UH [N[TNPOXYH[NRMYTG55E$D8;S
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MD*0<9^? )SDYK17&MWPOF;5=077[+0+>\6PBN#AKLK*'W1],X\L[!@98<=*
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M<KM/F?NC'D@^P?@<9Y]L &C9^#]!L6MS#8*PMO\ CW6:1Y5@_P"N:L2$_P"
MXI+WP?H>HR7DEU:/(UZT;7'[^0"0Q_<R V..V*HZ3XGU"YUK3[34+*&*#5+(
MWEG)"Q8IM"EHY,]\."".#S4OC'4-6T]-';2Y($$^I0V\_FKG*,2 !^. ?8T
M7[GPYHFHZI!J5S86\][;85)F&6&TY /K@\C/0\TZ'PUHMOJLVIPZ;;I>39\R
M4)RV0 3CID@#)[URHU^?1[C58K#1+*.=O$$=I*!.P$IFCC82D[>&PRY'L>3W
M=9^,=;%W;+?V=CY"ZL^E7#0,^YGVED= >BXQD$D]: .B7PCH*6EO:IID"0VX
M=8D4$;5?[R\'[I[KT/I5I=+TNPOI=56"&"<PB.2?.W]VO0'L ,?AS7/^&?%&
MLZWJ$<MQI0BTF[C:2WG! :,@\*WS'<2,G@#:1@YZT_X@_;?[+TPVDL"J=6LU
ME6:,N'#3(!T8<!BI_#M0!O7=EIGB+3!%<)!?6,N' R'1\'(/'!YILOA[1YQ=
M"73;9_M3I)<90?O63&UF]2,#!]A7&+KTNCP:I/I%EI\&FZ7J*VUW:QQ%7F9M
MGF2+R IRXP,'=M//(K9\+ZMK^KZMJ37O]G+IMI<36BK"'\UI$88;).-N">.N
M1^% &I+X9T@S37=MIMC#J#L95N_LR%UE(P'SCDBK&CZ<^FV7ESW/VJZD8R7%
MR8U0RN<#)"\#  4>R@<UA^(-<U0:_P#V%H\UE;WG]GO>H]V"1*P? 08(PO!W
M'D@$8'>LS4_%FK1)JUY:M;;=&FMHYK0?,;@2(C.0W4?ZP!/4H<YR  #N+RQM
M-1MFMKVUAN8&^]%-&'4_4'BHGTC39+%;%]/M6M%.5@:%3&#UX7&*X&?Q'XG^
MWOY=_9)!_;S:4J&U)(5DRK$[N2I(X[\]*FBUOQ-(;"P&I62S/K-SILMR]ODL
MBQ/(K!0P 8!,8Z9(H ]#1%C0(BA548  P *B^RV_G--Y$7FL-K/L&XCT)KS,
M>+O$-PT>D-?Z?97\2W:M>S.(H[AX9=@*Y5QC )91SUP1BI;GQ)X@B35[S^U8
M"NGOIY6*&)3%+YVS>-Q&XJ=YP>#P#Z@@'I MH 01#&,+M&%' ]/I3A%&N"$4
M8&!@=J\XU7Q1JVER:JUUJ0MTQ<_8ID2.:%MLBHH& &61,@,')4DDY !QF:AK
MEUJ(:WO=5\D6?B.T4,MPA*0NB-AG3 R&+?0C&3C- 'I]E>Z?>7%U#:/&\MG)
MY$X5<>6V =OY$5=V+C&T8SG%>;7VKZH+Z_@MM:FAQXEM;176.,_N9(8F*#*X
M/+GGKP,DU!_PD5Q:);6FHZW,UHFK7MG)+YRQSNJ E,L-O )&<8_A[9R >HX
M[4A /4"L3PA)?S>$]/DU.^CO;YXLSSQ.C*S]P"@VG'3CTKC3JE_!KFH2OKUR
MPMO$D%E' SJ$,4L<>4(QS]YL>F/6@#TW ]*-HSG S7E^FZUJ%Q/H-P=4N/M]
M]>7<&I6?F'; BB3)"GB/RRJ#<,9SSG(J/PIK>H-)X;N8]8FU.;4],NBUO=7
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M#G"YP03@\'C'6K/BS4;S2/".JZG8M"+FSM9+A/.0LIV*6((!!YQCK^=<I?\
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ML^Q"BF+.#O9-QDP<D9QZ# ![$[;$+8)P,X R35'1=8M]=TJ+4+99$BD+@+*
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M)R #TI]%TI_-+Z;9MYT:QRY@4[T7HIXY P, U7M[3P_?W!U&WM=.GFMMUO\
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M'T>QT^#4G=IF$SQ2HS*JJ 1NRC#DXQB@#H9_!VB77VP7%HTPO4C2<232,'V
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M#6XO"FNPZGJ%W:ZAH5C=++/YV?-DD'F0,&XR54 =.K<4 =[<^*M&LUU$S3R
M:=;I=7.(';;&X)5A@<C"G.,XP<XJW?:Q8Z=!:37+NL=W-'!$5B9LO(0%!P/E
MR2.3@5YMKM_;,OCOS+F+S9?"]N5#.,ME+CG\W3_OH>HKH/&<D,_@?2)?M)BM
MVOM/=KF-P!&GFH2^[H !SGITH [C HP*\BO]5NK&%X#XBN1X<_M<Q+JDK22;
M4,)/EF1'5]@E^7?NZ\$X!KHM0O[RQ^$LMW'K,MY,D0 O_):%I$,F,@<E?E.
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M2)]1N+.ZO+>0PBWAWO*!@%%!4@D[@-O4@G'<@ NZEXLTG2W@%S).8Y0C>?%
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MR00K* R]&R>*'ASQ%JMU8:+8?:K=[_4(+JZ-U/&S+B.0#8%# L<OG[PPJXH
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M&R2(RCA65@".&ST[Y[UPDT=Y<Z-KMR)QJEFNJ65_'>)  TJQO$90JJ,-M2(
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MM$\*,'B,I8QL2PPH( )&3CIF@#0_X0'0A!' J7*Q1PS6X47,G,4I!>,\_=R
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M9ET6YTFQOET..&XGO[MIYDOIB(QO^]C"GCI\N*TM"TF'0M"LM+MP/+M85C!
MQN(')Q[G)_&N>TOQ7K&L:Y:VEOI-G':O8VU_+(]XQ=8Y@_ 4)@L&0]\$#MGB
MWK'B"_AUN?2]+M[:2XM;$7T@N'*B52S*$4CH?D;).0/EX.3@ N:OX8L=:N6E
MNY+G;)$L,T*2D1S(&+!67ZD\C!P<9J"7P7I$K7KLMP#=72WAQ.P\J=0,2)S\
MK<<GOTZ<5S",OC3QE8R7*1RZ5/HD-_!!(A#PEWSE6# A\A?F'9<=R3?\37>H
M3>([S1Y)X#I3Z)<W+PF'YB0549;=U!Y''0D8/! !KW7@G1;VTBAGBG:2.9IQ
M=+.Z3^8PPS>8I#<C@C., #& ,)<^!M NXY(Y;-BDEJEFRB9P/+1MR8YX())W
M=>3SS7*Z5XNU#0/#5K#=VML\<>D64UH8F)/[QEA ?..Y4\8XR/>NQ\/ZCJ]_
M%>1ZI8BUEAEVPR8 $R$ AM@9BO.1@D]* -F&)88$B4LRHH4%F+$@>I/)/N:R
M8?#6FV-U+?6=HHN3*]PBM*XC$K+@L%R54D$Y(&>3ZFN-T[Q7XE:PL;9#:W>I
M7T^HF-O)PJK!,R! &E7=DXQ\P(4<YP36A:^(?%5_K4%A'%I-J?[.BO)EE9I<
M,6='161L$ J#G\.^0 7?!W@N'0='MH=0BBGO81*F]9GDCVR,2=JMPN1@' YQ
M[U?C\,>&](BAN39P0Q64#Q1O+(=L<39W+R<8.>_MZ"N3T_Q5XIU6/07BN=*M
MSK>GR7,8>W=OL[1A"?XQOW;^G&W_ &L<Z&L:JVO_  0OM5NH8UDN]$DF9!RH
M8Q$\9]^GI0!T4'A;08]/DM(]-MS:SPK"Z'+!HQDJO/\ ",G Z<TZ;PMH5Q))
M)+I=L\DBHK.R9;"#"8/4$#H1R*XZ;Q7JVAF[L+VZM&\L:>([A8O+6%9V=2#E
MB#CR^&/&6Y&!3X]9\5W=Y::8FJ:7!+-<W4/G)%Y[;8T#H6 (4/A@& X]/2@#
MOK2SM["U2VM(4A@C&%C08 JO_8NE"]GOO[.M/M4Z;)I_*7>Z_P!UFQDCCITK
MSU/&NNM93:O;W6FW"F"\/]E-)^^22+<454"!N OS[F.<_+C@&^VLZA<0RVHU
MAKFTO- ?4!=)'&KP,-HQP-NU@QQD9&UN3V .@TVT\(ZI9W&GZ?::7<6T3J9;
M>.%"@.,*=N,=!P>F!Q6U=7=KIMD]S=31V]M"N6=SA5%<[X'DL+?PYHUJ+Z*>
M_FTR&?YB@E:(*H!PH&54D*#C\2:7XCDCX?ZOC_GFH_\ 'UH ?<ZKX-2;S;N?
M24GF:.;,X179L$1L<\[L9 [\U);77A/5I?[,MQIMTTV^Y:W6)6!*L%9V&,9R
MP'//-4?'PM+72;"63R8C+K6GF1S@;\3IU/?"@_@*@\20"3QQHEK;ZD^F-+97
MK226WEB0_- W\:L,?)R<9^7ZT =LJJB!% 55& !T K*L- MK#5=2U$.\T]_,
MLS&15_=D(J *0 <;57KG]:\QB\9:OJ%KI?VGQ%!IDDVE6]Q!*T)87,^XB0*H
MX=AA04'/S<"N]\6ZC-8KHR-=-;65U>K!>7*?*44HY7#?PY<(,^AZT =#]DM@
MSMY$6YSN8[1ECC&3^'%13K96MG)YL<2P1JTK*$R,#DG:.M><QZO?2W6E6U[K
MUQ;V$E]>VT=V"J&YA1<HQ8C&00P##KC/4YJ+0+FXD\1:-<ZSJ5RD]SI%VL$\
MCE%E"S*$8*?EW&+8Y '. <<4 >D6;Z?JMC!J%LD<L%U$LL<ACQO1@""01GIC
MK5D6T Z0QCI_".W2O+]*\0WUS::1'K6JS6L,_AT7$=SOV>9=?QDD=65<';]>
M*H7VMZXNEZO=WVIW=IJ%KX>M+Q($<(HN6+ALKW.0@*]/FZ=* /4;74-(N=2O
M]*MY(6N[4)]J@"X*AQE<\<Y%:2JJ+A0 /05SGBDP1^&[S4+:_AT^>>.*,7Y!
MQM+C:"R\A27(W#[NXFJ7AC5+J\\%ZA/9QRRWL#W"1+)<FY220#*^7*W+QG(
M)]QVH [# -+7D>G7<^H:+<R-XJU%II+2*,0QP2PO!=E@%W,SD;BQ(9!M4@9P
M !5F?6+_ /X1P--<WT5VNL"/6RK2N+5<-S&%8,(MPCQM(X)SSF@#U+BH;RZC
ML;*:ZE#F.%"["-"[$ 9X Y)]J\WTQ)+S6M$L_P"W]7GM9+2[DCE=Y(/.=98S
M$K G<1M\S!8Y95.21FJ]C>7$V@7C3WVO)K\6EW0OH&,JQK-U5P3PO/W F,AN
MG!H ],B2UOQ::AY1+!-\)D4J4##^Z>AQQZ]1ZU;KRY[K4?[3TR:&\N+QI+>S
M1H/-ECFAD*9WX^Y+&V<N#TQUX&+OP_>:;4!)/J>JRW@M"M_:7,$BQQ3AADEF
M)7=G<!LP"!TX% 'HE5[Z\CT^RFNY4E>.)=S+#&TCD>RJ"3^%><>)A+_PD/B>
M"VU+6$NXM.M[FP@M[F4J+AC*!M0'&"40%3P1GBC5X+]=,\9W\>H:PM[;Y6RB
MCN9=@9H(CE%S@_O=X &0"" !DT >FJRLH8=QW&*7 KA)+YI?$]Q#<SZO$_VF
MU?3VMHW,<\/EJ6!XV %C)NW8. /08J^#I+RZUJWDNM2U%=0C61;^SEM)54D]
M"SLQ3 (^38!P?K@ ]%P*J7]]%I\432132"25(@(8FD(+' ) Z 9Y/05ROBNT
MU9=7,>FS7FS6+5K0,D[A+.=?F64 '@;0^<=2@'\1K*FU+6&T6SU.\^V6-V=1
ML;.2%96*E8Y0)VQTVMF3GNJJ3TH ZX^+='4.YEF 6^73F_T=^)V( 4C' )8<
MGCGK6C>ZG:6%Q9V]R[J]Y+Y,.(V8,V"V"0,+P#U(SBO-]0O8([762THQ_P )
M99."%SA5:W8GZ#8_/L:Z?Q[&CVVB-+.]M FJQ-+.AV^4NQQDM_",D#/;/4=:
M .LVKQP.*4# P*\ENM1U>&V@@N]:N[/2)6NH[/4I(996DPRF+<496S@,5)R'
M'7.17I^F&=M*M#<RF6<PKYDC1>67;')V?PY].U %NBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JA_8>D_P!JG5/[,L_[0./]*\A?
M-X&W[^,]./I5^B@"@FAZ5&9"FG6J^8K(^(EPRL<L#[$\GU[TTZ#HYC\LZ79E
M/(^S;3 I'E?W.GW?;I6C10!FOX?T:2.1&TJR*R0K X\A?FC7[J'CE1V'2GOH
M>E2&X+Z;:/\ :4$<^Z%3YBCHK<<@>AJ_10!GOH6D2111/I=FT<4WGQH8%(23
M^^!CAO?K4]IIUE8+*MG:06XE<O((HPF]CU8XZGWJS10!F)X=T6.UGM4TFR6V
MG 66$0+L<#H"N,$#TI[:#I#WD5XVF6ANH@HCF,*[U"_=P<9XR<>E:%% %!M#
MTE[R:\;3+,W4Z&.6<P+O=2,%2V,D8[5 ^@V5LJ2Z78:=;7L4?E03&U!\I"<E
M1C!VY). 1S6M10!D^']&;1_#T&ESSK<F,,K2;-H?+$]"3Z^IJ+3_  S:6VGV
MUC>1P7\-DW^AF> ,\*=%&23D@<;ACBMNB@#,M_#FAVCP/;:/80M;EC"8[=%,
M6[[VW XSWQUJ33M$TK1_-_LS3;.R,IS(;>!8]Y]6P.3]:OT4 (RJZ%64,K#!
M!&016=;>'M&LI/,M=*LH7VE=T<"J<'J.!T/<5I44 8UMX2\/6<T$MMHMA"]O
MO,)C@5?+W?>VX'&:9#X-\-6[Q/!H=C$T2NB-'"%*AQAN1Z@G-;E% &4GAK1$
MT0Z,-+M?[,((^RF,&/KGH??FJTG@KPY):V]L=)A6&W4K&B%D&TD,0V"-P)&<
M-GFMZB@!DF\1/Y04R;3M#' SVS6?HFDKI-K,K2>;<7,[W-Q+MV[Y&ZX'8
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MX8=/M8XK@DS(L*@29Z[ACG/O5VB@"M!I]E:F,V]I!$8T\M/+C"[4SG:,=!D
MX]JJ^(='&OZ%=:6UPUN+A0#*BABN"#T/':M.B@"K%:%[.**_:.[E0?,YB"AC
MTR%YQUJ9X(I&#/&K,!@$CG%244 1&V@)0F)"4.4)7[I]J>Z+(A5U#*>"",@T
MZB@#)OM!AOM8TS4&GD3[ ) L"JI20.NTALC/'&,$5JE0<9'2EHH 3:IQD#CI
M054G)%+10 4  # Z444 %%%% !BBBB@ HHHH S+;1+>UUZ\UA)9VN;N-(I%=
M\IM0DK@=L;F_,UIT44 %%%% !1110 4444 )CG-+110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%(>E(: '44T=OK2]Z %HI.
M](* '444E "T4WN*44 +12#K0?N_A0 M%(.M% "T4G>B@!:*2CM0 M%(*!0
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C*JZA_P >$G^>]2M]R/\ WA0!-FBH)_\ EG_O'_T$T4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .) L0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSMW?=SG[O/TKE]*^(-MJ&IVJ.]M':7=Q<6D7SGS!)$S8W#& &5">N02HYSP
M=M168?$FAJ]RAU>Q#6R%YQ]H7]TH."6YXP1CFH-0\5Z/IVA3:R]VDME$YC+P
MD-EPVTJ/?/% &U17-Z?XKMI=4O[2_N;*W"7<<%D1+S.'B1UQGJ3N(P*T8_$6
MC3:PVDQZG:OJ"YS;+*"X(&2,>H!SB@#3HKFO%/BJ'1(HH[:XM&OC<VT36\K'
M=LED"< =\;B/]TUH3^)-'M_M2M?PO):QR22QQG<^(_OX4<D@\$#H>#0!JT5B
MQ^*]'.G65[/=K;I=P1SJLO!1'P%+=E&2!D\9[U;U/6;#1XHY+ZX$8D;;&H!9
MG.,X50"3P">!T% %^BN6U+Q+//>:79Z#+:R/J-K+<PW,L3R1$+LVCY2.I?KG
M@#I6K>:_IVE-!#J5Y%!-)L!Z[59C@9.,*"00"V,XH U**R+3Q/I-].L-M<M)
M(T\EMM$+@B2, N#D<8!')XJ./Q=H,BW##4HE2"(3.S@H#&3M#J2!N4D8!7(S
MQ0!MT5D0>)])N9X8(KEC-+*\"QF%PPD1-[(P(^5MO.#C(Z9JBGC/3KR[BM+(
MSM]HLIKJ.Z-L_E*(V"D'@'(.>..F.I% '2T5SG_"8:38:/97-_J*RB2RCNWN
M8K=PAC.!YA4 E%)/&3Z\\&I)/&FA1:B]C)=NLT<D<3DP2>6K/]S+[=H#9&"3
M@]J -^BL[5-<L=',2W3R>9*KLD<432.RH,L=J@G XY]P.XK U#Q)=ZEJVGZ;
MX?NHD^V6+WT5V]NTL;@,@ XQ@$,<GJ,KTH ["BN(\6^,;G3+'7(;#;%>Z5!;
MW$DLT1,;+(Y! Y '"GDGUX.*NW?BZSG6#['J'V8IJD5C.)[*0EF8C" 8&W=N
M7#GC![T =51679>(=-U&_:SMI9'F7S#DP.J-Y;['VN1M;#$#@FHX?%&D3ZL=
M-CN2;@-(F3$P0M& 74.1M) /(!/0^AH V**P&\::"EO-</>,L,-JMX[F"3 A
M8X5Q\O(.#T]#2_\ "9:&(4F-VXC8KEC!( FYRBE_E^0%@<%L9Z]* -ZBN<E\
M<Z!#?O9/=L)E68C$+D.8<^:%P/F*X.0,]#C.#4(^(7AXQO()[HHEN+O<+.7F
M Y_>CY?N#!RW2@#J:*Y^\\9:/9:E#8RS,7EF2W#K@J)74,B$9SDAEP<8Y&2*
MJQ^/=,N(B\%O>D-!-/ 9(#&)_*^^JEL?,/?% '545GZ%J$FK:!I^HRPF%[JW
M28QGMN&?RK,\607Z:==ZG:ZM<6:V5C/(L4**=\@7<K,6!R!M(QCG- '1T5PE
MQ+J6FV6@:DE_J%Y]LN8/,M=R?,6BDR 3C@L4."<#;5T>/(I+2)[?2;V:[*W+
M26:@&1!;OLD'&06W8"COGJ* .NHJO878O["WNUAFA$T:OY4Z%)$R,X93T([B
MK% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q6@
M:I8Z3>^*8+^[@M9AJCSA)W"EHWCCVL 3R#T^HQ61/#Y,6CW%IK,&DZ];:-$)
MK74$'E7,./N."00596R5Y&>G->CR002.DLL4;/'DH[*"5]<'M3VC208=%89S
MR,T >>:;K5@/$?A>^N7M]+2X\/S'[+,ZH(@'@(&3VP&Q[*?PN^"HFE\3^+=4
MME8:->W$!M#M*I(ZQXED0'J"<?,.#CC-=I(L29G>,%E&=P7+8'IW]:BL+ZUU
M.QAO;*59;:9=R.!@,/QH \W\-7-AIGCNXL=-NK>]TF93/$#\TEBP#EL'LF69
M2#@@L!TXK3\4^(_"=Y8-I\VKZ9;C4(HIY99F WP;@<CH2Q4$+Z=>W/<K;0)-
M),L,8ED #N%&6 Z9/?&3^=2  #  QZ4 <+JMQ:1>)(;K0M89]6>\MX[S31-O
M$D1P&S&>4VH2^X=QSUJEJ$L\NEPZG!?1V_\ :E\]QY4ER]JMS$%VQ+YZ<QG8
MB-Z$Y'(Z^CD*.H%5+34+>]GN[>$/NM)!%)NC*C.T-\I(P1@CD4 >5WFJQE+[
M4X]4U&UEM-'TR55>4+*Y$LH/F@??)##(Z'S <'(K1&NO-XWVI?ZBMM]MFM[A
M<R%$0P$H<#]VBEE!5OO-G/ R*].P/048'H* /)(GOQX:\.W%UJ^K"TO[,_VA
M<GS96ANA'&JKA"&0964>F[&>3FO0= U2&5(M+,U[/=V]I%+)+=0%&<,, L<
M;CCD=16W@48 H YSQ]!)=> -=MX8WDFELI$C2.-G9F*X  4$G)K/UV ZO)X/
M:2.\:,W?FS^4DBLJFVE&7*@%!N95.<?>P:[+(-,DGAB,8DEC3S&V(&8#<W7
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MK-(&CN+9U*84(6)=<;_F]0O3.*UM(^(&E:CHMCJ$RS6SW<$ERL!B9F$2<L_
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M+B8QP)%++,EM(T21RC*.7"XVGUS_ "-:%EXBT_4-3GL+9IGEA=XW?R7\O<F
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M0S,,$D>X&#@ ['2M/32M(L].CD>2.UA2%7DQN8*  3@ 9XJW4%G)/+:1274
M@G907B#[]A],]ZGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWEI#<Q$^7*BNN1@X(R/YT 34444 %%%% !1110 4444 %%%% !1110 4444
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MH_'$MS'IU_,GV&5TFMMT4A"*,E"3S\N1R<8'I7;6WA#P]:%C!H]FF^%H&_=
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M%L=)LO($BS",0J!O7&&X'48'/M4UII5EIJW/]GVT-L]S(992B_?D/\3>IZ4
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M*4,;;M\BN?,98\X++@D@<Y&#7I'_  D>B_;C9"\C\X3>1]T[/-_YY[\;=_\
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MTNT@@=H]KL?+=<C:<*%*!#NZCI7J7'M3#<1"X6W,B"9E+JF>2HP"<>@R/S%
M',> Y+IM,O$N8V)2Y(6X$DC1W VK\T8D)95[8R1D-@FNKHHH **** "BBB@
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M92T9"I+C*GY,G&T$=^.<U=;PC9-X0A\-?:;I;*%(T1PR^8%1@RC.W'! [=J
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MK&VF9[6*VN<Y<2!!P 6YP#D@=L\5=/A_2614>QB<+.MR#)ECYJ@!7)/)8
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MJ]#O=/L]2M_L]_:074&X-Y<\8=<CD'!]*S-2LO#.F6]I<ZC9Z9!%9G%L\L*
M0GKA,CY>A/'I[4 97BW4F\/6FFV6F7$&G+*SJJ)&B@*B%N"WR(HP"<@DC@<U
M+;:]?:E\,H-;MY[.#4)].6?S)6 A24H"<GG !]>G>KMSK/A:_NK.SNKW3+F>
M1T>UBD9'+,1E2@/?!R"/4>M:,UMIECI,L,L%K!IT<;&2-D58E3!+9'3'7- '
M$V'B*]GN](CN;B7[2-8>SNK>[@C\R+-L\@4.@VMC (9<9#<XK.L_&.LWUC=W
M,6KVH\C2[NXN%Q&3'.C'8(QU9  >2#T&3DXKT*WTO1Y[.V>TL[/R /-MGBB7
M";AD.F!@$]<BL71_ \>FS0&YOA?0V\9CC22SB5FRNW+N!ESM)!Z Y)(SB@#F
M[CQ1KFEV]Z9-4-V7TFTU .8% M_,F*.5"J245?F^;<>.II]MXJF2>RM;SQ5;
M-I\]Q.&U*W"E$941TA,K+L).]CG'\.WKG/HT=I;1/OCMXE?9LW*@!V^GT]JJ
MP76EQ:B=$@,27,<(G^S(F L>< ],=: .3\)WYA^#T=U;ZA%&]O9SD7;KO5&4
MO\[ =0,9(KGK35;FXDT<ZMJLZRVFLQI)(ERDENRO;.5*R!0""0#AAE2V.XKU
MS:NW:0,>E-2"*)=L<:HN2V%&.2<D_G0!Y%:^*M0U19[276)I$OM,O]H"JD@G
MC<!5"J/D8(6^7<20 3@U-#J\Y73;2#Q++9P+86LEC(MNT_VIPQ\U1M(#G@*5
MYP"".]>M;5]!0%4 8 XZ4 >86M[?WFH6JCQ!?F.37[NPD",F%@59& ^[Q\PC
M7=U&[@C-90\0ZS?Z?IL5SKMQ8VTEG.B:@EJ\OF7"S%5!\ME^?8JD*00V3P:]
MD  Z4@=2Y0,-P )&>0#T_D: /+;C5+V#4;Z>76[PR6FNV$*QL^Q/*D2$2Y0=
MN9>#D+M)&"":Z?P+&+8:]:'[1YD6K3G$^\_*QRI#-UR.>#W]ZZVC- 'E,=PM
MQK&DWES<WMQ;V?B6\0S/O?8K0R>6, ?=W%0,<8/'6L^?4-:E\-:U))?:Y'K,
M%A*L]O%!*BI/YGR,KEBI]O+ RI.>V/9J* /*-9@O(9=7GM+O7I?L<EC<V0$D
MK;GD<>=@'AAM RI^5<G 7-:-]-<6ZZ]$]OJ5U,=;1;")Y)@B^9!&-Q8'B%6\
MUB.@V^N*]">:*)HUDD1&D;8@9@-S8)P/4X!/X&EBFBF4M%(KJ&*DJ<@$'!'U
M!!% 'FL4-W;_ &%+6ZUNZ1M+OTEN629 \Y\MU91_"<F0)WP, G K-$.J:9X9
M,L:ZL+JYT"UFN?,\YVDN?,7<F3G#D,RX'(!Z' KU^J&I6.G:S;2Z9?)',C*K
MO$6PP&<JW!R.5X([CVH Y[P/=QWD^L2^==+-+.DQLKA)T^RHRX 42JO#,LC9
M4 <XYQ7850TS2+/2(G2T67+D%Y)IWF=L=,NY+$#TS5^@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWQ/XOFL/[?T^S@FAN].TH
MZ@ETZ!HSPW&#U^[CZY]*O6_C32VLYWF>9)K8Q(\4D+1O(T@^38K $AB" ?8]
MAFJOBCPQJ>K7&J/8W%JB:AI+:<ZSJV5)+X8$?]=#GC^$>O%74_!FI:K?7]VU
MY!;22PVAM]J^:%EA\S.X$ ,A\PC'7'I0!T6E^)-+U?2Y]1M;D?9[=G2X+C:8
M63[P8=B/_KUBQ?$C0Y[>[FA%S*MM MTRQHKLT!./, 4G@=P<,.ZUIV6ASR^&
M+G2M7>U+W<<D<WV&'R8U5Q@A023T/4YYK(T?P]XJTW3);-]6TMF2-8;>:*RV
M,5W#<\F206V@X &,G)S0!H7/C;2[:U%UY=U-;/=):0RP0^8LSNN1LVYR.V?7
MBH)?B#HL5G%+B?SWDEC-JX6*5&CQO#!V4#&5[\[AC-8.K>'KW0-.MK*RN&>R
M36;>XL(%M9)OLJ [G5MI)* Y/; ./2M.7P5J27HU:QUM;?5C<S3LSVPDA*2K
M&IC*;@< 0QX;(.03WH L/\1-(4,Z6]_) D,%Q),L&%CBF)"NV2#@$'(QGT!P
M<6?^$WTW[7J,1BN1!IQD6ZNM@,<;(NY@0#O'&<$J >Q/%4]0\%7>IG5Q<:Q_
MR$;*UM3(+8;E:%F;?C.#DN>,8%)?>!?[6U>>YU*]26"6*:)O*@$4KQR(5,;N
M#\R+G*Y&00.>.0!!\2M*%M/+):W<1BFCB D\M5;?G:?,W[!]T@[F!!X/49U-
M3U99O!5]JCQ:C9HMK+(RQ!!<1A0<E<DKG R#D@\533PUKATB2RNO$:WK954^
MTV"&-HP""LB@@L6SR<CH/?-J#PI#;^!Y?#$=S(L,MO+;F4 942;L[1T &X@#
ML !0!G7/CJ#39+JW_L^]N(]/MK>YGN"R<PR9^?&<L1M.0!V/M6F/$S37C16F
MFW-S;I<26K7"8VK*BDG(SD+D%-W][C'>L^\\!Q7BWX?4YU^VZ=#I\A6-00L9
M)##W.YO;GVJSIW@U--URXU"'5;[[/<3&YDL0P$+3D -)TSSC.,XSS0!4E^(-
MO_9=E?VVGSSQWFE3:E$N\*P$6PNC9Z'YQSST/M21>--2EN[6#_A'64W%H;Y<
MW:\0AD!/3KA\X_V2/0TD/PWL(8HX?[5U1H(K2XLX(FDCQ%%-C<J_)DXP,$Y/
M ZXK3@\)6\.K:=J/V^\>2QLC8K&WE[)(SC.X;,Y.%Z$?=^N0#+A\?F>%;D:+
M=_9+B&%[.<AE65Y75$C8LH"L2ZG*EAC)SQ@N\'2WG_"3>*X+V(Q.EU"ZI]J:
M=5#1*?E+ $#()Q@8R1TJS'X T:/3Y]/WWK64B[8H&N7*VPW!AY7/RD, 0><8
MXP.*FM/!UI9W,URFHZHUQ/+#++*UT<OY1^53CC:1P1CD4 =&>AKR_2XKC2/$
M=E;ZQ'=I>R7DQM=7CG:2WO@ROMCE4'Y6 /"D8RG%>H5A6OA/3K2X@>-[HPV\
MK3PV[SLT<<C9RP!.?XFP"2!G@#C !S[_ ! GL])L=3O;.+R9K&[N)(XG^8/
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M]9MX9'^W0MICPHYC:(ML [\*N6W9!W# %=FOAS0U4*NCZ>%$WGX%LF/,_O\
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M;>22\+M&27DX<K\G&0<?RQ4ND>!M+TJXL)C)<W;Z=$8;'[2P(MD( .T  9(
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MMC$A@*>68RHV[<8QCTQVK,T_PMI&E^6+6";9$,11RW,LJ1?[BNQ"\<< <<4
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ML6&C=0R$#J#R#0!Y=-JT6IQ6+:7KNK+IS:!=718SL)?-1TVEVY(;)D&,X^7
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M8P7!C<D!<@YR"#6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME2O%;VZ1Q!4_=Q.,Y7)^8E1GWZTZ^UF[TV]U&U.O32K;ZUIGSNZ@B.8IYB'
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M2<D'YR?F(;'.>O6O1:RCK<:^*(]"^S2[Y+-[M9\KY9"NJE>N<_.IZ8YZUJT
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MVAU9BEL\,FW.<_N_,9#Z9'M77W7BPVVJ0V']A:I)-/))';E1"HF\L98KND!
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M>T:6(,74H,@C#<,>O8#'(H BM?$^_P 17.H0W5Y>:1-HT5]!;)""P+.5^50
MV3@?>/!)Z#I>7QS;,ZPKIUY)<?V@^FM%&T9VS+&9,9+@8*CKG@\'%49/A]*M
ML]O::PT"?V9%IZ$P;F 1]^YCN 8,2P9<#(.,BEB\"7T5W'.-:B 758M2V)9E
M1E8/):,8?A2O3KCONZT 6%^(-B\-D4L;LW%T9U%L2@??"^R1%);:[9S@*3D
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M14C10J*HP% X % 'G?A;0-(\6?#^+4-:@AFU&^622ZO75?.BE#G.UB/DV$
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MYZG!STKO)/"=O*ZN^I:L2N<9O&./SI\?A6T7'F7VK2 #:H.HS(%'/9&7U[T
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M<GW-<WXGT6:YU_7-0CT>ZGN(QIS64Z1Y.])29#&>V%P">.XKTLD#J11N7U%
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MI-WE%A)G9&2,$*!P<[LG&#6E!XLU"]\Q+30)C<6\4#W5M/,L<B&0G*KP0Q4
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MFP*^UW(+,,@X)P,GOBH+[1?">F63M?:=I%M:2F*)_-@C5'P<1J<C!P<8!Z4
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M'!],C(JT !T H \K\>ZEOO=<L-2N+J!88K2738XRX28"0&1L+PY!P"#G  (
MY-2W^IW<E[XJA764AMX-1M3!]LE=860PAVC,B\QJ6#<] 1@]<'U# /:C ]*
M/)[36?,G$&L/K]H98+<Z5Y4K2NY!;> X!#L6&"SCE"IXSFK,DMS#J^H QWT>
MG2>)@UXT"NI,1M$522.3'YJ@,1Z<\5Z=@>@I<4 >27IU2'3O,\R\N+>WN+HV
MEK<+-OGMPR[=D@&Y9@0PC+9RI]\U;TE[NX\:LM_)KT.IQ:A.RQB "![8EB@,
MF,% FSY<YW X&2:]/P/2EH X;QAI\C^./"VH0V#S-$EW'YP@:18W*+Y6X@':
M-W0G@<UF>%+.^'B'P_<P6E_;RKILD.O&Y1U628;=IRPP[[_,.X9^7VQ7IE%
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MIA%,OW#D@D8QU[[:T]:\27-EJTNFZ?9)<SV]@U_-YLIC!3<555(!^8E6Z\#
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M;41MF=F5I)B#\Q&"1T&2!5&VU*^TC6=5TVWNK<3WVONAN6Q&.+.%PHR& 8G
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M.9%:5F(:3/#!,XQCG)/%=UI<-Y;Z7;0ZC=+=7B1@33J@02-CDA1TH MT444
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MK#C@@CIBNQKFX_!T*&,R:OJLODVSVT&9D3R59=NY=BK\X'1CDBM^V@^S6L,
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M#;=3201F!(_E$\K@!%7/3<S <^M<QX-DOM UO4M'U"&Y1[^,ZE;?:Y8\R2X
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M,+H(LQ1BJC 7(!P3C!.!CGH:R++Q-?7]Q#81^)%1CKHM?,@DCF+0/:EP Y0
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M>/N@C&.G% $7A2ZO+K1G>^U*TU&19Y%%Q:L&4J#P"P506'0D #CI7FM[,8-
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MLKAD8HPP0",,&%7L#&* /)=?OQ?^%O$\=GJMS?Z*^B+<1322%BEP=X\O=WW
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M?*&)V\^V&7?P_P!,O(98C>:A$D]K';7"Q2JHG6/[C-\OWATR,9'!R* &?\)
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M?+#=)J\6GQF121'"DD<94?,,%F=V)[@@=@1WFGZ38Z6)/L< C,F-[9+,V!@
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M$K/,Q=MRCY6WL21M' YX'2JDUGX2O]/L6FBTFXLX)0EHS%&19#QM4],GT[T
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M4:%00NQ!D @$\Y+<]<   ')-XTU2ZTW3A#?6T=[=Z3:74?EJ&#3.Y$H?.=B
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M1MCS+X&1&79CYB655*=#D\=,>Q!55<   =A6='HT$7B"?6?/F-Q-;I;LA*[
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M=5S['TK+U[PU?ZI%K%];:!+;V]W:VL7]F@H&DG27<TG#;5PGRYSDUZM+-%#
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MK)&ZAD=3D,#T(/<4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[O>I&\/:._GA]+LV$\0@ES"OSQCHIXY [#M0!!X>O;^_LKG^U'TYYH[AX_\
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M,".>>U;- !1110 4444 %%%% !1110 4444 %%(,[1NZ]\4M !1110 4444
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MO0'U&QCO([-[VW6ZD&Y(#*H=ASR%SD]#^1HU&XDM--N;B%8FEBB9T663RT+
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MM>BU'5M/M8=+MY;\W4WVA5A$,N6#[/?^(MSGVZ;G@"Q:WT4S&XCN8,_9[&9
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MNJ3ZD,0;2S2[P4SN.%Q(WZ>E #Q\0M ^WK:/.\9)E7>^W"M&"74@'<N-K<D
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MD?8I(8#%"R,9#AD;*[B..S C=U[5(_BJ]LM3N]-EUPR6L&L16\^H&.,M;PO
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M0!QT?AC4KC2K_P K0?L)FT%M/DM/,C_TBY/ ?@XPOS?,Q!._IQ70:[I5_?>
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M.>*]4-Q"%5C-'M;[IW#![<?F/SK,TO74U&_U.S>+R)+*[-J-[@^;^[23<O\
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M);.W.G!Y4&T$@.>S #D#OT[XUK;Q%I-ZL36]V)1+.ULFU6YE4$LO3@C!S]*
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M><_7$FK^$;R2X\606&@H+.\AT]+55,2QOY+'> NX8PI Y SC%>EFY@4,3-&
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M#N)PRX^4 YX)J+6?%\.L:'=FP-Y9W-A=V+2Y<#Y9)D!&8V((V[@03QWJ];^
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MO;W47AO4+"]>668O;:E'--#)Y:*#)YC[)%;&TC)X4=":]"&KZ:V-NH6IS+Y
MQ,O,G]SK][VZU2F\010ZFZ%[,Z=%;/+-<BZ7>CHV"OE]<#G)SP>* .9LM!UI
M/$-C>&S6WE40?;61T>TFVPA69$)WQR*254@ %1SFG^(_#.K7VH>((;:WAGL]
M<LHH/.=PIM9$RN2#R5PVX8_B'09S6C_PG.G+K%JLEW9Q:/=:=]LBO)9@F6W@
M;>>.ASZ]:V[G7M*M)7AGU"W29$,AC,@W[0I;[O4_*"?H* .-O/#FL'4=1G@T
MU75]8L;R)WF3=)'"J*_?@_(<#_:^M;.OZ3J4OB2VU6RL+2]0:?<63Q3R;<&1
MD8,<@Y7Y"".OS<9J[:>,= N],M-0&IV\<-VF^(2N%8C@<CM@D9],BK!\2Z(-
M1&G_ -JVAO#+Y/D"4;P^,[2.QQVH X:S^'^JZ5?):16NCZCITL=L);J]4F:(
MQ1)&<)@J_P#JU9<G@DU>3POXD#VY1-,A:/4[Z[WF9GVI.KA2%,>&8&4D@D [
M>OS<:5[XQ5?&.B:392V\MK>O<Q3N5;<K1(S':WW2 5P>N*FLO&6FPZ+8SZKJ
M=H]S/;-<EK.*0HZ*<,R+@M@9'7W]* .5_P"$%\4/H^L6TO\ 9!FU&QMH,BXE
MXDB=CN+,IR"&SP!V  QD]=HNF:Q:>*M;O[R*Q6RO_*:+R9V:12B!?F!0#GKP
M>,=\\7+OQ3HMB?W]\ -L;%D1G51(2$+,H(&XC R>:=X@\06OAVSM[BZCGD6>
MYBMD$,32'<[8'"@G_'H.2* ,"P\'7T%S;VMS/;OI=CJ4NHVK)GSG9R[;'!&
M TK<@\@#@<UI:#H>J:=8ZM!=7EOYE[<RW$4EO&1Y32=>&)S@X(]:IZ!XO$^H
M7>GZK+BZ_M.:TMVCMG6(A%W*I?E0Q4$X)R<=*U=.\5Z1JE_'96MP[2S0F> M
M$RK/&" 61B,,!D=/7/2@#DHOAYK(MIUDU;3_ #9X[,2.MDWS/;SF578F3+%L
MD$G],59U[1IK6SUU)Q/=S:]=(UJMG;MFVE2-51V?)  ,2MN. #5OQ!XBO(?$
MSZ7!=G3H+2R^WS7<EN)(RH;E6ST7:K<@@YQSQSH3>.-&M8KM[EKJ$VL<<LB/
M;.&\MSA7 QRN>">W?% $7B336L_ACJNE6D4US)_9DMM$B(7>1VC*C@ \DG-4
MCX/EUNT34+_4I%U,V\ M;B*V,)MRC;U)C8G+;C\P..!C"\U;N?'^CV<R172W
M$#F18Y5D55: LY1=REMQ!(SE0>,$X!!JV?%U@+Z*#RI_*EO'LDN=H\LS(I++
MUR,;'&2,?(?;( RVT#44U73;^ZUC[3):K,LNZV"^9Y@7[N&^4#8.Q[^O&6_@
M#SY+FXFU!([R3RW2>TMA#F5) ZRR+N*NX(QG R"1W&)[OQG:76E70A^WV32Z
M=+>6ET(5?S8EX,D8R<D95@&QD,/?"2>/+'3;4K<0ZA=FVL8+RYN8X%"B*0'Y
MS\P ^ZQ('X9Q0!,?!K37\.H3ZDQO!?)?3,D("2,D?EJH!)*KMW=R<MG/:M/P
MYH0\/:=)9K=R7*O<2W&Z0 $&1BY'';)/YU4NO%UO;:F+1;*YF3[:E@T\93:L
MS(' (+ X (R0.]=%0 4444 %%%% !1110 4444 %%%% %;3@HTRUV1M$GDIM
M1CDJ,#@FK-5-+79I-FN[=B!!G.<_**MT %%%% !1110 4444 %%%% !7/_\
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MR!\HX'M6A61X59G\(Z*[[=S6,).SIG8.F>U:] !1110 4444 %%%% !1110
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MP!@$\]:[R>[\,6")I$\FF6\<6TK:ML5$.<K\O0'/3WK:\M-V_:-Q&,XYQZ4
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M %%%% !1110 4444 97AB1I?"NDN[F1FLXB7)SN.T<Y[UJU7L<"P@   "
M8 '88JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&
M<<XP:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **.E,26.2,2(ZLAY#*<B@!]%-CD26-9(V#(PRK*<@CU%.H **** "BBB@
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M@B622\N+J+S"% &-J_\ ?1)]JN^$9=4N/">FSZU*)=0FA$LK! GWN0-HZ8!
M_"K.N:6=9TF;3_M!@CGVK*P7):/(WKUXW+E<]LU"=)O?^$GCU-=6F6P6U\C^
MS@@\LOG/F9ZYQQC_ /50!KT444 %4-9M+V^TXV]A?-8SM)&?M"(K,J!P6 #
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MW?R6*S6>ULR#Y\\.A3=TS@X^85D:3?W=Y%HEC%'86FE3Z+>R3:?#"1&61T3
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M,D\IHF$A&QEYR<<4 >-:9HE[-X7L+K3].O[F>327COQ+.X%RQ9 @Y;Y\*'(
M(&WC(W8K1L?"]Q+J%I%<Z%<O8QZX]S_I"1!?L\EIL.47 "F4 E<=^0>:[O[9
MI^AV5QI>C6T4MS8VWG)I\4@0[23@9/"Y(/6M<74 DCB>2-)I!E8F8;C]!WH
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MHH7EAM[B<1>=M&6"\$DXZ #KBKR:SIX@#S7MM$P,:.K2J-CN!M4^YR,#OD4
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MJ,UK$L=X[)M"J-OEX"XZ'=R<DU;\1:AJ:^(K328!$+"ZTZ[EF/F%9,IY8RI
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M[-B@M-(M=4,,\;%G\P2%H]^\ ?ZL_-CCT[U=M?$^L:MJ#R:=]E2QBOEMI5N
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MF+80CD?(,Y/?G(P!;U?Q'J@_MM[;43!=:7:V<UI:A%VW>X;CP1E@Y/EC;C!
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M4].CM7(!\R*2-W96 Z$'?R">WO6EH^AW4.NW6N:D]N;V>UBM=EN#M"H6);)
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MHH IZ5"+?3(859F\O*DL<G()SS]:N57L2#:@C&"[D8&/XC5B@ HHHH ****
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MN6G5XKE;L,HC"*N#&R$Y^5N P'S'U- '2:OKES::C%ING6"7M\]M)=>6\XB
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M<+[U4?)M^]DDXR<_A2S>"+*XN+F>2^OMT^HQ:DP#1X66, )CY.GRKQ_LCWR
M7->U^31KG3;:'3YKV:_E>&-8G5<,L;/R6(XPI_*LB/QW+<O(]IH=W/:!9PLX
M5PN^+=PS%=@5BI 8,>V0*W]2T.#5+_3+R6>XCDTZ8S1")E 9BI4[L@DC:6'&
M/O'VQFKX'TN*6\-O/?00W7F,;:.X/DQNX(9U0Y )R?;)SC- &4?'U]]EFN!H
M'RIIB:JJF[&3 =V[.%X?Y> ,@YY*U<O?&XM1?7,=@9=/T\PB\E,NV1/,56^5
M-OS!5=">1U.,XJPW@?3FB>(W5Z4?31I97S%QY [?=ZX)&?>GOX*TQWE)DNO+
MG$ N8O,&RX,0 4N,=<!0<8R  >* *P\7W!O;K3SIB+J$.H1VB0&X/[R-UW^:
M#LZ! YQ_L$9K.TOQ%-90V5IIVD-(]]J=_;L+B_8B.2)I"3N*D[24/ ''O77#
M1=/&MG6/LZ_;S!]G\W_8SG&/J3S6=;^#=(MKFVGC6Y\RVN9[J(FY?B2;/F-C
M/.<MQ[GUH QYO'\W]E6]W%IJ)))I\]Z8[B?:I:)@IB5@#N;)/;ICCGC3\1:Q
MJ=EX+_M2VCCM[TK"6CERWEEV4,.@Y&['(_"L75/ \T%YI_\ 8]L)+.T@DCB5
MM6N+:2)W;<S;U#%@<#Y3T_EU T-+WPS%H^KRO=YB1)Y-[*SLN#NW Y'(SG.:
M .1AU6^T'Q+KLXLX98)-1L8;L^<P*O*D48\L$'(#.#R5XK;TKQ/J>JZK'Y.D
M!M(DGN(/M:RC,9B)4,P[ABI&!R.*NR^#]'G%R)8KE_M,T,\I-W+EGAQY9SNS
MQM7ZX!.:GM?#6D66J/J-O9B.Y=VD8AVV[V^\P3.T,<G) SR?4T <_J.EVFI?
M$Y8+I)&B?1VD95F= 6650#A2.0">?>L2UOI7U :==(-2M=,\2I:V=U<3L9(R
M8MV,CEV3<R_,>AYR17=W?AS3;W4SJ,RW'VHP^1YD=U+'B/.2N%8#!//X"E_X
M1K2!9V=HEDD4%G,+B!(F,8609^;Y2,GD]<YSS0!RT/C37)-HDTZR3[3J$^G6
MQCE:0^9$TNYF#; 01$<#<"3Z9XGB\5Z_<R?V<FE6MOK$%D;R:VFF#+(/,9%5
M65L+NV,223MRHP<\;DGA'0Y=+ETV2Q#VDD[7)1I')65CN+JV<J<DG((ZGUJ&
M[\$>';V"UAFTY<6RLD;)(R-M8Y8,RD%@3R<DY).>M &&?%NI6>HZV)WMI$34
MK2QM$VD+'YR1D,S9Y \P]N2.",\/N/&.LP7ATQ;&Q>^CU%+&21I&6-A)$9$=
M1R1QU4GMP3G-='+X7T6<W1ETZ%A=1+%,I'RLJXVC'08P,$<\#T%#>&=(<0!K
M3<8;D7:L9'+&8# =CG+'''.>.* *WB'5]1T+2++4&2V:..>)=1/S$1Q,=K.A
MR/ND@\]LU@V?BR]UQ;W3FALFEC^T-(DD3%)K3R\Q2 ;LX?>O7L&X%=Q=VL%]
M:36EU$DUO,A22-QE64C!!%0-I-@QG/V9 T\"V\C*,%HQNPN1S@;F_.@#SB'4
M)-2T6VMC%;P:7/X1>Z^P1)^[1SMZ9]!P/3GUK=\$ZM?B2QT6[%LT']BVMY;M
M"A5D4@H4;).[H#D8^E;G_"(:%LMD_L] MK;O:PX9ALB<89.O3'Y=L5<M-$TZ
MQN(Y[:U2.:*W6U1QU$2]$SZ"@#C+OQ!?:7JNNFTM]-25-8L;620PL#*DRQ+N
M<AOO+O SZ+TYI8/$VN)J5N)[FSDA&NOI3QQPE2Z%"ZOG<<,#@8] ?6NMD\.:
M+-///+I=K)+/*DTK/$&+N@PC'/<=CVIP\/Z.KEQIEIN-S]K)\E<^?_STZ??_
M -KK0!Q-GKGB2Y3P_-+J=NB:G=W-A*$M01&R>:4=>?O$18YR.>G%0-XOUBYB
ML+5=4T^RG:VNG-U<L(8Y9(IC$.J," %W%1@\\$5WT7A_1H$B2'2K&-(9#+$J
M6Z (YZLN!P3ZBGKHNE+;1VPTRS\B-_,2/R%VJW]X#& ?>@#S[5M;?59(!=ZA
M#%/8^(K.$VBA<% R?/S\V&+%@<XP /7+;OQ=>[5M4UU(W?4[ZV639&N4C!VK
MN*D;AD$ *2QP,CDGTPVT!E,I@C,AQ\Q09XZ<TY(HXP0D:J"<D*,<T >/CQ%?
MR)-JMK>32ZG>>&K*=1$I?Y_,D$Y2/IE1SCL?K7:^"KMKV#4)8-:EU2U9E:%G
MMWC6(E>4#.Q9N@)STS^ ZW:/0>G2EH \BTZ:\U?0-5&I:KJPNVTN:.]LVMYD
M2&?)Z.6(SNR $P"HY%7;"T+:CX>DLTU%[I= G :5YB$GW0LBN6^4?,K_ "GC
MY1QP*]0P*,#TH \FAM=;?3'EBM_$\LWE6RZE:W+A1)MD7S1$>"S%-XRIP0 ,
M\C&C'HZW&L>'+Y/#M['9VVI3,OVP>;)&K1':^ULF-1)T'\. >,XKTBB@#S?X
MCZ3J.J7<HM-*NKDIIX-M/ %8K,)=Q4;CA#A5.X#<> ",<[_A33YK'5_$DDNG
M/;"[OEN89"J@.AAC&.#U#*^?<]ZZFB@#R=_#NM7.I74DGA^93,FIPRD20^4?
M-.8V!+%V!V@G/"DX  %:$/AG3M+MKB/6K*RTW0[G1+>UNY))8XT^T*S9R<XW
M9DX;U'7I7I%1SP0W,1BGB26-NJ2*&!_ T <_X*M;I=!COM0E6>^O%5Y)U4KY
MB!0L9P>02@#$?WF;ITK&M= UJ*32HGLK=8K'7KN]+B;.Z&7SRI QU_?XQ_LU
MWM% '!:1X8U:R_X1EY;:U4:?)>M<)')T$N[9MXY/(S]>]9%MX!UBWM[*"73]
M)OHGTY+*XCN)I-D+))(RL !^\7#_ '3@Y P1S7JE% &'XHTN^U32(+?3S;B:
M*\MKC]\Q52(I5DQD GG8!62WA*^>:YMFN+<V,NKQ:HKE3YJE65S'CI]Y  V>
MA(QQ7944 8?A32KS1M%>RO3 9/M5Q,K0L2"LDK2#.0.1OQ^%<D_@#79I;V6?
M4=.>:XL[ZS:8Q.7D6<@JS$G V[0 H& ,XZ\>DT4 <7=Z2^F?VC>:E ]_:7FF
MVVG2VME TDC%/,!./0^:WT 'X;WAW3KG2_#EG:74S2WB1#SI9#N)D/)SC&<'
MCZ"M:B@#C+;P3?V^BV%LNO%=1L+J:X@O8[4 $2LQ9'C+'</G(ZCHOI3;[P'<
MW\\LLGB"XS*EOO8P1LWF0R>8I!Q\JY_A _'M7:T4 <?=> UU"[N;N]U%WNGB
M\N*>*%8Y$Q(LB,Q'WV1D7:<# SUS4]QX,6\DDN;G4)7OI;FVGDG6-0,6[;XT
M5><+NY/<DGGICJ:* ,+3/#;:;>3W"ZG=L)KV6\>(!%1BZA=I^7) P".0<CO6
M[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%H2;<;FW$,RD
MXQT8BIZK6$OG6:O@#+/T_P!XU9H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"KIYW6@.]'&]\%#D8WGC\.E6JP/!5O?6OA*R@U
M,1"]0R"40G*9\QON^WI6_0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %+2_(^Q$V\ADC,TIW$YY,C;A] <C\*NU6L!&+0>4(PF
M]S^[.5SN.?UJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &-X5<R>'H6**@,LQ"+T4>:^!^6*V:J:<8#;LMN8S&LK\QD8R6)/
M3W)JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MR7C*[\2:797FK:;>6,5I90"5;:6!G>Y89W(6R-N> , DDUUM<WX@L/$5[>Q-
MIK:2;6(*ZQWJ2-^]!R&^7TXQ[\^E '2#I13(1(L$:S.KRA0'91@$XY(':GT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *EE+YCW0W*=DQ7 &,?*
M.#5NJUI,9O.W*599"I4]N!C].?QJS0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !111F@ HHJI)JFGPC,M_:H/5IE']: +=%9S>(-%
M0#=J]@,G S<IS^M5W\7>&X\[_$&E+C@YO(QC]: -FBL ^./"2DAO%&B*1P0=
M0B'_ +-1_P )UX0_Z&K0_P#P81?_ !5 &_17-S?$+P;  7\4:0<_\\[Q'_\
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M^=*_WE^M #Z*@E^X?J/YUS_B'_C[C_W?ZF@#IZ*\ZF_UL?XUY-XO_P"/T?\
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MTO8=OAZ\+=@9U /XXKYTHH ^@W_:5M@A\OPQ*7[!KT ?GL-5&_:5N"#M\+Q
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M \(_X9KML?\ (S3$_P#7H/\ XNFR?LVVX7Y/$LQ8GC_0Q@?7YZ]YI$^Z* /
M%_9KD!^;Q,&'M:8[_P"^>W^33U_9O4L<Z^^WGD0#KV[U[[10!X4O[-UD3SXA
MN".^(%X_6E/[-MCGCQ%<@>]NO_Q5>XQ]#]:?0!X-)^S7 1^[\3R*?]JR#?\
MLXIA_9J1<D^*F(SG T_G'I_K.M>^44 >$0_LVV@*F;Q+.ZD\[+0*<8]V/?\
MSWJVG[-^B@G?KVH,,<8C0<U[5)T'U'\Z=0!XU_PSCX<_Z#&J?G'_ /$T5[+1
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /0 LP# 2(  A$! Q$!_\0
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M?VPQB(SX^;8#D+GTR: +-)M7=NP-V,9II^4 %QN.=N>YIH_?1,C'YL8...:
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MI3&ABDD21HU9D.58]C[4]6##@^U1KY_GN&""' V$'GWS0 -(Z2!2K,""=P'
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MKS:O;2O<:5>:;-#(8VBNE')'.5(.&7GK]:U:** &NS@KM3<"<'G&!ZTH92<
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M0, M"IP/RJ3^SK+_ )](/^_8JS10!5DTVSE1D>!=K#:R@D CTX[>U"Z=9J%
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M+%:F//[T3.P./]G /ZU3N9?$*FZ^RV>GL R"U$D[C*X^<OA>/0 9]3Z5M44
M0KYAAS(OSD<J&Z?0T\,Q13L*D]03G%/HH 8'.T$HP)ZCTIBRLZ@F-TR"3D=*
MFHH CWE(R6#-@9Z<G\*42@QA]K\C.-IS3Z* *H:XGDMY8W\J$%O-BDC^9NPY
MSQSSWS3M[(S#]ZW/7;_*K%% %>Q\_P"Q1?:2AGV_.4Z9]JL5!9LC6J>7G:,J
M,KMZ$CI4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M< !6<K\OJ<$9S4=I97WV:PN+*TNEU Z+?VMC++:N/)D$JF($D?)\O0M@8Z4
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ME\RVBD:)H2Z!C&^,ID=#@XR*XKQ='+/J6N1?9IWC;PW,JLD;'+EC\H('WNF
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MZXH ]5BNK!]3N;")H_MB1K+-&HPVULA2?KM/Y58MK:&SMH[>WC6.&-0J(HP
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MDUK;F!44X5A_"2/50T@'_70UG_#ZZO;OPNTE_//-<+?741:<@N DSJ <<<
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MDN%5U(:4["0<+RHW DYSQ6CJOA/6M1N/$,JK8+_:+6+0@W+C @8,P;]WQG!
MQGWQ77'6=-74I=.:]@%Y%%Y[PEP&6/IN(].1S4,GB318I($?5+56G5'CS*/F
M5_N'\<''KB@#F-/\(:AIVL7DIM-)NH);V>^@NI6?SXWD#'9MV[>"Q&_.=O\
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M3I-'@$.K8'!SW Z5IY ZF@#S:PTC5M/DT>Y&C7+I::OJ$CPH\9?RIS(8V&6
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MNQ-R]J)X5B(:18-QCE0*&1_E9]RDJ0<8&1@ [ Z1IK! VGVI"*R)F%?E5OO
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MV9T]+9]5U:66"1);6YEN \ELR9"[,KCHQ!R#N!YSQ4\_A".8V,HU;41=6OG
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MT^^-E'L58YV0F16&W<1D#Y2?XOI@ ]-T/1(-"TT6<4C2@,[&1U4,=S%L' '
MW'%6+.6PO;=GM##+"':)B@!&Y&*LOX$$?A6;XEUA[#0@]C+#]MO62VLBY^5I
M9#A3[@9+?0&N4T"9O"6IZUX;+6MJ\MJ=2L$><R -LVR;F('\2!^F?F8_0 ]$
M\B$NK^4FY!A6QRH]O2LN;P]#-K5MJ!N[I8K=<)8H^VW+Y)$A4#EN3U..AQD
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M.,9@D@#;7'."#O;(/8XS33\1M.M],BN+VUGM[IWN(WM&DCWHT+8<;BP4GE<
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MIUW8W-Y'.1#:EA<&2-D:(J Q#*P!'!!Z=#38?$6C7#(L6I6SE[;[6H#]8?\
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M&*XTF\BFC62)X7#(W0C!KS'P4(M.\$V&O1^'I([RSTAK@W;2JBW?&64E"Q/
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M?:787D%^=T<EP6@C>3S72+:JA7DP"YX."<D# R<5S"?#W5HTM474H@EI,]I
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MADD=8D+E8T+,V!G  Y)]JQIO%NGV[2+-%>(\=@+]T-LVY8B<=,9W>H[8.<4
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M@TS^SY+VYM(S(DA>VV!B48,!\RL,;@#T[?6K=_?66D:>UU>RI!:Q;0SD<#)
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M;0,S1R*=O#99B<Y!W'CIB:'PF8M3TR_?6+^XGL?.^:X*L9?,P&W8  P%4 *
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MP6&JH97PRR&&950E1]Y]G)QR<5':^,]2&DZJ8_$"S/#I]C>Q2R"(N2[E9,@
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MZE++%_<1BV47V4BM:QLH-.L8+*V#+! @CC5G+$*. ,DDGCUH L4444 %%%%
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M"HR@*.>5?/MCGK7+ZUXDU>ZBU(8-H=,\06=I&+28EID9HLJPP,@B0\>^.V2
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MG7'^F0V\@^47CH8W)_V2H!^KM6S%K*OJ5X&GL/[/M[>.;SEN07&[))=<85,
M$-GGFK2:OIDL9DCU"U>,2^06692!)G&S.?O9[=: /*9/"?B9M&U.'^PC]HN-
M"2Q4+<Q;?.$F6")N"HF#E0. %YY/.]K.DZU<W^OW,.B2RQ7,FGO"&>(NPB;+
ME 7QO7.0&PI([C@]P=8TP6B79U&T^S.VQ9O.78S>@;.">#^56C+&L?F%U"8S
MN)XQZYH \NL_#E_'<6<VJ^')[NVAU&_F:&1HIF*S<HV-V#SG/3!/''-'_"+Z
MY;Z3#IEO9RK,/#]W:JZR_NXY))%9(M^<\*I7/0<<UW^L:];Z3%:8C>XGO9A!
M;11D?O'()Y)X P"2?YU<L;J2ZL(+B>UEM))%#-!*06C/H<$C\C0!RG@73EM[
MF^O5T74M,::*&.1;V92'= 1\JKQ@# W<9]!BJ,EC(WCF_34]"N[R62\@N=,U
M"-/DAC5%4JS@C:%8.2I/S;SP<UVFHZK;:;#*TA+RI;R7 MXR/,=$QN*@D>H'
M7N*DTV^CU+3;6^C1T2YA295<?,H8 @'WYH \V\/:++<3Z#%-IEW;:C$EQ%KD
MTD+*EP"I#9<C$A:0JRD$X&ZD;2/$=MX4GB^SWC3:4T=A%]G(\ZZMEF#22)G@
MEXM@P><JWK7J@Q39'$<;.02%!)"C)/T ZT >6SV$>H7.D&UC\2BPNM89ITF6
M2!8T,+*P"H%9$+E1EL<[CG!R6Q27T7CFR:%-5AABUB:WE5X9Y T/E,J%I/N%
M"0A48..I;-=[I?B6RU@6+6<-TT5[;?:HI3 P39D#!;H#STK6EBCFB>*10R.I
M5AZ@]: /%K36;O4M"N)M/U6\.IQZ8\*P(TJ37+F3<\RJV%W!-V",\DXX45W/
M@7R99K^ZLM4U&\M)EB(CNX'C6)P#NV;NY&-P' /UK8TKPMI^CR1-;O>.L"[(
M(I[IY4A7&,*K$@<<9Z@$CI6TK*V=I!P<''K0!YU%JS2^++VQO[W4[?58=5!L
M[>%7\N:VV+@'C84/S,QZC'7I5;PW>7^IOH2+J5\]Y=6]PNN0M,^;=MOW@I_U
M+"3 4#'!. <9'I^!1@>E 'EO]H^(K;PGJ+O+?)<:(OV*:X96D-QF93).!G+%
M80&!XY=P#QFJZZC.\5A%:^-9KRWOM92W6:W0QA(VC<NB/(SE\$#G)VDXZ]/6
MJ8T,3E2T:,5.02H.#0!YAJ.K7]K)JUE#K]PGV37]/M8YF*,XBD6'>IR,'EW/
M3MS2GQ#<V1%G=:U*ME%KMQ:/<-*@FV+$74;F&"-YP?; Z5Z5)96DN?-M8'RV
MX[HP<GGGZ\G\ZX_7E\-ZE>+MUJ'3[JR9RZI%&PE+':<HZD.=RD KD@Y'<B@#
M4\#W&I7GA*SNM7O8[N]F#/(\9C*KR<+F/Y20,9QGG-<KI=YHG_"#^*_[5E@>
MR;5M04HQ'S$R,5"CJ6.01CG)&*Z[PB-$_L=UT2^@OH6D+331%,-(R@G(0!5.
M-O  _/-7K70-'L9Q/::58P3 8$D5NBL/Q H \[L]7UW2-(NDO;H)J%GX1BO"
M'B4NDJ^9RQ(RQ^7D$D9R<<U9N-;\1)J,FG1Z]81306$.H>?>;(8W#NVX$!&R
MBA0."I^;))[=[=Z)I=_+)+=Z?;3221>3(SQ EX\YVGU7VI+C0M(NQ:BYTRSF
M^R8^S^; K>5CIMR/EQ@=/2@#E-/UC5=:O)RFNV=GY5]-9/;"-22 GR,F[DN6
M^?GC;V[U2\+:YK%QI/AS2QJ,/VN_T^XO6O)XS(25= $ R,G]YDGT7IS786MO
MX=N];N+^TCTV;58AY4T\01ID'(VL1R.XY]/:E7POH20)"FDVB1I(TBA(@-K,
M,,1CID<'U''2@#E="\6:YX@UK2K>*73[2WGTN+49D:!I';]X4=5.\  XR#CO
MWKOF+/"3$RABORL1N'L<9&?SJA)H.F-</<K86RW+6WV7S?+&?*_N?[OMTI^B
MZ3;:%I%OIMH#Y$ (7/N2>@X R>G;I0!P47Q(OK1H$U5+17B-S;ZAY4;!8;A"
M_DJ"7/$BH<#GMS\PI-7U;5-.C\6W,*6%KK%K864DEW# 6+LV\$$,Q!Q@[>O7
MG-=[+HFESM-YME"[37"7,A*YW2IMV,?<;5_*J]YX7TB_FU&6YMG=]1A6&Z_?
MR .J_=X#8!'.",'GK0!QWVF[\.>,_%5]:6EO,DKZ;]H&\H?GS&=HP>>2W)']
M:UE\:7)>SN_L4?\ 9EWJ;Z9&0Y\U7#,@=AC&"Z,,=<8//2M6;P=HTXNO,BN2
M;H0B9OM<N7\G_5\[N"#SQU[YIT/A'2(+\W:0RY^U->+"TS&)9V&#($SC/7V!
M.1@T 8!\>7KV.F;-,B2ZO[.^G&Z8E(WM\#'W02#GVQ72>%;R\U#PGI-[J&S[
M7<6D<LI3H2R@YZ#&<YQCBLV+X?:!%<Q3K'=YB$ZQH;N38BS??4+G !R>/\!C
M:T;2H=$TFWTZ":>6&!=B-/)O;;V&?0#@>P% %^BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"M?7UMIUE/>7<FR""-I9&VEB%49)P.
M3@>E26\L-U;QW,)#1S('5L8W*1D?SK@/%L,$?B^\>YGD5;CP[=)&C3NJ,RXW
M +G:3M.3@?PYK!_X234=&TJ%;75)9UET.QNYBX$GV9#(L<LB*HS@(2<<],T
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MRW5V!?QQQW\:LH6["< O\O!(^4[=N1Q1IVNS:K\/8]<NK::WDGT_[2R6SJ7
M*;LH2<9],_C66/'MMIMA#"--U>],&E0ZB\Q,18VY',C$N,L,'( R3T!H Z+1
M=#&C7.IRI=23+J%T;ID=5 C8@+@$#IA5'/I63J/@K[;J-[=QZK-"MU>VU\T)
MC5E$L&S:?7!\M.,^OKQK:OXAL]&TN&_F#O'.Z1Q!2J[F?[N2Q"K]21^=4F\8
M6T8F$NGZA%-%927S0O&H?RT;:P'S8)R,CG!!!!- &?)X%N1>SZA:Z[-:WSWD
MMU'-' I""145XRK$AE(C0^H(S6OJWAS^UO#::7+?SBYB,<L5\0ID69&#+)C
M'WATX&..*:GB_2Y'MU0S,LQ@4NL1*QM,,QJQ'0D$?3(SC(K)\'>+EOHX=+U*
MXGEU-I[N-9FMBB2B*9EP& "E@@7@4 7X_#VL&ZTFYO-<BNI;*:264FR""7<A
M3:H5OE !/7<<^W%9I\$7TVDW]M/J, N7U;^U;.:.$XAD#APK*3\PR,=>AK?U
M7Q/I6C7'DWDSJRJKR%(F=8E9MJLY PH)!'/H?0TU?%>D/>RVJSN7C$N6$+E6
M,7$BJP&"R]P.: ,B3PEJ,FI)J3W=J;J748;VX4*0@6.+RPB=R<$G<?R%/M/"
M]]!XR;6%DM;>-I)&F-L74W2$$(LD9^7<O!WCDXQ5RS\=>&[Z-Y(M258TMOM9
MDEC>-3%TWJ6 # ' .,X)P>:N1>)=)EMGG%WM6.<V[(\;+()<9V;"-V<<XQR.
M>E &!J_@Z_O;C7+>&[B_L_6WA><R9\RW*!5;9@8.Y47&2-IYYZ5J^&='O]*N
MM<>\:W*7NH/=0"%B2JE57#9 YP@/&>I';)9)XKLDN_/34K"73!IS7N(F+SE0
MP&\*.J8./7-6K+Q5HM]"DB7T2,UH+UHI& 9(?[[#L!Z]* .;?PAJCM<Z8S0M
M82ZRNJK>%SYBKY@E,>W'7<-H.<;3ZC!-,\-:S;SZ&US;6@6RU>]O9?+DS\DP
ME*XXY(,V#_N_2NZAFCN(4FA=7BD4,CJ<A@>013Z /.;#PKJ]O:Z5'/IMM*+>
MRU&":+S\*QF=61<XS@@$$]L]*C3POK26;1>5>[89HFL95GA-W;%8W4Y<_+*@
MWE0'YPS9[5Z510!YI?>%_$-U;7J)96D<S:9IT0\LJD,TMO*TCQ@#E4(8*,C&
M!Z4:SX:O=0U#4[\:')Y5[=Z9NM6:)BWDR!Y96^;:/D.S@Y.T]C7I=% 'E=[H
M6IHUX]MIEY ZZE=SVY2&.6%D>-%V/'NY63#<C!'MFNAURRU"70_#>_3 \%M<
MP/J.GP?O,($(P!_&J.5;'?;79T4 >7'1[B+^QHYM*G>U'B.6[@B-L7^RVI5\
M X!V#>RD+V!''RG&]XKMC-XETM]2TZ6^T(VL\<D<4#3>7.=I5V103]T.H('!
M;MFNSP** /(--TW4=)MM*DUNUNKC41H-]"+HV[2R [PT:LP!*MY?')ZY'7K7
M$%Y8::R:3%J*N^CZ;)=((I':4K*?/'S=7$?!4$'''I7L]&* /)H[..;4=$LD
MU#6!8WNHW+LT:RV:JI@/RJH(*KYF,$_Q9 X-=/XLNUL]<T2WOGO8]&DCF$DE
MNTG,X">4KLGS8QYA'JP'I798HQF@#R+PM>/':>'[9[R\@0>%9S-!O= '5XP&
MQQA@/,PPYP.N*A%W=6OAWPVUWXEU"TM-4L"]QJ%W)+(([LI$JH65T*#_ %A&
M3@D'.3S7L>!Z4UD5EVLH(]"* /,K/57EUF2PUC7]1@O(FL9+!MC0F]C*(7Q#
M_$6?S PP=O'3;5/0-0CLY=/T\:G+;6USK>I1W;FX9F$BN_E1LSDE2P^;L6P.
MN>?62BE@Q4;AT..137@ADC:-XD9'^\K*"#]10!YGI&I:UJNLZ+83:[=PPR0W
MS^9&D8:ZCAG587.5.-Z$G(ZCIZUH^!M9O[[56M[^_DNY&LA<1RPRI);3H6P)
M%P T;=04;WQTKO?+3>'V+O P&QR!3(;6WMRQ@@BBW'+;$"Y^N* /-QXGU1[V
M&XBOW:Z;Q&=-ETUD&$M]Q7.,!@0@$F[..?2MWP'-J5_I5QJ=_K,]\'N)X8XV
MBB546.:1 1L4$D@#K76"W@$[3B&,3,-ID"C<1Z9ZTVUM+:RA\FUMXH(LD[(D
M"KD]>!0!YQX=\1ZOJ,?AF^?4Y9?[;>YBNK4QQ@6K*CG*87(V%-OS$YW#-4=/
MLVF\,^!)CJ4X)U8X)6,YRLQZE?8\_P"T?8CU!-+T^.::9+&V66?/FNL2@R9Z
M[CCG/O4 \/Z,(HHAI-B(X7\R)!;IB-O[RC'!X'(]* .,M?$4MK=MIBW5G:0S
M:[/9"XBA5!&B0[PH'W=Y;"Y.<\\=*9<>*/$(F;3;74]#EO+2R%U)=/)Y4,I\
MV1""#D[5$>&P00QZ]J[5_#NB26L]J^CV#6\\GFS1-;(4D?KN88P3[FBY\.Z+
M>1VL=SI-E*EH0;</;J?)QC&SCY>@Z4 <?_;_ (KNKGQ*UG-82)I=R+>&U6'#
MR[D1N'+8W#<0,CDUN^&]6GUCPG+=_;BTZF5-\EMY<D)4GY9$/&]>^.">G%:#
M>&M'<7H-C'B^=9+G!(\QU.58X/4$#GV'I5F'2;&WTY]/@@$=LX;<J,06W$EB
M3G.22><YH \X\%7=[_9>AZ=I[:?'JD^@+=M>3VQ=F3< D9PP)PS.2<]^G-:V
MA^+M?U_5],MXK?3[6*:R^UW*2AW8;9O*<(00.<$J2/3.:Z(>$-$6VM+>.TDC
M2S5DMVBN)$>)6ZJKA@P4X'RYQP..!5BU\.Z59:C%?VUJ(KB*V%K&4=@JQ Y"
M!<[0,\]* ,;Q!XEO](\1V-EL@M]/N#&OVN>)G1W9\-&64CRFVX*E@0Q.,C%5
M[#QAJ%Q<:'=36]N=,UJXEMX50,)8&4.REB3ALB,YP%VGCGK707GAS2K_ %#[
M;<V[O,0@8><X1PC;DW(#M;!.1D'%1V?A;2;&[6X@@8%)I)XHVD9HXI'SO9%)
MPI.3T]3C&30!SFNZC;^'_'6HZW-%E+7PZTK[>"^V7(7/J>@^M.OO&^JZ,M[!
M?Z3;2WL%M#=QK!<$))&\@C(W%3AE8^F"".:Z*[\-:=?ZG<WUVLDS7-D;&6)W
M_=F(G)&WUSGGWJJ_@O2I;">TD:ZD$T<,)D>8EQ'$VY$#>@/XG/)- %$>,;R!
M[NUOM+CCO8;^"R18[@O$QE564E]@(P#@_+UQZUIZ1X@GU+PW/J\FG/&T9F"V
M\<@=I/+9E."0!R5./;![UB>,O"D]U;3W&EVTMW+=7D4][;_:1&TBHA5?++ J
M"#M.&X.WL<5=T?0;Z[\(W^D:\\RQW>^)(Q.C/#"4"A=Z(HSD,>!QD#G% %%/
MB(J:9=W-U911R6T\,+O'<E[=1*,AS+LX4="=I /<]:Z[3+QM0TVWNWB\IID#
M[ X?&?\ :'!^M<[:^"'LWNI8O$&IR2W/E^:;CRI%DV+M 9=@X(X(&!^/-;VB
MZ1;:%H]OIEIN\B!2%W8SR23T  Y/0  4 7Z*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** &LBL<LH)''(I!%&%VB- N,8QQBGT4 -2.
M.- B(JH. JC _*JEOH^F6D_GVVG6D,V,>9' JM^8&:NT4 4[K2=.OFD:[L+6
M<R((W\V%6W(#D*<CD9YQZT3Z1IMS+;2W%A:RR6IS TD*L8C_ +)(^7\*N44
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M";)'0I@Y'S(O;'KZ$ ]PR**\9\0W,UK\4[LV\%YJ%I)HD<YCANV2-6:4+YY
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M"!DCDX/7C%95_P"+M6TG4/%^@R7;RS:9I3:G8WIC7S,!,E'&W:<-C''(]^:
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M>9&S'YU4LHRW'S<[<$BM_4;VYMO 6@&6/58#-<1QS++*\CJN'/[UU&\ID#D
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MX]>*575UW*P9?4'(H =12 AAD$$>U+0 4444 %%&110 4444 %%%% !1110
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MOM;D9/;!- &WX<\('PWJ6LWD.I2W+:K,;B431K\LO/(VXXYZ>W6L6S^%ML-
MUK1=5U#[;9ZI=M>DI!Y3PS-C+*=S>@QQ^>:N7'Q*TVRM4EO+&\MY&A^T""1H
MED:(@8=5+_-G)PHRWRD8R,5=_P"$ZTWS;W;;WC6UDK-<7*QJ5CVQ^9\R[MXR
MO0E<$\ T 6[#3-?@6);W7XKD0J0I2R\LRG& 9?G.['7Y=F2*YW0/A_JOA_2?
ML%MK]L2T\DAN5T\K,J2,K2(K>;A<E1S@XQ[5KR^.M-MM-BO;F&>!9Y_(@61X
M5\[Y/,W*_F;"NWONZ@CKQ2Z?X^T/55M6LGN)A<)%)\D)/EB1S&N['3YE()Y
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MFT'J!2/%'(5+HK%3E21G!]10!Y]X:\0ZAJ&H>&I$U.2\&HVDSZC;R1J/L\B
M<@ 93#DI@GD8[@FJ?BS4;K3/$WB34K+4_LLECI=C(4 0K)^^F^5]P)VX)Z8/
M(YKTJ.V@BD>2.&-'?EV50"WU/?K44NF:?/)))-8VTCR@"1GB4E\=,\<]!^5
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M5KJLRM&S/.S;#M&-WE[<9P%48^\176)XCNO.>STO2&NTLS;Q7 ^TA73S%#9
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M*N2,J58X.1RK88=Q3=4\6Z?I.HK9W"7!P\22S+&#'$TK%4!)()R0?N@X[XH
MPA\/9;>,W-AJ<5IJ*7(N(?)M=MJIV;'4P[CPX)W8(YP1C',]_P"#]4O]1T^Z
MFU&U,ML487B6YBGB(?<ZIM."C#"[6S@<_,:W=/\ $FGZGJ4EC:F9G42%9#$1
M')Y;A'VMT)#'!%+JWB33-%F2*]FD5VC,I$<+R;(P0"[;0=JY(&30!/K5C)J6
MCW%G%]GW2J%Q<Q>9&PSR&7N",C\:X(Z9>^'=2\.V:2Q23G49I;>V>21XK:(P
M,@C$A!8+NZ$C@M@#@5U:^./#K:F=.&H8NEN?LC*T,@"S8&%+%< G/&3AN@S5
ME/%&BRW,L'VY%:*-Y2TBLB%$.&978!6"GJ5) [T <E#\.[NQNXKBV.C71FC*
MW2ZA9F41N99)2\7.>LK#:3V'-:6F>'=<TVXN+7.EW&G)/<W%K-*&^T*9BS;#
MQA<,YRP))'&*TYO$EI<FR?3]4L%1[P6\R7&0[$J3Y:C((<_*1D=,G%8__"8W
M.H:JZ:=?:1!:0:FMC*EZ'624%5_U9R!O+%E"X[9SVH DT7PUK&F_\(D)DT]A
MI%A+9W+1RMDY5 I3*#.?+!.<=>^*QK;P;K]E9:<[V>EWTD/VV&>RFN'6,I<3
M&3<KA"<@'!!'(]Z[]=9TQ]0>P6_MS=H"6A$@W #&>/;(S]:R-.\5P:GXRGTB
MSN;*YM$L%NED@DW-N+E2#@XQC!_&@#FM2\+:_;VM]8:?INFS6MU=V5VC13>3
MY/D^2&C"D'Y<0_+SP&/X]GXGTVZUGPKJ>FV<X@N;JV>*.0G 5B,<GT[5-=W\
M]OJ]E;*MK]FE21YGDGVR)M QM3'S#U.>*LV]]:7;,MM=0S,JJQ$<@8@,,@\=
MB.E 'FVL^&=8UFWOKH:"+9YK*SMFL?.B(E:.8.S<-MPJ@JI)!(/05U?AG3KC
M3M:\1EM/-I975XDUJ%*;&40HC$*I^7+(3R!U%6?$/B$Z1+8V=K%!<:A?2,D$
M$T_E*=J,Y);#8X7 XZD56A\37ZS:'!?Z.MK-JEQ- 46[67R=B.X.5&&R$/'8
MT 8OC#1M1N-6UR>TTJ2Z6_\ #TEC%+$4RLW[S ;)!&=ZC(S[XQ61J6A:C$^H
M?8-#NELR-.DDMX BFX6,/Y@4'*EE+(<-][9CFO2].NYKRS$US9R6<FYAY4C*
M3@,0#D'&" #^-6\C&<C% &!X.L4T_1##%9WMI"9GDCAO&3S &.3\J\(,DX4=
M!Z=*Y*YTRY3Q;J%S'IUY<P3+=-(TMHPDB)BV@QRK_K(WP (^2#@C@5Z;D>M&
M0.M 'BNHQRM]EL+VPOY"/#%O#YGV229["<EAYFU 65C@Y/R_ZL<GM=O(5%QJ
MFIZ?_:<L:7.E26$L2S>6Z?)YCH -K?)OW=>,BO1K_P -Z3J6H?;[B&077EB)
MI8;B2(N@.0K;&&X9)X.>M:L<:11K'&H5$ 55'0 =J /))&N;W7[B V^JK'>#
M4;>:*6VE;>W_ "RW/CRR,*2@ PH."3FFI<S6?AFP"_VFJR^%I+= D,P;[7'M
M_A RK ECDXXSSBO4=.U6TU0W8MC)NM+AK>421LA5P >XY&&!!Z'-6Y72*)Y'
MSM0%C@9./H* /)7N-2F36KVTOM7>]M-.LY8+<2R<[HR)B(R1N8 YQQAL=":Z
M;X?SBY?4Y;?7SJMFQC*(MO,B6[$'<H:61R2>"5S\O' S75Z9J-EK&G0W]A*)
M;:89C?:1D9QT/(Z5<H \T\8ZC<VWB76;=?$MSIQAT6.]M(5= 'F#RKPI&6'R
MJ"HZ[OI5:#Q;>CQ59)<:J(7?48[6ZM;AQ'Y8>WW>6(_3?R)"02?E&17=3Z;9
M:?K5WXDNKZ5<VBQ2I(4\I(T)8'[N<@LQZ_Q?3&A"UIJ5C%<PE9(+B-9(Y%&"
MRD9!'<<&@#R^S\7:O+I-[J%KK$-Y<6^F3RW%LDL3D7 D 5TC&7"*NXX('\.<
MG-=9X)O[J^DOC)K5EJ5ILAD@^SS^<\>Y3NW-M7@X! /(Y[8J?1/!D.D3VTDE
M_/>+9AEM$FBB!B4C;RRJ&;Y>.3SU.3@UIO>:%H+);/<:?IYF)98RZ1;SW('&
M: .-\8W%_8^)]5O]-O?LLUGX;DN1A%?>4D9E4AL@ XP>,\]12IXJUG4?$$D=
ME?Z7;6]O/:(8[J;:9HY8T8E5V$LQ+D+AQRN"*[:72])U$M<RV-E<F>((TK1*
M_F1]0"<<KWQTI5T32EGAG73+,30)Y<,@@7=&O]U3C('L* //K+Q)XDFM-):;
M4K=CJ]Q<0QLL2PB+R3+@!B&&Y]J]5(^4]SFF2>(_$>E32ZAJ=S%+-9Z$]Q/8
MV[!HFE$K(#N'3HI8\XPP&*[V7PSH4VEMI;Z/8FP9_,-L+=1'N_O;<8!]Z<?#
MNC;[9_[,M ;:$P0_NA\D9&"@]B.,4 9>B:MJ1\2W&C:A-;78%C%>Q7%O&4 #
M,RE2,GNN0?3/I4FMZS?1>(K#0]-DM8+BYMIKDS74;.N$*@(%#*227SUX"GCG
MC5TW1]/TB-H["UC@5@ =HY('09]!V'0=J34M&T_5C U[;B1X&+1."59,C!P0
M0<$<$=".#0!QVB^+=>U_6--M[8:;;Q3:>E[.DL4CL<2F.0(P8#!QE21Z9!SQ
MW^>..M9(\,Z5'?\ VZ&U\JY%I]B4QNRJL/\ <"@@ ?0<5-H>D1:%HEMID#,T
M<"D LS-C))P"Q)P,X&2>,<F@#@=0U*>70M1BL(+>U+>*([*Z4R.XFWS1!CDG
M@,& (Z8R*[E++^PO#<T&EQ(K0Q2211LS.H8Y; R<[<G@9X' JD_@C19(IHRE
MT%EOAJ#XNY.;@<A_O=B <=.!QQ70E0T91OF4C!SSF@#@=#\8:W>Z)IT8M;2[
MU5]&74Y=TAC5U. H&!PS'=GL,>]=CI&JQZWH-GJMHI\N[MUFC5^"-PR :QD\
M!Z1!':+:S7UL;6%[9'CN6+&!N3$2V?DX& ,8P,8KHK6U@LK.&TMHUB@AC6.-
M%Z*H& !^% 'FUGXAUS5)_"^HO&#<3W>H1BUBNF2&14#A=_RC[NWKM8\9ZG U
M1\1C<:?:7%AH5[=SRV8O);>)69D4N4"J54@L2CXW;00O4=*UK/P5I]A<64MO
M=7RBRGGG@C:4,J&4'<O(^[R2/KU-58OAWI=M'9+:7NIVK6L3P>9!<[&EB9BV
MQR!R S$C&",\&@#H;O4!:Z+-J)B;$5NTYC;Y6P%W8/H:Y+0K+5/$7A&PUS^W
M;RWU.^2.ZW1O^YC0D-Y0B^[C;QG&[/.>U=N(8Q (=H,87;M//'3%<_I?A$:-
M"MG8ZQJ$>F(^Z.RRA5!G.P.5WA/;.1V- $<?C2WDFA9;&Y-C/?-81W?R[3,I
M*_=SD*64J#ZCL,$U+'X@Q:BUD+;0M4/V^.9[7<(@9#$<.I_>?+C/4X![>]RV
M\%6MK,!'?7ALEOSJ"6;%2B2DEN#C=MW'=C/7VXIFF^"HM,?1WCU&Y=M+6X6/
M>J_/YQRV[ [$#&,4 5V^(5H]O;2V>DZG=FXL&OU2)(P1&K!7!W./F!/3OVS4
MZ^/](=[-HX[MK:Z%OMN?*"Q@S?ZL<D$DG&=H.,\XK"LO#VHZ1XHT_3-/O)DC
MMM&FMQ>RV3.A+3!@,@A=P SU[=.:LR?#9U>,6NLND,*VGD":V65XC;LK#:Q(
MPK%<L !ECG..* -RS\::;>:A#9I!>H\MQ-:H\D&$,T6XN@.>3A6.1QP><\5-
MI7BO3M96R-HMQNNS,%1TPT?E-M?>,_+AB!^(]:RH/!UU:3V5T=361K/4[G4L
M"U/S^<'#(/G["1\'Z<<',6B::=FO>(K&&]T^?4"6MXKNW8M%A1EO)R#EG!)'
M4X'K0!VK-M4D*6('0=37+Z7XZT^_TJUO)H+BWEO+B>"WM?+,DLAB9@2 N>RY
M)Z#IFMW26O7T:R;4E5;XP(;@+T$F!NZ>^>YKA[/P-K>F2Z5=VE_9M=:7=79B
M1U94FMYW+LKD9(8$Y! QQWZT =SIFIV>L:?%?6,PFMY<[6 (Y!P00>00000>
M017)ZKX["&<V*>2EAJ]O87C7<# ,DFW<4Y&"-_&<].F"#6]X8T1M!T@VTLHE
MN)IY;F=EX7S)'+L%]AG ^E<UJ?A/7I-0U*2S.G/;7.L6FIHLDKQO^Z6/<IPA
M')B 'U)]J .DC\6:-+IZ7L=T[Q/*\*HL$AE+IG<OE[=^1@G&.G/2M.RO;;4;
M*&\LYDFMID#QR(<A@>]>=WG@S7)9S?+9:;<RP:K<745K<3'RYHI0!RP7*.-H
M(Z]2*[O0K$Z;HEI9M;6ELT28,-FNV)"3DA<]N>O?KQ0!H4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 4=5CTNXM?LNK+:O;RGB.YV
M[6(YZ'N,9JG;:-X>NM*GLK:ULY[*<XF5"'#D8QDY))&!CG(K+\>6R72>'XBM
MNSG5XM@G&03L<X_('\,U2OY-3T&QN+C3X]+BOHKE))K*UC.;N \*B]Q(<-@X
MZCTH Z4>&='$4$8L4Q!/]IC.YMPEQC?G.2V.,GMQ4*^&M$CD006J>?;W!O40
M3N-LSYRY&>_(Z=SZFN>MO%.I7JZ-:0:A8K=:M!<74<[Q$HFS;B$+D$L-QW'K
M\C<#MD7.LZGHNM^(-=MH]*D*:5875Z(V9EF4&8,8V&,\9PQST'![ &_X:\ V
MMEH)L]9MTGG;[4C!;F1XPDS,6"J<!25.TD 'KSR:MCX>: LC.J7H=FB<LU_,
MQW1-NC.6<Y*G&,^F.E5;CQ??VWBF*Q^SP36<E\MD3""QC)CW!FDSMW9!S&%)
M P2>0#4TKQIKLRV<]YIMG)%=VUW)'#:2,9-\#8P,\'=TQV(Z^@!HZKX3DDM[
MK3]/BMWLM7N&EU-KN5G89"C,:X(SA<=1C /:NI,"?9OLZ_(FS8-G&!C''I7"
M+\0[G[#)<+8V]T'ALVMWMYL(TMPQ41$MP"N,GD<$<"NDTO5]4N-)OKC4M'DL
M[FV:0+%O5O.4#*L-I/4'&/4&@"/1/"EKHNHRW_VZ\O;MX%MO.NV0N(U.0"55
M2Q]VW'WJMKW@6QU^_N;R74-1MGN;=+>5;:10K!&+H>5)!!)/!P>X-9.@Z1=>
M)O!%MJ[ZU?0:SJ$(N%NHKAPD+-RJ",$+L7.",<XY.>:T)?&_D>=<_8!)I5OJ
M TZ>Y67]XDF0I;R]OW-Y"_>SWQB@![>!+9KY9QJVII"M\NH"V5X_+\\=6.4S
M\QY(SC). *BM/ *Z??65S::Y?B/3S/\ 8[:18VCB64<I]T,5!QC+=  ,5'#X
M\NI[F")=!DQ/?SZ=&3<IDS1;B2?]C"-SG/'0\4]?'Z26UC)#H]Y++=VD]R$1
MDPIA8+(I)8=">N.>* &P^ YK+2](BL-<N+74-,@-K'=I"K"2$D$J\;9!^ZO/
M'(S[58NO!LMYJMC=SZH9!9O')%(UN/M*LOW@)01\K\[E*D') Q5.?QY9WNAW
MTOV35;1/[(_M.*2(1^:]N0<NF6(##KAO45HQ^,;-=:BT2.WO+BX5(2[_ +O(
M$@X<@L&8#^)E4@4 +X;\*/H6H7=_->I/<72*LOD6X@25@2?-= Q!D.<%ACIT
MK-\1^"-2UC69[^VU:W1)#;LD-U:^=Y312*^$.X;58K\P')]:+KQK:ZMX?N[J
MV;5+""%UW7<"0LRXD"D$,3M.>JL V#G%;,_B[2[:\>"0S>5%<I9R7.S,23L
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M3VSQFWC^SX5DDP T1X'EGD,=U:GC6)KG5_#4 &H>4UZ_VDVIE""$Q.#YA3@
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MXQP<*"&&<&H]0\&ZO/%9-9VVEV5]# 8UNK&5X!"6<LR&+85EBZ?*V"3D\9R
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MLXH90K;AN50IY_"@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***#R* #-%<!\/&NIYO&%I/J%[/Y&L2V\4D\I=T0(N,$YQ_
M*K7PLO;O4/!8N+V[GNIOMEPOFSMN8A9& _0=!0!VM%%% !117GXUS4->^*.K
M^&Q>2V.F:3:1RR&#:'FD<*W+$$A0&[8/'7M0!Z!17F'B+QA>Z-IEM::1K]MJ
MMUJ6KQV4%W^[D-I&ZCA@F%+ @XR.AYSBKVJZ]J/A#QMX=TJ2^GU'3]<+P_Z0
M%\R"5=OS*RJ,@[QD$<8XQTH ]!HKS+3/%6N*?$_A[4+SS-?L[E(K"80HH=9<
M")MN,<'ENO%1>(_&.J:!X^M-$O-86WTY]+%R\ZVRNYE5BIXQT;;T]30!ZE17
MGWB77]<\-2^&[2\U>RC^WWDMO<W;P@*$R3&W)PIV[0>V2:32?%OB+6]$UQ].
MCL)KJQO/L]E>&-EMKT9QP"_'/&0Q'IGI0!Z%17G_ (8^(%QXF%E;"&*QU2&]
M-IJEG,A9HR(Y&RAR."8\<YQS[$UM+\<>(-4\.ZY>6]M82:AIVK?V=';['59O
MG5 22WRDE_<#!]> #TFBN(\-^._^$CL[6Z6.*U,)FBU6UF#>9;RHN<#MC@]>
MWN,4[1O%NM>(O#\OB+2M)MWL6#FTM)YRDUR%)&2P!5,D<##9]10!VM%5+FYG
MCTB6ZC@!N%@,BPLV!N"YVD_7BL#X?>*[GQIX876I[*.S665DCB24R?*O!).!
MSG/'TH ZJBL+4O%FFZ7XGTK0+AS]LU(.8\=%VC(W?[Q! ]2#56_\6R6/C*#P
MX=-/F75J\]I</,%29E'*="0?Z<^U '3T5QFB_$&'7=+DN[;395FCU%=/>U>5
M?,5R0&)QQ@9)^BGZ5V= !15+4KZ6QCA,-A<WKRR>6$@V_+P3N8L0 O'7/<5S
MJ^/H7T%M970]6^Q*CMOV1=4DV,,>9D$')YQD*<9H Z^BJM[>-:+"4M)[GS)E
MB(A"G8"?OMDCY1WQD^U6J "BJNHZC:Z3IMQJ%],(;6WC,DKGLHZ_7Z5/%-'/
M"DT3J\;J&5E/!!Z$4 /HHHH **** "BBB@ HHJL-0LFU!M/6[@-ZL?F-;B0>
M8$SC<5ZXSWH LT4572^M)&C5+F%C(2J .#N(Z@>N* +%%-:1$*AG4%CA03C)
M]J=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%<UXPU:XTZ*QM[2]6UGNY70$!-Y"QLWRE_D&" 26[9P,D5RD'C#Q!J&BK
M>07EG"X\/?VHW[C>#*K'(Z\*0,'N.U 'I[.J#+L%'J3BEKRGQ/KMSKVB7[/)
M9Q1:?>:>KVLD>YSO:%S)DG*C,F <=%;UXZ_Q7>:C::EX:6RNEAAN=2$%PICW
M;U,4C =1QE?U![8(!TP(/0@TI&1BO*O"VJZAX>CE00VQTZ3Q%>6<D2@^8&+.
MX=6SC "XVXYZY'2NC\(>)-=UZ6"ZN[""/2[VV^T6TJ,@9.1A"!(Q?AN6PF",
M%>: -;2O"MAHC:DVGR7,+ZC(9IW,I<F0]7!;.#^GM5&#P!I%MX?31(IKY;)+
ML7:A;@JP<-N(W#!P3GCWXQQC-U[7]5F_X2BT;3+"?2M+M7-P&NI$DF!A\P!=
MJ\<9!Y^E3:EXMNM)+VMEIT<GV2TM9%@FF(:X\U_+"QM@D[<#)P22P''4@';#
MTHKSO3M;OM(U[5D-J);6?Q#':R.]P2T1D@B(" C[H8YZCAN!3H?'.IZ?I<UU
MJEM:R ZM<V2S>:T4$*QLZ@R-L;;DI@$\'=R10!Z%7.WWA*"7Q'_PD.G74FGZ
MHT7D32(H=)X^P=3U(P,$8/'<<5-JGB+^S/#]IJ+6A>XNW@AAMEE!!EE(55+C
M(P"W+#(P.,US/B'Q;JLNE7-G:V:VVJ6NI6EI=1K='!29TP8Y H)#!MN<*5Y/
M89 +\/PTT9/#C:1--=3%KPWXNBRK+'<'!WI@8'(Z8(^M6H_!JW/B6RUW6;]K
M^[T^,QV:B(1)'GJY )W.1WX'H!46L7NI>%=.TBWTZ-KY[S48[=C=W)9D5R6*
MAB,G ! )Z#DYJAHOC":RO9K+58[N6*;6KFQ@OGV;$(RR1G!!Z*><8]Z -RY\
M&Z9<^-[3Q4RD7MM;M" .C$]&/N 7'_ O850U?P5<:AXY@\30ZC!&T5BUE]EG
MM#*CH2Q).'7^]^E6/#_CBP\1:C]DM;:Y57@^T0S, 4D3('."=IY!PV#@_4"*
M\\?65AJ-[:W&FZBL5A<)!=W7EJ8H=X!1CABQ4[AT&1GD"@"KJG@K5=5O=%NK
MO68+AM/O6NI4:TVK*K<%%&X[5"Y'.XG/6DT?P=K'AJSO=.TK5;>336NEGLK>
MYB)-JN\,R!@>5/..!C.:U%\:6 U.>RFMKR%D2:2-GB_URQ'#E5!+<9XR!GMF
MJ5K\0(=0U+3;:TTC4C;WRNZ74L7EJ5"JV54G+CYAR!CZ]* +%SX)LG\<V/BN
MV/D7L:O'=*!\MPI0J,_[0)'/H,>E9>@^#M9T>/6U:YLI&U+6%U/(W )F0.Z8
MQ_L@ ^_MS=M?&VGV7ANQOK^^DO'F@><R);>6S1H?FD,>3M R.,Y]JT[7Q=I5
M]J<=E:22W'F%5$\49:(,T?F@%ATRGS>G/7/% &6_@"S7QQ=:_"P2#4+.2WOK
M;H'=L 2#'?&X'/K]:Y^7P1XKL/ @\):->0Q&WFW6FJ1WDENZQERQ#J@ZX)'4
M@YSP171ZGXQCT'Q=<6.K3P1::+!+J-UA=I%.\JV[&?E& <X '?UK8F\2Z1;W
MZ64EX!,[B,$(Q3>5W!"X&T,5Y"DY(Z"@"Q]EFBT/[(G[V9;?RP7D)W-MQRQR
M>3W.37"^"="\7>#O!UIH:V.GS3)<G=<"[.U8V?+-M*C) )XS73P^./#ES!)-
M;ZDLRH0"(HG=CD,>%"Y; 5LX!Q@YIUMXST2\UA--MKP2R/:B[610?+,9S@AN
MAX!/X4 <5XG\%>(M<MKG68I7AUN+48KFRM28C&JQL%3Y_O ;2S$9^\3QZ[WC
M+PUJ7BC1]'OK3_B7Z]87,<\3;P?*W$"5<C@C'/OM [UT^F:UINLI(^G7D5P(
MR ^P\KD9&1UP1R#W'2L[7/%EEIFGZJ]I+:WFH:=;27+V9N C%4&6YP<8'MU(
M!QF@##T+P$=#\?WNJ0-MTA[:)H8,YQ<!3&7QZA!^/F'TX['3[J>[@>2XLY+1
MUD= DC*Q*AB V03P0 ?QJ"#7]*FM9[@:E9F*V?R[AQ,NV%^/E8YP#R.#4$_B
M"-=4TNTMH1=1:BDKQ7,4@*?(N['X^M &PS;5+8)P,X'4UYREAJ,GP<OM..GW
M8OG,P%NZXD;?.S ]?1@?;GTKJ;7Q,EUX+/B06<@1;9[@V^X%L+G(STSQ6CI^
MIV^H:?'=HZ*#&KR+O!\O*YPQ[$9H \^N=):QU.YALM(GCLAK]C/ (K8E HC3
MS7  ^49#9/K]:M^%([VW\93AK:ZDMY1=,;B:VD@DC)E4[),_)+U^1UYV@CI7
MH$4L<T:R1.KHPRK*<@CV-4!K4!\1MHGE2B=;477F$#85+;<9SG.?:@#'\0BX
MUC7+'1(K?-I'_I=V\\#F*3:1LC#8VD[L,>?X!ZUR+:A>:/X-MM(NH+\_V5JT
M5FZ):R8O+4,=H4X^9=O!]=A!X;GU&XO+>T\K[1/'%YKB./>V-['H!ZFJ^K:/
M9:W:I!>HY$<@EC>*5HWC<9 964@@\D<'H30!YMI\"WDNBV47B'4U2XO;WSTA
MO)0\"%2T43;N4*@Q\8'/3(.3%_;&N?9M0NX]6OO[6MXKE9M-2QD.Q=Q*O\S;
M?E4 J5 +9 .>WJ&F:9!I=LT4+S2%VWO)/*9'=L 9+$^@ ^@%27]['IVGW%Y*
MLCQP1F1EB0NQ '91R30!YB=28Q69LO%T]S;W6JV\0:-)(UC1U(= \C.6SMS@
MG*$]LBHM.UF^LYM.ECUJ[NRFO7FFK!-,&$L*)*4!_O-E8_F.3R!GGGUF-EDC
M5U!"D9 8$'\CR*&C1L;E4X.1D9P: /'CXIUAO"E[J]KXKM6NOL$4LMM&JLUO
M-YJAMP9?W>0678>XR.A-:&LW]_\ VA<:?/KMRT-GKVGA9B8T;9(JNRMM4 J#
MR./SQ7HGG:6=3DTS$)NY(O/>'9RR9QN/&#R:B@&B7]Q>V<4-I-) Z"YC\H':
MP 9=W'4<$>E %;Q7<ZE:Z1'_ &4Z"Z>=$"&14>5>K)&7!7>0#C(]>AY'!MJ]
M[>72ZS8:A(MY;^'[MVEN;15D9HI\%'0' ^9"#CT.,9%>IW=E:W\!@O+:&XA/
M6.9 ZG\#50>'M%"E1I%AM,!MR/LZ8\HG)CZ?=SSCI0!Q\OC#47UFS^SSQ2VS
M7-G;S1Q*I1#,N6#,3DMR"-F0!UZU0M(H/,\.D0JKQ>+M016"X*J3=G ] <+^
M0KM%T#PM-J#QKI>E/>0+&600QEXU7_5\8RH&./I[597PWHJ212)I=HCPSM<1
ME(@NV5NKC'\1QR: ,7QW#)(_AQK;R$NAK$0BEFBWA,QR9.,@]/<5BVOCG7KR
M8Z+:V,$^MVS723LJKY3F%U4%0TB8#;P3R2OH>W<:GIVG:LD-K?(':-Q-" Y1
MT9>-ZE2"",XR/6J-UX+\/7EO;P3:9$4MW9XBK,K!F.7.X$$[CUR>>^: +-Q/
M<S>%9;BXMHH[A[,O+ \FY%8IDJ6&,CJ,BN*A\5ZK9:191:78:=';Q^'$U55=
MG 4*%S&!D]N <_7/?T*2QMI=.>P,06U>(PF-"5 0C&!C!''I60/!>AB$P_9I
M3&;$Z=@W4O\ Q[G^#[WZ]?>@#GSXRU*WOM4G=([BUS9Q65LD95P\X!Y89)QD
MD\=ACWF/C+Q!_H5LOAD"^N;B6!%N+DP*^Q"^]<J3M(!Z\@\<]:UI?!&BS1SQ
MR1SLL\4,;C[0XYBQY;CGAQ@?,.>*D@\)V%M/8W FO)9[*5YHY)KAI&=V782Q
M;K\O&.@H QX/&NK/-"TVA0);27T^FAX[TN?M$98*?N#$;%"N3R"?NXP3#;?$
M6YGTK3;Q]#V-JD)FLXTF>8LH7+%A'&67!*C@'[PSCFK6A>$YF@N9-8\Z*4ZE
M=WEO"LRLL9E9]KC ^\%<C!R <G'>KG_"#6$>CZ;I]K>7UH=,R+.Z@D42QJ1@
MKDJ0P(XP0>@[\T 9L?CRZ6YFN+O29+73XM,AO&CFW+<K([NGEE"!SN7'X@YY
MQ5RT\;?:I/LG]EW"7KW @A4AEBERA<N'91PJJ=W&0<#!R,S7O@;3M1WB\N[V
M9);)+*=7D4^<J,71V;;N#AF)!! SVJ-_!)DBM7D\0:K+?VDRRV][*T9>,!2I
M7:$"D$,<Y&3W/ H 7X?7E[?>%/.OY9I+C[9=1DS,&8!9W4*2.#@#''I5*U\8
M1Z>TZ2VNL7<EQK$UE&C>4[)($WA%P0 F <9SCG)%=!X<T(>'=*-@M[/=@SRS
M>9,%#9D<NWW0!]YB?QK(C\%21W<<ZZI]S6'U8J;?JSH4*?>Z;6;GZ4 ;7A_7
MK;Q'I":C:QS1(SO&T<R@.CHQ5E."1P0>A-9@\=Z0MU+'<+<6L*0SS+/.@"R)
M"VV0@ EA@GNHSVS5OPKX?D\-Z3+8R7BW6^YEN XB\O'F,7(QN/<G\,5S+?#*
M2XGD-WK7FQRPW<$K"T FE2<@_-(6.67  .,8   H Z!O&%I&7CELK^.XW1+%
M T(W3&3.P(<[2?E;.2,8.<4D7C?2)K..>+[3([Q23- D#-+&L9VON4=,-Q[G
MIFLVX\)^([JSMS<>)XIKVRGBGM)/L(2/*!@WF*')8LKD'!'; %65\/:Y!K,.
MLKJ=K<7K6KVMPLD!2+:7WJ4 )(VY(P2<YZB@"T/'&@MJ-O8I=2O+/"EQ&R6\
MAC\I\[7+[=H7C&2< \5EKXZA?Q6(_M*)H:Z1+J#32VTB$A70!U8\,A#'&!V]
MQ4>G> 9;$7%@UVK:;+HB:2'&1-\N_+^@SYC<>PJM+X0\5-!$(]3TR.:VTJ73
MH9(X6!.2A#'.<?ZL< <9)&: .F?QCH,47F37QA'GK;;9H7C;S&4,J[64'D$$
M<<U)_P )9HGV".^%\I@=G48C8L"F=^4QN&W!SD<=ZY&W\%Z[;7AEC@TI(GU6
MVU!D6ZE)4)%L<9*98DC.3C.3G%.MO"?B:PU?^UH$TJ:4W-Z7M9IWV/!<.CCY
MQ&<."@!&"".] '7R^)M%ADA1]1@_?!&1@<H0_P!PEAP-W;)Y[59U+5K#1X$F
MU"Y2WB=Q&K/G!8]!^/2N%E\$:E_PD$TLNF:)?6=X+=Y'E+Q_9GC1$(2, [D^
M0%5)&">M=EXFT@:]X:U#3-Q1KB(B-QU1QRK#Z, ?PH E&NZ23,!J=G^XE6&7
M]\OR2,<!#SPQ/0=:RK?QA9[--M[N>RCU+41+Y$,5R)(F*$C_ %@'?@=.N1@X
MK*TCPOK<.NP:OJ<MO(UQ"L^H0Q9Q]I166,)G^$*^#SUC4]S5+2- UO3F\)SO
MI;$Z<;Y+B)9H]RB5LH1S@C''7.<?6@#J_#/B:U\1Z7;SAH(;R2+S9+1)Q(\0
MR0"> <<=<"MRO+M%T[5/#2:!>S:!+']@TJ]6\\N2'F1G1U4D/SGRR<G@;ASG
M./1=*OQJND6>H+#)"MS"LHCEQN4,,X..] %RBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"K>Z;8ZDD:7UG;W2Q.)(Q/&'",.C#/0\
MGFJ?_"+^'P"!H>G &(PD?94YC)R4/'W<DG'3-:U% &+>^#_#>HI&MWH>GRB)
M!''N@7Y%'11QP/;I5W4M(T_5[5+;4+2.X@CD614<<!EZ$?Y]JNT4 8*>#- C
MGCF2Q(>.Z:]7]_)CSVZN1NP3]?4^IJ;2?"VB:%=W%UIFG16TTY)=E).,G)"@
MG"@GG"X%;%% &!)X/TN4ZR7-T?[8 6\'VE_G&,8'/R_+\O';BN;UCP5JL^M/
M-8M((&MX;>&>/5IK9XA&#RZJI$IR2<G'I[UZ'10!R[^!["59#)=WOFRWR:C)
M(L@4M.@ !Z<#@?+TX%*? ]DEQ--:ZAJ-LTUQ+<,J2ATW29WC8ZLNTDDD8Z\U
MT]% &%/X2TR;PK!X="RQVEND8@='Q)$R$%75NS @'_ZU4[WP1;WEK+&=2O5N
M)KN*\FN@(S)(\6WRP?EV@#8O  Z>YKJ:* ,G7="76[:SC-Y-;2VEU'=131!2
M=Z9Z@@@@@FL5O F][8R:F[+%J\FJLODCYV<$%.OW<,_OR/3GL** .>\-^&)O
M#JK;KK%W=6$"&*TMI57$*$@@%@,OC  )Z#-8 T"\UKQ;XHBG>XM-,NY+7=NM
MR/M"QK\P1\\ D;3P<CIZUZ!10!PR> [Z"^-S!K41P+L*9;/=(PGY^=PX+%3C
M' ^48]ZT8?#%[ WAJ1+^ R:/;M;R P'$RLBJ2OS?*?D'7/4\5U%% ' V7@75
MM-LM(>UU.S^WV-M)9R&>U,D4L;MNW;=P*L#[X/2KK>$+T^*K/5EN;6,V[)NN
M(HRDLT0CVF*0 [6!;Y@2/EZ 5V-% '&^)?"^IZQ?ZQ):RVJ0WVB/IJ^86W*[
M,QW' Z8:J]CX/U"R\02W?V;1)[>>9+HS3PEKF&1452B-CD?+PW!7)X-=U10!
MYW'X(U:+1_#P:+2;J\TI)XY+6Y):"=92#D-LRK#:/X3U(I=1\%:G=+<PVMMI
MEG'=:*^GL+8F..%P[.H"A>4.[!Z=SWQ7H=% '+Z)I6HGQ)<:Y?VD-F\EA#:&
M"*3?N9&9F8XXQ\P"]\9SCI7,ZEX5UXC7X]/T]4AU"UO(FA>X5HVDE.%>$GYH
MRP^:13A<@8R>:].HH \WU3P_JL6IW=Q:Z'') \FGO&8VBWQF+<'9 S!=RAEV
M[OEX/H 3P[I&L:;=:$EQI-RD=I=:E)+(TL;X61V:-LALDD-CIZ\ <UZ110!Q
MFC:3J(^%#:3+9O!J+V,\/D2.I.]MX'()'.0>O>N4O/"6H2:9)<:7HLME&FGV
MT=Y:)LC>ZEBF1VV@$J6"B09((;<!R*]>HH X[PYI=Q9>$]673(M1AN+IYI[8
M:B8T<2,O!"H (UW=L>I[UQT&DW0MKEM,\/ZG:74N@I;3'9Y3RRK)F0>9T+E2
MV'/7UKV*B@#RF30+&6PMKT:5JD]LNL0W#P7=@%,2D8<1Q*NX)G;N &"03S42
M6EX4U66\;68M7CAO?/2WM719U.XQ$3J/F_@V $D<C&,UZW10!Y!_81BDMK1-
M1\0^5/H,]U*SW4Y(GS$RC.1ALAS@8/&#QQ4<DFJP^']2D^VZNMY>>&(KZ4F2
M3<EYR,)_<).!M7'':O8Z* /)]?O+B._UN_BU?4(UL_[-FM4,I6(LS;7X_B&U
MAD=/FY&:E@UW5W\1WL@UK;?VUU<QC1I(')GA4MY01>!@@*?,'<\G'%>I$ ]1
MFC: V['.,9H \T\):G:ZAXYLKI=::_N+C1"TJR%04D\U2ZA0,IC'W>V/Q-77
M;V]TSQ-XEO\ 3M6:&\@N;(Q:<JH1>%D1=K C<<C(!4C!R3G''JH4*,  <YXI
MC6\+7"W#0H9D!59"HW 'J ?2@#BM/NM;@\476AW.J7,GEW0OEN'@CP;(ICRR
M0H /F9''.!GBM3QC>&;X=ZU?Z7J)39I\TT5S:NISM0GY6Y'.,9'/H0:OZ9HK
MV,E[-<ZA/?7%TW^LF51Y<8)*QJ% &!N/7DYYJQ8Z19V&E#38H4-KA@T;(-K;
MB2V5 Q@DG@ #G  % 'G&I37^F:A<ZKI6J1/=6OAA+F2>YB\TW"H[LH^4@#."
M,@$]/K6O9^*=;U'Q),ML;%+"TOX[2XAEF56V,@.X9&2Q9OE[$#&,\CK$\/:+
M&NQ-(L%7R?(VBW0#R\YV=/NYYQTS2GP_H[:E!J1TNS^VP($BN/)7>BC@ ''
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MS8I<R1D8&TKS\K?> /IS@&LB[\4:I<^%]-U30;G4]9TK[?(+]($5+V*(#B/
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **.E% !1110 4444 %%%%
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M45BP_$*,W=C>7,<T&EW.CF_:$6SR31MO7).T$[ I/.,<9S0!?T7PUJ>G^/\
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MB+* & /8X)&?QH \VT%I#XC\+3SZ?J$>J1M>0ZI)):2?-(R\,TF-I4D#:0<
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M1?#<%_)8JUSE!="+=+';@CYW.!N9%/H,]^F:;#X%\.6UFMM#8-'&DZ7"E9Y
MRNA)3#;LX7)PN<#/2M34])M-9MXH[@S#R9/-BD@G>)D?:RY#*1V8\'(YZ4 <
M$_BFZLM1N/$$%M%>P'1(KRZ6*_)A55=PYCR""V%X&%SCD@UT,_C)H/$":;)I
M^(9+I+42"<&3+IN#E " G;)8$GH*DD\ Z UM<V\<$L,5S9_8I@DS?-%O+G))
M/)9F);J=QYI/^$$TS[4UPMS?JS727FU;E@HF4 ;L>X !S^&* .=TJ]NVA\-
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M"* '4444 %%%% !1110 4444 %%%% !10!@8HH **** "BBB@ HHHH ****
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M5"JR\NI(;)!/8Y'% '(W_BC4KVSU^>[AM[C3HO#UK?\ V(.T7S2!V8>8O/\
M"?3HHXY)W[GQCJ"ZU=V&EZ-)?0Z=-%;S[&)=RRJQ*D\#:&!^8\X/3K5N;X?:
M%+:RVP%Y'%+9)8R!;I_FB0DJ#DG)&2 3T!XQ4LO@?2)=6.I[KQ+F5$6Z,=RR
M+=[  IE52 Q&/;/0Y'% $7A[Q5<ZSKUYIT]I#:-;ART+R$3IA]JDH0,JP^8,
MI([4GB+QE_PC^I+;O9+)"!$SN9PKL'DV?NTP=VWJ<E1R.2:OZ;X8M-.U);_[
M1=7,\<300FX<-Y,;,&900 2,@?>)QC Q6=K?@*SUJ_OKMM2U"U:^CBCG2W=
MK>4VY#\RDC![ @'N#0 U/'!_M5;6;2)X;7^T7TUKII5($@0LIV]<$#KQC(Z\
MXS[;Q#?:IXX\/W$$<\.D:C8W$D8,F5F *%'*X^4X)(Z\,/<#3_X0B,LI?5+J
M0#5#J9#JG+[2NWA1\N#]?>FZ5X'_ ++OM,F77+^6WTP21VELZQ[4B8 ;"=NX
MX  !SG QZY -;5]?BTN\M+%+::[OKL2-#;PE02J %F)8@ #('7J1[UR?_"=R
MMXCM[JR@O[_2KG1WO%M((4\Q'24*Q.[!R!D$;CST!-=1K&@/J&K:?JUI=BUO
M[%9(XW>+S$=)  RLN03]T$$$8([UG0^"WTY;+^R=3-N]O9RVCM+ )-XD8.7P
M"N&W#/<<]* ,G4O%9W:U?0ZM<II0T>TOK:2WAC=XO->52RAASPBY#$XR:Z*]
M\8:7IUY/;3F=OLSQ17$L<198I)?]6IQR2V1T!QN&<9K"O?AU*UGJ%GI^IPP6
MT^EP:;!');%VB6)F(8MO&XG<W8=O3G.U*TU1O&5_(EE&6>>T81RV5P8KAXU!
M#^:F4&&.,L,C8"1P* .JF\;:5#+<1A;AVBCGD3;%Q-Y)Q*$SU*GCG&>V:KZ9
MXN34CHUU/-_9\=YI\EY):SP$Y5=F6$O  7/IR&!XJA'X)U5]6%[<ZG:2G%TC
M2M;$S.DOW<MG'RC"@  8'3GB"/P-JUSI>F:;J%Y:-#:Z/<Z9+)"&W$2JBA@#
MQD",=_XCP,<@'0_\)MH*V=Q=2WC01V\:S2":%T81L<*^TKDJ?49%21>,=#GM
MIYXKQG6"98658)"Y=@"H5=NYL@Y!4$$9/8URFK^"-?UC1[M9)=.COVT@:7'L
ME?RW!<,TC'9D?=&%P<9//-6=1\*:I?7^IRSZ?9S0W+VC1E+YXI8S$C9='"?*
MP8C'J,YQG% ';V5];:C917EI,LUO*-R2+T(K.A\5Z'<V]W/;:C#,EK&99=AY
M"<_,/53@X(X-1V&DZ@?!@TK4KM6OGMGADN(N.6R 1P.0".<#)YKEK3PUK7V?
M3))]/CAGTC1YM/VQ2J?MC,JHNWD83";OFP<MC'&: .C\*^(+OQ!IRZG-#:QV
M,\*30M%,6=2PRR."H&1QR#@YZ<<U!\0-*EGTV>"XM6TF[:=)+V2?R_):($G(
M*XP<=2PZCKFM/PA:W5AX0TFPO;5K>YM+2*WD0LK LBA205)&#C(KD]*T+6+:
M?PZE[HI>/3;V_EED66-EQ)O,;@%L\[\8QD4 =Y_:FGF&VE-[;^7=$"W8R "4
MGD;?7/M5NO'X?#&J&QMH+[P]J%Q:36!L_LUO<QQ&!Q,[Y;+8",&0[E)(V=#Q
M7KL2[(E7GY1CDY/Y]Z 'T444 %%%% !1110 4444 %%%% !UHHHH **** "B
MBB@ HHHH **** (+NRM;^'R;RVAN(LYV2H'7/T-4]+M]$%O<0Z3%8" 2-%.E
MJJ;0XX96"\9'<&JGBO5I-)L;,I,+9;J\BM7N2 ?(5S][!XSG"C/ +9YQ@\AI
M&HW5AJ<*IK!FAN/$5S9W,A6,B0&W9X^B\,-B=,#.>#F@#N[;P]HME/;SVNE6
M4$MLA2%HH%0QJ>H7 X!]J(?#VC6[WKPZ79HU]D716!09\YSOX^;.3U]37#:'
MJFLZMJ>C,-=<M<:=?C 6-HVEBG1%<@*,\,.GIQC)SN>$M=U/6KIH;N1%DT^(
MP:A&(Q@W7F,IVGLH";@.ZR(?J ;$?A;0(M.CTZ/1[)+..43I L*A1(/XL8Z^
M]">&-&BEFECLE1Y?,)*.R[2XP[( <(S=RN":YO5/$^K:=>:U&LL$BV-_8K&&
MCQNBG959#[C)(/TIMKXKUN.^22]:PDL/[6GTUQ%"RR?*C,K@EB/X=I&.<YSV
MH [#3=.L='T^#3+&,16T2D11%RVU<]!DDXY_"L5/AYX6C@EACTL(DD#VS;9I
M,^4Y!9 =W"Y'0<#G'4UQ]QXBN[?6M*\77<-JZ3>'[RZCA@7#",-"ZH[DG<?F
M7D8 );BMNZ\4>*].L]UUI-HLDMY:6]L[N$643-M885W(*GOGD'IQ0!LW'@?1
M+LW;7$5Q(]TD*2.URY8>5_JV4YRK DG(YY/K3&\!Z"]M- 8[PF6Y2[,IO9C*
MLRJ%$BN6RK8&"1C(J'Q1J/B#3O"%I-!)9Q:M)<VMO,R(SQ@R2K&VP'GJW?M6
M+:ZQJ&C^+=;(MXY[635[.UG9IF#(9880-BX/&Y\G)'' H ZRS\,:;8ZI#J%O
M]H$\-N;9=T[,"A;<=V2=Q+<DGDFFZOX6L]7U'[=)<74,YLY;)C#( &C?J""#
MR.HKF1XJ?0M,OKD:;' IUFXAN)I+B22&-L9WLVTE0QP.@5<^E=G-JL-GH+:M
M>,D<,=MY\I1MX "[C@_Q>WK0!@S_  _T^>":%K_4!'-I\6FN Z?ZF,Y7^#KR
MW/\ M'VQ<D\(V]QJ<%Y=:A?W @N$NHX)70HLJIL##Y=PXYV@A<DG%8O@CQ/=
M71UN#5[J.>X@87R>3R%AD7/EKZ[&#+[\>M31>/9)+&ZNCI#E8](75XA'<!M\
M+;MH.0-KX4G'(]S0!T+:,7\2IK+7<A,=LUO';E5V*&969@<9R=J]\<"N6U_P
M?>Q:5?QV%S?7:WNII?201"'=%AMQ\L284\JIPQQU/KFU<^/_ +%#_I.BW:W*
MH)WME97D\AF*HXVY!9L-\O!^4^V; \>63ZNMC#97<JM<&U$B+R)=N[!4X(7^
M'<<8/7 YH J^'?#6HA=-NKVXGMOL$TS06TD,"LR2* ?,$0V YW$;?7DDFID\
M" 6E]ICZS>MH]R)MEF H,1ESNP^,D L2 >A]<"H+?XBQW=O%-!H.I,)[.2\M
MP3$/,2,@/_'@8W#KUSQGC-JZ^(FA6GV8R/(5FC@D<@IF$38\O<I8,<YZ*&P.
M3@4 13>$-9NM-BM;OQ,US)%<6\R/):*%Q"X< JK#)+*,DGH. .M++X-OG^U%
M=6AS/K$6J@-:G";-O[L?/WV#GZ\<\6(O'6G3WPM4M+_<;R2P\QH0J"=5+;,D
M]P#@CCU(JUX?\12:WX9.LMI\\/S3;8 59V",P&,'&3M]>OM@D PH_ NJ0>'-
M2T&+6;<V,]M+:VVZSQ(B2<8D?=\^T$@8"YZG-&H^"-5U"34)FU2W66Y%@R9B
M8J'MGW\_-R&)/3&..M:EKX[TB[6%HENL3::VIQYC^]"N,XYQN&1Q[U3G\8KI
MZZA<L;B\ OK6V2U%L87MO-V 9+??Y8G(^GO0!H>)M!O]:2P$%W$J0,YG@E5O
M+G#(5Y"GG!.=IX/?UKG]!\":G8V=O8WT]J8$T672WE@9MP+OG<%*XZ8[]:TM
M'\7,-:U'3-7E!E75#9VKQ6S*F#"DBJS<@,=S 9.3BMA/%6CRW;VT=V6D59""
M(G*R>7]\(V,.5[A22* ,SPAX;O-!#I=6VB1A(Q"L]A:^7+<!?NM(>QQU49&2
M3D=*Y[2=-N]?O]6@@:R6R@\2B]><2DRYCV,%5-N.2H&[=TW<5U=]XVT6RTJ7
M4/.EGB2Q^WJL4+DR0G #+Q@\D?3.3@5:U7Q'9:-H4>K7:3B"0QJJK$Q?+D!0
M1C(Y(ZX_.@#@5\#:W!X5O-+.E:5)=1Z>]A!>+.Q>=6(&2K ",;1EAELGZ5N:
MIX=U.Y\0VU[IUE%9LC6YDE\Q3%)&K[V22+G+*22C+R">HZG3T_QC:2:YJ&DZ
MC/:VMS#=I!:IYG-PK1K(I&<<_-C'J.O-;<&K:=<W\MC!>V\EW$"7A60%U X/
M'MQ],T <+;>%M9AL-(LYK2-VT=[EOM,<B[KM'C<! #C!8NI;=@93J<UF1^%=
M;MM(T^"#P\!+%X?CL[@&2'#3B6,M_'AFPKL"?ER1D\D5Z3-KND6UU]EGU2RB
MN-ZQ^4\ZJ^YONK@G.3V'>F:GJZ6EG,]I]GNKJ/&+=KE8\_, <L>F,_T[T <+
M8:!K,>H6[2Z1=K&/$G]I/)+/"Q\IK9H]QPWW@Y&0!@=LU9^(NCZGJT\B66E3
M7 .EW$4-Q!Y;,LS%2%.\X5?ESN4;N.".,]\UW;)<I;-/$MPXRL1<;B/4#K3D
MN(9)"B2HSJ,E58$CDC^8/Y4 >57NBS79UV^_L&[CO9&T^:W<0'S!(I!D93S\
MPQR1R<=3FK,-E=_\)%IYN-#O7U*'7YIYK_R2R-;,DHC(?^Z%:-=O8K7IRLK#
M*D$'N*&8*I8#<0. .IH XCQ3:>7XO@U)]/EFC&C7D"S10-)B0E"JDJ#MRH?&
M?4CJ>>2MTU;3-&6/2H=6CD?0;*6XCP^_S%D43!=_ D$08 #'\..U>JV&K17D
M%H;B%[*[N4:1;.Y*B4!2 W )Z9'3U%78)H;F".>"1)89%#(Z'*LIZ$'N* /+
M4MX;R\T:""_UY=,O-0F##$UJJH;=AM51A@OF;>6'WB<<&I=$GN7UP1:GJ.K6
M]]%<7*WENT4OE-#AMI\TML5 H0JPP<^Y)/J.!Z48% 'D'AO4%30_"UG<7]Q:
M:3-97 N)Q=NNVY4*%0OGY/EWL%R 3VXYL66JZ]>O )-5NTU2'01?+8*54W$P
M=@FY"I/S #<!_>Z XKU? ]*,"@#A?A_J3ZE+<RCQ(NJ(]O"\EOY3;K>0YW;F
M+':QQR@P!C@"N>&W[;-;C5)#<'Q=A3*RNT/[LX."!V! SD<#@X.?6@JKG  R
M<G JN^GV4DIE>SMVD+!RYB4DL. <XZX[T >:2>*-61[;2CK<$3&YOXEO[F1(
M=YAD"QJS>6RYVDL0%7=MZCG.UXY#7WPAO&O9(+B1[.)WDAR(Y'RAW+G^$GD>
MU=:VCZ8\)@;3K0Q%_,,9A7;NQC=C'7'>GWVFV.J6OV74+*WN[8D$PSQ*Z$CI
MP1B@#C_$B0V_CCPP=*6.+5)I)4N-@'S6HC8MY@'4!MF,]^G6J&B^(M8EAT2V
ML4TRU@FTR>]DCBLVQ^[FC4A%##&Y7/'8\\UV5M8>'M.NWL[2VTVUN;A#NAA1
M(WD7Z#!(I;?0-#TVXM)H+"TMI8%:*W*(%V!CDJOU/:@#B[3QWKR>'/\ A(;R
MTLFL)K$W$824+LER,)U)*C.&)&00>W U-6U'Q+;W.G6S76G+YVJ11!X(FS+$
M8V;)7?\ )\R,.IW =N16ZGA+P_'/>3IH]FLEXC1W#"(?O%;[P/L>_K44?@W0
M(K-+6*QV1)<+<KME<,)%&%.[.>!QC.,4 8]OXQOYH=.OQ;VS6.I:A+8PHI(D
MB8%PC,>AR8SD #&>^*T/".N:QX@\-QZO=V5G"+B$2VT<4S'/!^\2O R!TSP?
M;F[%X5T6&Z,\5IMD\Y[@ 2N%65QM9U7.U6()Y SR?4U9TS1;+1]&CTFP22&T
MC0I&OFLS(#GHS$GC/'I0!Q]AX_U>_M["1-"MU?4=->_M5:\.,)MW!CLXSO4C
M /OBIKKXB&&.QN(]+9K6YM;6Y.Z8>;MG8*-J '[NX9+%0>@)K5B\#:3;+9BW
M:ZB^QV4MC!B;.V)^HY!R1QC/3 JI)\-]&:V-O'-?Q1-!;P,L=QC<("/*)XY*
MX'UQR#0!:@\5R/JEQIDNG%;R*_6U6-9@2T3(9!-R!A=H/'/(Q4NO^*3HFI6U
M@FEW5Y/<V\UQ&8F15Q%MW EB,?>'YU%I.D7,WBFZUS4=-BM9XH/L5LRW'FM+
M$&+;V^4;2<C Y(^;UJWJOAU-4U>WU%KVXA>"UGMD2,+MQ*!N8Y!.?E7'/:@#
M-;Q_8-827]O97=Q:064%[<O&JYACE&Y<KG)8+\Q Z#U/%6M!\1SZSKNL6GV4
M)9V9B$%PKAA*'C#@\'N&!''3O6=%\/8[6S:RM=5N([6?3X]/NUV*6FCC78K
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MPV@0)Y.HS+LO6E3*CY;5RQ>V]T)=SD\C(_NBIM3\):E>W&KS17=I&;J\L[N
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M$V[? ZD!L8//\0Z>A[UJ^*O&-SX8MM1NI8H&M[>:WA1R&_=^80&:3'8=>.O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=D^)-(%_%9&]C\^4JJ#!V[F7<JEL8#%1D G)'2E;Q)HJ3W$+ZI:*]LC/,&E
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MJ5N+R.&[TG4&ELTF*@O$\2C'0;@68!B!U'2@#6@\!V$*WEL9Y6L+K3$TQK?
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MM0TRWBN ]BL;/(\+*C;P2-I/7C'USQ5.'Q58V]QJ U'5;/RX[X6D0CC=2C%
M0C9SEN<Y''(J72=$OM.\2:I?2W4=Q;7L4 !;B4/&NTY  7!Z\=STK(NO">K2
M:C=7,9L&6;7(-1 =V!$<<:(1]T_,=F?3G\P#IK'7--U#27U*SG\VT0-N94;<
MI7.X%<;@1@\8S7/P?$'3Y;_3Y)9(+71[[36O8KJY?RV#!T780>.0^>O8U<\-
M:#?Z5INL6]ZUL9+V_N;J/R69@%E.0#E1R,XKF;/PEKZ:=90SV=D)+;PU-I/R
MW!8-*VP*>5& 1'D^F['..0#N[S4])22.RO+JUW7.%2&5E/F;N@P>N<''K5B:
MYL[%(TGG@MT8A(UD<(#Z 9KS^#PAJAO(S>Z7:WEK=VUJEQ%->R*+=X0 ?E48
MD'&X=.?3-:OCC1]0U*>VETZRN);B."6-94>(Q'=MS%-'(0'C; SCD8XZT =8
M;ZT%S]F-U )]I?RO,&[;ZXZXY'-(;^S D)NX (U#.?,'R@]">>!7G+>'-?'B
MBUO)=)1[:+57N)%MI8Q$T;P&/?M;YF;.-V3C"@*.M4=/\%WT%AI<<_AI%DAT
M.Z@N%!B8-<,RF,$[OF/RL0>@W#D<X /6BZ*0"P!;ID]:=7D3^&]:NAIL6K6.
MKS!M+LXD:TFB4VUQ%_K-S-DI\Q!WIU (YXKUV@ HHHH **** "BBB@ HHHH
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MV[*[E97".X! 9DSM9AD_,1GWK9HH R-1\-Z;JMW-=7:3-++9/8MMG=1Y+G+
M ' )XYZ\#FEL?#MAI]^UY#YQD:TCLR))"X\I,[1SU/S-R>>36M10!SQ\&:2F
MGV%E:">RBL)S/;F"4Y1R&!Y;.>&(YZ#IBH+'P+8Z>;4P7^H?Z+!<01;W1L+,
MP9\DIDG(&"?3G/-=110!Q<_PXL6L#:6NJ:E:QOI@TN;RVC(G@4,%#AD/(#$
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M31)GRU=6#.%.00?7/% ':45YS%XIO[KXGV.@6.K>?ILFG-<2N8D+^8I*XSM
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M/%+$\B11E'!#N[A%&?J1GT&: ,:7SE^*,,_V.Y-M_9;VYN1"QC$AD5PN<8Z
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M:3->W:W$K((U5BJ[-O)+8+#., #.<UIZM=QV?PQTV>>*>6(1V(?RK@Q.,M&
M=PYZD9'?FM"]\":/?0Q(SWL;)#) TL5TXDECD.YU=LY8%OFY[_4U<U#PS9ZA
MX;CT)I;B*TC\K:T;Y<"-E91E@>ZB@#'_ .$VN1K9LCHK"TCU0:9)=&X'#M&K
MHP7'(.X9Y&,CKR!)XAU?5H_$:Z-;0Q)9SZ5<W+7"S,LJ,A105 7'!<=^=V<C
M;AK,G@NUDN'F_M&_5GU1-4(!CQYJJ%"_<^[M"C'7@<]<V]6\.1:IJ,-^+VZM
M;B*UFM<P%<,DF,Y# ]"JD8QTYR* ..M_&)?P&8-1BUB&>+08;Y[NW=!--&5
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MWF!8IH7C(:,G>AW  .,$E3SCG&*RF\*:M--I$\]QI@DL]0%Y(MM;&)"!&R8
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MT-=3T>">TM[*Y$C%D=()))Q+&@!.XA I4$# R,=\>DT %%%% !1110 4444
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MG:=JY[\=1DTFB:9<S^*-0\07^F+83O$MI%&)Q(7568^8=O&2"H'<!?>NGHH
MQ_$FB2:]IJ6L5X;5DGCFR8Q(C[3G:ZDC<I]*PK7P)<VDD+)K32",WS'S+<;G
M-R=Q)((&0>>!@^@KM:* //I/AU?II+:=:Z['%%<6,%I=E[/=O,("JZ_.-I*C
M!!)]L5VE_;W5QHUQ;0O!]JDA9%:6/='N(QDKGE<]L]*NT4 <%IG@K4M-N],D
MBEM$MK/4'NEM!+(Z1(T#1%(RW(&79\< < >M95YX!\13:$^F;].D22WOD/[Z
M1 DD\ID4\+EP-VW:< ;0V#P*]2HH \\U'PQKUQ8Z^B6=H9;W[ 842Y.W]SM+
M@DJ,=#@]^.E=EKD$]UX>OX((1+/+;.B1[@-S%2 ,GCK6C10!Y7)X5UD1P1VF
MC"!DTJP5P98Q'++;RF1H6VMT8'&[!'KQ4VK^'=9NKJ[UJ#1Y!YFJ6-V-.:6+
MS"(@5E?.XH"RD#&[D+[XKTZB@#$\50W%QX/U*"UL/M<TMLR"T\PIOR,%<J0>
MA/0C/3(ZUY_'INH1VNI++H>HM#+JVG74226\9)C1HC(=D?"G$; CKT!)->MT
M4 >:ZM9WOF^+&TG2[N)YFLC&T4'EM<11E?-5"1@G;N4 ]<\53-FEHMM*FC:]
M<^'[BYN?/LY+7YD=XT",MNJ@J@/F#IP3N[@UZM10!Y_X8T]+#QS-+)I5[$UQ
MH]FL,\\1D92GF;UDE&1OP8P<GG'?%:?BR62#Q%X6>*6[&Z]DCFCAWE&B:%P2
MX7CABF">A-=;10!Y1X0>>#5?#4QN-1:6ZDU&*Y6XEE<>6)&:'<&) . "">3D
M]:Z?QYJ7V$:1 9[B!;JX>,M&TB(3Y;85C&-^<X(52,D=:["@@&@#Q%/$5]=^
M')IGU^]6ZM_#27/EB4QM]L1F )'4G(4%>ASR#FNPG.J+XJ%M97UW-8:]#%-%
M<)+N2T\H@R[<DA0Z,,8[GTKO=H]*S+30K:TUBYU3SKF:YG!4>=,76%3C*QJ>
M%!P"<=<4 3:O:W-[I%U;V=W):73QD0SIC*/V/(.1GK7GFD^*->U#4+&*1;R&
M'58%MXV(7,%S 1]I;D< @N!G.3&< 9%>HTWRTR#M&1G!QTSUH \PTCQ1J>M:
M_P#8;/7U\N_L[QH&80^9#+'*HC_=8)4!6QAB2VTDJN*Z/P1JVJ:] UY?231B
MWA2SFMY(U4&Z3/G/D '&2%&./E/%;M]I$-S XM66RN\-Y5W#"ADB+8R1N!'.
M!GCFIM,T^/2]/CM(W>3;EFD?[TCL2S,<=R22?K0!R?B::X3QWI,#7S1V4^F7
MNZW+#9(ZF/J".3AOTXQSGF].\3:MX;\(:9&+BUFB_L&RGB,J%%@R\<1+$9RH
M5]Q/^R>QP/4KO3K*_P!OVRT@N-@8+YL8;;N&#C/3(.#59?#VBJ,+I%@ 8#;<
M6Z?ZD\F/I]S_ &>E %#PI=ZK<P7JZK>Z;=M'/B)[*;S-J%5(5SM4;N<\#H17
M.ZQXKU^QU/6Q;RZ;]FTZ^L[=(Y(7W.)]@Y;?QCS,YQSCM7<Z?IMCI-HMIIUG
M!:6ZDD101A%!/4X%4KKPOHEZ;HW&G0N;MTDG."#(R?<)QU([4 <I=>,=<L9F
MTMTL)M0_M==/2Y"%(MK6ZS@E"_WL-M W\G\J-0\;:YI-B#>6FGF]MX&GN(8'
M,FX"78!PV(@0"<L6YR #@UU-UX4T.^M;ZVNM.AFBOI1-<J^3YCC&&//!&!T]
M*JW/@3PU=6D=K)I40AC@-NJ(S("A).#@C."2P)R03D<\T 9C>+M475;B)K.S
M^Q0:W'I;$.V]A)&C*P[ @R+GU&>F.:>E>([RVM;:WTK1[!9;S6KZS>,W#HBR
M(97WYVL3GRV)X[\5TP\(:*)"_P!FEW&\COC_ *1)S.BA58_-Z #'0X&120^#
M]&M[B"XC@E66"[EO8S]HDXFD&';&[!R">.G)XYH Y^7XB3QZ';7W]E1>:]A=
M7CQR76Q28&"F-&VG<S$Y''05V<%V6TJ*]N8_LY, EE0DGR_ER1D@'CZ#Z5P6
MK_#^ZBETZ/2/,DL[**18O^)D]O,DKR;V8ML8,OM@$>_&.[TVUGM](MK2^N/M
M4Z0K'-*P_P!8<8)Q[T <S#XYE:TLKNXTDQV^HV<EW8E)P[.$3S-CC ",4Y&"
MPX//%;GA[5KG6]*BU"?3VLDF59(5:57+HR!@W'3KC'M67#X!TRVMOLT%S>I;
MQPS0VD1D#+:"488QY&<XX&XM@$@<&MW2=/&DZ1::<L\DR6T2PI)(!N*J,#.
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M5!!X.:=10!$+:!41!#&%0Y50HPI]O2HVT^R<Y:T@8[_,R8P?F_O?7D\U9HH
MIC2=-6X2X&GVHF21IED$*[E=AAF!Q]XC@GJ:N444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!T.,,IW#(P>HIV1ZUYI;:%J6DW6DWR:1/+:Q:A>NEC$Z%[:&9,(G+!0NX$D
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MYSCUSSGUYJ*&RT7P^9;A5M[1IR/,GE?YI#T&YV.3Z#)[UEZWJ=Z?%%OHUOJ
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M1&?"H2  J=#D],DFO2TUW2)+>&X35+-H9@S1N)UPX7AL'/.._I4&O^(;;0M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %94=C!-/=226"DM,?G+YWX &?;IC'
MM6K66+FZ9I!;M JK(RD2*2<[CZ$>U &E&"L:ACD@<GUIU .1D44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '>BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZ>ZSV,;V4\!A^894;Q
MN!(;D$=\@^X-:!JEI%LMII5O C;E5<YV@=3GM]: +%LTCVL3RH$D9 64'.#C
MD5+3(7\R%'*E2R@X/44^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQWI V[^$CZT 0) S!G<NCDG@2E@!V]*K7=C>O#.EK?-"S*#&2-Q5LG/))X/
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MT9;'KGYAG\,?C27D\EI;2W+W%O#!$I=WE4X50.23D4 7**C1CY2EW0MC)*C
M/ZU7NWO5\K['Y#Y<"3S,C"^HP>M %RBLA1KJWH,E_I;6@;Y@+9U?Z9\PC-:3
M^=GY'C QW4DY_.@"6BJ=V]]'!(]JD,L@ V1.2N>><GGMGM3FDNRB%8XD8XW!
MV)VCOT'UH M45%ND#@80ICD[L'/TQ_6J\=S>><XGMX(8@^U',^2P['&W],T
M7:*H:EJ+Z9IKW;6SSLA4>5"<L<L!Q^>?PI;.^GN59I;-K<*Q5MTBGIWXH O4
M50T[58=2A>2*.:,([(1*FP\'&<'L?6I_M0(!6-B-V&.1\GN>?Y>M %BBL'1?
M%EAKT]W%9P7>;28P3-)%M4."1@'//0],^_45<N-;MK9X5,<TGG$A#$H;)'T-
M &E168-?T_?'&[RQRR.46.2%U<GV4C)'OT]ZL'4K12BM+M>095'4JY'^Z>:
M+=%93^)-(CW@WBDI+Y+!5+$/C.W@=<$'Z4H\1:45W?;$5<XW,"%!]R1@4 :E
M%4QJNG%-_P#:%KMQG=YRX_G2#6-+*,XU*S*+U;SUP/UH NT55&I6!Z7MMTS_
M *U?\:='?V<IQ'=P.?19 : +%%(&!&00?H:6@".X5GMI55MC%" WH<=:XV]\
M>6_AVY.EWVFZW>7$  :X@M%*29&00=PSUQTZ@UV4\BPV\DC'"HI8GV J&UO;
22^M8KJWF22&50R.IR"* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .W K<# 2(  A$! Q$!_\0
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M/&V^-6^8;AG##!'U%.IK!<%F&<#TSQ0 ZJ\=_:RWDEHDP-Q&-S1X((%)-/\
M9X6N625H\!F15+,OT4#)^@IMS-96*F]N"D><)YA7GD\#UZF@"RVXD 9 [FC<
M""%(8CMGO0KJZ!U.Y2,@CN*CBBP6D#,-W\)'2@!YD42A"1N89 SR<4^JLMBD
MMU'<>8ZL@P #P*M4 ,<@ DJ3M&>.M1[Q'E_+*J0#@#G)]:F9MHS@GZ"ESVH
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M)&>XI(T$<:H"Q '5CDG\:C$@A\N)F9WVXW$=?<U%?W,\$ -O;M*['''\(]:
M++.%XZGT'6G57M(RD>YMQ<@99^IJQ0 4'IQ110 4QT9F0ARH4Y('>GTBG<H.
M,4 ! /49HI:* (")6O 1Q$HYR.N:F "@ 9P/4YI:CBE\U6.QTPQ7##K@XS]#
MUH (I4F3?&VY<XSBJFJ:3#JT,4<LUS"8I!(DEO,T; @$=1VP3Q5_&.E54C0S
M+<NSH[9 7) /ID4 6NE%%% $<48B#*'=LL6^9LD9.<?2I*88U:59"/F48%/H
M :TB*P#, 3ZTX\BD)X)QGVH'"C.?QH ,4T2(7* \BG @]^G6D90?FV@L.A-
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M*T./E93G)[TZ5BH4[P@W <_Q>U5K7R+33HQ:68B4_,+>-0NTDY(P. <DY]Z
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MN[@1F5@J *6))^@-6!<12S/#%*C2Q8\Q >5STSZ5EC1]05PPUAI&7A7FMT+
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MMQ0!:+88#GFF.T@E553*=68GI[42.?*#1D'.,'MS3+B&.X0"0-\C!AM;!S0
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MIL(=8D263S)%4;G"[0Q]<=J &-!;MYFY58.1O!Y!QTI[R+%&TC'Y .@&3_\
M7J@=.%G(#I\*(DDC-,NX@9;DL/Q[4L-W<C67T\V,BVJ0B1;HG*NV?NX['KW[
M4 72)&9&# #^(8IT;.V[?'LPQ ^;.1ZT^FI(DB[D964]U.10 O./>E' &3D^
MM,5V:1U,;*%QACC#?2GCZ8H A:-Q.7W.R. NS@!>N3Z^E3 8&*K"^A.H&R&_
MS@GF'Y#C'UQBK!."!ZT !. 30K!AD'(JO=6:7,UO))+*JPOO$:OM5SC W>N.
MN.F:L !1@ #Z4 )L D+\Y(QUI'W[EVXQWS3Z1AN&,D<YX-  <XXZT4M% "*0
M<D?C2UDZ!I5SI%K<P76H2WS27+RK+*26"MC"GZ=/\*UJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***8\22,C,,F-MRG/0X(_D30 ^BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY
M8(9P!+%'(!R Z@XJ2B@"LNGV2.KI9VZNOW6$2@C]*BN-%TN\MWM[K3K2>!SE
MXY8%96^H(P:O44 8$O@?PM-LW^']- 0 *%ME4#'3H*@_X5[X3\Y)AHEL)$<.
M"N1R#D9 //(Z&NFHH C:%6!!+\^CD?UJ'[&2%!N9R ,8)'/N>*M44 <QJ/@;
M2]4OVOKF:[%RZ!'>.0*' Z9&,5IV^B_9-(CTVUO[N".)%1)%V%U4#&/F4C]*
MU** *<-I<0VYC^W2S/VDG12?_'0HK+MM%UN+5C=S>(WGMRA7[&;1%C'^T"#N
MS^-=!10!5DBO&;Y+B)5P./*).?KFJL]E?&?S+:2V3/+ADR"?7\O>M2B@#(6U
MU:,L1):E2O$62%W=CG;D59@2[1G>:.$G'"QL>3]2*O44 9Y;4GOK5U1(K8>8
M)XSAF;IL(.1COG@T^^C65H ]C)<A90PP5PAY^8Y(SBKM% '"/HVH66MB2WTR
M>6)M16<W+SJQVD_,<9S@ D#OP*ZZ;4HH"HDANLMG[EL[_P#H(-7:* *-S=E$
MBD5G50XW@PL2P].!Q4C:A;QQ-)([*JKN.4()'L,<U:Q10!D:5XCL-6LEND,E
ML&D,8CNU\I]P.,8/KQ^=0ZEJT689;;5K2*VCDVW>!O?G[JC'W3GC!'>MVC ]
M* ,^XO\ S;60:?+;-=!08UF8A#]2.:L6DSR6B/.T0FQ^\\HDJ&[X) J9D5_O
M*#]12&&,YS&AR,'Y10!0U#4O):*UMI(1>7 )A\T'8<<G..>E6'NH)+)Y5N8@
MG*^8&!4$<'\C3IK&TN559[6&55Y >,$#\ZC;2=.>V^SO8VS0 Y\LQ*5S],8H
M +*"*PTV&!!#%%&H51'\J#T _.KG:H9+6"2(1/&#&!@+T&*4P(4V?. /1R#^
M=  SN67RP&7)#'/2I"0 22,"J,>CV<5OY$0FBCYXCN)%ZDD\ALYR3S4MM806
ML7EQF9E_Z;3/*3^+$F@ EU"PAO$M9KRWCN7 *0M* [ G PN<GD&IXXTAC6.)
M%1%&%51@ 5!)IMI+=?:V@C-ULV+.4!=1SP"1QU-216YB _>R.< %FQDX[\"@
M":FJI#LQ8G/8]!]*38W'SGKGF@K(>CJ/^ __ %Z ';1NW8&<8S1SO]L5#+'<
MLA$<Z(W8^7G^M,*7HFRLL31_W64@T 3%"78L0R\87'0U)6/:V^LIKEQ//):&
MPD&$12V]< 8SQCU_.M*1Y@X"1!E/4EL8H <LL4DC*DB,Z<, P)'UIEW>6]C"
M)KF58HRP7<W3).!573-/-I+=2R1Q"665CO0=5SD9]_6I9&FFN);>6R#VNS[[
M,"'/IMH N45FOIT%SK,-_+;SK/!&4CD^T,%P>HV!MI/N110!)I<%S!;R+=7!
MG<R,0V, *>@ ],5>ID>2"QR,GH>W%/H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *E@Y83(SEWC<(Q/J%%6Z9&0=Q!4\\XI] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7M6G9I_.B6/$A";6
MW;EP,'IQ]*L56M"<SJ225DP21[#'Z8JS0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 06LC2([.,?-@?2IZHZ5<S75JTDZLK;R "NTX^
ME7J "BBB@ HHHH **** "BBB@ HHHH **I:EJ]AI"VYOKE8?M,R6\(.29)&.
M%4 =231+J]C#J4.G/.#>2KN6%068+S\QQ]T<8R<#/% %VBBB@ HHS@9-)N'J
M* %HI,CU%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4(OG0L9 2<$E/NY)./?K5/4/AM'<6NH6=EJLUK9WM^M^UN8E=8I%(;Y.F 6
M)'/MB@#H/#5S>WEG)<SWT=[:R-FVE$/E/@<$,,XZC((QUZ53TGQA#J?C'5]!
M$:H+*))(9=W^O&660CV5QM^N:N6&F:M:"^>;4K65Y8]MO%#:F&*%\L2Q!=BQ
M9FR3GM7-I\/Y[+6O#NJ6$\0N-/5X[UIII7^T(XPP 8G;R6?'3<: +NB^+M2\
M0Z/=:[IFFQ2Z8DDB6T+.1/<JAP7!&0,D, O? Y&:9J'CR:QO?$D0TM)8M 6&
M2Z*W&'>.1"^57;C( Z$CZUG?\(1K^F^&3X:T/4(K2TAO/M%K=I<20R)$SEFB
M8*#NQN8 YYXZ$5E^(/AYK6LZWXLOHQ'"U^]K-8,9<J6@3:4E7&"K]<<C@9H
MZR7QK*^O6^E:=I#WDESIPU*%_/6,-$3C!ST;)'MSUIW_  G*)KMGHTFBZB+Z
M[L?MJ1 1@J.Z-N<88'CT]ZYF?1M;U'QKIFM:EH%S!:VNEBWE2TN4SYZR"0;
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MP7,)BB>42%01(J[<[0#N_C'.,'GGBGMXML(IHX;B"]AFD=D"&W+[2I4,24W
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M8 LA_N@C)QD8X'2GI'A6\N8HTO9IH[6);F$K-'B:=)PNYF;S&PP8?>[Y(VC
M)UY?%?V76AIUW:I$3?+:!_.ZJ\6]),$#@D%,=B.]9MAXK-CJ>H?VFMTMC/<E
MX+B4?) @M(YBA[]%F;IQC!Y- $;^![]K>V\R71KF>U8(BS:?B.6+:5/F#<=S
M]#D8 Q@ 9-7(- U>"]MG\K3###?_ &A@C,FZ,6A@ "A" 2<'&2 .,G%%MX]L
M-6DCM--BN3<REXV9HP5MF\OS%+X;^(<C![$'!!%2Z+XTTR[\/Q7=S=EYXK>%
MKGRX'.6=,Y10,L.&^[D?*?0T <YI?A#4["WLK>_TM-06&Q@7<E^T8CDBA$13
M9D*X8 D$@??8'BF0^'[NU>U4^&Y(XK5--E*P>4=\L9D64C!Y(#IR<$@&N^M-
M>TF^N1;6FI6LTY7<(XYE9B, YP#TPRG/N*M_:[;[0UO]HB\Y5WM'O&X+ZD=<
M4 <1X6G.AWES%<Z??)%>7,<<4[VS*VYMYQ+R5)4@+YH^]N3/3-:WCJ:2WT>R
ME2\N+.,:C;+-+ Y5A&T@5NG;!YSQW[5T;K%+L8JCE&W(3S@],CWP366$M?%6
MBV5RZW,$321W*+N".&0Y7=@D<$ XR1Q0!PC:KK%M%<FRUB[G:RLKRYLH&VN;
MM(Y"(RV0688.W(.6"J>_-M_$.J_VL+#3]7$]I)>6J17LD:.2)HI69.  2I16
M&,?? ->C[5]!5=M.L75%:SMV5)/-4&,$*_\ >'O[T >>7?B#63ITL=\VFWUN
MUH)L26Q 8I.(FR-_4Y#9['M6M)XPU.WU2ZT^6RMUN5G$5O"V5+HS824,3AUQ
MG(^4AL+W!KIIM"TF>/RY-.M2OEF(#R@,(3DK],X./4 ]JIR>%=!NX[G?8Q2I
M<%M_SD@$L&8IS\A+J&.W'S#/49H R8?&&IIK.G:9J6D1V4MU@$RS\2'<P;RR
M 5) "MM)#8;ID5V6>,UA#PGIL8@6#SXHH=N(1,Q1RK[U9LY)8/SNSD]R1Q5W
M1-/FTS1K:RN+N:[DB7:9IGW.PSQEOXB!QGOC- &3%XSMY(5N/[/O1;SLJV<@
M12+IF8JH7YN"<9^;'R\G&#B2V\9Z;<7$5NT=S%,YG1ED0?NWA_UB-@G# 8/<
M$$$$BJB^!((H5AAU?4%A@G^T64)*;+5]^_Y0%!89R,,3\K$#%2R>"[>:VC#W
M3BY_M(ZC+,B@;V8%'3'93&2G7..>30!9;QGH48!ENVB'E-*3)"X "H)&7.,;
MPIR5ZX!XXJQ!XHT2Y@>:+486C1@I.<$DKN&!U.0"1CJ ?2L;4O"NHW$^J+;7
M%@;6[AE\OS[?,T4CH5(#CHF3GH3R1TZ5KCPSKT=]-=6AL'\S[+N0SO$S".)T
M8!PA*<L"".< CC- '4)K^D22)&FIV9DD"%$\]=S;QE,#.?FP<>M.M-:TV^C>
M2VOH)$29H&8.,;U.&7Z@D#\:X&U\)ZW96-Q!/IMI<R)865K$T<P8.8;AY&Y8
M C*NI^J_2EUKP[J4ME<+'I4LEW'?7DENRF.2&9)CNVR(6!V-PI(PRE01Q0!Z
M!8:7:::]R]I&4-U*9Y?G+!G/4\GCM5OC/:L_2-2;4HKD/9W%J]M<-;LLP'S;
M<$,I!.5(((-<#K%Q)#\0/.D34+:-;PQ2ND4Q#P-:, PD'R*GF;/E'(92Q([
M'IC)'(0656(.1D9P:@FTRPN(I8IK*VDCE(:1'B4AR.A((Y-><:.RH_AN6;6M
M79Y]$>\FA%S(S2S1>02-I/7_ %@*@#/S9J"R\3:C=JD5GKS$RC3)MWF1RR 3
M3&*3<I7"D@QY5>%)'//(!ZK%%'!"D,,:1Q( JH@P% Z  =!56/2+"&:":.UB
M22 2")E7&SS#E\?4C)KBEU[6H[7[.EZ\\T#:BJRF%6DF:!P(E=57&""<E0,G
M:!@FK]AKGB6^U*6*&TMVBMIQ;7&Y=@!\E'+9+E@=SCY=I^7OF@"Z/ ND)##%
M$]W$L5O<6R[9B<QSG+J<YSSR,]"!5W3?#EMIFJOJ$5Q<O(UG#9E)&!79'N*G
MIG/S-GZURL7CO7/[(74I-*L&B?1DU=56X92(PN9%)VG+8(V]!ZFMD>,FEU&6
M&VTNXN;:.;[.98@2QE\OS,;<8V_P[BW#=<#F@!^I^$#J/]M'^T'B?49+>:-E
M0'[/)#M*,.?F^9%.*I:GX6UW5+&%;K4K%[V)F>*X@@:W:U<@!7C(9B<8.5;A
MLXR *A/Q)CDT)]2@T._!-JEY"DS1*)820"X(<X"DC(//(P.>.AM_$]A<:P=*
M"W"70?RCNB.P2>6)"F\97<%.<9H XU=#N/%FG:G8PS11VRZM=,+I9#YBML=!
MA=N!RP.<\CZT]- U>$6E_P#\(Y;+<6$\32P17?FM>J(Y8R5+X V^8&4-CN..
M*](P!5>*_LYY)XXKJ!W@_P!<JR F/_>&>.AZ^E '):)I3V?BRVN6T,V<+Z;Y
M484K(+=A+(Q4L.A*N.G&<@$U4\9V-RGB"74--L96U"31+J*">&)MQE!0JN\#
MAMN_;D]>E=^KJPRK @]P:7(]: .-\,S^?XHO&TVXNY-'-C S+<-(PCGRPV@O
MR#L"[E[<9Y-8WBN^<ZMKEO)JT\=O;W6C2;5<8M]UP Y ((QC:V#D9P>AQ7I0
MQVJ.6VMYU=98(Y%<8<,H(8>_K0!R&E:U?+XS>QO]0:6VN6F6P\H1M#+LQN4D
M#>DB8;()(.[CI@3>(]=U71O$5F ]M'HLJQI+.T1D,4K28_>88%%9<A6P1NSG
MBNABTG3+6\:^BL+6&YPVZ=(E5B#@G+8SS@?E5:^T#2-<ECN[JW2XRB@,)#M=
M0=R@@'##)S@Y'- '-S>)+R\TG3[:[M;>9=1N]0TZX**0H$/G@, 2>HAZ$GK6
M6FLS)X%ATK5-)4VI\.B^C:&^9#+'$L>]20H*-AT/&1SC-=A_PAVB_:5N!!,K
MBY:[VK<R!/-8,K$+NP,AVR !G/-8NM>$'@T*XT_2H9;R:ZL)=+CENK@#['"Z
MD#'&2N=N>K85>N* +8\;6\6HBRCTV]>WBNH[&29(F81R,BMDG&-@# $DY'/&
M.:BU+QXUOX>EU6QT2^N4^Q+>P,P5(Y(V.,[MQP<$-@C.#TZXT7\+,FN/J%GJ
MMW:0W$D<EY:1A#'.R  ')!*Y 4-@C(4"LE? E\GAR[T/_A()I++[*UK8QO"
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MD  C?+ '<-J\;@"5'% $-EXYT6SL;"&6ZNG:4?,;HIYR R&,%P",_,I'R@X
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MOK?PI-'#HD]M=6_A^:SO1!;L?M%QE%A*%1F0@J[[NP89ZFO8Z* .:O;*QLO
MFH"SDGM[9[66</YSHZE@6SN)W+R>G&.E<+]KOK"ST^T7Q4]M%?::E[%>ZC=8
M3[1\@90^,%5"Y\OOO?/8CU_K4$ME:SHB2VT,BHVY5= 0#ZC/>@#SJ36_$5I>
M7=VVLK-#;ZS;61M#;KATGBA)V\!OE:;<O.<*=V<\26'BKQ*+6R5WM;ZYOS<K
M;B.  CR'=6X,BAMPV$ $$ -UKJ-.\+PVVMZIJEZMG=W%W=K<PR&U"R0;8UC"
M[B23@*.1CEF]:?-X/T.?34T]K/;;1S>?$$E=&BDSG<C AE.<]".I]30!@_\
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MYO7+ XR<=,G%<;I\=JTT$]CIDMI9#0)X]9BDC:)5D7:$#\#=)E9.>NTYZ$4
M=[I^JVWBO3;B'[%?V]M/;J0\Z>7YL4@.&1@3V!XX89&0,BM2PL8M.T^"RB9V
MB@01H9&W':!@ GOQ7-^#+FV@^&&EW44F$CTY))2A\PHXC!<8)/(8$8[8Q7"Q
M^*=3LM'OQ9ZM*SC2;.\BDFN1<.9&FV,S]0FX$9120.Q% 'LK1HQ4LH)7[I(Z
M54&CZ8LMS*NG6@EN@5N'$*[I1Z,<?,/K7%:AK&NZ0-9)U1[F#2KNTGF=X(][
M6S@>:G  &!E@<9P,>]=7H%Y=:A:7%[++')!+</\ 9-@_Y8@[5)/?=@L#Z,*
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MV!N-R#.0I') RW% '6T5FZ FI1Z);)J]P+B^"GS90@3=R<$J. <8R!QG-:5
M!1110 4444 %%%% !1110 4444 %%%% %330PL4WJ5;<Q((.?O'UJW5339+F
M6Q5KM%6;>X(7I@.0/T JW0 4444 %%%% !1110 4444 %%%% !1110 4444
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M[CGD83LR!5C"\[AGNZC&.^>U '045G:!JR:[H%CJJ1-$MU"LGEL<E<]1GO\
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M?RRI.$9@AP<9()Q75:#_ ,B[IF?^?6+_ - % &C1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 8UC)_Q-[^+(RDBC'ID;OZY_&MFLRVA_XFEY
M*. S)GCJ0,5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %;4-/M-5LI+*_MTN+:48>*095AG/-30PQV\*0PH$CC4*JKT '
M  I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 06Z;=V3
MEOXB!C)J>HH#NC+9)RS=?J:EH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *.CWUOJ6DVU[:2M+;S+OCD88W+G@U>ID,:10I'&H55& H
MZ"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/29+R
M72;1]1CACO3$OGK"V4#XYVGTSTJY4-K'#%:QI;J%A480#L*FH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BFEF$JJ$RI!);/0\8&/S_*G4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M2TB6TGT>SEL'#V;PJ86 P&3'!Q]*NU5TVV@L],M;:VA6&"*)5CB4Y"*!P!]*
MM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5NRM;1,
MA!4J"".XQ4M16L1AM(8B02B!<J,#@5+0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ,A.Z%#@C*C@]J?4-K&L5I#&B>6BH J9SM&.E34
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;3YC<:;:S
ME54R1*Y5>@R <#VJS4-JJ):0K$JI&$ 55Z 8X ]JFH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &0IY4"1CHJ@4^HK60S6D,I7:70-M
M],CI4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!' 5
M:",KG:5!&?2I*9"%$"!!A0HP/04^@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH BMX_)MHHLD[$"Y/L*EID7,2?04^@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :@PBCT'>G4BG<H;U&:6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0#: !VI:13E0:
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0#  SF
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H(SWHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **CD64RQ%'54!/F KDL,<8
M.>.<>O\ 6I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 9%$D$2QH,*O04X+@#D\>]%% %9K>
M&&*1O*&QFWN/<8Y_058PKKR 01WHHH J?V;'&2;61[<GM&?E_P"^3D?I3I9Y
MK6)Y)5$J(I8E.#P,]":** $TS5+75[,75HS-&25^92"".HJY110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /9 NL# 2(  A$! Q$!_\0
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MH ?)?6D5PEO)<PI,YPD;. S'V'>IZX_3/!.DZ7J:WE[?SW]X\@>,W<@^^.A
M')(QWS[5U?G*'1&*[F&1@T 2UPWC7Q?K/AWQ#HEGIMC!>07I8S1[',H"D$[<
M'J5W8X/W3782W:AFA@*37"A6,0D 8*3C=SVZ_7%5X[&)=5EU"XMHS<"(1K<$
MY(0$G'^S]XYQU_"@"S<0"\@0>;+%R'!C;:?H?\*9%$EMB)6GFD4%LR.QSD^I
MX[=.WXT[SXWB47&V*0J'*%P2OXCM4XD0H'5@5(X(Y!H J:AIT6HVPA=B@#A_
ME]??\_SYJ:"$06<4"NSB- @;/)P,9-)9745[;BXA5@KG^-"I)Z=#4H+>:1L^
M7&=WO0 ; Q0G.5Z?,?U]:S9=97_A(+?28$$CLCR3,&'[M0!CCW++],^]5=?N
MKC3Y(+N&4^:ZO;+#@E26*D/CNRA3@=]U+H>DS:792SR$2WTRY;<<9/)Y/J22
M2?4^U &E,MP-1@DC+^7@JZ[AM([''J#_ #-.U*QMM3TVXL;R#S[:="DD>XKN
M![9!&/KFHYWU)HP;6*!7!Y$Y.#]-N:F@8W%MLG\OSE 698G)"/@$@'@]QSQ0
M!+#$D$$<,8VQQJ%49)P ,#DTXD!23T%*!CI43)MG:=I7V!,>7_".^?7- $B@
M <#&>>E,D2$M&9%3<K90GJ&((X]\$_K44+RSV9D29"S@F-_+( ],J3D_F/PJ
M.2&8VBY\J:^BB($C+M!?'IG@$C.* +:((T"KT%,C:1T;S8PA#$ !LY'8^V:$
MD,=LC7+QJX4>8<X4'_\ 75768;^XTBXCTNZBM;UE'E2RQ[U!SG!&1P>GMG-
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M.9'7:,%S_>]??-<5XKA;3?$.IPO//]GU_3C';(MRZ$7L9PJH0?E+!UZ#^ T
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M\Z.,2KN=/[P&<E??I0!:HJC'K.ERI;O'J5FZ7/,#+.I$O./EY^;\*O9XSVH
M**K_ &^S\J67[7!Y<3;9'\P80^A/8U*)HV"E9%(<94@]1[4 /HJ-9XG1721&
M5ONL#D'Z4_<,XR* %HK+O-=@LM?T[2)(9C+?K(T4JA=@,8RP/.<X]L>]7;R]
MM["W^T74RQ1!E0NQP,L0H'XD@?C0!/16?8ZQ;W][J-I&LB26$RP2[P "S(KC
M;@\C#CTJQ;W0GDN4,,T7D2^7ND7 D^4'<OJO.,^H- %BBBLVPURTU'5-0TZ
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MJ5EJIN%U#[9;W=J81;I&44%&<CS, *%* X; /T]'%[;@1B2>))'V_(9!G)Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKO%)J7SY=4V*PW'82H)VG;MR 3SFLO0_#FIZ/I.A:>US:S+I\[O*^UE+HRN
M .<'Y\_\!KJZ* .,G^'ME-J6J 2;=(U"QDMVL@/EBED8,\D>>%SM4XQ]X9[F
MM'2HO%4 CL[YM,>"':HO(F</*H'>(C ;.,_,1UXKHJ* *MC]OQ<?;Q; ^>_D
M>06/[K^'=G^+UQQ5JBB@ HHHH ***;O7!.X8'4YZ4 .HJ.&X@N 3#-'*!U*,
M&_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!$8/<YR6(ZGV KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI 0>A!YQ2T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
MR]]XMN;35=1L8]$GG-A;I=2LLZ#=&Q8 J#W^1^"1T'K4D?C.QN_"\>O:=!/>
M0LZQ-"NU)4=F"[6#$8() QGOGI0!TE%<R?%L_P#;-]IL?AW4II+)8WF>)X2-
MK@[< R G[K<=L42>.=,%MI]Q!!=7$=Y>?8/W:JK03]-DBNP*G(/8X_*@#IJ*
MYW4O%T&D6]_/>Z9J$4=D8O,;8A#+(2%92&P1N&".H[C!!J*\\<6&GVFIS7=G
M?12Z9&LMS;M&OF+&Q(#CYMK+D'H3TH Z>BL6'Q$)'V2Z5J,#F)ID62-3Y@4
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MN[GDMXYW6ZC3S#;30R13%?41LH9A[@&J@\;:";&.]-W,()+AK5&-I,"TJ\%
M-F2<Y'3J".QH Z"BLJ+Q)I,]A=WD5WNBL\BY41OYD)')#1XW*<<X(Z<U%8>*
M]&U.:WBM;F0M<#,/F6\D8E^4M\I90#\H)X["@#:HK%D\6:'$[AKX;(Y/*>98
MG,2OG&TR ;0V>,9SGCK0_BW0X[DV[7P$WF/$$\IR69,[@O'.,'./2@#:HK+D
M\1:3':VUQ]L5TN5+P+$K2/(!U*HH+'&>>..].?Q#H\>FKJ+:E;?8F8()Q("F
MXG&,^N>/KQ0!I453L=5T_4_-%C>0W!A;;*L;@F-O1AU!]C5R@ HHHH ****
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MP/FYZ>N#GZ4?$:[L[3P[:O>311J-3LF D<*&"W$9;KZ*"3["NM\N/?OV+O\
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M%[2VEGCFDMXFEC_U<C("R?0]JFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGK@^AJ,WCWCR061^X2KW!7**>X'(R?T!Z^E3VUI':ABI9Y'.7D<Y9OJ?Z=J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOH5Q9M:3:5:26[3&X,;Q CS#U?\ WCSD]\T 0Z)>:I?_ &2YO);%$DM!YMM
M^\B8-AF5@<%.U;M5(=+L+>ZCN8;2&.:*'[.CH@4K'D'8,=L@<59D3?&R9(W
MC(ZB@#"3Q1:QZ)<ZE>200(DDRPJ91F94=E4C/=MO ]ZM'61'I4-T8GDE=1E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2&9F'\.=B #.>#G!.!T>** .+M[?4+J=KB?1)C;33?:<>:L<DA&-@E!(/RX
MV].!G-:]E<:O<ZQ>+=6CV5N]K']F^<28?+;]V. PRO&3D=^H&[10!Q%_=:N+
M9-1OK9EETU(T ,9,37#G8\P RQ1%;/T)Z$9&KX9O[>]63[/X@MM50*#MA1%\
MK_OGI]#S714@4+T 'TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 0L!1N&*6B@!"R@<FDWKC.X8^M.HQ0 TNH&2P
M]:0S1KG+J,#)R1P*?1B@!HD1NCJ?H:198V)"R(2.N&%/HP* &^8A) =>/>E#
M*>A!^AHP/2C ]!0 M%)@ ]*38N[=M&[UQ0 ZBDP/2EZ4 %%&,=** "BBB@ H
MHHH *0J&QD X.1FEHH SEL)I=:34)W51#"\,4:'((9E)8DCK\B\?7K6C110
M48YS110 F :9/!#<P/!/$DL3C:R.H96'H0>M28HH , 5%!;16R,D*!%9VD('
M=F))/XDDU+10!4DTO3YK>&WEL;:2&$@Q1O$I5".A4$<?A5H *  , = *6B@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A!/ICO2T44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M(<;NO)%*,]Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &"52
MVT9/N <?G3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **3G/M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44$XZT4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :
M*** "BDQUYH)P?NDT +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %!&1BBB@ HH[T4 !&112;AD#GGVI: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ^QHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $7./FQGVI:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ .>U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !39"X7]VJLV1PS8XSR>A[9_P#K=:=10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0> >,^U
M%% !VHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HH.>U% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 44A&2#D\4M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$X'-%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>19
<FILENAME>ex10_3.htm
<DESCRIPTION>INDEPENDENT DIRECTORS CONTRACT BETWEEN THE COMPANY AND TIMOTHY G. GLYNN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CBD BRANDS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEPENDENT DIRECTOR&rsquo;S CONTRACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;)
is made as of March __, 2019, and is by and between CBD Brands, Inc., a Delaware corporation (hereinafter referred to as the &ldquo;<U>Company</U>&rdquo;)
and Timothy Glenn (hereinafter referred to as the &ldquo;<U>Director</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BACKGROUND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors
of the Company desires to appoint the Director to the Board of Directors of the Company and to have the Director perform the duties
of an independent director and the Director desires to be so appointed for such position and to perform the duties required of
such position in accordance with the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 4in"><B>AGREEMENT</B></TD><TD STYLE="text-align: center"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration for the
above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged,
the Company and the Director hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>DUTIES</B>.
The Company requires that the Director be available to perform the duties of an independent director customarily related to this
function as may be determined and assigned by the Board of Directors of the Company and as may be required by the Company&rsquo;s
constituent instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and board
committee charters, each as amended or modified from time to time, and by applicable law. The Director agrees to devote as much
time as is necessary to perform completely the duties as the Director of the Company, including duties as a member of board committees
as the Director may hereafter be appointed to. The Company represents that the time required for Director to carry out his duties
as described herein shall be approximately five (5) hours per month. The Director will perform such duties described herein in
accordance with the general fiduciary duty of directors arising under the Delaware General Corporation Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>TERM</B>.
The term of this Agreement shall commence as of the date of the Director&rsquo;s appointment by the board of directors of the Company
(in the event the Director is appointed to fill a vacancy) or the date of the Director&rsquo;s election by the stockholders of
the Company and shall continue until the Director&rsquo;s removal or resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: justify; text-indent: 0.5in"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>COMPENSATION</B>.
The Company will pay the Director a director&rsquo;s fee of $1,000.00 per quarter, per annum, payable on the first day of each
calendar quarter. This fee represents a retainer for services rendered as a member of the Company&rsquo;s Board of Directors,
and is in addition to any fees to which the Director may be entitled under guidelines and rules established by the Company from
time to time for compensating non-employee directors for serving on, and attending meetings of, committees of its Board of Directors
and the board of directors of its subsidiaries. In addition to the foregoing, the Director will be granted 50,000 shares of restricted
common stock/options (the &ldquo;<B>Shares</B>&rdquo;) each year of the term hereof. [The option&rsquo;s exercise price will be
USD $.25/share. The option shall expire 3 years after the date of execution of this agreement. The stock option grant shall be
evidenced by a stock option agreement (the &ldquo;<B>Stock Option Agreement</B>&rdquo;) and the stock options will be subject
to the terms and conditions of such Stock Option Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>EXPENSES</B>.
In addition to the compensation provided in paragraph 3 hereof, the Company will reimburse the Director for pre-approved reasonable
business related expenses incurred in good faith in the performance of the Director&rsquo;s duties for the Company. Such payments
shall be made by the Company upon submission by the Director of a signed statement itemizing the expenses incurred. Such statement
shall be accompanied by sufficient documentary matter to support the expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>CONFIDENTIALITY</B>.
The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished,
the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs,
including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets
of the Company (&ldquo;<U>Confidential Information</U>&rdquo;). The Director covenants not to, either directly or indirectly, in
any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NON-COMPETE</B>.
During the term of this Agreement and for a period of twelve (12) months following the Director&rsquo;s removal or resignation
from the Board of Directors of the Company or any of its subsidiaries or affiliates (the &ldquo;<U>Restricted Period</U>&rdquo;),
the Director shall not, directly or indirectly, (i) in any manner whatsoever engage in any capacity with any business competitive
with the Company&rsquo;s current lines of business or any business then engaged in by the Company, any of its subsidiaries or any
of its affiliates (the &ldquo;<U>Company&rsquo;s Business</U>&rdquo;) for the Director&rsquo;s own benefit or for the benefit of
any person or entity other than the Company or any subsidiary or affiliate; or (ii) have any interest as owner, sole proprietor,
stockholder, partner, lender, director, officer, manager, employee, consultant, agent or otherwise in any business competitive
with the Company&rsquo;s Business; <U>provided</U>, <U>however</U>, that the Director may hold, directly or indirectly, solely
as an investment, not more than one percent (1%) of the outstanding securities of any person or entity which is listed on any national
securities exchange or regularly traded in the over-the-counter market notwithstanding the fact that such person or entity is engaged
in a business competitive with the Company&rsquo;s Business; provided further, however, that none of his duties with Rosendin or
its affiliates shall constitute competition with the Company. In addition, during the Restricted Period, the Director shall not
develop any property for use in the Company&rsquo;s Business on behalf of any person or entity other than the Company, its subsidiaries
and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>TERMINATION</B>.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination.
Nothing contained herein or omitted here from shall prevent the stockholder(s) of the Company from removing the Director with immediate
effect at any time for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>INDEMNIFICATION</B>.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Delaware,
and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the
Indemnification Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in
the Director&rsquo;s official capacity and as to action in another capacity while holding such office. The Company and the Director
are executing the Indemnification Agreement in the form attached hereto as Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company represents
and warrants that it currently maintains a policy of Directors &amp; Officers insurance that will cover the Director for all acts
within the coarse and scope of his duties as a director of the Company. Further, the Company covenants that it will maintain a
policy of Directors &amp; Officers insurance with the broadest available coverage covering Director, without set-off for any amounts
paid for the errors or omissions of other directors or officers for so long as the Director continues to act in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>EFFECT
OF WAIVER</B>. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOTICE</B>.
Any and all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature
page hereto or, if to the Company, to the Company&rsquo;s address as specified in filings made by the Company with the U.S. Securities
and Exchange Commission.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>GOVERNING
LAW</B>. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the
laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ASSIGNMENT</B>.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder
shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the
Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without
the prior written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>MISCELLANEOUS</B>.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such
invalidity or illegality, the remaining terms and provisions of this Agreement shall remain in full force and effect in the same
manner as if the invalid or illegal provision had not been contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ARTICLE
HEADINGS</B>. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>15.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>COUNTERPARTS</B>.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument. Facsimile
execution and delivery of this Agreement is legal, valid and binding for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="letter-spacing: -0.15pt"><B>ENTIRE
AGREEMENT</B>. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect
to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or
warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Independent Director&rsquo;s Contract to be duly executed and signed as of the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 9pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD BRANDS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BY:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid">Name:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEPENDENT DIRECTOR</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;BY:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Address:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>SS#</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>20
<FILENAME>ex10_4.htm
<DESCRIPTION>INDEPENDENT DIRECTORS CONTRACT BETWEEN THE COMPANY AND CHRISTOPHER MELTON
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CBD BRANDS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEPENDENT DIRECTOR&rsquo;S CONTRACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;)
is made as of July 29, 2019 and is by and between CBD Brands, Inc., a Delaware corporation (hereinafter referred to as the &ldquo;<U>Company</U>&rdquo;)
and Christopher Melton (hereinafter referred to as the &ldquo;<U>Director</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BACKGROUND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors
of the Company desires to appoint the Director to the Board of Directors of the Company and to have the Director perform the duties
of an independent director and Audit Committee chairperson. The Director desires to be so appointed for such position and to perform
the duties required of such position in accordance with the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 4in"><B>AGREEMENT</B></TD><TD STYLE="text-align: center"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration for the
above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged,
the Company and the Director hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>DUTIES</B>.
The Company requires that the Director be available to perform the duties of an independent director customarily related to this
function as may be determined and assigned by the Board of Directors of the Company and as may be required by the Company&rsquo;s
constituent instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and board
committee charters, each as amended or modified from time to time, and by applicable law. The Director agrees to devote as much
time as is necessary to perform completely the duties as the Director of the Company, including duties as a member of board committees
as the Director may hereafter be appointed to. The Company represents that the time required for Director to carry out his duties
as described herein shall be approximately Ten (10) hours per month. The Director will perform such duties described herein in
accordance with the general fiduciary duty of directors arising under the Delaware General Corporation Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>TERM</B>.
The term of this Agreement shall commence as of the date of the Director&rsquo;s appointment by the board of directors of the Company
(in the event the Director is appointed to fill a vacancy) or the date of the Director&rsquo;s election by the stockholders of
the Company and shall continue until the Director&rsquo;s removal or resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: justify; text-indent: 0.5in"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>COMPENSATION</B>.
The Company will pay the Director a director&rsquo;s fee of $1,000.00 per quarter, per annum, payable on the first day of each
calendar quarter. This fee represents a retainer for services rendered as a member of the Company&rsquo;s Board of Directors,
and is in addition to any fees to which the Director may be entitled under guidelines and rules established by the Company from
time to time for compensating non-employee directors for serving on, and attending meetings of, committees of its Board of Directors
and the board of directors of its subsidiaries. In addition to the foregoing, the Director will be granted 33,000 shares of restricted
common stock/options (the &ldquo;<B>Shares</B>&rdquo;) each year of the term hereof. [The option&rsquo;s exercise price will be
USD $.25/share. The option shall expire 3 years after the date of execution of this agreement. The stock option grant shall be
evidenced by a stock option agreement (the &ldquo;<B>Stock Option Agreement</B>&rdquo;) and the stock options will be subject
to the terms and conditions of such Stock Option Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>EXPENSES</B>.
In addition to the compensation provided in paragraph 3 hereof, the Company will reimburse the Director for pre-approved reasonable
business related expenses incurred in good faith in the performance of the Director&rsquo;s duties for the Company. Such payments
shall be made by the Company upon submission by the Director of a signed statement itemizing the expenses incurred. Such statement
shall be accompanied by sufficient documentary matter to support the expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>CONFIDENTIALITY</B>.
The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished,
the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs,
including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets
of the Company (&ldquo;<U>Confidential Information</U>&rdquo;). The Director covenants not to, either directly or indirectly, in
any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NON-COMPETE</B>.
During the term of this Agreement and for a period of twelve (12) months following the Director&rsquo;s removal or resignation
from the Board of Directors of the Company or any of its subsidiaries or affiliates (the &ldquo;<U>Restricted Period</U>&rdquo;),
the Director shall not, directly or indirectly, (i) in any manner whatsoever engage in any capacity with any business competitive
with the Company&rsquo;s current lines of business or any business then engaged in by the Company, any of its subsidiaries or any
of its affiliates (the &ldquo;<U>Company&rsquo;s Business</U>&rdquo;) for the Director&rsquo;s own benefit or for the benefit of
any person or entity other than the Company or any subsidiary or affiliate; or (ii) have any interest as owner, sole proprietor,
stockholder, partner, lender, director, officer, manager, employee, consultant, agent or otherwise in any business competitive
with the Company&rsquo;s Business; <U>provided</U>, <U>however</U>, that the Director may hold, directly or indirectly, solely
as an investment, not more than one percent (1%) of the outstanding securities of any person or entity which is listed on any national
securities exchange or regularly traded in the over-the-counter market notwithstanding the fact that such person or entity is engaged
in a business competitive with the Company&rsquo;s Business; provided further, however, that none of his duties with Rosendin or
its affiliates shall constitute competition with the Company. In addition, during the Restricted Period, the Director shall not
develop any property for use in the Company&rsquo;s Business on behalf of any person or entity other than the Company, its subsidiaries
and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>TERMINATION</B>.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination.
Nothing contained herein or omitted here from shall prevent the stockholder(s) of the Company from removing the Director with immediate
effect at any time for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>INDEMNIFICATION</B>.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Delaware,
and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the
Indemnification Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in
the Director&rsquo;s official capacity and as to action in another capacity while holding such office. The Company and the Director
are executing the Indemnification Agreement in the form attached hereto as Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company represents
and warrants that it currently maintains a policy of Directors &amp; Officers insurance that will cover the Director for all acts
within the coarse and scope of his duties as a director of the Company. Further, the Company covenants that it will maintain a
policy of Directors &amp; Officers insurance with the broadest available coverage covering Director, without set-off for any amounts
paid for the errors or omissions of other directors or officers for so long as the Director continues to act in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>EFFECT
OF WAIVER</B>. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOTICE</B>.
Any and all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature
page hereto or, if to the Company, to the Company&rsquo;s address as specified in filings made by the Company with the U.S. Securities
and Exchange Commission.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>GOVERNING
LAW</B>. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the
laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ASSIGNMENT</B>.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder
shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the
Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without
the prior written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>MISCELLANEOUS</B>.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such
invalidity or illegality, the remaining terms and provisions of this Agreement shall remain in full force and effect in the same
manner as if the invalid or illegal provision had not been contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ARTICLE
HEADINGS</B>. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>15.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>COUNTERPARTS</B>.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument. Facsimile
execution and delivery of this Agreement is legal, valid and binding for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="letter-spacing: -0.15pt"><B>ENTIRE
AGREEMENT</B>. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect
to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or
warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to
such subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Independent Director&rsquo;s Contract to be duly executed and signed as of the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 9pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD BRANDS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BY:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid">Name:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEPENDENT DIRECTOR</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;BY:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Address:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>SS#</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>21
<FILENAME>ex10_5.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT WITH DOUGLAS O. MCKINNON
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">Exhibit 10.5</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 3.55pt 169.75pt 0 155.05pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 3.55pt 169.75pt 0 155.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYMENT
AGREEMENT</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/107% Times New Roman, Times, Serif; margin: 0 5.05pt 0 9.05pt; text-align: justify; text-indent: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
EMPLOYMENT AGREEMENT (the &quot;Agreement&quot;) is made by and between CBD Brands, Inc., a duly organized Delaware corporation
(&quot;Employer&quot;), and Douglas O. McKinnon, a resident of the State of Colorado (&quot;Employee&quot;).</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 150.3pt 0 155.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESSETH:</FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 7.7pt 5.5pt 0 43.1pt; text-align: justify; text-indent: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Employer needs persons with experience at the executive level in developing and executing the business plan and related financial
and reporting systems of start-up companies with the intent of listing on a recognized exchange;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 43.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Employee has a substantial amount of the executive experience needed by Employer; and</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt/108% Times New Roman, Times, Serif; margin: 0 5.95pt 0 43.35pt; text-align: justify; text-indent: -0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Employee is willing to be employed by Employer, and Employer is willing to employ Employee, on the terms, covenants and conditions
hereinafter set forth; and</FONT></P>

<P STYLE="font: 9pt/108% Times New Roman, Times, Serif; margin: 6.5pt 6.3pt 0 8.6pt; text-align: justify; text-indent: 34.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of such employment and other valuable consideration, the receipt and adequacy of which is hereby acknowledged,
Employer and Employee hereby agree as follows:</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 8.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
I. EMPLOYMENT OF EMPLOYEE</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0 6.05pt 0 8.25pt; text-align: justify; text-indent: 34.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employer
hereby employs, engages and hires Employee as Chief Financial Officer of Employer, and Employee hereby accepts and agrees to such
hiring, engagement and employment, subject to the general supervision and pursuant to the orders, advice and direction of the
Chief Executive Officer and Board of Directors of Employer. Employee shall perform duties as are customarily performed by one
holding such position in other, same or similar businesses or enterprises as that engaged in by Employer, and shall also additionally
render such other and unrelated services and duties as may be assigned to him from time to time by Employer.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 8.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
II. COMPENSATION OF EMPLOYEE</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0 7.7pt 0 8.25pt; text-align: justify; text-indent: 34.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employer
shall pay Employee, and Employee shall accept from Employer, in full payment for Employee's services hereunder, compensation as
follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 8.85pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.8pt"></TD><TD STYLE="width: 33.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">A.</FONT></TD><TD STYLE="text-align: left; padding-right: 8.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
                                         of Agreement. Employee is aware of the general financial condition of the Employer and
                                         has agreed to waive Salary until such time as Employer has completed a satisfactory offering
                                         such that the Company can commence paying salaries to the executive team. In consideration
                                         of Employee's executing this Employment Agreement, Employer shall issue to Employee up
                                         to 300,000 shares of its common stock (&quot;Employee Shares&quot;). It is agreed by
                                         Employer and Employee that such shares shall be valued at par value and issued and released
                                         from escrow as follows:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 112.7pt"></TD><TD STYLE="width: 14.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">i.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000
                                         Employee Shares shall be issued upon signing of this Agreement;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0.75pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 110.05pt"></TD><TD STYLE="width: 16pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">ii.</FONT></TD><TD STYLE="text-align: left; padding-right: 16.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
                                         i) 100,000 Employee Shares or ii) an option to purchase 100,000 Employee Shares, issued
                                         pursuant to the Company's contemplated equity incentive plan, shall be granted to Employee
                                         on the one year anniversary of this Agreement, subject to Employee's continued employment;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/9.3pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 107.4pt"></TD><TD STYLE="width: 18.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">iii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
                                         i) 100,000 Employee Shares or ii) an option to purchase 100,000 Employee</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 1.9pt 18.45pt 0 126.05pt; text-align: justify; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares,
issued pursuant to the Company's contemplated equity incentive plan, shall be granted to Employee on the two year anniversary
of this Agreement, subject to Employee's continued employment.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.2pt"></TD><TD STYLE="width: 33.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">B.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary.
                                         Employee shall be paid a salary in an amount commensurate with that of similar position
                                         in similar companies subject to mutual agreement between Employer and Employee.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.05pt"></TD><TD STYLE="width: 34.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">C.</FONT></TD><TD STYLE="text-align: justify; padding-right: 9.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
                                         and Other Benefits. As further consideration for the covenants contained herein, Employer
                                         will provide Employee with such insurance, welfare, sick leave and other benefits as
                                         may be established by Employer from time to time with respect to its employees in accordance
                                         with Employer's established procedures. Employee shall be entitled to Directors' and
                                         Officers' indemnification insurance coverage to the same extent as is provided to other
                                         persons employed as officers of Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/107% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.25pt"></TD><TD STYLE="width: 34.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">D.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                         Compensation Plans. Employee shall be entitled to participate, to the same extent as
                                         is provided to other persons employed by Employer, in any future stock bonus plan, stock
                                         option plan or employee stock ownership plan of Employer.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 3.85pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.85pt"></TD><TD STYLE="width: 33.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">E.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses.
                                         It is acknowledged that, during the term of employment, Employee will be required to
                                         incur ordinary and necessary business expenses on behalf of Employer in connection with
                                         the performance of his duties hereunder. Employer shall reimburse Employee promptly the
                                         amount of all such expenses upon presentation of itemized vouchers or other evidence
                                         of those expenditures. Any single expense item in excess of $1,000.00 shall be approved
                                         by Employer prior to the incurrence of such expense.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.45pt"></TD><TD STYLE="width: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">F.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacations.
                                         Employee shall be entitled to three (3) weeks paid vacation each year for the term of
                                         this Agreement. Such vacations shall be taken at such times as Employer designates as
                                         to time-of year. Vacation time can be accumulated year-to-year up to three years maximum.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 8.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
III. COMPANY POLICIES</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0 7.4pt 0 8.25pt; text-align: justify; text-indent: 34.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
agrees to abide by the policies, rules, regulations or usages applicable to Employee as established by Employer from time to time
and provided to Employee in writing.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 7.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
IV. CONFIDENTIALITY</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0 6.6pt 0 7.9pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
shall not disclose to any non-party to the Agreement, any confidential information of Employer. Confidential information is information
that relates to the Employer's research, development, trade secrets or business affairs, but does not include information which
is generally known or easily ascertainable by non-parties. Employee hereby acknowledges that during the performance of this Agreement,
Employee may learn or receive confidential Employer information and therefore Employee hereby confirms that all such information
relating to the Employer's business will be kept confidential by the Employee, except to the extent that such information is required
to be divulged to attorneys, accountants/auditors and other professionals in performance of their duties to the Employer.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 7.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
V. TERM AND TERMINATION</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.75pt"></TD><TD STYLE="width: 34.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">A.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term.
                                         The term of this Agreement shall be a period of three years, commencing on the date hereof.
                                         At the expiration date, this Agreement shall be renewed for additional one-year periods,
                                         provided neither party hereto submits a written notice of termination within sixty (60)
                                         days prior to the termination of either the initial term hereof or any renewal term.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 33.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">B.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination.
                                         Employer agrees not to terminate this Agreement except for &quot;just cause&quot; and
                                         agrees to give Employee written notice of its belief that acts or events constituting
                                         &quot;just cause&quot; exist. Employee has the right to cure, within thirty (30) days
                                         of Employer's giving of such notice, the acts, events or conditions which led to Employer's
                                         notice. For purposes of this Agreement, &quot;just cause&quot; shall mean (I) the willful
                                         failure or refusal of Employee to implement or follow the written policies or directions
                                         of Employer's Board of Directors, provided that Employee's failure or refusal is not
                                         based upon Employee's belief in good faith, as expressed to Employer in writing, that
                                         the implementation thereof would be unlawful; (2) conduct which is inconsistent with
                                         Employee's position with Employer and which results in a material adverse effect (financial
                                         or otherwise) or misappropriation of assets of Employer; (3) conduct which violates the
                                         provisions contained in the Confidentiality Agreement or the Non-Competition Agreement;
                                         (4) the intentional causing of material damage to Employer's physical property; and (5)
                                         any act involving personal dishonesty or criminal conduct against Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt/105% Times New Roman, Times, Serif; margin: 0 7.85pt 0 75.2pt; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Employer retains the right to terminate Employee for any reason not specified above, Employer agrees that if it discharges Employee
for any reason other than just cause, as is solely defined above, Employee will be entitled to full compensation, including participation
in all benefit programs, for one year or the remainder of the current term, original or renewal, as the case may be, of employment,
whichever is more.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0 7.3pt 0 74.85pt; text-align: justify; text-indent: 0.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of paragraph C below, if Employee should cease his employment hereunder voluntarily for any reason, or is terminated
for just cause, all compensation and benefits payable to Employee shall thereupon, without any further writing or act, cease,
lapse and be terminated. However, all defined compensation, benefits and reimbursements which accrued prior to Employee's ceasing
employment or termination, will become immediately due and payable and shall be payable to Employee's estate should his employment
cease due to death.&nbsp;</FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0 7.3pt 0 74.85pt; text-align: justify; text-indent: 0.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 3.35pt 6.1pt 0 77.35pt; text-align: justify; text-indent: 0.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of paragraph C below, should Employee voluntarily cease his employment, Employee retains the right to participate
for the period of this Agreement in Employee's medical insurance plan and will be responsible for 100% of the cost of participation.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 3.35pt 6.1pt 0 77.35pt; text-align: justify; text-indent: 0.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 3.35pt 6.1pt 0 77.35pt; text-align: justify; text-indent: 0.45pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 3.35pt 6.1pt 0 77.35pt; text-align: justify; text-indent: 0.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 34.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">C.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee's
                                         Right to Terminate.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.2pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/100% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.3pt"></TD><TD STYLE="width: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
                                         in Control of Employer. If, at any time during the term of this Agreement, including
                                         any renewal term, Employer (a) shall issue an amount of stock, in a single transaction
                                         or a related series of transactions, in excess of 50% of the then-outstanding common
                                         stock of Employer, as measured after the completion of such transaction, (b) sell all
                                         or substantially of its assets, or (c) have in excess of 50% of its stock purchased by
                                         a single buyer or group of buyers, then Employee may, in his sole discretion, terminate
                                         his employment hereunder and Employer shall be liable to Employee for all compensation
                                         remaining to be paid to Employee during the then-current term hereof, plus an additional
                                         one year period.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/101% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.8pt"></TD><TD STYLE="width: 34.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
                                         for Cause. If, at any time during the term of this Agreement, including any renewal term,
                                         Employer should change the responsibilities of Employee hereunder, then Employee may,
                                         in his sole discretion, terminate his employment hereunder and Employer shall be liable
                                         to Employee for all compensation remaining to be paid to Employee during the then-current
                                         term hereof, plus an additional one year period.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 8.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
VI. COMPLETE AGREEMENT</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/100% Times New Roman, Times, Serif; margin: 0 6.65pt 0 7.9pt; text-align: justify; text-indent: 34.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement contains the complete agreement concerning the employment arrangement between the parties hereto and shall, as of the
effective date hereof, supersede all other agreements between the parties. The parties hereto stipulate that neither of them has
made any representation with respect to the subject matter of this Agreement or any representations including the execution and
delivery hereof, except such representations as are specifically set forth herein and each of the parties hereto acknowledges
that he or it has relied on his or its own judgment in entering into this Agreement. The parties hereto further acknowledge that
any payments or representations that may have heretofore been made by either of them to the other are of no effect and that neither
of them has relied thereon in connection with his or its dealings with the other.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 7.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
VII. WAIVER; MODIFICATION</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/101% Times New Roman, Times, Serif; margin: 0 7.45pt 0 7.4pt; text-align: justify; text-indent: 34.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
waiver by either party of a breach or violation of any provision of this Agreement shall not operate as, or be construed to be,
a waiver of any subsequent breach hereof. No waiver or modification of this Agreement or of any covenant, condition or limitation
herein contained shall be valid unless in writing and duly executed by the party to be charged therewith and no evidence of any
waiver or modification shall be offered or received in evidence of any proceeding or litigation between the parties hereto arising
out of, or affecting, this Agreement, or the rights or obligations of the parties hereunder, unless such waiver or modification
is in writing, duly executed as aforesaid, and the parties further agree that the provisions of this Section IX may not be waived
except as herein set forth.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
VIII. SEVERABILITY</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 7.75pt 0 6.9pt; text-align: justify; text-indent: 34.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
agreements and covenants contained herein are severable, and in the event any one of them, with the exception of those contained
in Sections I, II, III, and IV hereof, shall be held to be invalid in any proceeding or litigation between the parties, this Agreement
shall be interpreted as if such invalid agreements or covenants were not contained herein.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 6.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
IX. NOTICES</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/100% Times New Roman, Times, Serif; margin: 0 8.9pt 0 6.95pt; text-align: justify; text-indent: 33.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
and all notices will be sufficient if furnished in writing, sent by registered mail to his last known residence, in case of Employee,
or, in case of Employer, to its principal office address.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 6.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
XI. CORPORATE AUTHORITY OF EMPLOYER</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 40.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
execution of this Agreement by Employer has been approved by the Board of Directors of Employer.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 6.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
XII. REPRESENTATIONS OF EMPLOYEE</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 4.1pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 34.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">A.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                         hereby represents to Employer that he is under no legal disability with respect to his
                                         entering into this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/105% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.9pt"></TD><TD STYLE="width: 34.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">B.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt
                                         of Disclosure. Employee hereby represents and warrants that he has had an opportunity
                                         to ask questions of, and to receive answers from, the officers of Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.5pt"></TD><TD STYLE="width: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">C.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
                                         Relating to Employer Common Stock. Employee represents and warrants to Employer that
                                         the shares of Employer common stock being acquired pursuant to this Employment Agreement
                                         are being acquired for his own account and for investment and not with a view to the
                                         public resale or distribution of such shares and further acknowledges that the shares
                                         being issued have not been registered under the Securities Act or any state securities
                                         law and are &quot;restricted securities&quot;, as that term is defined in Rule 144 promulgated
                                         by the SEC, and must be held indefinitely, unless they are subsequently registered or
                                         an exemption from such registration is available.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
XIII. COUNTERPARTS</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0.05pt 7.85pt 0 7.15pt; text-align: justify; text-indent: 33.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in duplicate counterparts, each of which shall be deemed an original and, together, shall constitute
one and the same agreement, with one counterpart being delivered to each party hereto.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.2pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
XIV. BENEFIT</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/105% Times New Roman, Times, Serif; margin: 0 7.6pt 0 6.7pt; text-align: justify; text-indent: 34.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of this Agreement shall extend to the successors, surviving corporations and assigns of Employer and to any purchaser
of substantially all of the assets and business of Employer. The term &quot;Employer&quot; shall be deemed to include Employer,
any joint venture, partnership, limited liability company, corporation or other juridical entity, in which Employer shall have
an interest, financial or otherwise.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 6.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
XV. ARBITRATION</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/106% Times New Roman, Times, Serif; margin: 0.05pt 8.3pt 0 6.35pt; text-align: justify; text-indent: 34.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties agree that any dispute arising between them related to this Agreement or the performance hereof shall be submitted for
resolution to the American Arbitration Association for arbitration in the Denver, Colorado, office of the Association under the
then-current rules of arbitration. The Arbitrator or Arbitrators shall have the authority to award to the prevailing party its
reasonable costs and attorney's fees. Any award of the Arbitrators may be entered as a judgment in any court competent jurisdiction.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 0 6.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
XVI. GOVERNING LAW</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 9pt/105% Times New Roman, Times, Serif; margin: 0 8.55pt 0 5.95pt; text-align: justify; text-indent: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the intention of the parties hereto that this Agreement and the performance hereunder and all suits and special proceedings
hereunder be construed in accordance with and under and pursuant to the laws of the State of Florida, and that, in any action,
special proceeding or other proceeding that may be brought arising out of, in connection with or by reason of this Agreement,
the laws of the State of Florida shall be applicable and shall govern to the exclusion of the law of any other forum, without
regard to the jurisdiction in which any such action or special proceeding may be instituted.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the 5th day of August,</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 9pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD BRANDS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian John</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas O. McKinnon</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4.65pt 0 0 5.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 164.15pt 0 176.8pt; text-align: center"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>22
<FILENAME>ex10_7.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT WITH DR. GLYNN WILSON
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">Exhibit 10.7</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.4pt 170.9pt 0 154.95pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.4pt 170.9pt 0 154.95pt; text-align: center">EMPLOYMENT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0.05pt 6.85pt 0 9.1pt; text-align: justify; text-indent: 33.9pt">THIS
EMPLOYMENT AGREEMENT (the &quot;Agreement&quot;) is made by and between CBD Brands, Inc., a duly organized Delaware corporation
(&quot;Employer&quot;), and Dr. Glynn Wilson, a resident of the State of Florida (&quot;Employee&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 151.65pt 0 154.95pt; text-align: center">WITNESSETH:</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 5.05pt 7.45pt 0 42.25pt; text-align: justify; text-indent: 0.15pt">WHEREAS,
Employer needs persons with experience at the executive level in developing and executing the business plan and related financial
and reporting systems of start-up companies with the intent of listing on a recognized exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.45pt; text-align: justify">WHEREAS, Employee has a substantial
amount of the executive experience needed by Employer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 8.2pt 0 42.15pt; text-align: justify; text-indent: 0.05pt">WHEREAS,
Employee is willing to be employed by Employer, and Employer is willing to employ Employee, on the terms, covenants and conditions
hereinafter set forth; and</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 8.1pt 7.6pt 0 9.1pt; text-align: justify; text-indent: 34.05pt">NOW,
THEREFORE, in consideration of such employment and other valuable consideration, the receipt and adequacy of which is hereby acknowledged,
Employer and Employee hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.95pt">SECTION I. EMPLOYMENT OF EMPLOYEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 6.9pt 0 8.6pt; text-align: justify; text-indent: 34.5pt">Employer
hereby employs, engages and hires Employee as Chairman of the board and head of R &amp; D of Employer, and Employee hereby accepts
and agrees to such hiring, engagement and employment, subject to the general supervision and pursuant to the orders, advice and
direction of the Chief Executive Officer and Board of Directors of Employer. Employee shall perform duties as are customarily performed
by one holding such position in other, same or similar businesses or enterprises as that engaged in by Employer, and shall also
additionally render such other and unrelated services and duties as may be assigned to him from time to time by Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 8.45pt">SECTION II. COMPENSATION OF EMPLOYEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/101% Times New Roman, Times, Serif; margin: 0 8.7pt 0 8.25pt; text-align: justify; text-indent: 34.35pt">Employer
shall pay Employee, and Employee shall accept from Employer, in full payment for Employee's services hereunder, compensation as
follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 7pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.6pt"></TD><TD STYLE="width: 35.35pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">A.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Execution of Agreement. Employee is aware of the general financial condition
of the Employer and has agreed to waive Salary until such time as Employer has completed a satisfactory offering such that the
Company can commence paying salaries to the executive team. In consideration of Employee's executing this Employment Agreement,
Employer shall issue to Employee up to</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 1.35pt 0 0 75.65pt; text-indent: -0.05pt">700,000 shares of its
common stock (&quot;Employee Shares&quot;). It is agreed by Employer and Employee that such shares shall be valued at par value
and issued and released from escrow as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 7.25pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.9pt"></TD><TD STYLE="width: 71.55pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">B.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">i. 300,000 Employee Shares shall be issued upon signing of this Agreement;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0.85pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 110.8pt"></TD><TD STYLE="width: 16pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.05pt">ii.</FONT></TD><TD STYLE="text-align: left; padding-right: 16.95pt"><FONT STYLE="font-size: 10pt">Either i) 200,000 Employee Shares or ii) an
option to purchase 200,000 Employee Shares, issued pursuant to the Company's contemplated equity incentive plan, shall be granted
to Employee on the one year anniversary of this Agreement, subject to Employee's continued employment; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/9.65pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 107.55pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; letter-spacing: -0.05pt">iii.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Either i) 200,000 Employee Shares or ii) an option to purchase 200,000
Employee</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0.6pt 0 0 126.45pt; text-indent: 0.15pt">Shares, issued pursuant
to the Company's contemplated equity incentive plan, shall be granted to Employee on the two year anniversary of this Agreement,
subject to Employee's continued employment.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/102% Times New Roman, Times, Serif; margin-top: 5.45pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.05pt"></TD><TD STYLE="width: 34.2pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">C.</FONT></TD><TD STYLE="text-align: justify; padding-right: 8.75pt"><FONT STYLE="font-size: 10pt">Insurance and Other Benefits. As further consideration
for the covenants contained herein, Employer will provide Employee with such insurance, welfare, sick leave and other benefits
as may be established by Employer from time to time with respect to its employees in accordance with Employer's established procedures.
Employee shall be entitled to Directors' and Officers' indemnification insurance coverage to the same extent as is provided to
other persons employed as officers of Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/107% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.45pt"></TD><TD STYLE="width: 34.5pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">D.</FONT></TD><TD STYLE="text-align: justify; padding-right: 9.7pt"><FONT STYLE="font-size: 10pt">Other Compensation Plans. Employee shall be
entitled to participate, to the same extent as is provided to other persons employed by Employer, in any future stock bonus plan,
stock option plan or employee stock ownership plan of Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.4pt"></TD><TD STYLE="width: 33.35pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">E.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.1pt"><FONT STYLE="font-size: 10pt">Expenses. It is acknowledged that, during
the term of employment, Employee will be required to incur ordinary and necessary business expenses on behalf of Employer in connection
with the performance of his duties hereunder. Employer shall reimburse Employee promptly the amount of</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 3.4pt 6.7pt 0 77.85pt; text-align: justify; text-indent: -0.05pt">all
such expenses upon presentation of itemized vouchers or other evidence of those expenditures. Any single expense item in excess
of $1,000.00 shall be approved by Employer prior to the incurrence of such expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/105% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.65pt"></TD><TD STYLE="width: 34.2pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">F.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt"><FONT STYLE="font-size: 10pt">Vacations. Employee shall be entitled to three
(3) weeks paid vacation each year for the term of this Agreement. Such vacations shall be taken at such times as Employer designates
as to time-of year. Vacation time can be accumulated year-to-year up to three years maximum.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 9.15pt">SECTION III. COMPANY POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/108% Times New Roman, Times, Serif; margin: 0 7.95pt 0 9.7pt; text-align: justify; text-indent: 33.9pt">Employee
agrees to abide by the policies, rules, regulations or usages applicable to Employee as established by Employer from time to time
and provided to Employee in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.15pt">SECTION IV. CONFIDENTIALITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 7.15pt 0 9.1pt; text-align: justify; text-indent: 34.5pt">Executive
shall not disclose to any non-party to the Agreement, any confidential information of Employer. Confidential information is information
that relates to the Employer's research, development, trade secrets or business affairs, but does not include information which
is generally known or easily ascertainable by non-parties. Employee hereby acknowledges that during the performance of this Agreement,
Employee may learn or receive confidential Employer information and therefore Employee hereby confirms that all such information
relating to the Employer's business will be kept confidential by the Employee, except to the extent that such information is required
to be divulged to attorneys, accountants/auditors and other professionals in performance of their duties to the Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.9pt">SECTION V. TERM AND TERMINATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.95pt"></TD><TD STYLE="width: 34.4pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">A.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Term. The term of this Agreement shall be a
period of three years, commencing on the date hereof At the expiration date, this Agreement shall be renewed for additional one-year
periods, provided neither party hereto submits a written notice of termination within sixty (60) days prior to the termination
of either the initial term hereof or any renewal term.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.9pt"></TD><TD STYLE="width: 33.5pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">B.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt"><FONT STYLE="font-size: 10pt">Termination. Employer agrees not to terminate
this Agreement except for &quot;just cause&quot; and agrees to give Employee written notice of its belief that acts or events constituting
&quot;just cause&quot; exist. Employee has the right to cure, within thirty (30) days of Employer's giving of such notice, the
acts, events or conditions which led to Employer's notice. For purposes of this Agreement, &quot;just cause&quot; shall mean (I)
the willful failure or refusal of Employee to implement or follow the written policies or directions of Employer's Board of Directors,
provided that Employee's failure or refusal is not based upon Employee's belief in good faith, as expressed to Employer in writing,
that the implementation thereof would be unlawful; (2) conduct which is inconsistent with Employee's position with Employer and
which results in a material adverse effect (financial or otherwise) or misappropriation of assets of Employer; (3) conduct which
violates the provisions contained in the Confidentiality Agreement or the Non-Competition Agreement; (4) the intentional causing
of material damage to Employer's physical property; and (5) any act involving personal dishonesty or criminal conduct against Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 7.7pt 0 76.15pt; text-align: justify; text-indent: 0.45pt">Although
Employer retains the right to terminate Employee for any reason not specified above, Employer agrees that if it discharges Employee
for any reason other than just cause, as is solely defined above, Employee will be entitled to full compensation, including participation
in all benefit programs, for one year or the remainder of the current term, original or renewal, as the case may be, of employment,
whichever is more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 8pt 0 76.05pt; text-align: justify; text-indent: 0.3pt">Notwithstanding
the provisions of paragraph C below, if Employee should cease his employment hereunder voluntarily for any reason, or is terminated
for just cause, all compensation and benefits payable to Employee shall thereupon, without any further writing or act, cease, lapse
and be terminated. However, all defined compensation, benefits and reimbursements which accrued prior to Employee's ceasing employment
or termination, will become immediately due and payable and shall be payable to Employee's estate should his employment cease due
to death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0.05pt 8.55pt 0 75.9pt; text-align: justify; text-indent: 0.2pt">Notwithstanding
the provisions of paragraph C below, should Employee voluntarily cease his employment, Employee retains the right to participate
for the period of this Agreement in Employee's medical insurance plan and will be responsible for 100% of the cost of participation.</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0.05pt 8.55pt 0 75.9pt; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0.05pt 8.55pt 0 75.9pt; text-align: justify; text-indent: 0.2pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0.05pt 8.55pt 0 75.9pt; text-align: justify; text-indent: 0.2pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0.05pt 8.55pt 0 75.9pt; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 4.1pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 34.35pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Employee's Right to Terminate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 81pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt"><FONT STYLE="font-size: 10pt">Change in Control of Employer. If<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">,
</FONT>at any time during the term of this Agreement, including any renewal term, Employer (a) shall issue an amount of stock,
in a single transaction or a related series of transactions, in excess of 50% of the then-outstanding common stock of Employer,
as measured after the completion of such transaction, (b) sell all or substantially of its assets, or (c) have in excess of 50%
of its stock purchased by a single buyer or group of buyers, then Employee may, in his sole discretion, terminate his employment
hereunder and Employer shall be liable to Employee for all compensation remaining to be paid to Employee during the then-current
term hereof, plus an additional one year period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 111.85pt; text-align: justify; text-indent: -34.55pt">(2)
Termination for Cause. If<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">, </FONT>at any time during the term of this Agreement,
including any renewal term, Employer should change the responsibilities of Employee hereunder, then Employee may, in his sole discretion,
terminate his employment hereunder and Employer shall be liable to Employee for all compensation remaining to be paid to Employee
during the then-current term hereof, plus an additional one year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.7pt">SECTION VI. COMPLETE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 7.7pt 0 8.6pt; text-align: justify; text-indent: 33.95pt">This
Agreement contains the complete agreement concerning the employment arrangement between the parties hereto and shall, as of the
effective date hereof, supersede all other agreements between the parties. The parties hereto stipulate that neither of them has
made any representation with respect to the subject matter of this Agreement or any representations including the execution and
delivery hereof, except such representations as are specifically set forth herein and each of the parties hereto acknowledges that
he or it has relied on his or its own judgment in entering into this Agreement. The parties hereto further acknowledge that any
payments or representations that may have heretofore been made by either of them to the other are of no effect and that neither
of them has relied thereon in connection with his or its dealings with the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.2pt">SECTION VII. WAIVER; MODIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 7.85pt 0 8.1pt; text-align: justify; text-indent: 33.95pt">The
waiver by either party of a breach or violation of any provision of this Agreement shall not operate as, or be construed to be,
a waiver of any subsequent breach hereof. No waiver or modification of this Agreement or of any covenant, condition or limitation
herein contained shall be valid unless in writing and duly executed by the party to be charged therewith and no evidence of any
waiver or modification shall be offered or received in evidence of any proceeding or litigation between the parties hereto arising
out of, or affecting, this Agreement, or the rights or obligations of the parties hereunder, unless such waiver or modification
is in writing, duly executed as aforesaid, and the parties further agree that the provisions of this Section IX may not be waived
except as herein set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.7pt">SECTION VIII. SEVERABILITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 8.75pt 0 7.65pt; text-align: justify; text-indent: 34.15pt">All
agreements and covenants contained herein are severable, and in the event any one of them, with the exception of those contained
in Sections I, II, III, and IV hereof, shall be held to be invalid in any proceeding or litigation between the parties, this Agreement
shall be interpreted as if such invalid agreements or covenants were not contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.25pt">SECTION IX. NOTICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 9.5pt 0 7.9pt; text-align: justify; text-indent: 33.6pt">Any
and all notices will be sufficient if furnished in writing, sent by registered mail to his last known residence, in case of Employee,
or, in case of Employer, to its principal office address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.25pt">SECTION XI. CORPORATE AUTHORITY OF EMPLOYER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41.1pt">The execution of this Agreement by Employer has been
approved by the Board of Directors of Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 7pt">SECTION XII. REPRESENTATIONS OF EMPLOYEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.4pt"></TD><TD STYLE="width: 33.8pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; letter-spacing: -0.05pt">A.</FONT></TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><FONT STYLE="font-size: 10pt">Employee hereby represents to Employer that
he is under no legal disability with respect to his entering into this Agreement.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 3.4pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.15pt"></TD><TD STYLE="width: 33.75pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.05pt">B.</FONT></TD><TD STYLE="text-align: justify; padding-right: 9.25pt"><FONT STYLE="font-size: 10pt">Receipt of Disclosure. Employee hereby represents
and warrants that he has had an opportunity to ask questions of, and to receive answers from, the officers of Employer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/106% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.5pt"></TD><TD STYLE="width: 34.05pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.05pt">C.</FONT></TD><TD STYLE="text-align: justify; padding-right: 9.05pt"><FONT STYLE="font-size: 10pt">Representations Relating to Employer Common
Stock. Employee represents and warrants to Employer that the shares of Employer common stock being acquired pursuant to this Employment
Agreement are being acquired for his own account and for investment and not with a view to the public resale or distribution of
such shares and further acknowledges that the shares being issued have not been registered under the Securities Act or any state
securities law and are &quot;restricted securities&quot;, as that term is defined in Rule 144 promulgated by the SEC, and must
be held indefinitely, unless they are subsequently registered or an exemption from such registration is available.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 7pt">SECTION XIII. COUNTERPARTS&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 9.5pt 0 7.15pt; text-align: justify; text-indent: 33.95pt">&nbsp;</P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 9.5pt 0 7.15pt; text-align: justify; text-indent: 33.95pt">This
Agreement may be executed in duplicate counterparts, each of which shall be deemed an original and, together, shall constitute
one and the same agreement, with one counterpart being delivered to each party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6.75pt">SECTION XIV. BENEFIT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 9.8pt 0 6.9pt; text-align: justify; text-indent: 33.95pt">The
provisions of this Agreement shall extend to the successors, surviving corporations and assigns of Employer and to any purchaser
of substantially all of the assets and business of Employer. The term &quot;Employer&quot; shall be deemed to include Employer,
any joint venture, partnership, limited liability company, corporation or other juridical entity, in which Employer shall have
an interest, financial or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 6.75pt">SECTION XV. ARBITRATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/105% Times New Roman, Times, Serif; margin: 0 9.55pt 0 6.45pt; text-align: justify; text-indent: 34.15pt">The
parties agree that any dispute arising between them related to this Agreement or the performance hereof shall be submitted for
resolution to the American Arbitration Association for arbitration in the Denver, Colorado, office of the Association under the
then-current rules of arbitration. The Arbitrator or Arbitrators shall have the authority to award to the prevailing party its
reasonable costs and attorney's fees. Any award of the Arbitrators may be entered as a judgment in any court competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6.3pt">SECTION XVI. GOVERNING LAW</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 10.15pt 0 5.95pt; text-align: justify; text-indent: 34.65pt">It
is the intention of the parties hereto that this Agreement and the performance hereunder and all suits and special proceedings
hereunder be construed in accordance with and under and pursuant to the laws of the State of Florida, and that, in any action,
special proceeding or other proceeding that may be brought arising out of, in connection with or by reason of this Agreement, the
laws of the State of Florida shall be applicable and shall govern to the exclusion of the law of any other forum, without regard
to the jurisdiction in which any such action or special proceeding may be instituted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.85pt">2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 5.85pt">IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the 15th day of October,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 9pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD BRANDS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian John</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Glynn Wilson</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14
<SEQUENCE>23
<FILENAME>ex14_1.htm
<DESCRIPTION>CODE OF ETHICS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 14.1</B></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">CBD BRANDS, INC.</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">CODE OF BUSINESS CONDUCT AND ETHICS</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;<U>Introduction</U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;1.1&nbsp;&nbsp;
The Board of Directors of CBD Brands, Inc. (together with its subsidiaries, the &ldquo;<B>Company</B>&rdquo;) has adopted this
<FONT STYLE="color: #252525; background-color: white">Code</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">of
<FONT STYLE="color: #252525">Business Conduct</FONT> and Ethics</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
<FONT STYLE="background-color: white">&ldquo;<FONT STYLE="color: #252525"><B>Code</B></FONT>&rdquo;) </FONT>in order to:&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;promote
honest and ethical <FONT STYLE="color: #252525; background-color: white">conduct</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">including the ethical handling of actual or apparent
conflicts of interest;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;promote
full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to,
the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) and in other public communications made by the Company;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;promote
compliance with applicable governmental laws, rules and regulations;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;promote
the protection of Company assets, including corporate opportunities and confidential information;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;promote
fair dealing practices;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;deter
wrongdoing; and&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;ensure
accountability for adherence to the <FONT STYLE="color: #252525; background-color: white">Code</FONT>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;1.2&nbsp;&nbsp;All
directors, officers and employees are required to be familiar with the <FONT STYLE="color: #252525; background-color: white">Code</FONT>,
comply with its provisions and report any suspected violations as described below in Section 10, Reporting and Enforcement.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;<U>Honest
and Ethical <FONT STYLE="color: #252525; background-color: white">Conduct</FONT></U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;The
Company&rsquo;s policy is to promote high standards of integrity by conducting its affairs honestly and ethically.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;Each
director, officer and employee must act with integrity and observe the highest ethical standards of <FONT STYLE="color: #252525; background-color: white">business
conduct</FONT> in his or her dealings with the Company&rsquo;s customers, suppliers, partners, service providers, competitors,
employees and anyone else with whom he or she has contact in the course of performing his or her job.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;<U>Conflicts
of Interest</U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;3.1&nbsp;&nbsp;A
conflict of interest occurs when an individual&rsquo;s private interest (or the interest of a member of his or her family) interferes,
or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee,
officer or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his
or her work for the Company objectively and effectively. Conflicts of interest also arise when an employee, officer or director
(or a member of his or her family) receives improper personal benefits as a result of his or her position in the Company.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;3.2&nbsp;&nbsp;Loans
by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and
could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances.
Loans by the Company to, or guarantees by the Company of obligations of, any director or officer or their family members are expressly
prohibited.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;3.3&nbsp;&nbsp;Whether
or not a conflict of interest exists or will exist can be unclear. Conflicts of interest should be avoided unless specifically
authorized as described in Section 3.4.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;3.4&nbsp;&nbsp;Persons
other than directors and executive officers who have questions about a potential conflict of interest or who become aware of an
actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from,
their supervisor, the Chief Executive Officer or Chief Operating Officer.&nbsp; A supervisor may not authorize or approve conflict
of interest matters or make determinations as to whether a problematic conflict of interest exists without first providing the
Chief Executive Officer or Chief Operating Officer with a written description of the activity and seeking the Chief Executive
Officer or Chief Operating Officer&rsquo;s written approval. If the supervisor is himself involved in the potential or actual
conflict, the matter should instead be discussed directly with the Chief Executive Officer or Chief Operating Officer.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Directors
and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively
from the Nominating and Corporate Governance Committee&nbsp;.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;<U>Compliance</U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;4.1&nbsp;&nbsp;Employees,
officers and directors should comply, both in letter and spirit, with all applicable laws, rules and regulations in the cities,
states and countries in which the Company operates.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;4.2&nbsp;&nbsp;Although
not all employees, officers and directors are expected to know the details of all applicable laws, rules and regulations, it is
important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed
to the Legal Department.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;4.3&nbsp;&nbsp;No
director, officer or employee may purchase or sell any Company securities while in possession of material nonpublic information
regarding the Company, nor may any director, officer or employee purchase or sell another company&rsquo;s securities while in
possession of material nonpublic information regarding that company. It is against Company policies and illegal for any director,
officer or employee to use material nonpublic information regarding the Company or any other company to:&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;obtain
profit for himself or herself; or&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;directly
or indirectly &ldquo;tip&rdquo; others who might make an investment decision on the basis of that information.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;<U>Disclosure</U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;5.1&nbsp;&nbsp;The
Company&rsquo;s periodic reports and other documents filed with the SEC, including all financial statements and other financial
information, must comply with applicable federal securities laws and SEC rules.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;5.2&nbsp;&nbsp;Each
director, officer and employee who contributes in any way to the preparation or verification of the Company&rsquo;s financial
statements and other financial information must ensure that the Company&rsquo;s books, records and accounts are accurately maintained.
Each director, officer and employee must cooperate fully with the Company&rsquo;s accounting and internal audit departments, as
well as the Company&rsquo;s independent public accountants and counsel.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;5.3&nbsp;&nbsp;Each
director, officer and employee who is involved in the Company&rsquo;s disclosure process must:&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;be
familiar with and comply with the Company&rsquo;s disclosure controls and procedures and its internal control over financial reporting;
and&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;take
all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and <FONT STYLE="color: #252525; background-color: white">business
</FONT>condition of the Company provide full, fair, accurate, timely and understandable disclosure.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;<U>Protection
and Proper Use of Company Assets</U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;6.1&nbsp;&nbsp;All
directors, officers and employees should protect the Company&rsquo;s assets and ensure their efficient use. Theft, carelessness
and waste have a direct impact on the Company&rsquo;s profitability and are prohibited.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;6.2&nbsp;&nbsp;All
Company assets should be used only for legitimate <FONT STYLE="color: #252525; background-color: white">business</FONT> purposes.
Any suspected incident of fraud or theft should be reported for investigation immediately.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;6.3&nbsp;&nbsp;The
obligation to protect Company assets includes the Company&rsquo;s proprietary information. Proprietary information includes intellectual
property such as trade secrets, patents, trademarks, and copyrights, as well as <FONT STYLE="color: #252525; background-color: white">business
</FONT>and marketing plans, engineering and manufacturing ideas, designs, databases, records and any nonpublic financial data
or reports. Unauthorized use or distribution of this information is prohibited and could also be illegal and result in civil or
criminal penalties.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;<U>Corporate
Opportunities</U>. All directors, officers and employees owe a duty to the Company to advance its interests when the opportunity
arises. Directors, officers and employees are prohibited from taking for themselves personally (or for the benefit of friends
or family members) opportunities that are discovered through the use of Company assets, property, information or position. Directors,
officers and employees may not use Company assets, property, information or position for personal gain (including gain of friends
or family members). In addition, no director, officer or employee may compete with the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;<U>Confidentiality</U>.
Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Company or by its
customers, suppliers or partners, except when disclosure is expressly authorized or is required or permitted by law. Confidential
information includes all nonpublic information (regardless of its source) that might be of use to the Company&rsquo;s competitors
or harmful to the Company or its customers, suppliers or partners if disclosed.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;<U>Fair
Dealing</U>. Each director, officer and employee must deal fairly with the Company&rsquo;s customers, suppliers, partners, service
providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job.
No director, officer or employee may take unfair advantage of anyone through manipulation, concealment, abuse or privileged information,
misrepresentation of facts or any other unfair dealing practice.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;<U>Reporting
and Enforcement</U>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;10.1&nbsp;&nbsp;Reporting
and Investigation of Violations.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;Actions
prohibited by this <FONT STYLE="color: #252525; background-color: white">Code</FONT> involving directors or executive officers
must be reported to the Nominating and Corporate Governance Committee&nbsp;.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;Actions
prohibited by this <FONT STYLE="color: #252525; background-color: white">Code</FONT> involving anyone other than a director or
executive officer must be reported to the reporting person&rsquo;s supervisor, the Chief Executive Officer or Chief Operating
Officer.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;After
receiving a report of an alleged prohibited action, the Nominating and Corporate Governance Committee&nbsp;, the relevant supervisor,
the Chief Executive Officer or Chief Operating Officer must promptly take all appropriate actions necessary to investigate.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;All
directors, officers and employees are expected to cooperate in any internal investigation of misconduct.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;10.2&nbsp;&nbsp;Enforcement.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;The
Company must ensure prompt and consistent action against violations of <FONT STYLE="background-color: white">this <FONT STYLE="color: #252525">Code</FONT></FONT>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;If,
after investigating a report of an alleged prohibited action by a director or executive officer, the Nominating and Corporate
Governance Committee&nbsp; determines that a violation of this <FONT STYLE="color: #252525; background-color: white">Code </FONT>has
occurred, the Nominating and Corporate Governance Committee&nbsp; will report such determination to the Board of Directors.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;If,
after investigating a report of an alleged prohibited action by any other person, the relevant supervisor, the Chief Executive
Officer or Chief Operating Officer determines that a violation of this <FONT STYLE="color: #252525; background-color: white">Code
</FONT>has occurred, the relevant supervisor, the Chief Executive Officer or Chief Operating Officer will report such determination
to the General Counsel.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;Upon
receipt of a determination that there has been a violation of this <FONT STYLE="color: #252525; background-color: white">Code</FONT>,
the Board of Directors or the General Counsel will take such preventative or disciplinary action as it deems appropriate, including,
but not limited to, reassignment, demotion, dismissal and, in the event of criminal <FONT STYLE="color: #252525; background-color: white">conduct
</FONT>or other serious violations of the law, notification of appropriate governmental authorities.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;10.3&nbsp;&nbsp;Waivers.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;The
Nominating and Corporate Governance Committee&nbsp; (in the case of a violation by a director or executive officer) and the General
Counsel (in the case of a violation by any other person) may, in its discretion, waive any violation of this <FONT STYLE="color: #252525; background-color: white">Code</FONT>.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;Any
waiver for a director or an executive officer shall be disclosed as required by SEC and NASDAQ rules.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;10.4&nbsp;&nbsp;Prohibition
on Retaliation.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; color: #0E568C"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;The
Company does not tolerate acts of retaliation against any director, officer or employee who makes a good faith report of known
or suspected acts of misconduct or other violations of this <FONT STYLE="color: #252525; background-color: white">Code</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGMENT
OF RECEIPT AND REVIEW</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be signed and returned to the Chief Executive Officer or Chief Operating Officer.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
_______________________, acknowledge that I have received and read a copy of the CBD Brands, Inc. <FONT STYLE="color: #252525; background-color: white">Code
</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">of <FONT STYLE="color: #252525">Business
Conduct and Ethics</FONT>.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I understand the contents
of the <FONT STYLE="color: #252525; background-color: white">Code </FONT>and I agree to comply with the policies and procedures
set out in the <FONT STYLE="color: #252525; background-color: white">Code</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that I should approach my supervisor, the Chief Executive Officer or Chief Operating Officer if I have any questions
about <FONT STYLE="background-color: white">the <FONT STYLE="color: #252525">Code</FONT></FONT> generally or any questions about
reporting a suspected conflict of interest or other violation of the <FONT STYLE="color: #252525; background-color: white">Code</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 1.35pt; padding-left: 1.35pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 50%; padding-right: 1.35pt; padding-left: 1.35pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME]</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PRINTED
        NAME]</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[DATE]</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1.35pt 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14
<SEQUENCE>24
<FILENAME>ex14_2.htm
<DESCRIPTION>CORPORATE GOVERNANCE GUIDELINES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"><B>Exhibit 14.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>CBD BRANDS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>CORPORATE GOVERNANCE
GUIDELINES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Responsibility of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
primary mission of the Board of Directors of CBD Brands, Inc. (the &quot;Company&quot;) is to advance the interests of the Company&rsquo;s
stockholders by creating a valuable long-term business.&nbsp;&nbsp;The Board believes that this mission is best served by establishing
a corporate culture of accountability, responsibility and ethical behavior through the careful selection and evaluation of senior
management and members of the Board and by carrying out the Board&rsquo;s responsibilities with honesty and integrity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
basic responsibility of the directors is to exercise their business judgment to act in what they reasonably believe to be the best
interests of the Company and its shareholders.&nbsp;&nbsp;In discharging their obligations, directors should be entitled to rely
on the honesty and integrity of the Company&rsquo;s senior executives and its outside advisors and auditors.&nbsp;&nbsp;The directors
shall also be entitled to have the Company purchase reasonable directors' and officers' liability insurance on their behalf, to
the benefits of indemnification to the fullest extent permitted by law and the Company's Certificate of Incorporation and Bylaws
and to exculpation as provided by state law and the Company's Certificate of Incorporation.&nbsp;&nbsp;Board members are expected
attend meetings of the Board and the Board committees on which they serve and to spend the time needed to appropriately discharge
their responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Director Selection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Board
Membership Criteria</I>.</B>&nbsp;&nbsp;The Nominating Committee is responsible for reviewing with the Board, at least annually,
the appropriate skills and experience of new Board members, as well as the composition of the Board as a whole.&nbsp;&nbsp;This
assessment should include factors such as independence, judgment, skill, diversity, integrity and experience in the context of
the needs of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Selection
of Director Nominees</I>.&nbsp;&nbsp;</B>The Nominating Committee will recommend candidates for election to the Board in accordance
with the policies and principles in its charter and the criteria described in these Guidelines.&nbsp;&nbsp;The invitation to join
the Board should be extended by the Board jointly through the Chief Executive Officer of the Company (the &quot;CEO&quot;) and
the Chair of the Nominating Committee.&nbsp;&nbsp;The Nominating Committee will review the nomination of an incumbent director
for re-election to the Board upon expiration of such director&rsquo;s term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Board Composition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Independent
Directors.</I></B>&nbsp;&nbsp;A majority of the members of the Board shall be &ldquo;independent&rdquo; under the rules of NASDAQ
and under applicable law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Size
of the Board.&nbsp;&nbsp;</I></B>The Board presently has six members, and it is the sense of the Board that a size of between three
and seven is appropriate.&nbsp;&nbsp;The Board determines the number of directors as permitted in the Company&rsquo;s Certificate
of Incorporation or Bylaws and will periodically review the size of the Board based on recommendations of the Nominating Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Positions
of Chairman and CEO.&nbsp;&nbsp;</I></B>The Board has no policy with respect to the separation of the offices of Chairman of the
Board and the CEO.&nbsp;&nbsp;The Board believes that this issue is part of the succession planning process and that it is in the
best interests of the Company for the Board, with the assistance of the Nominating Committee, to make a determination whenever
it elects a new chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Service
on Other Boards.&nbsp;&nbsp;</I></B>No director should serve on more than three other boards of directors of publicly-held companies
without the prior approval of the Nominating Committee.&nbsp;&nbsp;Directors should advise the CEO and the Chair of the Nominating
Committee in advance of accepting an invitation to serve on the board of directors of another company.&nbsp;&nbsp;Additionally,
the CEO and other executive officers must seek the approval of the Board before accepting membership on other boards (or similar
bodies), including corporate and charitable boards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Changes
in Professional Responsibility</I></B>.&nbsp;&nbsp;The Board should consider whether a change in an individual&rsquo;s professional
responsibility directly or indirectly impacts that person&rsquo;s ability to fulfill his or her obligations as a director of the
Company.&nbsp;&nbsp;Any director of the Company should submit his or her resignation upon retirement from, or other significant
change in, his or her principal employment.&nbsp;&nbsp;The Board may accept or reject such resignation in its discretion<B>&nbsp;</B>after
consultation with the Nominating Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Term
Limits</I></B>.&nbsp;&nbsp;The Board does not believe it should establish term limits.&nbsp;&nbsp;While term limits could help
insure that there are fresh ideas and viewpoints available to the Board, they have the disadvantage of losing the contribution
of directors who have been able to develop, over a period of time, increasing insight into the Company and its operations and,
therefore, provide an increasing contribution to the Board as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Director Compensation
and Performance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Compensation
Policy and Annual Compensation Review.&nbsp;</I>&nbsp;</B>It is the policy of the Board to provide independent directors with a
mix of compensation, including an annual fee, as well as equity and/or derivative security awards, which may be contingent upon
certain criteria as determined by the Board at the time of grant.&nbsp;&nbsp;Proposed changes in Board compensation shall initially
be reviewed by the Compensation Committee, but any changes in the compensation of directors shall require the approval of the Board.&nbsp;&nbsp;The
Compensation Committee shall periodically review the status of Board compensation in relation to other comparable companies and
consider other factors the Committee deems appropriate, including whether directors' independence may be jeopardized if (i) director
compensation and perquisites exceed customary levels, (ii) the Company makes substantial charitable contributions to organizations
with which a director is affiliated, or (iii) the Company enters into consulting contracts with (or provides other indirect forms
of compensation to) a director or an organization with which the director is affiliated.&nbsp;&nbsp;The Committee shall discuss
its review with the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Annual
Performance Evaluation.</I>&nbsp;</B>Commencing in 2020, the Board of Directors will conduct an annual self-evaluation to determine
whether it and its committees are functioning effectively.&nbsp;&nbsp;The Board of Directors will select an independent Director
to oversee this process and, in connection with such evaluation, will receive comments from all directors and report annually to
the Board with an assessment of the Board's performance and procedures.&nbsp;&nbsp;This will be discussed with the full Board following
the end of each fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Transactions
with Directors or their Affiliates.</I>&nbsp;</B>Except for employment arrangements with executive officers, the Company does not
engage in transactions with directors or their affiliates if a transaction would cast into doubt the independence of a director,
present the appearance of a conflict of interest, or is otherwise prohibited by law, rule or regulation.&nbsp;&nbsp;&nbsp;This
includes, directly or indirectly, any extension, maintenance or renewal of an extension of credit to any director or member of
management of the Company.&nbsp;&nbsp;This prohibition also includes significant business dealings with directors or their affiliates,
substantial charitable contributions to organizations in which a director is affiliated, and consulting contracts with, or other
indirect forms of compensation to, a director.&nbsp;&nbsp;Any waiver of this policy may be made only by the Board or a Board committee
and must be promptly disclosed to the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Board Meetings
and Communications to Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Schedule.</I></B>&nbsp;&nbsp;Board
meetings are scheduled in advance and held not less than quarterly.&nbsp;&nbsp;The Board holds special meetings as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Agendas.&nbsp;&nbsp;</I></B>The
CEO and other members of senior management will establish the agenda for each Board meeting.&nbsp;&nbsp;Each Board member may submit
items to be included on the agenda.&nbsp;&nbsp;Board members also may raise subjects that are not on the agenda at any meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Distribution
of Board Material.&nbsp;&nbsp;</I></B>Information that is important to the Board&rsquo;s understanding of the Company&rsquo;s business
should be distributed to the Board members a reasonable period of time before the Board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Strategic
Planning.&nbsp;&nbsp;</I></B>The Board will review the Company's long-term strategic plans and principal issues that the Company
will face in the future during at least one Board meeting each year.&nbsp;&nbsp;The timing and agenda of this meeting shall be
determined by the CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Meetings
of Independent Directors.&nbsp;&nbsp;</I></B> Independent directors shall meet at least annually without any non-independent directors
present. Meetings of the independent directors should generally coincide with regularly scheduled Board meetings; however,<B>&nbsp;</B>a
majority of the independent directors may call a meeting of the independent directors at any time.&nbsp;&nbsp;The director, or
method for selecting a director, who presides at any meeting of independent directors will be decided by the directors entitled
to attend such meeting, and his or her name or such method will be disclosed in the Company's annual proxy statement.&nbsp;&nbsp;The
director presiding at any such meeting shall supervise the conduct of such meeting, shall communicate the results of the meeting
to the CEO, as appropriate, and shall have other responsibilities which the non-management directors or independent directors may
designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Communications
with Independent Directors.</I></B>&nbsp;&nbsp;Interested parties wishing to communicate directly with the independent directors
may do so by writing, addressed as follows:&nbsp;Independent Directors, 725 N. Hwy A1A, Suite C-106, Jupiter, FL 33477, Attn: Corporate
Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Board
Presentations and Access to Employees and Advisors.&nbsp;&nbsp;</I></B>Directors shall have full access to officers and employees
of the Company and, as necessary and appropriate, the Company&rsquo;s independent advisors, including legal counsel and independent
accountants.&nbsp;&nbsp;Any meetings or contacts that a director wishes to initiate may be arranged through the CEO or the Corporate
Secretary or directly by the director.&nbsp;&nbsp;The directors will use their judgment to ensure that any such contact is not
disruptive to the business operations of the Company and will, to the extent appropriate, provide the<B>&nbsp;</B>CEO with a copy
of any written communications between a director and an officer or employee of, or adviser to, the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Board encourages senior management to invite to Board meetings officers and other key employees who can provide additional insight
into the items being discussed, or that senior management believes should be given exposure to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Board
Interaction with Investors, Media and Others.</I></B>&nbsp;&nbsp;The Board believes that senior management speaks for the Company.&nbsp;&nbsp;Individual
Board members may, from time to time, meet or otherwise communicate with various constituencies that are involved with the Company,
but the Board members will do so only with the knowledge and prior consent of senior management and, in most instances, only at
the request of senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Required
Committees.&nbsp;&nbsp;</I></B>Consistent with NASDAQ's listing requirements, the Board will have at all times an Audit Committee,
a Compensation Committee and a Nominating and Corporate Governance Committee.&nbsp;&nbsp;All of the members of those committees
will be &ldquo;independent&rdquo; under the criteria established by NASDAQ and under applicable law.&nbsp;&nbsp;In addition, the
Company has a Strategic Planning Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Committees
shall receive authority exclusively through delegation from the Board through the by-laws, Board resolutions, committee charters
or as provided by these guidelines.&nbsp;&nbsp;All committee actions must be ratified by the Board before becoming effective, unless
taken pursuant to an express delegation of authority.&nbsp;&nbsp;In addition to the authority granted hereunder or under each committee&rsquo;s
charter, the Board and each committee have the power to hire independent legal, financial or other advisors as they may deem necessary
without consulting or obtaining the approval of senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Appointment
and Term of Service of Committee Members.&nbsp;&nbsp;</I></B>Committee members will be appointed by the Board upon recommendation
of the Nominating Committee with consideration of the desires of individual directors.&nbsp;&nbsp;Consideration will be given to
rotating committee members periodically, but the Board does not believe that rotation should be mandated as a policy.&nbsp;&nbsp;Committee
chairs shall be selected by the respective committee members, except with respect to the Audit Committee chair who will be selected
by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Committee
Charters.&nbsp;&nbsp;</I></B>Consistent with NASDAQ&rsquo;s listing requirements, the Audit Committee, the Compensation Committee
and the Nominating Committee will have a written charter approved by the Board.&nbsp;&nbsp;The charters will set forth the purposes
and responsibilities of the committees as well as qualifications for committee membership, procedures for appointment and removal,
structure and operations, and reporting to the Board.&nbsp;&nbsp;The charters will also provide that each committee will annually
evaluate its performance.&nbsp;&nbsp;Consistent with NASDAQ&rsquo;s listing requirements, the charters will be included on the
Company&rsquo;s website and copies of the charters will be made available upon request to the Company&rsquo;s Corporate Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Committee
Meetings and Committee Agenda.&nbsp;&nbsp;</I></B>Each committee chair, in consultation with the committee members and appropriate
officers of the Company, will determine the frequency of committee meetings consistent with any requirements in the committee&rsquo;s
charter, provided that a majority of committee members may call a meeting of the committee on which they are members at any time.&nbsp;&nbsp;Each
committee chair, in consultation with the other members of the committee and senior management, will develop the committee&rsquo;s
agenda.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Other
Committees.&nbsp;&nbsp;</I></B>The Board may, from time to time, establish or maintain additional committees as necessary or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Management Succession</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>CEO
Selection.&nbsp;&nbsp;</I></B>The Board shall select a CEO in a manner that is in the best interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Evaluation
of Executive Officers.&nbsp;&nbsp;</I></B>The Compensation Committee will conduct an annual review of the performance of the<B>&nbsp;</B>CEO,
and the other executive officers of the Company in light of the goals and objectives of the Company.&nbsp;&nbsp;The Compensation
Committee will set executive officer compensation based on such factors as it deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Succession
Planning and Management Development.&nbsp;&nbsp;</I></B>The Nominating Committee should, at least annually, make a report to the
Board on succession planning.&nbsp;&nbsp;The Company&rsquo;s succession plan will include appropriate contingencies in case the
CEO retires or is incapacitated.&nbsp;&nbsp;The Board, with the assistance of the Nominating Committee, will evaluate potential
successors to the CEO.&nbsp;&nbsp;The CEO should at all times make available his recommendations and evaluations of potential successors,
along with a review of any development plans recommended for such individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">These guidelines will
be made available upon request to the Company&rsquo;s Corporate Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>25
<FILENAME>ex23_1.htm
<DESCRIPTION>CONSENT OF M&K CPAS PLLC, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_010.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">We hereby consent to the inclusion in this Registration
Statement on Form S-1 of our report dated June 17, 2020, of our audit of Jupiter Wellness, Inc, formerly known as CBD Brands, Inc.,
relating to the audit of the financial statements for the two years ended December 31, 2019 and 2018, and our audit of Magical
Beasts, LLC of our report dated June 17, 2020 for the two years ended December 31, 2019 and 2018, and the reference to our firm
under the caption &ldquo;Experts&rdquo; in the Registration Statement.</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">/s/ M&amp;K CPAS, PLLC</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">www.mkacpas.com</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">Houston, Texas</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">July 14, 2020</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 :H# 2(  A$! Q$!_\0
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+/110!?HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
